




Eur päisches
Patentamt

Eur pean
Patent Office

Office eur péen
des brevets

PCT/EP 03/03126

#2



Bescheinigung

Certificate

Attestation

PCT/EP03/09126

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n° ..

02018158.2

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)



Anmeldung Nr:
Application no.: 02018158.2
Demande no:

Anmeldetag:
Date of filing: 19.08.02
Date de dépôt:

Applicant(s)/Demandeur(s):

Bayer Aktiengesellschaft

51368 Leverkusen
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Single nucleotide polymorphisms sensitively predicting adverse drug reactions
(ADR) and drug efficacy

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12Q/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Single Nucleotide Polymorphisms sensitively predicting Adverse Drug Reactions (ADR) and Drug Efficacy

Technical Field

5

10

15

20

This invention relates to genetic polymorphisms useful for assessing cardiovascular risks in humans, including, but not limited to, atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial inflammation, myocardial infarction, and stroke. In addition it relates to genetic polymorphisms useful for assessing the response to lipid lowering drug therapy. Specifically, the present invention identifies and describes gene variations which are individually present in humans with cardiovascular disease states, relative to humans with normal, or non-cardiovascular disease states, and/or in response to medications relevant to cardiovascular disease. Further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Still further, the present invention provides methods to use gene variations to predict personal medication schemes omitting adverse drug reactions and allowing an adjustment of the drug dose to achieve maximum benefit for the patient. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

25

Background of the Invention

Cardiovascular disease is a major health risk throughout the industrialized world.

30

Cardiovascular diseases include but are not limited by the following disorders of the heart and the vascular system: congestive heart failure, myocardial infarction, atherosclerosis, ischemic diseases of the heart, coronary heart disease, all kinds of

atrial and ventricular arrhythmias, hypertensive vascular diseases and peripheral vascular diseases.

5 Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

10 Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

15 Ischemic diseases are conditions in which the coronary flow is restricted resulting in an perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases include stable angina, unstable angina and asymptomatic ischemia.

20 Arrhythmias include all forms of atrial and ventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation) as well as bradycardic forms of arrhythmias.

25 Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others).

30 Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD),

acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

Atherosclerosis, the most prevalent of vascular diseases, is the principal cause of heart attack, stroke, and gangrene of the extremities, and thereby the principal cause of death. Atherosclerosis is a complex disease involving many cell types and molecular factors (for a detailed review, see Ross, 1993, Nature 362: 801-809 and Lusis, A. J., Nature 407, 233-241 (2000)). The process, in normal circumstances a protective response to insults to the endothelium and smooth muscle cells (SMCs) of the wall of the artery, consists of the formation of fibrofatty and fibrous lesions or plaques, preceded and accompanied by inflammation. The advanced lesions of atherosclerosis may occlude the artery concerned, and result from an excessive inflammatory-fibroproliferative response to numerous different forms of insult. For example, shear stresses are thought to be responsible for the frequent occurrence of atherosclerotic plaques in regions of the circulatory system where turbulent blood flow occurs, such as branch points and irregular structures.

The first observable event in the formation of an atherosclerotic plaque occurs when blood-borne monocytes adhere to the vascular endothelial layer and transmigrate through to the sub-endothelial space. Adjacent endothelial cells at the same time produce oxidized low density lipoprotein (LDL). These oxidized LDLs are then taken up in large amounts by the monocytes through scavenger receptors expressed on their surfaces. In contrast to the regulated pathway by which native LDL (nLDL) is taken up by nLDL specific receptors, the scavenger pathway of uptake is not regulated by the monocytes.

These lipid-filled monocytes are called foam cells, and are the major constituent of the fatty streak. Interactions between foam cells and the endothelial and SMCs which surround them lead to a state of chronic local inflammation which can eventually lead to smooth muscle cell proliferation and migration, and the formation of a fibrous

plaque. Such plaques occlude the blood vessel concerned and thus restrict the flow of blood, resulting in ischemia.

5 Ischemia is a condition characterized by a lack of oxygen supply in tissues of organs due to inadequate perfusion. Such inadequate perfusion can have number of natural causes, including atherosclerotic or restenotic lesions, anemia, or stroke, to name a few. Many medical interventions, such as the interruption of the flow of blood during bypass surgery, for example, also lead to ischemia. In addition to sometimes being
10 caused by diseased cardiovascular tissue, ischemia may sometimes affect cardiovascular tissue, such as in ischemic heart disease. Ischemia may occur in any organ, however, that is suffering a lack of oxygen supply.

15 The most common cause of ischemia in the heart is atherosclerotic disease of epicardial coronary arteries. By reducing the lumen of these vessels, atherosclerosis causes an absolute decrease in myocardial perfusion in the basal state or limits appropriate increases in perfusion when the demand for flow is augmented. Coronary blood flow can also be limited by arterial thrombi, spasm, and, rarely, coronary emboli, as well as by ostial narrowing due to luetic aortitis. Congenital abnormalities, such as anomalous origin of the left anterior descending coronary artery from the
20 pulmonary artery, may cause myocardial ischemia and infarction in infancy, but this cause is very rare in adults. Myocardial ischemia can also occur if myocardial oxygen demands are abnormally increased, as in severe ventricular hypertrophy due to hypertension or aortic stenosis. The latter can be present with angina that is indistinguishable from that caused by coronary atherosclerosis. A reduction in the
25 oxygen-carrying capacity of the blood, as in extremely severe anemia or in the presence of carboxy-hemoglobin, is a rare cause of myocardial ischemia. Not infrequently, two or more causes of ischemia will coexist, such as an increase in oxygen demand due to left ventricular hypertrophy and a reduction in oxygen supply secondary to coronary atherosclerosis.

The foregoing studies are aimed at defining the role of particular gene variations presumed to be involved in the misleading of normal cellular function leading to cardiovascular disease. However, such approaches cannot identify the full panoply of gene variations that are involved in the disease process.

5

At present, the only available treatments for cardiovascular disorders are pharmaceutical based medications that are not targeted to an individual's actual defect; examples include angiotensin converting enzyme (ACE) inhibitors and diuretics for hypertension, insulin supplementation for non-insulin dependent diabetes mellitus (NIDDM), cholesterol reduction strategies for dyslipidaemia, anti-coagulants, β blockers for cardiovascular disorders and weight reduction strategies for obesity. If targeted treatment strategies were available it might be possible to predict the response to a particular regime of therapy and could markedly increase the effectiveness of such treatment. Although targeted therapy requires accurate diagnostic tests for disease susceptibility, once these tests are developed the opportunity to utilize targeted therapy will become widespread. Such diagnostic tests could initially serve to identify individuals at most risk of hypertension and could allow them to make changes in lifestyle or diet that would serve as preventative measures. The benefits associated by coupling the diagnostic tests with a system of targeted therapy could include the reduction in dosage of administered drugs and thus the amount of unpleasant side effects suffered by an individual. In more severe cases a diagnostic test may suggest that earlier surgical intervention would be useful in preventing a further deterioration in condition.

10

15

20

25

It is an object of the invention to provide genetic diagnosis of predisposition or susceptibility for cardiovascular diseases. Another related object is to provide treatment to reduce or prevent or delay the onset of disease in those predisposed or susceptible to this disease. A further object is to provide means for carrying out this diagnosis.

30

Accordingly, a first aspect of the invention provides a method of diagnosis of disease in an individual, said method comprising determining one, various or all genotypes in said individual of the genes listed in the Examples.

5 In another aspect, the invention provides a method of identifying an individual predisposed or susceptible to a disease, said method comprising determining one, various or all genotypes in said individual of the genes listed in the Examples.

10 The invention is of advantage in that it enables diagnosis of a disease or of certain disease states via genetic analysis which can yield useable results before onset of disease symptoms, or before onset of severe symptoms. The invention is further of advantage in that it enables diagnosis of predisposition or susceptibility to a disease or of certain disease states via genetic analysis.

15 The invention may also be of use in confirming or corroborating the results of other diagnostic methods. The diagnosis of the invention may thus suitably be used either as an isolated technique or in combination with other methods and apparatus for diagnosis, in which latter case the invention provides a further test on which a diagnosis may be assessed.

20

The present invention stems from using allelic association as a method for genotyping individuals; allowing the investigation of the molecular genetic basis for cardiovascular diseases. In a specific embodiment the invention tests for the polymorphisms in the sequences of the listed genes in the Examples. The invention demonstrates a link between this polymorphisms and predispositions to cardiovascular diseases by showing that allele frequencies significantly differ when individuals with "bad" serum lipids are compared to individuals with "good" serum levels. The meaning of "good and bad" serum lipid levels is defined in Table 1a.

25

30 Certain disease states would benefit, that is to say the suffering of the patient may be reduced or prevented or delayed, by administration of treatment or therapy in

advance of disease appearance; this can be more reliably carried out if advance diagnosis of predisposition or susceptibility to disease can be diagnosed.

Pharmacogenomics and adverse drug reactions

5

10

15

20

25

Adverse drug reactions (ADRs) remain a major clinical problem. A recent meta-analysis suggested that in the USA in 1994, ADRs were responsible for 100 000 deaths, making them between the fourth and sixth commonest cause of death (Lazarou 1998, J. Am. Med. Assoc. 279:1200). Although these figures have been heavily criticized, they emphasize the importance of ADRs. Indeed, there is good evidence that ADRs account for 5% of all hospital admissions and increase the length of stay in hospital by two days at an increased cost of ~\$2500 per patient. ADRs are also one of the commonest causes of drug withdrawal, which has enormous financial implications for the pharmaceutical industry. ADRs, perhaps fortunately, only affect a minority of those taking a particular drug. Although factors that determine susceptibility are unclear in most cases, there is increasing interest in the role of genetic factors. Indeed, the role of inheritable variations in predisposing patients to ADRs has been appreciated since the late 1950s and early 1960s through the discovery of deficiencies in enzymes such as pseudocholinesterase (butyrylcholinesterase) and glucose-6-phosphate dehydrogenase (G6PD). More recently, with the first draft of the human genome just completed, there has been renewed interest in this area with the introduction of terms such as pharmacogenomics and toxicogenomics. Essentially, the aim of pharmacogenomics is to produce personalized medicines, whereby administration of the drug class and dosage is tailored to an individual genotype. Thus, the term pharmacogenomics embraces both efficacy and toxicity.

30

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ("statins") specifically inhibit the enzyme HMG-CoA reductase which catalyzes the rate limiting step in cholesterol biosynthesis. These drugs are effective in reducing the primary and secondary risk of coronary artery disease and coronary events, such

as heart attack, in middle-aged and older men and women, in both diabetic and non-diabetic patients, and are often prescribed for patients with hyperlipidemia. Statins used in secondary prevention of coronary artery or heart disease significantly reduce the risk of stroke, total mortality and morbidity and attacks of myocardial ischemia; the use of statins is also associated with improvements in endothelial and fibrinolytic functions and decreased platelet thrombus formation.

The tolerability of these drugs during long term administration is an important issue. Adverse reactions involving skeletal muscle are not uncommon; and sometimes serious adverse reactions involving skeletal muscle such as myopathy and rhabdomyolysis may occur, requiring discontinuation of the drug. In addition an increase in serum creatine kinase (CK) may be a sign of a statin related adverse event. The extend of such adverse events can be read from the extend of the CK level increase (as compared to the upper limit of normal [ULN]).

Occasionally arthralgia, alone or in association with myalgia, has been reported. Also an elevation of liver transaminases has been associated with statin administration.

It was shown that the drug response to statin therapy is a class effects, i.e. all known and presumably also all so far undiscovered statins share the same beneficial and harmful effects (Ucar, M. et al., Drug Safety 2000, 22:441). It follows that the discovery of diagnostic tools to predict the drug response to a single statin will also be of aid to guide therapy with other statins.

The present invention provides diagnostic tests to predict the patient's individual response to statin therapy. Such responses include, but are not limited by the extent of adverse drug reactions, the level of lipid lowering or the drug's influence on disease states. Those diagnostic tests may predict the response to statin therapy either alone or in combination with another diagnostic test or another drug regimen.

Detailed Description of the Invention

5 The present invention is based at least in part on the discovery that a specific allele of a polymorphic region of a so called "candidate gene" (as defined below) is associated with CVD or drug response.

For the present invention the following candidate genes were analyzed:

-Genes found to be expressed in cardiac tissue (Hwang et al., Circulation 1997, 96:4146-4203).

10 -Genes from the following metabolic pathways and their regulatory elements:

Lipid metabolism

15 Numerous studies have shown a connection between serum lipid levels and cardiovascular diseases. Candidate genes falling into this group include but are not limited by genes of the cholesterol pathway, apolipoproteins and their modifying factors.

Coagulation

20 Ischemic diseases of the heart and in particular myocardial infarction may be caused by a thrombotic occlusion. Genes falling into this group include all genes of the coagulation cascade and their regulatory elements.

Inflammation

25 Complications of atherosclerosis are the most common causes of death in Western societies. In broad outline atherosclerosis can be considered to be a form of chronic inflammation resulting from interaction modified lipoproteins, monocyte-derived macrophages, T cells, and the normal cellular elements of the arterial wall. This
30 inflammatory process can ultimately lead to the development of complex lesions, or

plaques, that protrude into the arterial lumen. Finally plaque rupture and thrombosis result in the acute clinical complications of myocardial infarction and stroke (Glass et al., Cell 2001, 104:503-516).

5 It follows that all genes related to inflammatory processes, including but not limited by cytokines, cytokine receptors and cell adhesion molecules are candidate genes for CVD.

Glucose and energy metabolism

10

As glucose and energy metabolism is interdependent with the metabolism of lipids (see above) also the former pathways contain candidate genes. Energy metabolism in general also relates to obesity, which is an independent risk factor for CVD (Melanson et al., Cardiol Rev 2001 9:202-207). In addition high blood glucose levels
15 are associated with many microvascular and macrovascular complications and may therefore affect an individuals disposition to CVD (Duckworth, Curr Atheroscler Rep 2001, 3:383-391).

Hypertension

20

As hypertension is an independent risk factor for CVD, also genes that are involved in the regulation of systolic and diastolic blood pressure affect an individuals risk for CVD (Safar, Curr Opin Cardiol 2000, 15:258-263). Interestingly hypertension and diabetes (see above) appear to be interdependent, since hypertension is
25 approximately twice as frequent in patients with diabetes compared with patients without the disease. Conversely, recent data suggest that hypertensive persons are more predisposed to the development of diabetes than are normotensive persons (Sowers et al., Hypertension 2001, 37:1053-1059).

Genes related to drug response

Those genes include metabolic pathways involved in the absorption, distribution, metabolism, excretion and toxicity (ADMET) of drugs. Prominent members of this group are the cytochrome P450 proteins which catalyze many reactions involved in drug metabolism.

Unclassified genes

As stated above, the mechanisms that lead to cardiovascular diseases or define the patient's individual response to drugs are not completely elucidated. Hence also candidate genes were analysed, which could not be assigned to the above listed categories. The present invention is based at least in part on the discovery of polymorphisms, that lie in genomic regions of unknown physiological function.

Results

After conducting an association study, we surprisingly found polymorphic sites in a number of candidate genes which show a strong correlation with the following phenotypes of the patients analysed: "Healthy" as used herein refers to individuals that neither suffer from existing CVD, nor exhibit an increased risk for CVD through their serum lipid level profile. "CVD prone" as used herein refers to individuals with existing CVD and/or a serum lipid profile that confers a high risk to get CVD (see Table 1a for definitions of healthy and CVD prone serum lipid levels). "High responder" as used herein refers to patients who benefit from relatively small amounts of a given drug. "Low responder" as used herein refers to patients who need relatively high doses in order to obtain benefit from the medication. "Tolerant patient" refers to individuals who can tolerate high doses of a medicament without exhibiting adverse drug reactions. "ADR patient" as used herein refers to individuals who suffer from ADR or show clinical symptoms (like creatine kinase elevation in

blood) even after receiving only minor doses of a medicament (see Table 1b for a detailed definition of drug response phenotypes).

5 Polymorphic sites in candidate genes that were found to be significantly associated with either of the above mentioned phenotypes will be referred to as "phenotype associated SNPs" (PA SNPs). The respective genomic loci that harbour PA SNPs will be referred to as "phenotype associated genes" (PA genes), irrespective of the actual function of this gene locus:

10 In particular we surprisingly found PA SNPs associated with CVD, drug efficacy, (EFF) or adverse drug reactions (ADR) in the following genes.

ABCB11: ATP-binding cassette, sub-family B (MDR/TAP), member 11

15 The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of
20 the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is the major canalicular bile salt export pump in man. Mutations in this gene cause a form of progressive familial intrahepatic cholestases which are a group of inherited disorders with severe cholestatic liver disease from early infancy.

25 **ABCB4: ATP-binding cassette, sub-family B (MDR/TAP), member 4**

The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are
30 divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of

the MDR/TAP subfamily are involved in multidrug resistance as well as antigen presentation. This gene encodes a full transporter and member of the p-glycoprotein family of membrane proteins with phosphatidylcholine as its substrate. The function of this protein has not yet been determined; however, it may involve transport of phospholipids from liver hepatocytes into bile. Alternative splicing of this gene results in several products of undetermined function.

ABCC1: ATP-binding cassette, sub-family C (CFTR/MRP), member 1

The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This full transporter is a member of the MRP subfamily which is involved in multi-drug resistance. This protein functions as a multispecific organic anion transporter, with oxidized glutathione, cysteinyl leukotrienes, and activated aflatoxin B1 as substrates. This protein also transports glucuronides and sulfate conjugates of steroid hormones and bile salts. Alternative splicing by exon deletion results in several splice variants but maintains the original open reading frame in all forms.

ACTB mRNA for mutant beta-actin

Beta actin is one of six different actin isoforms which have been identified. ACTB is one of the two nonmuscle cytoskeletal actins. Actins are highly conserved proteins that are involved in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile apparatus.

ACTIN, ALPHA SKELETAL MUSCLE (ALPHA-ACTIN 1).

Actin alpha 1 which is expressed in skeletal muscle is one of six different actin isoforms which have been identified. Actins are highly conserved proteins that are

involved in cell motility, structure and integrity. Alpha actins are a major constituent of the contractile apparatus.

ADCYAP1: adenylate cyclase activating polypeptide 1 (pituitary)

5

This gene encodes adenylate cyclase activating polypeptide 1. Mediated by adenylate cyclase activating polypeptide 1 receptors, this polypeptide stimulates adenylate cyclase and subsequently increases the cAMP level in target cells. Adenylate cyclase activating polypeptide 1 is not only a hypophysiotropic hormone, but also functions as a neurotransmitter and neuromodulator. In addition, it plays a role in paracrine and autocrine regulation of certain types of cells. This gene is composed of five exons. Exons 1 and 2 encode the 5' UTR and signal peptide, respectively; exon 4 encodes an adenylate cyclase activating polypeptide 1-related peptide; and exon 5 encodes the mature peptide and 3' UTR. This gene encodes three different mature peptides, including two isotypes: a shorter form and a longer form.

10
15

ADRB3: adrenergic, beta-3-, receptor

The ADRB3 gene product, beta-3-adrenergic receptor, is located mainly in adipose tissue and is involved in the regulation of lipolysis and thermogenesis. Beta adrenergic receptors are involved in the epinephrine and norepinephrine-induced activation of adenylate cyclase through the action of G proteins.

20

AGL: amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen de-branching enzyme, glycogen storage disease type III)

25

Glycogen debranching enzyme is involved in glycogen degradation and has two independent catalytic activities: a 4-alpha-glucotransferase activity (EC 2.4.1.25) and a amylo-1,6-glucosidase activity (EC 3.4.1.33). Both activities occur at different sites on the single polypeptide chain. Mutations in this gene cause glycogen storage disease. A wide range of clinical and enzymatic variability occurs in glycogen

30

debrancher deficiency, some of which may be due to tissue-specific alternative splicing. Six splice variants that differ in the 5' end have been identified in liver and muscle tissue. Variants 1, 5, and 6 are present in both liver and muscle, whereas variants 2, 3, and 4 occur in muscle. Variants 1 through 4 encode identical proteins (isoform 1) that include 27 N-terminal amino acids not found in splice variants 5 and 6. Variants 5 and 6 encode different amino-terminal ends of 10 and 11 amino acids in protein isoforms 2 and 3, respectively, with the remainder of the peptide identical to that of isoforms 1..

AKAP1: A kinase (PRKA) anchor protein 1

Anchors cAMP-dependent protein kinase near its physiological substrates, interacts with both the type I and type II regulatory subunits.

Angiotensinogen gene

The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure and in the pathogenesis of essential hypertension and preeclampsia.

ANXA6: annexin A6

Annexin VI belongs to a family of calcium-dependent membrane and phospholipid binding proteins. Although their functions are still not clearly defined, several members of the annexin family have been implicated in membrane-related events along exocytotic and endocytotic pathways. The annexin VI gene is approximately 60 kbp long and contains 26 exons. It encodes a protein of about 68 kDa that consists of eight 68-amino acid repeats separated by linking sequences of variable lengths. It

is highly similar to human annexins I and II sequences, each of which contain four such repeats. Exon 21 of annexin VI is alternatively spliced, giving rise to two isoforms that differ by a 6-amino acid insertion at the start of the seventh repeat. Annexin VI has been implicated in mediating the endosome aggregation and vesicle fusion in secreting epithelia during exocytosis.

AP2B1: adaptor-related protein complex 2, beta 1 subunit

The beta adaptin subunit is part of the clathrin coat assembly complex which links clathrin to receptors in coated pits and vesicles. These vesicles are involved in endocytosis and Golgi processing. The beta 1 subunit is one of the assembly proteins which binds to clathrin and initiates coat formation.

APOA1: apolipoprotein A-I

APOA1 promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A-I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18-amino acid signal peptide is removed co-translationally and a 6-amino acid propeptide is cleaved post-translationally. Variation in the latter step, in addition to modifications leading to so-called isoforms, is responsible for some of the polymorphism observed. APOA1 is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the C-III gene is transcribed convergently in relation to A-I. Defects in the apolipoprotein A-1 gene are associated with HDL deficiency and Tangier disease.

APOA4: ap lip protein A-IV

Apolipoprotein (apo) A-IV gene contains 3 exons separated by two introns. A sequence polymorphism has been identified in the 3'UTR of the third exon. The primary translation product is a 396-residue preprotein which after proteolytic processing is secreted its primary site of synthesis, the intestine, in association with chylomicron particles. Although its precise function is not known, apo A-IV is a potent activator of lecithin-cholesterol acyltransferase in vitro.

APOB: apolipoprotein B

Apolipoprotein B (ApoB) is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL). The protein occurs in the plasma in 2 main isoforms, apoB-48 and apoB-100. The first is synthesized exclusively by the gut, the second by the liver. The intestinal (B-48) and hepatic (B-100) forms of apoB are coded by a single gene and by a single mRNA transcript larger than 16 kb. The 2 proteins share a common amino terminal sequence. In the ApoB-100 isoform the precursor has 4,563 amino acids, and the mature apoB-100 has 4,536 amino acid residues. Mature, circulating B-48 is homologous over its entire length (estimated to be between 2,130 and 2,144 amino acid residues) with the amino-terminal portion of B-100 and contains no sequence from the carboxyl end of B-100. From structural studies, it is thought that apoB-48 represents the amino-terminal 47% of apoB-100 and that the carboxyl terminus of apoB-48 is in the vicinity of residue 2151 of apoB-100. Apolipoprotein B-48 may be the product of an intestinal mRNA with an in-frame UAA stop codon resulting from a C-to-U change in the codon CAA encoding Gln(2153) in apoB-100 mRNA. Since only the sequence that codes B-100 is present in genomic DNA, this presents the possibility of an organ-specific introduction of a stop codon to an mRNA and the change from CAA to UAA of codon 2153 of the message as a unique RNA editing process..

APOD: apolipoprotein D

Apolipoprotein D (Apo-D) is a component of high density lipoprotein that has no marked similarity to other apolipoprotein sequences. It has a high degree of
5 homology to plasma retinol-binding protein and other members of the alpha 2 microglobulin protein superfamily of carrier proteins, also known as lipocalins. It is a glycoprotein of estimated molecular weight 33 KDa. Apo-D is closely associated with the enzyme lecithin:cholesterol acyltransferase - an enzyme involved in lipoprotein metabolism.

Apolipoprotein B

Apolipoprotein B (ApoB) is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL). The protein occurs in the plasma in 2 main isoforms,
15 apoB-48 and apoB-100. The first is synthesized exclusively by the gut, the second by the liver. The intestinal (B-48) and hepatic (B-100) forms of apoB are coded by a single gene and by a single mRNA transcript larger than 16 kb. The 2 proteins share a common amino terminal sequence. In the ApoB-100 isoform the precursor has 4,563 amino acids, and the mature apoB-100 has 4,536 amino acid residues. Mature,
20 circulating B-48 is homologous over its entire length (estimated to be between 2,130 and 2,144 amino acid residues) with the amino-terminal portion of B-100 and contains no sequence from the carboxyl end of B-100. From structural studies, it is thought that apoB-48 represents the amino-terminal 47% of apoB-100 and that the carboxyl terminus of apoB-48 is in the vicinity of residue 2151 of apoB-100.
25 Apolipoprotein B-48 may be the product of an intestinal mRNA with an in-frame UAA stop codon resulting from a C-to-U change in the codon CAA encoding Gln(2153) in apoB-100 mRNA. Since only the sequence that codes B-100 is present in genomic DNA, this presents the possibility of an organ-specific introduction of a stop codon to an mRNA and the change from CAA to UAA of codon 2153 of the
30 message as a unique RNA editing process..

APXL: apical protein-like (*Xenopus laevis*)

The protein encoded by this gene shares significant similarities with the apical protein from *Xenopus laevis* which is implicated in amiloride-sensitive sodium channel activity. This gene is a strong candidate gene for ocular albinism type 1 syndrome.

ARF4: ADP-ribosylation factor 4

ADP-ribosylation factor 4 (ARF4) is a member of the human ARF gene family. These genes encode small guanine nucleotide-binding proteins that stimulate the ADP-ribosyltransferase activity of cholera toxin and play a role in vesicular trafficking and as activators of phospholipase D. The gene products include 6 ARF proteins and 11 ARF-like proteins and constitute 1 family of the RAS superfamily. The ARF proteins are categorized as class I (ARF1, ARF2, and ARF3), class II (ARF4 and ARF5) and class III (ARF6). The members of each class share a common gene organization. The ARF4 gene spans approximately 12kb and contains six exons and five introns. The ARF4 is the most divergent member of the human ARFs. Conflicting Map positions at 3p14 or 3p21 have been reported for this gene.

ATP1A2: ATPase, Na⁺/K⁺ transporting, alpha 2 (+) polypeptide

Alpha 2 subunit of the sodium- and potassium-transporting ATPase; required for Na⁺ and K⁺ gradient maintenance across plasma membrane.

ATP1B1: ATPase, Na⁺/K⁺ transporting, beta 1 polypeptide

Beta 1 subunit of Na⁺/K⁺-ATPase.

ATP1B3: ATPase, Na⁺/K⁺ transporting, beta 3 polypeptide

Beta 3 subunit of the Na⁺/K⁺ -ATPase.

ATP2A2: ATPase, Ca⁺⁺ transporting, cardiac muscle, slow twitch 2

Slow twitch cardiac muscle Ca²⁺-ATPase; pumps calcium, may have a role in calcium signaling pathways.

5 **ATP5G1: ATP synthase, H⁺ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1**

Isoform 1 (P1) of subunit c, H⁺-translocating subunit of F0 ATP synthase; catalyzes the synthesis of ATP during oxidative phosphorylation.

10

ATP6V1E: ATPase, H⁺ transporting, lysosomal 31kD, V1 subunit E

This gene encodes a component of vacuolar ATPase (V-ATPase), a multisubunit enzyme that mediates acidification of eukaryotic intracellular organelles. V-ATPase dependent organelle acidification is necessary for such intracellular processes as protein sorting, zymogen activation, and receptor-mediated endocytosis. V-ATPase is comprised of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain consists of a hexamer of three A and three B subunits plus the C, D, and E subunits. It contains the ATP catalytic site. The encoded protein is known as the E subunit and is found ubiquitously. Pseudogenes for this gene have been found in the genome.

15

20

ATPase, Ca⁺⁺ transporting, cardiac muscle, fast twitch 1

25

Fast-twitch skeletal muscle sarcoplasmic reticulum Ca²⁺-ATPase; pumps calcium.

AXIN1: axin

Strongly similar to murine Axin; may regulate embryonic axis formation.

30

BMPR1A: bone morphogenetic protein receptor, type IA

The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.

BRD3: bromodomain containing 3

This gene was identified based on its homology to the gene encoding the RING3 protein, a serine/threonine kinase. The gene localizes to 9q34, a region which contains several major histocompatibility complex (MHC) genes. The function of the encoded protein is not known.

CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit

Alpha 1C subunit of the voltage-dependent calcium channel; channel is of the L type and is expressed in the heart.

CALB2: calbindin 2, (29kD, calretinin)

Calbindin 2 (calretinin), closely related to calbindin 1, is an intracellular calcium-binding protein belonging to the troponin C superfamily. Calbindin 1 is known to be involved in the vitamin-D-dependent calcium absorption through intestinal and renal epithelia, while the function of neuronal calbindin 1 and calbindin 2 is poorly

understood. The sequence of the calbindin 2 cDNA reveals an open reading frame of 271 codons coding for a protein of 31,520 Da, and shares 58% identical residues with human calbindin 1. Calbindin 2 contains five presumably active and one presumably inactive calcium-binding domains. Comparison with the partial sequences available for chick and guinea pig calbindin 2 reveals that the protein is highly conserved in evolution. The calbindin 2 message was detected in the brain, while absent from heart muscle, kidney, liver, lung, spleen, stomach and thyroid gland. There are two additional forms of alternatively spliced calbindin 2 mRNAs encoding C-terminally truncated proteins. Exon 7 can splice to exon 9, resulting in a frame shift and a translational stop at the second codon of exon 9, and encoding calretinin-20k. Exon 7 can also splice to exon 10, resulting in a frame shift and a translational stop at codon 15 of exon 10, and encoding calretinin-22k. The truncated proteins are able to bind calcium.

CALCIUM-TRANSPORTING ATPASE PLASMA MEMBRANE, ISOFORMS 3A/3B (EC 3.6.1.38) (CALCIUM PUMP) (PMCA3).

Plasma membrane Ca^{2+} -ATPase 3; pumps calcium.

CALM3: calmodulin 3 (phosphorylase kinase, delta).

Calmodulin 3; binds calcium.

CAV1: caveolin 1, caveolae protein, 22kD

The scaffolding protein encoded by this gene is the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 MAP kinase cascade. CAV1 and CAV2 are located next to each other on chromosome 7 and express colocalizing

proteins that form a stable hetero-oligomeric complex. By using alternative initiation codons in the same reading frame, two isoforms (alpha and beta) are encoded by a single transcript from this gene.

5 **CAV3: caveolin 3**

10 This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C); hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, 15 transcripts utilize multiple polyA sites and contain two potential translation initiation sites.

CCR2: chemokine (C-C motif) receptor 2

20 This gene encodes two isoforms of a receptor for monocyte chemoattractant protein-1, a chemokine which specifically mediates monocyte chemotaxis. Monocyte chemoattractant protein-1 is involved in monocyte infiltration in inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response against tumors. The receptors encoded by this gene mediate agonist-dependent calcium 25 mobilization and inhibition of adenylyl cyclase. This gene is located in the chemokine receptor gene cluster region. Two alternatively spliced transcript variants are expressed by the gene.

CDH1: cadherin 1, type 1, E-cadherin (epithelial)

This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular
5 cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein
mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is
10 required for internalization. Identified transcript variants arise from mutation at consensus splice sites.

CDH11: cadherin 11, type 2, OB-cadherin (osteoblast)

15 This gene encodes a type II classical cadherin from the cadherin superfamily, integral membrane proteins that mediate calcium-dependent cell-cell adhesion. Mature cadherin proteins are composed of a large N-terminal extracellular domain, a single membrane-spanning domain, and a small, highly conserved C-terminal cytoplasmic domain. Type II (atypical) cadherins are defined based on their lack of a HAV cell
20 adhesion recognition sequence specific to type I cadherins. Expression of this particular cadherin in osteoblastic cell lines, and its upregulation during differentiation, suggests a specific function in bone development and maintenance. Two splice variants have been identified, one of which encodes an isoform with a truncated cytoplasmic domain.

25

CDH13: cadherin 13, H-cadherin (heart)

This gene is a member of the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin
30 repeats, a transmembrane region but, unlike the typical cadherin superfamily member, lacks the highly conserved cytoplasmic region. This particular cadherin is a

putative mediator of cell-cell interaction in the heart and may act as a negative regulator of neural cell growth. The gene locus is hypermethylated or deleted in breast, ovarian and lung cancers. Two major mRNA transcripts encoding identical proteins are found, products of alternative polyadenylation sites.

5

CENPC1: centromere protein C 1

Centromere protein C 1 is a centromere autoantigen and a component of the inner kinetochore plate. The protein is required for maintaining proper kinetochore size and a timely transition to anaphase. A putative pseudogene exists on chromosome 12.

10

Cholesteryl ester transfer protein (CETP)

Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters between lipoproteins. CETP may effect susceptibility to atherosclerosis.

15

CLCN4: chloride channel 4

The CLCN family of voltage-dependent chloride channel genes comprises nine members (CLCN1-7, Ka and Kb) which demonstrate quite diverse functional characteristics while sharing significant sequence homology. Chloride channel 4 has an evolutionary conserved CpG island and is conserved in both mouse and hamster. This gene is mapped in close proximity to APXL (Apical protein *Xenopus laevis*-like) and OA1 (Ocular albinism type I), which are both located on the human X chromosome at band p22.3. The physiological role of chloride channel 4 remains unknown but may contribute to the pathogenesis of neuronal disorders.

20

25

CLCNKA: chloride channel Ka

Putative chloride channel; member of the CLC family of voltage-gated chloride channels.

30

COL6A3: collagen, type VI, alpha 3

5 This gene encodes the alpha 3 chain, one of the three alpha chains of type VI collagen, a beaded filament collagen found in most connective tissues. The alpha 3 chain of type VI collagen is much larger than the alpha 1 and 2 chains. This difference in size is largely due to an increase in the number of subdomains, similar to von Willebrand Factor type A domains, found in the amino terminal globular domain of all the alpha chains. These domains have been shown to bind extracellular matrix proteins, an interaction that explains the importance of this collagen in organizing matrix components. Mutations in the type VI collagen genes are associated with Bethlem myopathy. In addition to the full length transcript, four transcript variants have been identified that encode proteins with N-terminal globular domains of varying sizes.

15

COL7A1: collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)

20 This gene encodes the alpha chain of type VII collagen. The type VII collagen fibril, composed of three identical alpha collagen chains, is restricted to the basement zone beneath stratified squamous epithelia. It functions as an anchoring fibril between the external epithelia and the underlying stroma. Mutations in this gene are associated with all forms of dystrophic epidermolysis bullosa. In the absence of mutations, however, an acquired form of this disease can result from an autoimmune response made to type VII collagen.

25

COL9A3: collagen, type IX, alpha 3

30 This gene encodes one of the three alpha chains of type IX collagen, the major collagen component of hyaline cartilage. Type IX collagen, a heterotrimeric

molecule, is usually found in tissues containing type II collagen, a fibrillar collagen. Mutations in this gene are associated with multiple epiphyseal dysplasia.

COMT: catechol-O-methyltransferase

5

Catechol-O-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine. This O-methylation results in one of the major degradative pathways of the catecholamine transmitters. In addition to its role in the metabolism of endogenous substances, COMT is important in the metabolism of catechol drugs used in the treatment of hypertension, asthma, and Parkinson disease. COMT is found in two forms in tissues, a soluble form (S-COMT) and a membrane-bound form (MB-COMT). The differences between S-COMT and MB-COMT reside within the N-termini. The transcript variants are formed through the use of alternative translation initiation sites and promoters.

10

15

COX10: COX10 homolog, cytochrome c oxidase assembly protein, heme A:farnesyltransferase (yeast)

20

Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain, catalyzes the electron transfer from reduced cytochrome c to oxygen. This component is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, and the nuclear-encoded subunits may function in the regulation and assembly of the complex. This nuclear gene encodes heme A:farnesyltransferase, which is not a structural subunit but required for the expression of functional COX and functions in the maturation of the heme A prosthetic group of COX. This protein is predicted to contain 7-9 transmembrane domains localized in the mitochondrial inner membrane. A gene mutation, which results in the substitution of a lysine for an asparagine (N204K), is identified to be responsible for cytochrome c oxidase deficiency. In

25

30

addition, this gene is disrupted in patients with CMT1A (Charcot-Marie-Tooth type 1A) duplication and with HNPP (hereditary neuropathy with liability to pressure palsies) deletion.

5 **CPB2: carboxypeptidase B2 (plasma, carboxypeptidase U)**

Carboxypeptidases are enzymes that hydrolyze C-terminal peptide bonds. The carboxypeptidase family includes metallo-, serine, and cysteine carboxypeptidases. According to their substrate specificity, these enzymes are referred to as
 10 carboxypeptidase A (cleaving aliphatic residues) or carboxypeptidase B (cleaving basic amino residues). The protein encoded by this gene is activated by trypsin and acts on carboxypeptidase B substrates. After thrombin activation, the mature protein downregulates fibrinolysis. Polymorphisms have been described for this gene and its promoter region. Available sequence data analyses indicate splice variants that
 15 encode different isoforms.

CPO: coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin)

Coproporphyrinogen; catalyzes oxidative decarboxylation in sixth step of heme
 20 biosynthesis.

CRYAB: crystallin, alpha B

Crystallins are separated into two classes: taxon-specific, or enzyme, and ubiquitous.
 25 The latter class constitutes the major proteins of vertebrate eye lens and maintains the transparency and refractive index of the lens. Since lens central fiber cells lose their nuclei during development, these crystallins are made and then retained throughout life, making them extremely stable proteins. Mammalian lens crystallins are divided into alpha, beta, and gamma families; beta and gamma crystallins are also considered
 30 as a superfamily. Alpha and beta families are further divided into acidic and basic groups. Seven protein regions exist in crystallins: four homologous motifs, a

connecting peptide, and N- and C-terminal extensions. Alpha crystallins are composed of two gene products: alpha-A and alpha-B, for acidic and basic, respectively. Alpha crystallins can be induced by heat shock and are members of the small heat shock protein (sHSP also known as the HSP20) family. They act as molecular chaperones although they do not renature proteins and release them in the fashion of a true chaperone; instead they hold them in large soluble aggregates. Post-translational modifications decrease the ability to chaperone. These heterogeneous aggregates consist of 30-40 subunits; the alpha-A and alpha-B subunits have a 3:1 ratio, respectively. Two additional functions of alpha crystallins are an autokinase activity and participation in the intracellular architecture. Alpha-A and alpha-B gene products are differentially expressed; alpha-A is preferentially restricted to the lens and alpha-B is expressed widely in many tissues and organs. Elevated expression of alpha-B crystallin occurs in many neurological diseases; a missense mutation cosegregated in a family with a desmin-related myopathy..

CSF2RB: colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)

CSF2RB is a common beta chain of the high affinity receptor for IL-3, IL-5 and CSF. Defective CSF2RB has been reported to be associated with protein alveolar proteinosis.

CUBN: cubilin (intrinsic factor-cobalamin receptor)

Cubilin (CUBN) acts as a receptor for intrinsic factor-vitamin B12 complexes. The role of receptor is supported by the presence of 27 CUB domains. Cubilin is located within the epithelium of intestine and kidney. Mutations in CUBN may play a role in autosomal recessive megaloblastic anemia.

CXorf6: chromosome X open reading frame 6

CYP17: cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia

5 This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. It has both 17alpha-hydroxylase and 17,20-lyase activities and is a key enzyme in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. 10 Mutations in this gene are associated with isolated steroid-17 alpha-hydroxylase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, and adrenal hyperplasia.

15 **CYP2C8: cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8**

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. 20 This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize many xenobiotics; including the anticonvulsive drug mephenytoin, benzo(a)pyrene, 7-ethoxycoumarin, and the anti-cancer drug taxol. Two transcript variants for this gene have been described; it is thought that the longer form does not encode an active cytochrome P450 since its 25 protein product lacks the heme binding site. This gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

CYP2E: cytochrome P450, subfamily IIE (ethanol-inducible)

30 This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions

involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is induced by ethanol, the diabetic state, and starvation. The enzyme metabolizes both endogenous substrates, such as ethanol, acetone, and acetal, as well as exogenous substrates including benzene, carbon tetrachloride, ethylene glycol, and nitrosamines which are premutagens found in cigarette smoke. Due to its many substrates, this enzyme may be involved in such varied processes as gluconeogenesis, hepatic cirrhosis, diabetes, and cancer.

CYP3A4

This gene, CYP3A4, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. This enzyme is involved in the metabolism of approximately half the drugs which are used today, including acetaminophen, codeine, cyclosporin A, diazepam and erythromycin. The enzyme also metabolizes some steroids and carcinogens. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.

CYP4F8: cytochrome P450, subfamily IVF, polypeptide 8

This gene, CYP4F8, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and functions as a 19-hydroxylase of prostaglandins in seminal vesicles. This gene is part of a cluster of

cytochrome P450 genes on chromosome 19. Another member of this family, CYP4F3, is approximately 18 kb away.

CYP8B1: cytochrome P450, subfamily VIII B (sterol 12- α -hydroxylase), polypeptide 1

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids.

This endoplasmic reticulum membrane protein catalyzes the conversion of 7- α -hydroxy-4-cholesten-3-one into 7- α ,12- α -dihydroxy-4-cholesten-3-one. The balance between these two steroids determines the relative amounts of cholic acid and chenodeoxycholic acid both of which are secreted in the bile and affect the solubility of cholesterol. This gene is unique among the cytochrome P450 genes in that it is intronless.

DBI: diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A binding protein)

Diazepam binding inhibitor (acyl-CoA-binding protein); binds and induces medium-chain acyl-CoA ester synthesis.

DEFA6: defensin, alpha 6, Paneth cell-specific

Defensins are a family of microbicidal and cytotoxic peptides thought to be involved in host defense. They are abundant in the granules of neutrophils and also found in the epithelia of mucosal surfaces such as those of the intestine, respiratory tract, urinary tract, and vagina. Members of the defensin family are highly similar in protein sequence and distinguished by a conserved cysteine motif. Several alpha defensin genes appear to be clustered on chromosome 8. The protein encoded by this

gene, defensin, alpha 6, is highly expressed in the secretory granules of Paneth cells of the small intestine, and likely plays a role in host defense of human bowel.

DEK: DEK oncogene (DNA binding)

5

Site-specific DNA binding protein; involved in transcriptional regulation and signal transduction.

DFNA5: deafness, autosomal dominant 5

10

Hearing impairment is a heterogeneous condition with over 40 loci described. The protein encoded by this gene is expressed in fetal cochlea, however, its function is not known. Nonsyndromic hearing impairment is associated with a mutation in this gene.

15

DGKD: diacylglycerol kinase, delta (130kD)

Diacylglycerol kinase delta; phosphorylates the arachidonoyl type of diacylglycerol; contains a pleckstrin homology domain and an EPH domain.

20

DOCK1: dedicator of cyto-kinesis 1

Dedicator of cyto-kinesis 1 binds to the SH3 domain of CRK protein. It may regulate cell surface extension and may have a role in the cell surface extension of an engulfing cell around a dying cell during apoptosis.

25

ECE1: endothelin converting enzyme 1

Endothelin converting enzyme; metalloprotease that regulates a peptide involved in vasoconstriction.

30

E-Selectin (CD62E)

The endothelial leukocyte adhesion molecule-1 is expressed by cytokine-stimulated endothelial cells. It is thought to be responsible for the accumulation of blood leukocytes at sites of inflammation by mediating the adhesion of cells to the vascular lining. It exhibits structural features such as the presence of lectin- and EGF-like domains followed by short consensus repeat (SCR) domains that contain 6 conserved cysteine residues. These proteins are part of the selectin family of cell adhesion molecules. This gene is present in single copy in the human genome and contains 14 exons spanning about 13 kb of DNA. Adhesion molecules participate in the interaction between leukocytes and the endothelium and appear to be involved in the pathogenesis of atherosclerosis.

ESR1: estrogen receptor 1

Estrogen receptor; nuclear receptor transcription factor activated by ligand-binding, involved in hormone-mediated inhibition of gene expression.

ESR2: estrogen receptor 2 (ER beta)

Estrogen receptor beta 2; transcriptional activator involved in regulation of reproduction; exists in five isoforms.

F2: coagulation factor II (thrombin)

Coagulation factor II is proteolytically cleaved to form thrombin in the first step of the coagulation cascade which ultimately results in the stemming of blood loss. F2 also plays a role in maintaining vascular integrity during development and postnatal life. Mutations in F2 leads to various forms of thrombosis and dysprothrombinemia.

F3: coagulation factor III (thromboplastin, tissue factor)

5 This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described.

F5: coagulation factor V (proaccelerin, labile factor)

15 This gene encodes coagulation factor V which is an essential factor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The active factor V is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. Defects in this gene result in either an autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance.

F7: coagulation factor VII (serum prothrombin conversion accelerator)

25 This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and

calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Alternative splicing of this gene results in 2 transcripts. Defects in this gene can cause coagulopathy.

5 **F9: coagulation factor IX (plasma thromboplastic component, Christmas disease, hemophilia B)**

This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor
10 XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca⁺² ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX
15 deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease.

20 **FABP3: fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor)**

The intracellular fatty acid-binding proteins (FABPs) belongs to a multigene family. FABPs are divided into at least three distinct types, namely the hepatic-, intestinal- and cardiac-type. They form 14-15 kDa proteins and are thought to participate in the uptake; intracellular metabolism and/or transport of long-chain fatty acids. They may
25 also be responsible in the modulation of cell growth and proliferation. Fatty acid-binding protein 3 gene contains four exons and its function is to arrest growth of mammary epithelial cells. This gene is a candidate tumor suppressor gene for human breast cancer.

FACL3: fatty-acid-Coenzyme A ligase, long-chain 3

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme is highly expressed in brain, and preferentially utilizes myristate, arachidonate, and eicosapentaenoate as substrates. The amino acid sequence of this isozyme is 92% identical to that of rat homolog.

FACL4: fatty-acid-Coenzyme A ligase, long-chain 4

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme preferentially utilizes arachidonate as substrate. The absence of this enzyme may contribute to the mental retardation or Alport syndrome. Alternative splicing of this gene generates 2 transcript variants.

FMO1: flavin containing monooxygenase 1

Metabolic N-oxidation of the diet-derived amino-trimethylamine (TMA) is mediated by flavin-containing monooxygenase and is subject to an inherited FMO3 polymorphism in man resulting in a small subpopulation with reduced TMA N-oxidation capacity resulting in fish odor syndrome Trimethylaminuria. Three forms of the enzyme, FMO1 found in fetal liver, FMO2 found in adult liver, and FMO3 are encoded by genes clustered in the 1q23-q25 region. Flavin-containing

monooxygenases are NADPH-dependent flavoenzymes that catalyzes the oxidation of soft nucleophilic heteroatom centers in drugs, pesticides, and xenobiotics.

GAA: glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II)

5

This gene encodes acid alpha-glucosidase, which is essential for the degradation of glycogen to glucose in lysosomes. Different forms of acid alpha-glucosidase are obtained by proteolytic processing. Defects in this gene are the cause of glycogen storage disease II, also known as Pompe's disease, which is an autosomal recessive disorder with a broad clinical spectrum.

10

GAPD: glyceraldehyde-3-phosphate dehydrogenase

Glyceraldehyde-3-phosphate dehydrogenase catalyzes an important energy-yielding step in carbohydrate metabolism, the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD). The enzyme exists as a tetramer of identical chains. A GAPD pseudogene has been mapped to Xp21-p11 and 15 GAPD-like loci have been identified.

15

20

GARS: glycyl-tRNA synthetase

Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. Glycyl-tRNA synthetase is an $(\alpha)_2$ dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis.

25

GBE1: glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV)

5 This monomeric enzyme functions in glycogen synthesis by catalyzing the formation of alpha 1,6- glucosidic linkages. It is most highly expressed in liver and muscle. Deficiency can result in glycogen storage disease IV (Andersen's disease).

GP6: glycoprotein VI (platelet)

10 Platelet glycoprotein VI; member of the paired Ig-like receptor family.

GPR-55

15 Member of the G protein-coupled receptor family.

GPRC5C: G protein-coupled receptor, family C, group 5, member C

20 The protein encoded by this gene is a member of the type 3 G protein-coupled receptor family. Members of this superfamily are characterized by a signature 7-transmembrane domain motif. The specific function of this protein is unknown; however, this protein may mediate the cellular effects of retinoic acid on the G protein signal transduction cascade. Alternative splicing in the 5' UTR of this gene results in two transcript variants.

25 **3-hydroxy-3-methylglutaryl coenzyme A synthase**

3-hydroxy-3-methylglutaryl-Coenzyme A synthase; functions in the first step in ketogenesis.

HK1: hexokinase 1

Hexokinases phosphorylate glucose to produce glucose-6-phosphate, thus committing glucose to the glycolytic pathway. This gene encodes a ubiquitous form of hexokinase which localizes to the outer membrane of mitochondria. Mutations in this gene have been associated with hemolytic anemia due to hexokinase deficiency. Alternative splicing of this gene results in five transcript variants which encode different isoforms, some of which are tissue-specific. Each isoform has a distinct N-terminus; the remainder of the protein is identical among all the isoforms. A sixth transcript variant has been described, but due to the presence of several stop codons, it is not thought to encode a protein.

HLA-B associated transcript 3 (BAT3)

A cluster of genes, BAT1-BAT5, has been localized in the vicinity of the genes for TNF alpha and TNF beta. These genes are all within the human major histocompatibility complex class III region. The protein encoded by this gene is a nuclear protein. It has been implicated in the control of apoptosis and regulating heat shock protein. There are three alternatively spliced transcript variants described for this gene.

HMGCL: 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase (hydroxymethylglutaricaciduria)

3-Hydroxy-3-methylglutaryl coenzyme A lyase; cleaves 3-OH-3-methylglutaryl CoA to acetoacetic acid and acetyl CoA.

HNF4A: hepatocyte nuclear factor 4, alpha

Nuclear hormone receptor transcription factor; regulates liver specific gene expression.

Chromosome 12 BAC RP11-13J12

Cathepsin B

5

Cathepsin B; lysosomal cysteine (thiol) protease that cleaves APP.

Chromosome 5 clone CTD-2235C13

10

Chromosome 7 clone RP11-351B12

Cytochrome P450 3A locus

15

The CYP3A locus includes all the known members of the 3A subfamily of the cytochrome P450 superfamily of genes. These genes encode monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The CYP3A cluster consists of four genes, CYP3A43, CYP3A4, CYP3A7 and CYP3A5. The region also contains two pseudogenes, CYP3A5P1 and CYP3A5P2, as well as several extra exons which may or may not be included in transcripts produced from this region. Previously another CYP3A member, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.

20

25

ITGB3

30

The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling.

Methionine adenosyltransferase alpha subunit gene fragment.

5 MAT1A encodes methionine adenosyltransferase I (alpha isoform). MATIA catalyzes the formation of S-adenosylmethionine from methionine and ATP. Both the beta and alpha isoforms may be encoded by MATIA. Methionine adenosyltransferase deficiency is known to be caused by recessive as well as dominant mutations, the latter identified in autosomal dominant persistent hyper-methioninemia.

10

Homo sapiens PAC clone RP1-102K2 from 22q12.1-qter

Homo sapiens partial ZNF202 gene for zinc finger protein homolog, exon 4

15 Zinc-finger protein 202 may repress genes involved in lipid metabolism; contains zinc fingers.

Homo sapiens vHNF1-C mRNA

Hepatocyte Nuclear Factor 1.

20

Human 2.5 kb mRNA for cytoskeletal tropomyosin TM30(nm)

Human c-kit gene.

25 KIT encodes the human homolog of the proto-oncogene c-kit. C-kit was first identified as the cellular homolog of the feline sarcoma viral oncogene v-kit. KIT is a type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor). Mutations in KIT are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism.

30

Human coagulation factor VII (F7) gene exon 1 and factor X (F10) gene, exon 1.

This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Alternative splicing of this gene results in 2 transcripts. Defects in this gene can cause coagulopathy.

Human cytochrome P450 (CYP1A2) gene, exons 1 and 2.

This gene, CYP1A2, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The protein encoded by this gene localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. Other xenobiotic substrates for this enzyme include caffeine, aflatoxin B1, and acetaminophen. The transcript from this gene contains four Alu sequences flanked by direct repeats in the 3' untranslated region. A related family member, CYP1A1, is located approximately 25 kb away from CYP1A2 on chromosome .

Human multidrug resistance-associated protein mRNA

See ABCC1.

Human succinyl CoA:3-oxoacid CoA transferase precursor (OXCT) mRNA

5 The mitochondrial matrix enzyme 3-oxoacid CoA transferase is homodimeric. It is a key enzyme in the extrahepatic utilization of ketone bodies, catalyzing the reversible transfer of coenzyme A from succinyl-CoA to acetoacetate, a necessary step in ketolytic energy production. Deficiencies can result in intermittent ketoacidosis.

Human T-lymphoma invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA

10 Member of the GDP-GTP exchange factor family of proteins; modulates the activity of Rho-like proteins; has a Dbl homology and pleckstrin homology domains.

IL10: interleukin 10

15 Interleukin 10 (cytokine synthesis inhibitory factor); functions as a specific chemotactic factor for CD8+T cells.

IL17R: interleukin 17 receptor

20 Highly similar to murine Il17r; may play a role in T cell activation and induction of IL-2 (Il2).

IL3: interleukin 3 (colony-stimulating factor, multiple)

25 Interleukin-3 (colony-stimulating factor); plays a role in hematopoiesis; member of a family of growth factors.

IL6: interleukin 6 (interferon, beta 2)

Interleukin 6 (interferon-beta 2); induces the maturation of B cells into immunoglobulin-secreting cells.

5

IL8RA: interleukin 8 receptor, alpha

Interleukin 8 receptor alpha; G protein-coupled receptor that mediates neutrophil chemotaxis and binds interleukin 8 (IL8).

10

INHBC: inhibin, beta C

This gene encodes the beta C chain of inhibin, a member of the TGF-beta superfamily. This subunit forms heterodimers with beta A and beta B subunits.

15

Inhibins and activins, also members of the TGF-beta superfamily, are hormones with opposing actions and are involved in hypothalamic, pituitary, and gonadal hormone secretion, as well as growth and differentiation of various cell types.

20

ITGAL: integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)

ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling.

25

ITGB2: integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit)

The ITGB2 protein product is the integrin beta chain beta 2. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. For example, beta 2 combines with the alpha L chain to form the integrin LFA-1, and combines with the alpha M chain to form the integrin Mac-1. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling.

KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1

KCNQ1 encodes the K⁺ channel subunit responsible for the delayed-rectifier K⁺ current in cardiac myocytes. The delayed-rectifier channel is completed by the protein encoded by KCNE1. Mutations in KCNQ1 cause inherited long-QT syndrome.

LAMA3: laminin, alpha 3 (nicein (150kD), kalinin (165kD), BM600 (150kD), epilegrin)

Laminins are basement membrane components thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components. The protein encoded by this gene is the alpha-3 chain of laminin 5, which is a complex glycoprotein composed of three subunits (alpha, beta, and gamma). Laminin 5 is thought to be involved in cell adhesion, signal transduction and differentiation of keratinocytes. Mutations in this gene have been identified as the cause of Herlitz type junctional epidermolysis bullosa. Alternative splicing has been observed at this locus but the full-length nature of these variants has not been determined.

LAMR1: laminin receptor 1 (67kD, ribosomal protein SA)

Laminins, a family of extracellular matrix glycoproteins, are the major non-collagenous constituent of basement membranes. They have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and metastasis. Many of the effects of laminin are mediated through interactions with cell surface receptors. These receptors include members of the integrin family, as well as non-integrin laminin-binding proteins. This gene encodes a high-affinity, non-integrin family, laminin receptor 1. This receptor has been variously called 67 kD laminin receptor, 37 kD laminin receptor precursor (37LRP) and p40 ribosome-associated protein. The amino acid sequence of laminin receptor 1 is highly conserved through evolution, suggesting a key biological function. It has been observed that the level of the laminin receptor transcript is higher in colon carcinoma tissue and lung cancer cell line than their normal counterparts. Also, there is a correlation between the upregulation of this polypeptide in cancer cells and their invasive and metastatic phenotype. Multiple copies of this gene exist, however, most of them are pseudogenes thought to have arisen from retropositional events..

LDLR: low density lipoprotein receptor (familial hypercholesterolemia)

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in the LDL receptor (LDLR) gene cause the autosomal dominant disorder, familial hypercholesterolemia.

LGALS7: lectin, galactoside-binding, soluble, 7 (galectin 7)

The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. Differential and in situ hybridizations indicate that this lectin is specifically expressed in keratinocytes. It is expressed at all stages of epidermal differentiation (i.e., in basal and suprabasal layers). It is moderately repressed by retinoic acid. The protein was found mainly in stratified squamous epithelium. The antigen localized to basal keratinocytes, although it was also found, albeit at lower levels, in the suprabasal layers where it concentrated to areas of cell-to-cell contact. The cellular localization and its striking down-regulation in cultured keratinocytes imply a role in cell-cell and/or cell-matrix interactions necessary for normal growth control.

LIMK1: LIM domain kinase 1

There are approximately 40 known eukaryotic LIM proteins, so named for the LIM domains they contain. LIM domains are highly conserved cysteine-rich structures containing 2 zinc fingers. Although zinc fingers usually function by binding to DNA or RNA, the LIM motif probably mediates protein-protein interactions. LIM kinase-1 and LIM kinase-2 belong to a small subfamily with a unique combination of 2 N-terminal LIM motifs and a C-terminal protein kinase domain. LIMK1 is likely to be a component of an intracellular signaling pathway and may be involved in brain development. LIMK1 hemizyosity is implicated in the impaired visuospatial constructive cognition of Williams syndrome. Two splice variants have been identified.

LMNB2: lamin B2

Lamin B2; member of a family of structural nuclear envelope proteins.

LPL: lipoprotein lipase

LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride
5 hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.

10 **LRP8: low density lipoprotein receptor-related protein 8, apolipoprotein E receptor**

This gene encodes an apolipoprotein E receptor, a member of the low density lipoprotein receptor (LDLR) family. Apolipoprotein E is a small lipophilic plasma
15 protein and a component of lipoproteins such as chylomicron remnants, very low density lipoprotein (VLDL), and high density lipoprotein (HDL). The apolipoprotein E receptor is involved in cellular recognition and internalization of these lipoproteins. Alternative splicing generates three transcript variants for this gene; additional variants have been described, but their full length nature has not been determined.

20 **LSS: lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)**

Lanosterol synthase ((S)-2,3-epoxysqualene mutase); catalyzes the cyclization of (S)-2,3-oxidosqualene; forms lanosterol during sterol biosynthesis.

25 **LTA: lymphotoxin alpha (TNF superfamily, member 1)**

Lymphotoxin alpha, a member of the tumor necrosis factor family, is a cytokine produced by lymphocytes. LTA is highly inducible, secreted, and exists as
30 homotrimeric molecule. LTA forms heterotrimers with lymphotoxin-beta which anchors lymphotoxin-alpha to the cell surface. LTA mediates a large variety of inflammatory, immunostimulatory, and antiviral responses. LTA is also involved in

the formation of secondary lymphoid organs during development and plays a role in apoptosis.

MAOA: monoamine oxidase A

5

MAOA encodes monoamine oxidase A, an enzyme that degrades amine neurotransmitters, such as dopamine, norepinephrine, and serotonin. Deficiency of this enzyme results in Brunner syndrome.

10 **MARCKS: myristoylated alanine-rich protein kinase C substrate**

The protein encoded by this gene is a substrate for protein kinase C. It is localized to the plasma membrane and is an actin filament crosslinking protein. Phosphorylation by protein kinase C or binding to calcium-calmodulin inhibits its association with
15 actin and with the plasma membrane, leading to its presence in the cytoplasm. The protein is thought to be involved in cell motility, phagocytosis, membrane trafficking and mitogenesis.

MCL1: myeloid cell leukemia sequence 1 (BCL2-related)

20

Similar to BCL2.

MCP: membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen)

25

Membrane cofactor protein; acts as the receptor for the measles virus, may be involved in the regulation of complement activation; contains SCRs.

METTL1: methyltransferase-like 1

This gene is an ortholog of the *S. cerevisiae* YDL201w gene, which is predicted to encode a methyltransferase. The gene product contains a conserved S-adenosyl-methionine-binding motif, which is typical of a methyltransferase. Alternative splice variants encoding different protein isoforms and transcript variants utilizing alternative polyA sites have been described in the literature.

MLLT3: myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, *Drosophila*);

Serine and proline rich protein, has a nuclear targeting sequence.

MTHFD1: methylenetetrahydrofolate dehydrogenase (NADP+ dependent), methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase

This gene encodes a protein that possesses three distinct enzymatic activities, 5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase and 10-formyltetrahydrofolate synthetase. Each of these activities catalyzes one of three sequential reactions in the interconversion of 1-carbon derivatives of tetrahydrofolate, which are substrates for methionine, thymidylate, and de novo purine syntheses. The trifunctional enzymatic activities are conferred by two major domains, an aminoterminal portion containing the dehydrogenase and cyclohydrolase activities and a larger synthetase domain.

MTMR2 myotubularin related protein 2 (MTMR2)

This gene is a member of the myotubularin family and encodes a putative tyrosine phosphatase. Mutations in this gene are a cause of Charcot-Marie-Tooth disease type 4B, an autosomal recessive demyelinating neuropathy. This gene utilizes multiple polyA signals, only one of which has been determined.

Muscle specific serine kinase (MSSK1; serine/threonine kinase 23, STK23),

Highly similar to SRPK2; may be protein kinase for SR family of RNA splicing factors; contains a kinase domain...

MVD: mevalonate (diphospho) decarboxylase

The enzyme mevalonate pyrophosphate decarboxylase catalyzes the conversion of mevalonate pyrophosphate into isopentenyl pyrophosphate in one of the early steps in cholesterol biosynthesis. It decarboxylates and dehydrates its substrate while hydrolyzing ATP.

MYH11: myosin, heavy polypeptide 11, smooth muscle

The protein encoded by this gene is a smooth muscle myosin belonging to the myosin heavy chain family. The gene product is a subunit of a hexameric protein that consists of 2 heavy chain subunits and 2 pairs of non-identical light chain subunits. It functions as a major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP. The gene encoding a human ortholog of rat NUDE1 is transcribed from the reverse strand of MYH11 gene, and its 3' end overlaps with that of the latter. The pericentric inversion of chromosome 16 [inv(16)(p13q22)] produces a chimeric transcript consisting of the first 165 residues from the N terminus of core-binding factor beta in a fusion with the C-terminal portion of the smooth muscle myosin heavy chain. This chromosomal rearrangement

is associated with acute myeloid leukemia of the M4Eo subtype. Alternative splicing generates isoforms that are differentially expressed, with ratios changing during muscle cell maturation. Additional splice variants have been described but their full-length nature has not been determined..

5

MYH7: myosin, heavy polypeptide 7, cardiac muscle, beta

MYH7 encodes the cardiac muscle beta (or slow) isoform of myosin. Changes in the relative abundance of MYH7 and MYH6 (the alpha, or fast, isoform of cardiac myosin heavy chain) correlate with the contractile velocity of cardiac muscle. Mutations in MYH7 are associated with familial hypertrophic cardiomyopathy.

10

**NADH dehydrogenase (ubiquinone) 1, alpha subcomplex, 4 (9kD, MLRQ),
NDUFA4**

15

Subunit of NADH-ubiquinone oxidoreductase (complex I); transports electrons from NADH to ubiquinone.

NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 5 (EC 1.6.5.3).

20

Subunit of NADH-ubiquinone oxidoreductase (complex I); transports electrons from NADH to ubiquinone.

NDUFA9: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 (39kD)

25

NGFB: nerve growth factor, beta polypeptide

Nerve growth factor beta; has roles in neuronal differentiation and survival.

NGFR: nerve growth factor receptor (TNFR superfamily, member 16)

Nerve growth factor receptor contains an extracellular domain containing four 40-amino acid repeats with 6 cysteine residues at conserved positions followed by a serine/threonine-rich region, a single transmembrane domain, and a 155-amino acid cytoplasmic domain. The cysteine-rich region contains the nerve growth factor binding domain.

NID2: nidogen 2

10

Nidogen-2; basement membrane protein,.

HSU15552: acidic 82 kDa protein mRNA

15

Nonmuscle type myosin heavy chain 9 (MYH9)

Non-muscle myosin heavy chain 9; motor protein that provides force for muscle contraction, cytokinesis and phagocytosis; contains an ATPase head domain and a rod-like tail domain.

20

NPC1: Niemann-Pick disease, type C1

NPC1 was identified as the gene that when mutated, results in Niemann-Pick C disease. NPC1 encodes a putative integral membrane protein containing motifs consistent with a role in intracellular transport of cholesterol to post-lysosomal destinations.

25

Nth endonuclease III-like 1 (NTHL1)

30

Endonuclease; excises damaged pyrimidines.

NUCB2: nucleobindin 2

Nucleobindin 2; may bind DNA and calcium; has DNA-binding and EF-hand domains, and a leucine-zipper.

5

nuclear receptor subfamily 1, group I, member 2 (NR1I2)

The gene product belongs to the nuclear receptor superfamily, members of which are transcription factors characterized by a ligand-binding domain and a DNA-binding domain. The encoded protein is a transcriptional regulator of the cytochrome P450 gene CYP3A4, binding to the response element of the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor RXR. It is activated by a range of compounds that induce CYP3A4, including dexamethasone and rifampicin. The gene product contains a zinc finger domain. Three alternatively spliced transcripts that encode different isoforms have been described, one of which encodes two products through the use of alternative translation initiation codons. Additional transcript variants derived from alternative promoter usage, alternative splicing, and/or alternative polyadenylation exist, but they have not been fully described.

10

15

20

OGDH: oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)

Alpha-ketoglutarate or 2-oxoglutarate dehydrogenase; helps convert a-ketoglutarate to succinyl coenzyme A in Krebs cycle.

25

OXCT: 3-oxoacid CoA transferase

The mitochondrial matrix enzyme 3-oxoacid CoA transferase is homodimeric. It is a key enzyme in the extrahepatic utilization of ketone bodies, catalyzing the reversible transfer of coenzyme A from succinyl-CoA to acetoacetate, a necessary step in ketolytic energy production. Deficiencies can result in intermittent ketoacidosis.

30

P2RY1: purinergic receptor P2Y, G-protein coupled, 1

Purinergic receptor P2Y1, a G protein-coupled receptor; mediates responses to ATP and increases inositol phosphate levels.

5

PCCA: propionyl Coenzyme A carboxylase, alpha polypeptide

PCCA encodes the alpha subunit of the heterodimeric mitochondrial enzyme Propionyl-CoA carboxylase. PCCA encodes the biotin-binding region of this enzyme. Mutations in either PCCA or PCCB (encoding the beta subunit) lead to an enzyme deficiency result in propionic acidemia.

10

PDGFB: platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)

15

The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for cells of mesenchymal origin and are characterized by a motif of eight cysteines. This gene product can exist either as a homodimer or as a heterodimer with the platelet-derived growth factor alpha polypeptide, where the dimers are connected by disulfide bonds. Mutations in this gene are associated with meningioma. Reciprocal translocations between chromosomes 22 and 7, at sites where this gene and that for COL1A1 are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans resulting from unregulated expression of growth factor. Two splice variants have been identified for this gene.

20

25

PERIOD CIRCADIAN PROTEIN 2 (KIAA0347)

This gene is a member of the Period family of genes and is expressed in a circadian pattern in the suprachiasmatic nucleus, the primary circadian pacemaker in the mammalian brain. Genes in this family encode components of the circadian rhythms

30

of locomotor activity, metabolism, and behavior. Circadian expression in the suprachiasmatic nucleus continues in constant darkness, and a shift in the light/dark cycle evokes a proportional shift of gene expression in the suprachiasmatic nucleus. The specific function of this gene is not yet known.

5

Peroxisome proliferative activated receptor, delta (PPARD)

Peroxisome proliferator-activated receptor delta is a member of the steroid hormone receptor superfamily.

10

PGM5: phosphoglucomutase 5

Phosphoglucomutase-related (aciculin) putative structural protein; interacts with the cytoskeletal proteins dystrophin and utrophin.

15

PLA2G3: phospholipase A2, group III

Group III secreted phospholipase A2; calcium-dependent, displays a preference for phosphatidylglycerol over phosphatidylcholine.

20

PLA2G4C: phospholipase A2, group IVC (cytosolic, calcium-independent)

Group IVC calcium-independent phospholipase a2; hydrolyzes the phospholipid sn-2 ester bond; member of the phospholipase family.

25

PLA2G6: phospholipase A2, group VI (cytosolic, calcium-independent)

Cytosolic calcium-independent phospholipase_a2; hydrolyzes the phospholipid sn-2 ester bond; member of the phospholipase family.

30

PMVK: phosphomevalonate kinase

Phosphomevalonate kinase; converts mevalonate-5-phosphate to mevalonate-5-diphosphate.

5

PNMT: phenylethanolamine N-methyltransferase

Phenylethanolamine N-methyltransferase; converts norepinephrine to epinephrine.

10 **PON1: paraoxonase 1**

PON2: paraoxonase 2

15

Paraoxonase/arylesterase 2; possibly functions in protecting low density lipoprotein against oxidative modification; member of a family that hydrolyzes toxic organophosphates.

PPARA: peroxisome proliferative activated receptor, alpha

20

Peroxisome proliferators are a diverse group of chemicals which include hypolipidemic drugs, herbicides, leukotriene antagonists, and plasticizers, and are so called because they induce an increase in the size and number of peroxisomes. Peroxisomes are subcellular organelles found in plants and animals, and contain enzymes for respiration, cholesterol and lipid metabolism. Infact, the fibrates class of hypolipidemic drugs is used to reduce triglycerides and cholesterol in patients with hyperlipidemia, a major risk factor for coronary heart disease. The action of peroxisome proliferators is thought to be mediated via specific receptors belonging to the steroid hormone receptor superfamily, called PPARs. Thus far, four closely related subtypes, alpha, beta, gamma and delta, have been identified. The subtype PPAR-alpha, encoded by PPARA, is a nuclear transcription factor. Upon activation

25

30

by peroxisome proliferators, it modulates the expression of target genes involved in lipid metabolism, suggesting a role for PPAR-alpha in lipid homeostasis..

PPARG: peroxisome proliferative activated receptor, gamma

5

The protein encoded by this gene is a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Multiple transcript variants that use alternate promoters and splicing have been identified for this gene. At least three of these variants encode the same isoform.

15

PPM1A: protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform

20

Magnesium- or manganese-dependent alpha protein phosphatase 1A; regulates cell stress responses.

PROBABLE G PROTEIN-COUPLED RECEPTOR APJ.

25

PTPRA: protein tyrosine phosphatase, receptor type, A

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus represents a

30

receptor-type PTP. This PTP has been shown to dephosphorylate and activate Src family tyrosine kinases, and is implicated in the regulation of integrin signaling, cell adhesion and proliferation. Three alternatively spliced variants of this gene, which encode two distinct isoforms, have been reported.

5

PYGM: phosphorylase, glycogen; muscle (McArdle syndrome, glycogen storage disease type V)

Muscle glycogen phosphorylase.

10

RTN1: reticulon 1

RXRA: retinoid X receptor, alpha

15

Retinoid X receptors (RXRs) and retinoic acid receptors (RARs), are nuclear receptors that mediate the biological effects of retinoids by their involvement in retinoic acid-mediated gene activation. These receptors exert their action by binding, as homodimers or heterodimers, to specific sequences in the promoters of target genes and regulating their transcription. The protein encoded by this gene is a member of the steroid and thyroid hormone receptor superfamily of transcriptional regulators.

20

RXRB: retinoid X receptor, beta

25

Retinoid X receptor beta; binds to and serves as transcriptional coactivator for retinoic acid.

SCA1: spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1)

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the 'pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. The SCA1 locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele. Several transcript variants of SCA1 in the 5' UTR have been described; however, their full-length nature is not known..

SDF1: stromal cell-derived factor 1

Stromal cell-derived factor 1; lymphocyte chemoattractant that signals through the receptor CXCR4.

SERPINA5: serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5

Protein C inhibitor (plasminogen activator inhibitor III); may be a serine protease inhibitor; member of the serpin family of serine protease inhibitors.

SERPINH1: serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1)

5 Colligin; collagen-binding protein; Similar to HSPs and to serpin family serine protease inhibitors.

SLC21A6: solute carrier family 21 (organic anion transporter), member 6

10 Organic anion transporter.

SLC27A1: solute carrier family 27 (fatty acid transporter), member 1

15 **SULT1A2: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2**
Phenol-metabolizing sulfotransferase 2; sulfonates simple planar phenols.

THBS3: Thrombospondin 3

Thrombospondin 3 binds heparin and calcium; similar to murine Thbs3

20 **TBP: TATA box binding protein**

TATA box binding protein, component of the TFIID complex; functions in the initiation of mRNA synthesis and basal transcription.

25 **TBXA2R: thromboxane A2 receptor**

Thromboxane A2 receptor (prostaglandin H2 receptor); G protein-coupled receptor, activates Ca²⁺-activated chloride channels; stimulates platelet aggregation and smooth muscle constriction.

TCF2: transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor

TCF2 encodes transcription factor 2, a liver-specific factor of the homeobox-containing basic helix-turn-helix family. The TCF2 protein is believed to form heterodimers with another liver-specific member of this transcription factor family, TCF1; depending on the TCF2 isoform, the result may be to activate or inhibit transcription of target genes. Mutation of TCF2 that disrupts normal function has been identified as the cause of MODY5 (Maturity-Onset of Diabetes, Type 5). A third human transcript variant is believed to exist based on such a variant in the rat; however, to date such an mRNA species has not been isolated.

TETTRAN: tetracycline transporter-like protein

Similar to E. coli tetracycline resistance efflux protein.

TGFB1: transforming growth factor, beta 1 (Camurati-Engelmann disease)

Transforming growth factor-beta 1; regulates cell proliferation, differentiation, and apoptosis.

TGFB2: transforming growth factor, beta 2

Transforming growth factor-beta 2 (glioblastoma-derived T cell suppressor factor); suppresses IL2 - dependent growth of T cells; member of a family of cytokines that transmits signals through transmembrane serine/threonine kinases.

TGFB3: transforming growth factor, beta 3

Transforming growth factor-beta 3; transmits signals through transmembrane serine/threonine kinases, may be required for normal development of the lung and palate; member of family of cytokines, very strongly similar to murine Tgfb3.

THPO: thrombopoietin (myeloproliferative leukemia virus oncogene ligand, megakaryocyte growth and development factor)

5 Thrombopoietin; binds to c-Mpl receptor and regulates megakaryocyte development.

TNFAIP2: tumor necrosis factor, alpha-induced protein 2

10 Secreted by vascular endothelium, expression is induced by tumor necrosis factor alpha, interleukin-1 beta, and lipopolysaccharide.

TRAP1: heat shock protein 75

15 Heat shock protein 75; binds and refolds denatured RB1 during M phase and after heat shock; member of the HSP90 family of molecular chaperones.

TRIP10: thyroid hormone receptor interactor 10

20 Similar to the non-kinase domains of FER and Fes/Fps tyrosine kinases; binds to activated Cdc42 and may regulate actin cytoskeleton; contains an SH3 domain.

TXN: thioredoxin

25 Thioredoxin; has dithiol-disulfide oxidoreductase activity.

USP6: ubiquitin specific protease 6 (Tre-2 oncogene)

30 Ubiquitin specific protease 6 (Tre-2 oncogene); cleaves ubiquitin from proteins, has predicted nucleic acid-binding properties.

UTRN: utr phin (homologous to dystrophin)

This gene shares both structural and functional similarities with the dystrophin gene. It contains an actin-binding N-terminus, a triple coiled-coil repeat central region, and a C-terminus that consists of protein-protein interaction motifs which interact with dystroglycan protein components. The protein encoded by this gene is located at the neuromuscular synapse and myotendinous junctions, where it participates in post-synaptic membrane maintenance and acetylcholine receptor clustering. Mouse studies suggest that this gene may serve as a functional substitute for the dystrophin gene and therefore, may serve as a potential therapeutic alternative to muscular dystrophy which caused by mutations in the dystrophin gene. Alternative splicing of the utrophin gene has been described; however, the full-length nature of these variants has not yet been determined.

15 VEGF: vascular endothelial growth factor

Vascular endothelial growth factor; induces endothelial cell proliferation and vascular permeability.

20 VEGFB: vascular endothelial growth factor B

Vascular endothelial growth factor B; involved in angiogenesis and endothelial cell growth.

25 WISP1: WNT1 inducible signaling pathway protein 1

This gene encodes a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth

factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. This gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. It is expressed at a high level in fibroblast cells, and overexpressed in colon tumors. The encoded protein binds to decorin and biglycan, two members of a family of small leucine-rich proteoglycans present in the extracellular matrix of connective tissue, and possibly prevents the inhibitory activity of decorin and biglycan in tumor cell proliferation. It also attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. It is 83% identical to the mouse protein at the amino acid level. Alternative splicing of this gene generates 2 transcript variants..

XDH: xanthine dehydrogenase

Xanthine dehydrogenase belongs to the group of molybdenum-containing hydroxylases involved in the oxidative metabolism of purines. The enzyme is a homodimer. Xanthine dehydrogenase can be converted to xanthine oxidase by reversible sulfhydryl oxidation or by irreversible proteolytic modification. Defects in xanthine dehydrogenase cause xanthinuria, may contribute to adult respiratory stress syndrome, and may potentiate influenza infection through an oxygen metabolite-dependent mechanism. .

YAP1: Yes-associated protein 1, 65 kD

Yes-associated protein; binds to the proto-oncoprotein Yes; has a WW domain.

PROCR: protein C receptor, endothelial (EPCR)
Endothelial Protein C receptor; binds protein C in a calcium-dependent manner; member of the CD1/major histocompatibility complex superfamily.

STX1A: syntaxin 1A (brain)

Syntaxin 1A (brain); involved in intracellular transport and neurotransmitter release.

As SNPs are linked to other SNPs in neighboring genes on a chromosome (Linkage Disequilibrium) those SNPs could also be used as marker SNPs. In a recent publication it was shown that SNPs are linked over 100 kb in some cases more than 150 kb (Reich D.E. et al. Nature 411, 199-204, 2001). Hence SNPs lying in regions neighbouring PA SNPs could be linked to the latter and by this being a diagnostic marker. These associations could be performed as described for the gene polymorphism in methods.

Definitions

For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below. Moreover, the definitions by itself are intended to explain a further background of the invention.

The term "allele", which is used interchangeably herein with "allelic variant" refers to alternative forms of a gene or portions thereof. Alleles occupy the same locus or position on homologous chromosomes. When a subject has two identical alleles of a gene, the subject is said to be homozygous for the gene or allele. When a subject has two different alleles of a gene, the subject is said to be heterozygous for the gene.

Alleles of a specific gene can differ from each other in a single nucleotide, or several nucleotides, and can include substitutions, deletions, and insertions of nucleotides. An allele of a gene can also be a form of a gene containing a mutation.

The term "allelic variant of a polymorphic region of a gene" refers to a region of a gene having one of several nucleotide sequences found in that region of the gene in other individuals.

"Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base

or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 40% identity, though preferably less than 25% identity, with one of the sequences of the present invention.

The term "a homologue of a nucleic acid" refers to a nucleic acid having a nucleotide sequence having a certain degree of homology with the nucleotide sequence of the nucleic acid or complement thereof. A homologue of a double stranded-nucleic acid having SEQ ID NO. X is intended to include nucleic acids having a nucleotide sequence which has a certain degree of homology with SEQ ID NO. X or with the complement thereof. Preferred homologous of nucleic acids are capable of hybridizing to the nucleic acid or complement thereof.

The term "interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a hybridization assay.

The term interact is also meant to include "binding" interactions between molecules. Interactions may be, for example, protein-protein, protein-nucleic acid, protein-small molecule or small molecule-nucleic acid in nature.

The term "intronic sequence" or "intronic nucleotide sequence" refers to the nucleotide sequence of an intron or portion thereof.

The term "isolated" as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule. The term isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.

Moreover, an "isolated nucleic acid" is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and
5 recombinant polypeptides.

The term "lipid" shall refer to a fat or fat-like substance that is insoluble in polar solvents such as water. The term "lipid" is intended to include true fats (e.g. esters of fatty acids and glycerol); lipids (phospholipids, cerebrosides, waxes); sterols
10 (cholesterol, ergosterol) and lipoproteins (e.g. HDL, LDL and VLDL).

The term "locus" refers to a specific position in a chromosome. For example, a locus of a gene refers to the chromosomal position of the gene.

15 The term "modulation" as used herein refers to both up-regulation, (i.e., activation or stimulation), for example by agonizing, and down-regulation (i.e. inhibition or suppression), for example by antagonizing of a bioactivity (e.g. expression of a gene).

20 The term "molecular structure" of a gene or a portion thereof refers to the structure as defined by the nucleotide content (including deletions, substitutions, additions of one or more nucleotides), the nucleotide sequence, the state of methylation, and/or any other modification of the gene or portion thereof.

25 The term "mutated gene" refers to an allelic form of a gene, which is capable of altering the phenotype of a subject having the mutated gene relative to a subject which does not have the mutated gene. If a subject must be homozygous for this mutation to have an altered phenotype, the mutation is said to be recessive. If one copy of the mutated gene is sufficient to alter the genotype of the subject, the
30 mutation is said to be dominant. If a subject has one copy of the mutated gene and

has a phenotype that is intermediate between that of a homozygous and that of a heterozygous (for that gene) subject, the mutation is said to be co-dominant.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, including peptide nucleic acids (PNA), morpholino oligonucleotides (J. Summerton and D. Weller, Antisense and Nucleic Acid Drug Development 7:187 (1997)) and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides. Deoxyribonucleotides include deoxyadenosine, deoxycytidine, deoxyguanosine, and deoxythymidine. For purposes of clarity, when referring herein to a nucleotide of a nucleic acid, which can be DNA or an RNA, the term "adenosine", "cytidine", "guanosine", and "thymidine" are used. It is understood that if the nucleic acid is RNA, a nucleotide having a uracil base is uridine.

The term "nucleotide sequence complementary to the nucleotide sequence set forth in SEQ ID NO. x" refers to the nucleotide sequence of the complementary strand of a nucleic acid strand having SEQ ID NO. x. The term "complementary strand" is used herein interchangeably with the term "complement". The complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand. When referring to double stranded nucleic acids, the complement of a nucleic acid having SEQ ID NO. x refers to the complementary strand of the strand having SEQ ID NO. x or to any nucleic acid having the nucleotide sequence of the complementary strand of SEQ ID NO. x. When referring to a single stranded nucleic acid having the nucleotide sequence SEQ ID NO. x, the complement of this nucleic acid is a nucleic acid having a nucleotide sequence which is complementary to that of SEQ ID NO. x. The nucleotide sequences and complementary sequences thereof are always given in the 5' to 3' direction. The term "complement" and "reverse complement" are used interchangeably herein.

The term "operably linked" is intended to mean that the promoter is associated with the nucleic acid in such a manner as to facilitate transcription of the nucleic acid.

The term "polymorphism" refers to the coexistence of more than one form of a gene or portion thereof. A portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymorphic region of a gene". A polymorphic region can be a single nucleotide, the identity of which differs in different alleles. A polymorphic region can also be several nucleotides long.

A "polymorphic gene" refers to a gene having at least one polymorphic region.

To describe a "polymorphic site" in a nucleotide sequence often there is used an "ambiguity code" that stands for the possible variations of nucleotides in one site.

The list of ambiguity codes is summarized in the following table:

Ambiguity (IUPAC Nomenclature)	Codes
B	c/g/t
D	a/g/t
H	a/c/t
K	g/t
M	a/c
N	a/c/g/t
R	a/g
S	c/g
V	a/c/g
W	a/t
Y	c/t

So, for example, a "R" in a nucleotide sequence means that either an "a" or a "g" could be at that position.

The terms "protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product.

5 A "regulatory element", also termed herein "regulatory sequence" is intended to include elements which are capable of modulating transcription from a basic promoter and include elements such as enhancers and silencers. The term "enhancer", also referred to herein as "enhancer element", is intended to include regulatory
10 elements capable of increasing, stimulating, or enhancing transcription from a basic promoter. The term "silencer", also referred to herein as "silencer element" is intended to include regulatory elements capable of decreasing, inhibiting, or repressing transcription from a basic promoter. Regulatory elements are typically present in 5' flanking regions of genes. However, regulatory elements have also been shown to be present in other regions of a gene, in particular in introns. Thus, it is
15 possible that genes have regulatory elements located in introns, exons, coding regions, and 3' flanking sequences. Such regulatory elements are also intended to be encompassed by the present invention and can be identified by any of the assays that can be used to identify regulatory elements in 5' flanking regions of genes.

20 The term "regulatory element" further encompasses "tissue specific" regulatory elements, i.e., regulatory elements which effect expression of the selected DNA sequence preferentially in specific cells (e.g., cells of a specific tissue). gene expression occurs preferentially in a specific cell if expression in this cell type is significantly higher than expression in other cell types. The term "regulatory
25 element" also encompasses non-tissue specific regulatory elements, i.e., regulatory elements which are active in most cell types. Furthermore, a regulatory element can be a constitutive regulatory element, i.e., a regulatory element which constitutively regulates transcription, as opposed to a regulatory element which is inducible, i.e., a regulatory element which is active primarily in response to a stimulus. A stimulus
30 can be, e.g., a molecule, such as a hormone, cytokine, heavy metal, phorbol ester, cyclic AMP (cAMP), or retinoic acid.

Regulatory elements are typically bound by proteins, e.g., transcription factors. The term "transcription factor" is intended to include proteins or modified forms thereof, which interact preferentially with specific nucleic acid sequences, i.e., regulatory elements, and which in appropriate conditions stimulate or repress transcription. Some transcription factors are active when they are in the form of a monomer. Alternatively, other transcription factors are active in the form of a dimer consisting of two identical proteins or different proteins (heterodimer). Modified forms of transcription factors are intended to refer to transcription factors having a post-translational modification, such as the attachment of a phosphate group. The activity of a transcription factor is frequently modulated by a post-translational modification. For example, certain transcription factors are active only if they are phosphorylated on specific residues. Alternatively, transcription factors can be active in the absence of phosphorylated residues and become inactivated by phosphorylation. A list of known transcription factors and their DNA binding site can be found, e.g., in public databases, e.g., TFMATRIX Transcription Factor Binding Site Profile database.

As used herein, the term "specifically hybridizes" or "specifically detects" refers to the ability of a nucleic acid molecule of the invention to hybridize to at least approximately 6, 12, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130 or 140 consecutive nucleotides of either strand of a gene.

The term "wild-type allele" refers to an allele of a gene which, when present in two copies in a subject results in a wild-type phenotype. There can be several different wild-type alleles of a specific gene, since certain nucleotide changes in a gene may not affect the phenotype of a subject having two copies of the gene with the nucleotide changes.

"Adverse drug reaction" (ADR) as used herein refers to an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or

specific treatment, or alteration of the dosage regimen, or withdrawal of the product. In it's most severe form an ADR might lead to the death of an individual.

5 The term "Drug Response" is intended to mean any response that a patient exhibits upon drug administration. Specifically drug response includes beneficial, i.e. desired drug effects, ADR or no detectable reaction at all. More specifically the term drug response could also have a qualitative meaning, i.e. it embraces low or high beneficial effects, respectively and mild or severe ADR, respectively. The term "Statin Response" as used herein refers to drug response after statin administration.

10 An individual drug response includes also a good or bad metabolizing of the drug, meaning that "bad metabolizers" accumulate the drug in the body and by this could show side effects of the drug due to accumulative overdoses.

15 "Candidate gene" as used herein includes genes that can be assigned to either normal cardiovascular function or to metabolic pathways that are related to onset and/or progression of cardiovascular diseases.

20 With regard to drug response the term "candidate gene" includes genes that can be assigned to distinct phenotypes regarding the patient's response to drug administration. Those phenotypes may include patients who benefit from relatively small amounts of a given drug (high responders) or patients who need relatively high doses in order to obtain the same benefit (low responders). In addition those phenotypes may include patients who can tolerate high doses of a medicament without exhibiting ADR, or patients who suffer from ADR even after receiving only

25 low doses of a medicament.

As neither the development of cardiovascular diseases nor the patient's response to drug administration is completely understood, the term "candidate gene" may also comprise genes with presently unknown function.

"PA SNP" (phenotype associated SNP) refers to a polymorphic site which shows a significant association with a patient's phenotype (healthy, diseased, low or high responder, drug tolerant, ADR prone, etc.)

- 5 "PA gene" (phenotype associated gene) refers to a genomic locus harbouring a PA SNP, irrespective of the actual function of this gene locus.

PA gene polypeptide refers to a polypeptide encoded at least in part by a PA gene.

- 10 The term "Haplotype" as used herein refers to a group of two or more SNPs that are functionally and/or spatially linked. I.e. haplotypes define groups of SNPs that lie inside genes belonging to identical (or related metabolic) pathways and/or lie on the same chromosome. Haplotypes are expected to give better predictive/diagnostic information than a single SNP

- 15 The term "statin" is intended to embrace all inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Statins specifically inhibit the enzyme HMG-CoA reductase which catalyzes the rate limiting step in cholesterol biosynthesis. Known statins are Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, 20 Pravastatin and Simvastatin.

Methods for Assessing Cardiovascular Status

- 25 The present invention provides diagnostic methods for assessing cardiovascular status in a human individual. Cardiovascular status as used herein refers to the physiological status of an individual's cardiovascular system as reflected in one or more markers or indicators. Status markers include without limitation clinical measurements such as, e.g., blood pressure, electrocardiographic profile, and differentiated blood flow analysis as well as measurements of LDL- and HDL- 30 Cholesterol levels, other lipids and other well established clinical parameters that are standard in the art. Status markers according to the invention include diagnoses of

one or more cardiovascular syndromes, such as, e.g., hypertension, acute myocardial infarction, silent myocardial infarction, stroke, and atherosclerosis. It will be understood that a diagnosis of a cardiovascular syndrome made by a medical practitioner encompasses clinical measurements and medical judgement. Status markers according to the invention are assessed using conventional methods well known in the art. Also included in the evaluation of cardiovascular status are quantitative or qualitative changes in status markers with time, such as would be used, e.g., in the determination of an individual's response to a particular therapeutic regimen.

The methods are carried out by the steps of:

(i) determining the sequence of one or more polymorphic positions within one, several or all of the genes listed in Examples or other genes mentioned in this file in the individual to establish a polymorphic pattern for the individual; and

(ii) comparing the polymorphic pattern established in (i) with the polymorphic patterns of humans exhibiting different markers of cardiovascular status. The polymorphic pattern of the individual is, preferably, highly similar and, most preferably, identical to the polymorphic pattern of individuals who exhibit particular status markers, cardiovascular syndromes, and/or particular patterns of response to therapeutic interventions. Polymorphic patterns may also include polymorphic positions in other genes which are shown, in combination with one or more polymorphic positions in the genes listed in the Examples, to correlate with the presence of particular status markers. In one embodiment, the method involves comparing an individual's polymorphic pattern with polymorphic patterns of individuals who have been shown to respond positively or negatively to a particular therapeutic regimen. Therapeutic regimen as used herein refers to treatments aimed at the elimination or amelioration of symptoms and events associated cardiovascular disease. Such treatments include without limitation one or more of alteration in diet, lifestyle, and exercise regimen; invasive and noninvasive surgical techniques such as

atherectomy, angioplasty, and coronary bypass surgery; and pharmaceutical interventions, such as administration of ACE inhibitors, angiotensin II receptor antagonists, diuretics, alpha-adrenoreceptor antagonists, cardiac glycosides, phosphodiesterase inhibitors, beta-adrenoreceptor antagonists, calcium channel blockers, HMG-CoA reductase inhibitors, imidazoline receptor blockers, endothelin receptor blockers, organic nitrites, and modulators of protein function of genes listed in the Examples. Interventions with pharmaceutical agents not yet known whose activity correlates with particular polymorphic patterns associated with cardiovascular disease are also encompassed. It is contemplated, for example, that patients who are candidates for a particular therapeutic regimen will be screened for polymorphic patterns that correlate with responsivity to that particular regimen.

In a preferred embodiment, the method involves comparing an individual's polymorphic pattern with polymorphic patterns of individuals who exhibit or have exhibited one or more markers of cardiovascular disease, such as, e.g., elevated LDL-Cholesterol levels, high blood pressure, abnormal electrocardiographic profile, myocardial infarction, stroke, or atherosclerosis.

In another embodiment, the method involves comparing an individual's polymorphic pattern with polymorphic patterns of individuals who exhibit or have exhibited one or more drug related phenotypes, such as, e.g., low or high drug response, or adverse drug reactions.

In practicing the methods of the invention, an individual's polymorphic pattern can be established by obtaining DNA from the individual and determining the sequence at predetermined polymorphic positions in the genes such as those described in this file.

The DNA may be obtained from any cell source. Non-limiting examples of cell sources available in clinical practice include blood cells, buccal cells, cervicovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by

biopsy. Cells may also be obtained from body fluids, including without limitation blood, saliva, sweat, urine, cerebrospinal fluid, feces, and tissue exudates at the site of infection or inflammation. DNA is extracted from the cell source or body fluid using any of the numerous methods that are standard in the art. It will be understood that the particular method used to extract DNA will depend on the nature of the source.

Diagnostic and Prognostic Assays

The present invention provides methods for determining the molecular structure of at least one polymorphic region of a gene, specific allelic variants of said polymorphic region being associated with cardiovascular disease. In one embodiment, determining the molecular structure of a polymorphic region of a gene comprises determining the identity of the allelic variant. A polymorphic region of a gene, of which specific alleles are associated with cardiovascular disease can be located in an exon, an intron, at an intron/exon border, or in the promoter of the gene.

The invention provides methods for determining whether a subject has, or is at risk, of developing a cardiovascular disease. Such disorders can be associated with an aberrant gene activity, e.g., abnormal binding to a form of a lipid, or an aberrant gene protein level. An aberrant gene protein level can result from an aberrant transcription or post-transcriptional regulation. Thus, allelic differences in specific regions of a gene can result in differences of gene protein due to differences in regulation of expression. In particular, some of the identified polymorphisms in the human gene may be associated with differences in the level of transcription; RNA maturation; splicing, or translation of the gene or transcription product.

In preferred embodiments, the methods of the invention can be characterized as comprising detecting, in a sample of cells from the subject, the presence or absence of a specific allelic variant of one or more polymorphic regions of a gene. The allelic differences can be: (i) a difference in the identity of at least one nucleotide or (ii) a

difference in the number of nucleotides, which difference can be a single nucleotide or several nucleotides.

A preferred detection method is allele specific hybridization using probes over-
lapping the polymorphic site and having about 5, 10, 20, 25, or 30 nucleotides around
the polymorphic region. Examples of probes for detecting specific allelic variants of
the polymorphic region located in intron X are probes comprising a nucleotide
sequence set forth in any of SEQ ID NO. X. In a preferred embodiment of the
invention, several probes capable of hybridizing specifically to allelic variants are
attached to a solid phase support, e.g., a "chip". Oligonucleotides can be bound to a
solid support by a variety of processes, including lithography. For example a chip
can hold up to 250,000 oligonucleotides (GeneChip, Affymetrix). Mutation detection
analysis using these chips comprising oligonucleotides, also termed "DNA probe
arrays" is described e.g., in Cronin et al. (1996) Human Mutation 7:244 and in Kozal
et al. (1996) Nature Medicine 2:753. In one embodiment, a chip comprises all the
allelic variants of at least one polymorphic region of a gene. The solid phase support
is then contacted with a test nucleic acid and hybridization to the specific probes is
detected. Accordingly, the identity of numerous allelic variants of one or more genes
can be identified in a simple hybridization experiment. For example, the identity of
the allelic variant of the nucleotide polymorphism of nucleotide A or G at position 33
of Seq ID 1 (baySNP179) and that of other possible polymorphic regions can be
determined in a single hybridization experiment.

In other detection methods, it is necessary to first amplify at least a portion of a gene
prior to identifying the allelic variant. Amplification can be performed, e.g., by PCR
and/or LCR, according to methods known in the art. In one embodiment, genomic
DNA of a cell is exposed to two PCR primers and amplification for a number of
cycles sufficient to produce the required amount of amplified DNA. In preferred
embodiments, the primers are located between 40 and 350 base pairs apart. Preferred
primers for amplifying gene fragments of genes of this file are listed in Table 2 in
the Examples.

Alternative amplification methods include: self sustained sequence replication (Guatelli, J. C. et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1874-1878), transcriptional amplification system (Kwob, D. Y. et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:1173-1177), Q-Beta Replicase (Lizardi, P. M. et al., 1988, Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In one embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence at least a portion of a gene and detect allelic variants, e.g., mutations, by comparing the sequence of the sample sequence with the corresponding wild-type (control) sequence. Exemplary sequencing reactions include those based on techniques developed by Maxam and Gilbert (Proc. Natl Acad Sci USA (1977) 74:560) or Sanger (Sanger et al (1977) Proc. Nat. Acad. Sci 74:5463). It is also contemplated that any of a variety of automated sequencing procedures may be utilized when performing the subject assays (Biotechniques (1995) 19:448), including sequencing by mass spectrometry (see, for example, U.S. Pat. No. 5,547,835 and international patent application Publication Number WO 94/16101, entitled DNA Sequencing by Mass Spectrometry by H. Koster; U.S. Pat. No. 5,547,835 and international patent application Publication Number WO 94/21822 entitled "DNA Sequencing by Mass Spectrometry Via Exonuclease Degradation" by H. Koster), and U.S. Pat. No. 5,605,798 and International Patent Application No. PCT/US96/03651 entitled DNA Diagnostics Based on Mass Spectrometry by H. Koster; Cohen et al. (1996) Adv Chromatogr 36:127-162; and Griffin et al. (1993) Appl Biochem Biotechnol 38:147-159). It will be evident to one skilled in the art that, for certain embodiments, the occurrence of only one, two or three of the nucleic acid bases need be determined in the sequencing reaction. For instance, A-track or the like, e.g., where only one nucleotide is detected, can be carried out.

Yet other sequencing methods are disclosed, e.g., in U.S. Pat. No. 5,580,732 entitled "Method of DNA sequencing employing a mixed DNA-polymer chain probe" and U.S. Pat. No. 5,571,676 entitled "Method for mismatch-directed in vitro DNA sequencing".

5

In some cases, the presence of a specific allele of a gene in DNA from a subject can be shown by restriction enzyme analysis. For example, a specific nucleotide polymorphism can result in a nucleotide sequence comprising a restriction site which is absent from the nucleotide sequence of another allelic variant.

10

In other embodiments, alterations in electrophoretic mobility is used to identify the type of gene allelic variant. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA 86:2766, see also Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73-79). Single-stranded DNA fragments of sample and control nucleic acids are denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In another preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).

20

25

30

In yet another embodiment, the identity of an allelic variant of a polymorphic region is obtained by analyzing the movement of a nucleic acid comprising the polymorphic region in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to

insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing agent gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:1275).

Examples of techniques for detecting differences of at least one nucleotide between 2 nucleic acids include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide probes may be prepared in which the known polymorphic nucleotide is placed centrally (allele-specific probes) and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al (1989) Proc. Natl Acad. Sci USA 86:6230; and Wallace et al. (1979) Nucl. Acids Res. 6:3543). Such allele specific oligonucleotide hybridization techniques may be used for the simultaneous detection of several nucleotide changes in different polymorphic regions of gene. For example, oligonucleotides having nucleotide sequences of specific allelic variants are attached to a hybridizing membrane and this membrane is then hybridized with labeled sample nucleic acid. Analysis of the hybridization signal will then reveal the identity of the nucleotides of the sample nucleic acid.

Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used. Oligonucleotides used as primers for specific amplification may carry the allelic variant of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238; Newton et al. (1989) Nucl. Acids Res. 17:2503). This technique is also termed "PROBE" for Probe Oligo Base Extension. In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al (1992) Mol. Cell Probes 6:1).

In another embodiment, identification of the allelic variant is carried out using an oligonucleotide ligation assay (OLA), as described, e.g., in U.S. Pat. No. 4,998,617 and in Landegren, U. et al., Science 241:1077-1080 (1988). The OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target. One of the oligonucleotides is linked to a separation marker, e.g., biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand. Nickerson, D. A. et al. have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson, D. A. et al., Proc. Natl. Acad. Sci. (U.S.A.) 87:8923-8927 (1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Several techniques based on this OLA method have been developed and can be used to detect specific allelic variants of a polymorphic region of a gene. For example, U.S. Pat. No. 5,593,826 discloses an OLA using an oligonucleotide having 3'-amino group and a 5'-phosphorylated oligonucleotide to form a conjugate having a phosphoramidate linkage. In another variation of OLA described in Tobe et al. ((1996)Nucleic Acids Res 24: 3728), OLA combined with PCR permits typing of two alleles in a single microtiter well. By marking each of the allele-specific primers with a unique hapten, i.e. digoxigenin and fluorescein, each LA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase. This system permits the detection of the two alleles using a high throughput format that leads to the production of two different colors.

The invention further provides methods for detecting single nucleotide polymorphisms in a gene. Because single nucleotide polymorphisms constitute sites of variation flanked by regions of invariant sequence, their analysis requires no more

than the determination of the identity of the single nucleotide present at the site of variation and it is unnecessary to determine a complete gene sequence for each patient. Several methods have been developed to facilitate the analysis of such single nucleotide polymorphisms.

5

In one embodiment, the single base polymorphism can be detected by using a specialized exonuclease-resistant nucleotide, as disclosed, e.g., in Mundy, C. R. (U.S. Pat. No. 4,656,127). According to the method, a primer complementary to the allelic sequence immediately 3' to the polymorphic site is permitted to hybridize to a target molecule obtained from a particular animal or human. If the polymorphic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease-resistant nucleotide derivative present, then that derivative will be incorporated onto the end of the hybridized primer. Such incorporation renders the primer resistant to exonuclease, and thereby permits its detection. Since the identity of the exonuclease-resistant derivative of the sample is known, a finding that the primer has become resistant to exonucleases reveals that the nucleotide present in the polymorphic site of the target molecule was complementary to that of the nucleotide derivative used in the reaction. This method has the advantage that it does not require the determination of large amounts of extraneous sequence data.

10
15
20

In another embodiment of the invention, a solution-based method is used for determining the identity of the nucleotide of a polymorphic site. Cohen, D. et al. (French Patent 2,650,840; PCT Appln. No. WO91/02087). As in the Mundy method of U.S. Pat. No. 4,656,127, a primer is employed that is complementary to allelic sequences immediately 3' to a polymorphic site. The method determines the identity of the nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide of the polymorphic site will become incorporated onto the terminus of the primer.

25

30 An alternative method, known as Genetic Bit Analysis or GBA TM is described by Goelet, P. et al. (PCT Appln. No. 92/15712). The method of Goelet, P. et al. uses

mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site. The labeled terminator that is incorporated is thus determined by, and complementary to, the nucleotide present in the polymorphic site of the target molecule being evaluated. In contrast to the method of Cohen et al. (French Patent 2,650,840; PCT Appln. No. WO91/02087) the method of Goelet, P. et al. is preferably a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase.

Recently, several primer-guided nucleotide incorporation procedures for assaying polymorphic sites in DNA have been described (Komher, J. S. et al., Nucl. Acids Res. 17:7779-7784 (1989); Sokolov, B. P., Nucl. Acids Res. 18:3671 (1990); Syvanen, A. -C., et al., Genomics 8:684-692 (1990), Kuppuswamy, M. N. et al., Proc. Natl. Acad. Sci. (U.S.A.) 88:1143-1147 (1991); Prezant, T. R. et al., Hum. Mutat. 1:159-164 (1992); Ugozzoli, L. et al., GATA 9:107-112 (1992); Nyren, P. et al., Anal. Biochem. 208:171-175 (1993)). These methods differ from GBATM in that they all rely on the incorporation of labeled deoxynucleotides to discriminate between bases at a polymorphic site. In such a format, since the signal is proportional to the number of deoxynucleotides incorporated, polymorphisms that occur in runs of the same nucleotide can result in signals that are proportional to the length of the run (Syvanen, A.-C., et al., Amer. J. Hum. Genet. 52:46-59 (1993)).

For determining the identity of the allelic variant of a polymorphic region located in the coding region of a gene, yet other methods than those described above can be used. For example, identification of an allelic variant which encodes a mutated gene protein can be performed by using an antibody specifically recognizing the mutant protein in, e.g., immunohistochemistry or immunoprecipitation. Antibodies to wild-type gene protein are described, e.g., in Acton et al. (1999) Science 271:518 (anti-mouse gene antibody cross-reactive with human gene). Other antibodies to wild-type gene or mutated forms of gene proteins can be prepared according to methods known in the art. Alternatively, one can also measure an activity of an gene protein, such as binding to a lipid or lipoprotein. Binding assays are known in the art and involve;

e.g., obtaining cells from a subject, and performing binding experiments with a labeled lipid, to determine whether binding to the mutated form of the receptor differs from binding to the wild-type of the receptor.

5 If a polymorphic region is located in an exon, either in a coding or non-coding region of the gene, the identity of the allelic variant can be determined by determining the molecular structure of the mRNA, pre-mRNA, or cDNA. The molecular structure can be determined using any of the above described methods for determining the molecular structure of the genomic DNA, e.g., sequencing and SSCP.

10

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits, such as those described above, comprising at least one probe or primer nucleic acid described herein, which may be conveniently used, e.g., to determine whether a subject has or is at risk of developing a disease associated with a specific gene allelic variant.

15

Sample nucleic acid for using in the above-described diagnostic and prognostic methods can be obtained from any cell type or tissue of a subject. For example, a subject's bodily fluid (e.g. blood) can be obtained by known techniques (e.g. venipuncture) or from human tissues like heart (biopsies, transplanted organs). Alternatively, nucleic acid tests can be performed on dry samples (e.g. hair or skin). Fetal nucleic acid samples for prenatal diagnostics can be obtained from maternal blood as described in International Patent Application No. WO91/07660 to Bianchi. Alternatively, amniocytes or chorionic villi may be obtained for performing prenatal testing.

25

Diagnostic procedures may also be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G. J.,

30

1992, PCR in situ hybridization: protocols and applications, Raven Press, New York).

5 In addition to methods which focus primarily on the detection of one nucleic acid sequence, profiles may also be assessed in such detection schemes. Fingerprint profiles may be generated, for example, by utilizing a differential display procedure, Northern analysis and/or RT-PCR.

10 In practicing the present invention, the distribution of polymorphic patterns in a large number of individuals exhibiting particular markers of cardiovascular status or drug response is determined by any of the methods described above, and compared with the distribution of polymorphic patterns in patients that have been matched for age, ethnic origin, and/or any other statistically or medically relevant parameters, who exhibit quantitatively or qualitatively different status markers. Correlations are
15 achieved using any method known in the art, including nominal logistic regression, chi square tests or standard least squares regression analysis. In this manner, it is possible to establish statistically significant correlations between particular polymorphic patterns and particular cardiovascular statuses (given in p values). It is further possible to establish statistically significant correlations between particular
20 polymorphic patterns and changes in cardiovascular status or drug response such as, would result, e.g., from particular treatment regimens. In this manner, it is possible to correlate polymorphic patterns with responsivity to particular treatments.

25 In another embodiment of the present invention two or more polymorphic regions are combined to define so called 'haplotypes'. Haplotypes are groups of two or more SNPs that are functionally and/or spatially linked. It is possible to combine SNPs that are disclosed in the present invention either with each other or with additional polymorphic regions to form a haplotype. Haplotypes are expected to give better predictive/diagnostic information than a single SNP.

30 In a preferred embodiment of the present invention a panel of SNPs/haplotypes is defined that predicts the risk for CVD or drug response. This predictive panel is then

used for genotyping of patients on a platform that can genotype multiple SNPs at the same time (Multiplexing). Preferred platforms are e.g. gene chips (Affymetrix) or the Luminex LabMAP reader. The subsequent identification and evaluation of a patient's haplotype can then help to guide specific and individualized therapy.

5

For example the present invention can identify patients exhibiting genetic polymorphisms or haplotypes which indicate an increased risk for adverse drug reactions. In that case the drug dose should be lowered in a way that the risk for ADR is diminished. Also if the patient's response to drug administration is particularly high (or the patient is badly metabolizing the drug), the drug dose should be lowered to avoid the risk of ADR.

10

In turn if the patient's response to drug administration is low (or the patient is a particularly high metabolizer of the drug), and there is no evident risk of ADR, the drug dose should be raised to an efficacious level.

15

It is self evident that the ability to predict a patient's individual drug response should affect the formulation of a drug, i.e. drug formulations should be tailored in a way that they suit the different patient classes (low/high responder, poor/good metabolizer, ADR prone patients). Those different drug formulations may encompass different doses of the drug, i.e. the medicinal products contains low or high amounts of the active substance. In another embodiment of the invention the drug formulation may contain additional substances that facilitate the beneficial effects and/or diminish the risk for ADR (Folkers et al. 1991, US Pat. 5,316,765).

20

Isolated Polymorphic Nucleic Acids, Probes, and Vectors

25

The present invention provides isolated nucleic acids comprising the polymorphic positions described herein for human genes; vectors comprising the nucleic acids; and transformed host cells comprising the vectors. The invention also provides probes which are useful for detecting these polymorphisms.

30

In practicing the present invention, many conventional techniques in molecular biology, microbiology, and recombinant DNA, are used. Such techniques are well known and are explained fully in, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984, (M. L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Ausubel et al., Current Protocols in Molecular Biology, 1997, (John Wiley and Sons); and Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).

Insertion of nucleic acids (typically DNAs) comprising the sequences in a functional surrounding like full length cDNA of the present invention into a vector is easily accomplished when the termini of both the DNAs and the vector comprise compatible restriction sites. If this cannot be done, it may be necessary to modify the termini of the DNAs and/or vector by digesting back single-stranded DNA overhangs generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate DNA polymerase.

Alternatively, any site desired may be produced, e.g., by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. Restriction sites can also be generated by the use of the polymerase chain reaction (PCR). See, e.g., Saiki et al., 1988, Science 239:48. The cleaved vector and the DNA fragments may also be modified if required by homopolymeric tailing.

The nucleic acids may be isolated directly from cells or may be chemically synthesized using known methods. Alternatively, the polymerase chain reaction (PCR) method can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for

PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

5 The nucleic acids of the present invention may be flanked by native gene sequences, or may be associated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by many means known in the art. Non-limiting examples of such modifications include
10 methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, morpholines etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or
15 more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. PNAs are also included. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl
20 phosphoramidate linkage. Furthermore, the nucleic acid sequences of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

25 The invention also provides nucleic acid vectors comprising the gene sequences or derivatives or fragments thereof of genes described in the Examples. A large number of vectors, including plasmid and fungal vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression. Non-limiting
30 examples of suitable vectors include without limitation pUC plasmids, pET plasmids (Novagen, Inc., Madison, Wis.), or pRSET or pREP (Invitrogen, San Diego, Calif.),

and many appropriate host cells, using methods disclosed or cited herein or otherwise known to those skilled in the relevant art. The particular choice of vector/host is not critical to the practice of the invention.

5 Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation, CaCl_2 mediated DNA uptake, fungal or viral infection, microinjection, microprojectile, or other established methods. Appropriate host cells included bacteria, archebacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. A large number of transcription
10 initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts. Examples of these regions, methods of isolation, manner of manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source of recombinantly produced peptides and polypeptides encoded by genes
15 of the Examples. Nucleic acids encoding peptides or polypeptides from gene sequences of the Examples may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a cell and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination-based methods such as non-
20 homologous recombinations or deletion of endogenous genes by homologous recombination may also be used.

In case of proteins that form heterodimers or other multimers, both or all subunits have to be expressed in one system or cell.

25

The nucleic acids of the present invention find use as probes for the detection of genetic polymorphisms and as templates for the recombinant production of normal or variant peptides or polypeptides encoded by genes listed in the Examples.

30 Probes in accordance with the present invention comprise without limitation isolated nucleic acids of about 10-100 bp, preferably 15-75 bp and most preferably 17-25 bp

in length, which hybridize at high stringency to one or more of the polymorphic sequences disclosed herein or to a sequence immediately adjacent to a polymorphic position. Furthermore, in some embodiments a full-length gene sequence may be used as a probe. In one series of embodiments, the probes span the polymorphic positions in genes disclosed herein. In another series of embodiments, the probes correspond to sequences immediately adjacent to the polymorphic positions.

Polymorphic Polypeptides and Polymorphism-Specific Antibodies

10 The present invention encompasses isolated peptides and polypeptides encoded by genes listed in the Examples comprising polymorphic positions disclosed herein. In one preferred embodiment, the peptides and polypeptides are useful screening targets to identify cardiovascular drugs. In another preferred embodiment, the peptides and polypeptides are capable of eliciting antibodies in a suitable host animal that react specifically with a polypeptide comprising the polymorphic position and distinguish it from other polypeptides having a different sequence at that position.

Polypeptides according to the invention are preferably at least five or more residues in length, preferably at least fifteen residues. Methods for obtaining these polypeptides are described below. Many conventional techniques in protein biochemistry and immunology are used. Such techniques are well known and are explained in 20 Immunochemical Methods in Cell and Molecular Biology, 1987 (Mayer and Waler, eds; Academic Press, London); Scopes, 1987, Protein Purification: Principles and Practice, Second Edition (Springer-Verlag, N.Y.) and Handbook of Experimental 25 Immunology, 1986, Volumes I-IV (Weir and Blackwell eds.).

Nucleic acids comprising protein-coding sequences can be used to direct the ITT recombinant expression of polypeptides encoded by genes disclosed herein in intact cells or in cell-free translation systems. The known genetic code, tailored if desired for more efficient expression in a given host organism, can be used to synthesize 30 oligonucleotides encoding the desired amino acid sequences. The polypeptides may

be isolated from human cells, or from heterologous organisms or cells (including, but not limited to, bacteria, fungi, insect, plant, and mammalian cells) into which an appropriate protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

5

Peptides and polypeptides may be chemically synthesized by commercially available automated procedures, including, without limitation, exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, 1963, J. Am. Chem. Soc. 85:2149.

10

Methods for polypeptide purification are well-known in the art, including, without limitation, preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For some purposes, it is preferable to produce the polypeptide in a recombinant system in which the protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against peptides encoded by genes disclosed herein, can be used as purification reagents. Other purification methods are possible.

15

20

25

30

The present invention also encompasses derivatives and homologues of the polypeptides. For some purposes, nucleic acid sequences encoding the peptides may be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine); negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino acids.

The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

5

The present invention also encompasses antibodies that specifically recognize the polymorphic positions of the invention and distinguish a peptide or polypeptide containing a particular polymorphism from one that contains a different sequence at that position. Such polymorphic position-specific antibodies according to the present
10 invention include polyclonal and monoclonal antibodies. The antibodies may be elicited in an animal host by immunization with peptides encoded by genes disclosed herein or may be formed by in vitro immunization of immune cells. The immunogenic components used to elicit the antibodies may be isolated from human cells or produced in recombinant systems. The antibodies may also be produced in
15 recombinant systems programmed with appropriate antibody-encoding DNA. Alternatively, the antibodies may be constructed by biochemical reconstitution of purified heavy and light chains. The antibodies include hybrid antibodies (i.e., containing two sets of heavy chain/light chain combinations, each of which recognizes a different antigen), chimeric antibodies (i.e., in which either the heavy
20 chains, light chains, or both, are fusion proteins), and univalent antibodies (i.e., comprised of a heavy chain/light chain complex bound to the constant region of a second heavy chain). Also included are Fab fragments, including Fab' and F(ab).sub.2 fragments of antibodies. Methods for the production of all of the above types of antibodies and derivatives are well-known in the art and are discussed in
25 more detail below. For example, techniques for producing and processing polyclonal antisera are disclosed in Mayer and Walker, 1987, Immunochemical Methods in Cell and Molecular Biology, (Academic Press, London). The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such
30 as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., Schreier et al., 1980, Hybridoma Techniques; U.S. Pat.

Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,466,917; 4,472,500; 4,491,632; and 4,493,890. Panels of monoclonal antibodies produced against peptides encoded by genes disclosed herein can be screened for various properties; i.e. for isotype, epitope affinity, etc.

5

The antibodies of this invention can be purified by standard methods, including but not limited to preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. Purification methods for antibodies are disclosed, e.g., in
10 The Art of Antibody Purification, 1989, Amicon Division, W. R. Grace & Co. General protein purification methods are described in Protein Purification: Principles and Practice, R. K. Scopes, Ed., 1987, Springer-Verlag, New York, N.Y.

15

Methods for determining the immunogenic capability of the disclosed sequences and the characteristics of the resulting sequence-specific antibodies and immune cells are well-known in the art. For example, antibodies elicited in response to a peptide comprising a particular polymorphic sequence can be tested for their ability to specifically recognize that polymorphic sequence, i.e., to bind differentially to a peptide or polypeptide comprising the polymorphic sequence and thus distinguish it
20 from a similar peptide or polypeptide containing a different sequence at the same position.

Kits

As set forth herein, the invention provides diagnostic methods, e.g., for determining the identity of the allelic variants of polymorphic regions present in the gene loci of genes disclosed herein, wherein specific allelic variants of the polymorphic region are associated with cardiovascular diseases. In a preferred embodiment, the diagnostic kit can be used to determine whether a subject is at risk of developing a cardiovascular disease. This information could then be used, e.g., to optimize treatment of such individuals.

In preferred embodiments, the kit comprises a probe or primer which is capable of hybridizing to a gene and thereby identifying whether the gene contains an allelic variant of a polymorphic region which is associated with a risk for cardiovascular disease. The kit preferably further comprises instructions for use in diagnosing a subject as having, or having a predisposition, towards developing a cardiovascular disease. The probe or primers of the kit can be any of the probes or primers described in this file:

Preferred kits for amplifying a region of a gene comprising a polymorphic region of interest comprise one, two or more primers.

Antibody-based diagnostic methods and kits:

The invention also provides antibody-based methods for detecting polymorphic patterns in a biological sample. The methods comprise the steps of: (i) contacting a sample with one or more antibody preparations, wherein each of the antibody preparations is specific for a particular polymorphic form of the proteins encoded by genes disclosed herein, under conditions in which a stable antigen-antibody complex can form between the antibody and antigenic components in the sample; and (ii) detecting any antigen-antibody complex formed in step (i) using any suitable means

known in the art, wherein the detection of a complex indicates the presence of the particular polymorphic form in the sample.

Typically, immunoassays use either a labelled antibody or a labelled antigenic component (e.g., that competes with the antigen in the sample for binding to the antibody). Suitable labels include without limitation enzyme-based, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays that amplify the signals from the probe are also known, such as, for example, those that utilize biotin and avidin, and enzyme-labelled immunoassays, such as ELISA assays.

The present invention also provides kits suitable for antibody-based diagnostic applications. Diagnostic kits typically include one or more of the following components:

(i) Polymorphism-specific antibodies. The antibodies may be pre-labelled; alternatively, the antibody may be unlabelled and the ingredients for labelling may be included in the kit in separate containers, or a secondary, labelled antibody is provided; and

(ii) Reaction components: The kit may also contain other suitably packaged reagents and materials needed for the particular immunoassay protocol, including solid-phase matrices, if applicable, and standards.

The kits referred to above may include instructions for conducting the test. Furthermore, in preferred embodiments, the diagnostic kits are adaptable to high-throughput and/or automated operation.

Drug Targets and Screening Methods

According to the present invention, nucleotide sequences derived from genes disclosed herein and peptide sequences encoded by genes disclosed herein, particularly

those that contain one or more polymorphic sequences, comprise useful targets to identify cardiovascular drugs, i.e., compounds that are effective in treating one or more clinical symptoms of cardiovascular disease. Furthermore, especially when a protein is a multimeric protein that are build of two or more subunits, is a combination of different polymorphic subunits very useful.

Drug targets include without limitation (i) isolated nucleic acids derived from the genes disclosed herein, and (ii) isolated peptides and polypeptides encoded by genes disclosed herein, each of which comprises one or more polymorphic positions.

In vitro screening methods:

In one series of embodiments, an isolated nucleic acid comprising one or more polymorphic positions is tested in vitro for its ability to bind test compounds in a sequence-specific manner. The methods comprise:

(i) providing a first nucleic acid containing a particular sequence at a polymorphic position and a second nucleic acid whose sequence is identical to that of the first nucleic acid except for a different sequence at the same polymorphic position;

(ii) contacting the nucleic acids with a multiplicity of test compounds under conditions appropriate for binding; and

(iii) identifying those compounds that bind selectively to either the first or second nucleic acid sequence.

Selective binding as used herein refers to any measurable difference in any parameter of binding, such as, e.g., binding affinity, binding capacity, etc.

In another series of embodiments, an isolated peptide or polypeptide comprising one or more polymorphic positions is tested in vitro for its ability to bind test compounds in a sequence-specific manner. The screening methods involve:

5 (i) providing a first peptide or polypeptide containing a particular sequence at a polymorphic position and a second peptide or polypeptide whose sequence is identical to the first peptide or polypeptide except for a different sequence at the same polymorphic position;

10 (ii) contacting the polypeptides with a multiplicity of test compounds under conditions appropriate for binding; and

(iii) identifying those compounds that bind selectively to one of the nucleic acid sequences.

15

In preferred embodiments, high-throughput screening protocols are used to survey a large number of test compounds for their ability to bind the genes or peptides disclosed above in a sequence-specific manner.

20 Test compounds are screened from large libraries of synthetic or natural compounds. Numerous means are currently used for random and directed synthesis of saccharide, peptide, and nucleic acid based compounds. Synthetic compound libraries are commercially available from Maybridge Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princeton, N.J.), Brandon Associates (Merrimack, N.H.), and
25 Microsource (New Milford, Conn.). A rare chemical library is available from Aldrich (Milwaukee, Wis.). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available from e.g. Pan Laboratories (Bothell, Wash.) or MycoSearch (N.C.), or are readily producible. Additionally, natural and synthetically produced libraries and compounds are readily modified
30 through conventional chemical, physical, and biochemical means.

In vivo screening methods:

Intact cells or whole animals expressing polymorphic variants of genes disclosed herein can be used in screening methods to identify candidate cardiovascular drugs.

5

In one series of embodiments, a permanent cell line is established from an individual exhibiting a particular polymorphic pattern. Alternatively, cells (including without limitation mammalian, insect, yeast, or bacterial cells) are programmed to express a gene comprising one or more polymorphic sequences by introduction of appropriate DNA. Identification of candidate compounds can be achieved using any suitable assay, including without limitation (i) assays that measure selective binding of test compounds to particular polymorphic variants of proteins encoded by genes disclosed herein; (ii) assays that measure the ability of a test compound to modify (i.e., inhibit or enhance) a measurable activity or function of proteins encoded by genes disclosed herein; and (iii) assays that measure the ability of a compound to modify (i.e., inhibit or enhance) the transcriptional activity of sequences derived from the promoter (i.e., regulatory) regions of genes disclosed herein.

10

15

20

25

In another series of embodiments, transgenic animals are created in which (i) one or more human genes disclosed herein, having different sequences at particular polymorphic positions are stably inserted into the genome of the transgenic animal; and/or (ii) the endogenous genes disclosed herein are inactivated and replaced with human genes disclosed herein, having different sequences at particular polymorphic positions. See, e.g., Coffman, Semin. Nephrol. 17:404, 1997; Esther et al., Lab. Invest. 74:953, 1996; Murakami et al., Blood Press. Suppl. 2:36, 1996. Such animals can be treated with candidate compounds and monitored for one or more clinical markers of cardiovascular status.

The following are intended as non-limiting examples of the invention.

Material and Methods

Genotyping of patient DNA with the PyrosequencingTM Method as described in the patent application WO 9813523:

5

10

First a PCR is set up to amplify the flanking regions around a SNP. Therefor 2 ng of genomic DNA (patient sample) are mixed with a primerset (20 – 40 pmol) producing a 75 to 320 bp PCR fragment with 0,3 to 1 U Qiagens Hot Star Taq PolymeraseTM in a total volume of 20 µL. One primer is biotinylated depending on the direction of the sequencing primer. To force the biotinylated primer to be incorporated it is used 0,8 fold.

15

For primer design, programmes like Oligo 6TM (Molecular Biology Insights) or Primer SelectTM (DNASar) are used. PCR setup is performed by a BioRobot 3000TM from Qiagen. PCR takes place in T1 or Tgradient ThermocyclersTM from Biometra. The whole PCR reaction is transferred into a PSQ plateTM (Pyrosequencing) and prepared using the Sample Prep ToolTM and SNP Reagent KitTM from Pyrosequencing according to their instructions.

20

Preparation of template for PyrosequencingTM:

Sample preparation using PSQ 96 Sample Prep Tool:

25

30

1. Mount the PSQ 96 Sample Prep Tool Cover onto the PSQ 96 Sample Prep Tool as follows: Place the cover on the desk, retract the 4 attachment rods by separating the handle from the magnetic rod holder, fit the magnetic rods into the holes of the cover plate, push the handle downward until a click is heard. The PSQ 96 Sample Prep Tool is now ready for use.
2. To transfer beads from one plate to another, place the covered tool into the PSQ 96 Plate containing the samples and lower the magnetic rods by separating the handle from the magnetic rod holder. Move the tool up and

down a few times then wait for 30-60 seconds. Transfer the beads into a new PSQ 96 plate containing the solution of choice.

3. Release the beads by lifting the magnetic rod holder, bringing it together with the handle. Move the tool up and down a few times to make sure that the beads are released.

All steps are performed at room temperature unless otherwise stated.

Immobilization of PCR product:

Biotinylated PCR products are immobilized on streptavidin-coated Dynabeads™ M-280 Streptavidin. Parallel immobilization of several samples are performed in the PSQ 96 Plate.

1. Mix PCR product, 20 µl of a well optimized PCR, with 25 µl 2X BW-buffer II. Add 60-150 µg Dynabeads. It is also possible to add a mix of Dynabeads and 2X BW-buffer II to the PCR product yielding a final BW-buffer II concentration of approximately 1x.
2. Incubate at 65°C for 15 min agitation constantly to keep the beads dispersed. For optimal immobilization of fragments longer than 300 bp use 30 min incubation time.

Strand separation:

4. For strand separation, use the PSQ 96 Sample Prep Tool to transfer the beads with the immobilized sample to a PSQ 96 Plate containing 50 µl 0.50 M NaOH per well. Release the beads.
5. After approximately 1 min, transfer the beads with the immobilized strand to a PSQ 96 Plate containing 99 µl 1x Annealing buffer per well and mix thoroughly.
6. Transfer the beads to a PSQ 96 Plate containing 45 µl of a mix of 1x Annealing buffer and 3-15 pmoles sequencing primer per well.

7. Heat at 80°C for 2 minutes in the PSQ 96 Sample Prep Thermoplate and move to room temperature.
8. After reaching room temperature, continue with the sequencing reaction.

5

Sequencing reaction:

1. Choose the method to be used ("SNP Method") and enter relevant information in the PSQ 96 Instrument Control software.
2. Place the cartridge and PSQ 96 Plate in the PSQ 96 Instrument.
3. Start the run.

10

Genotyping using the ABI 7700/7900 instrument (TaqMan)

- 15 SNP genotyping using the TaqMan (Applied Biosystems/Perkin Elmer) was performed according to the manufacturer's instructions. The TaqMan assay is discussed by Lee et al., Nucleic Acids Research 1993, 21: 3761-3766.

20 **Genotyping with a service contractor:**

- 25 Qiagen Genomics, formerly Rapigene, is a service contractor for genotyping SNPs in patient samples. Their method is based on a primer extension method where two complementary primers are designed for each genotype that are labeled with different tags. Depending on the genotype only one primer will be elongated together with a certain tag. This tag can be detected with mass spectrometry and is a measure for the respective genotype. The method is described in the following patent: "Detection and identification of nucleic acid molecules - using tags which may be detected by non-fluorescent spectrometry or potentiometry" (WO 9727325).

Examples

To exemplify the present invention and its utility baySNP 28 will be used in the following:

5.

baySNP 28 is a C to T polymorphism and presumably resides in the gene of the human acidic 82 kDa protein (information taken from table 3). baySNP 28 was genotyped in various patient cohorts using the primers from table 2. As a result the following number of patients carrying different genotypes were found (information combined from tables 3 and 5a):

10.

baySNP	Cohort	Total	Genotype 11 "CC"	Genotype 12 "CT"	Genotype 22 "TT"
28	HELD_FEM_HIRES	12	1	2	9
28	HELD_FEM_LORES	22	3	12	7

When comparing the number of female patients exhibiting a high response to statin therapy (HELD_FEM_HIRES) with the control cohort (HELD_FEM_LORES) it appears that the number of low responders carrying the CT genotype is increased. This points to a lower statin response among female individuals with the CT genotype. Applying statistical tests on those findings the following p-values were obtained (data taken from table 5b):

15.

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL
28	HELD_FEM_EFF	0,0506	0,0508	0,0442

20.

As at least one of the GTYPE p values is below 0,05 the association of genotype and statin response phenotype is regarded as statistically significant. I.e. the analysis of a patient's genotype can predict the response to statin therapy. In more detail one can calculate the relative risk to exhibit a certain statin response phenotype when carrying a certain genotype (data taken from table 6a):

25.

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3
28	HELD_FEM_EFF	CC	CT	TT	0,68	0,29	3,38

In case of baySNP 28 the risk to exhibit a high responder phenotype is 3,38 times higher when carrying the TT genotype. This indicates that a TT polymorphism in baySNP 28 is an independent risk factor for high statin response in females. On the other hand carriers of a CT or CC genotype have a reduced risk of being a high responder.

In addition statistical associations can be calculated on the basis on alleles. This calculation would identify risk alleles instead of risk genotypes.

In case of baySNP 28 the following allele counts were obtained (data combined from tables 3 and 5a):

baySNP	Cohort	Total	Allele 1 "C"	Allele 2 "T"
28	HELD_FEM_HIRES	12	4	20
28	HELD_FEM_LORES	22	18	26

When comparing the number of female patients with high statin response (HELD_FEM_HIRES) with the control cohort (HELD_FEM_LORES) it appears that the number of high responders carrying the T allele is increased, whereas the number of high responders carrying the C allele is diminished. This points to a higher statin response among female individuals with the T allele. Applying statistical tests on those findings the following p-values were obtained (data taken from table 5b):

BAYSNP	COMPARISON	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
28	HELD_FEM_EFF	0,0411	0,0579	0,0349

As at least one of the ALLELE p values is below 0,05 the association of allele and statin response phenotype is regarded as statistically significant (in this example significant p values were obtained from two statistical tests). I.e. also the analysis of a patient's alleles from baySNP 28 can predict the extend of statin response. In more detail one can calculate the relative risk to exhibit a certain statin response phenotype when carrying a certain allele (data taken from table 6b):

baySNP	Allele 1	Allele 2	COMPARISON	RR1	RR2
28	C	T	HELD_FEM_EFF	0,42	2,39

In case of baySNP 28 the risk to exhibit a high responder phenotype is 2,39 times higher when carrying the T allele. This indicates that the T allele of baySNP28 is an independent risk factor for a high statin response in females. In other words those patients should receive lower doses of statins in order to avoid ADR. However due to their 'high responder' phenotype they will still benefit from the drug. In turn carriers of the C allele should receive higher drug doses in order to experience a beneficial therapeutic effect.

Another example is baySNP 29, which is taken to exemplify polymorphisms relevant for adverse drug reactions. baySNP 29 was found significant when comparing male patients with severe ADR to the respective controls (as defined in table 1b).

The relative risk ratios for the genotypes AA, AG and GG were as follows (data taken from table 6a):

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3
29	HELD_MAL_ADR5ULN	AA	AG	GG	3,15	0,66	0,32

In this case male patients carrying the AA genotype have a 3,15 times higher risk to suffer from ADR. In other words those patients should either receive lower doses of statins or switch to an alternative therapy in order to avoid ADR. On the other hand male patients with AG or GG genotypes appear to be more resistant to ADR and hence better tolerate statin therapy.

As can be seen from the following tables some of the associations that are disclosed in the present invention are indicative for more than one phenotype. baySNP 1837 is for example linked to ADR, but also to the risk to suffer from CVD (table 6).

Table 1a Definition of "good" and "bad" serum lipid levels

	"Good"	"Bad"
LDL-Cholesterol [mg/dL]	125 -150	170 - 200
Cholesterol [mg/dL]	190 - 240	265 - 315
HDL-Cholesterol [mg/dL]	60 -105	30 - 55
Triglycerides [mg/dL]	45 - 115	170 - 450

Table 1b Definition of drug response phenotypes

Low responder	Decrease of serum LDL of at least 10% and at most 50% upon administration of 0.8 mg Cerivastatin (female patients)
High responder	Decrease of serum LDL of at least 50% upon administration of 0.4 mg Cerivastatin (female patients)
Very low responder	Decrease of serum LDL of at least 10% and at most 35% upon administration of 0.8 mg Cerivastatin (female patients)
Very high responder	Decrease of serum LDL of at least 55% upon administration of 0.4 mg Cerivastatin (female patients)

Ultra low responder	Decrease of serum LDL of at least 10% and at most 25% upon administration of 0.8 mg Cerivastatin (female patients)
Ultra high responder	Decrease of serum LDL of at least 60% upon administration of 0.4 mg Cerivastatin (female patients)
Tolerant patient	No diagnosis of muscle cramps, muscle pain, muscle weakness, myalgia or myopathy AND serum CK levels below 70 mg/dl in women and below 80 mg/dl in men.
ADR patient (CK increase at least 2×ULN)	Diagnosis of muscle cramps, muscle pain, muscle weakness, myalgia or myopathy OR serum CK levels higher than 140 mg/dl in women and 160 mg/dl in men.
Advanced ADR patient [ADR3] (advanced CK increase, at least 3×ULN)*	Serum CK levels higher than 210 mg/dl in women and 240 mg/dl in men
Severe ADR patient [ADR5] (severe CK increase, at least 5×ULN)*	Serum CK levels higher than 350 mg/dl in women and 400 mg/dl in men

*: When assembling the cohorts for advanced and severe ADR we focused on the CK serum levels as those provide a more independent measure of statin related ADR.

Table 1c Definition of “high” and “low” serum HDL cholesterol levels

	Male individuals	Female individuals
,High' HDL-Cholesterol [mg/dL]	≥ 80	≥ 104
,Low' HDL-Cholesterol [mg/dL]	≤ 35	≤ 37

An informed consent was signed by the patients and control people. Blood was taken by a physician according to medical standard procedures.

Samples were collected anonymous and labeled with a patient number.

DNA was extracted using kits from Qiagen.

Table 2a Oligonucleotide primers used for genotyping using mass spectrometry

The baySNP number refers to an internal numbering of the PA SNPs. Primer sequences are listed for preamplification of the genomic fragments (primers EF and ER) and for subsequent allele specific PCR of the SNP.

baySNP	SNP	Name	Sequence
28	C137T	CF	gggacggtcggtagatTCTAGAATTGTGCTTCCC
28	C137T	EF	TGTCCAGTGTTAGGAAAAA
28	C137T	ER	GACGATGCCTTCAGCACAGATGTGGCTTCTGTATGAG
28	C137T	TF	gctggctcggtcaagaTCTAGAATTGTGCTTCCT
29	A464G	AF	gggacggtcggtagatCATCGGTCAGTGTCCTCCA
29	A464G	EF	GATGTCTGTCTCCTTGATGT
29	A464G	ER	GACGATGCCTTCAGCACAAATGTGGGGGTTTTATTTT
29	A464G	GF	gctggctcggtcaagaCATCGGTCAGTGTCCTCCG
52	C397G	CR	gggacggtcggtagatTATTTTATAATGCAAAAG
52	C397G	EF	GACGATGCCTTCAGCACAGTGAATTGCCAGATTAGTG
52	C397G	ER	TCTAAAGTGCTGGGATTG
52	C397G	GR	gctggctcggtcaagaTATTTTATAATGCAAAAC
56	A429G	AF	gggacggtcggtagatAAGGTCTTTGTACGTGTA

baySNP	SNP	Name	Sequence
56	A429G	EF	CCAGGTACTGCCTTACAAA
56	A429G	ER	GACGATGCCTTCAGCACAGCTCCCAAAATAAATCACTC
56	A429G	GF	gctggctcggtcaagaAAGGTCTTTGTACGTGTG
89	A159G	AR	gggacggtcggtagatTGGAGTCGGGGGAGTCAT
89	A159G	EF	GACGATGCCTTCAGCACATAGTTCAAGGGTAAAGGA
89	A159G	ER	GAGGACGAGATGTAAGAG
89	A159G	GR	gctggctcggtcaagaTGGAGTCGGGGGAGTCAC
90	C154T	CF	gggacggtcggtagatCAGCGCATCCTGAACCAC
90	C154T	EF	GCTGGAACGAGTTCATCCT
90	C154T	ER	GACGATGCCTTCAGCACAGGACCCACCTTTCTTGT
90	C154T	TF	gctggctcggtcaagaCAGCGCATCCTGAACCAT
99	C58T	CR	gggacggtcggtagatTCCTGCTCTTTTCTCTAG
99	C58T	EF	GACGATGCCTTCAGCACACACTGACTGCTTACTCTACC
99	C58T	ER	TACTGTGTCTCAGCTCCA
99	C58T	TR	gctggctcggtcaagaTCCTGCTCTTTTCTCTAA
140	C468T	CR	gggacggtcggtagatGTGAATCCCAATACGAAG
140	C468T	EF	GACGATGCCTTCAGCACATAAAAAATAACCAGGTACTCCA
140	C468T	ER	GATGAGTCCTTCACCAAACATACA
140	C468T	TR	gctggctcggtcaagaGTGAATCCCAATACGAAA
152	A587G	AF	gggacggtcggtagatGGTGGGAGGTTCCAGCCA
152	A587G	EF	GCAGGAAGAAAGCTAGAA
152	A587G	ER	GACGATGCCTTCAGCACAAGGCAGGATAATGACAAC
152	A587G	GF	gctggctcggtcaagaGGTGGGAGGTTCCAGCCG
214	A209G	AF	gggacggtcggtagatCATTTCCACCTCACCAA
214	A209G	EF	AGGTATTCCCGGCGTTTC
214	A209G	ER	GACGATGCCTTCAGCACATGTTGTGCGTCTGCTTCC
214	A209G	GF	gctggctcggtcaagaCATTTCCACCTCACCAAG
221	C339G	CF	gggacggtcggtagatTGTGAAGAACTGTTGCTC
221	C339G	EF	CTGAAGCTCATCTGCCTTCT
221	C339G	ER	GACGATGCCTTCAGCACATCCCCTTCCTTCTTACCT
221	C339G	GF	gctggctcggtcaagaTGTGAAGAACTGTTGCTG

baySNP	SNP	Name	Sequence
224	C189T	CR	gggacggtcggtagatGCCCGCTTTTCTTCATCG
224	C189T	EF	GACGATGCCTTCAGCACACTGTCTTCAAGGGCTTACAC
224	C189T	ER	TCCAACCTTCAGGCAAAAC
224	C189T	TR	gctggctcggtcaagaGCCCGCTTTTCTTCATCA
294	C465T	CR	gggacggtcggtagatCCCAAGGCCAACAGGGAG
294	C465T	EF	GACGATGCCTTCAGCACAGCATTCTTATGCCAGTGTTC
294	C465T	ER	ATCCATCCCATCCTGTGT
294	C465T	TR	gctggctcggtcaagaCCCAAGGCCAACAGGGAA
307	C215T	CR	gggacggtcggtagatGAGTGGGTGCTGTTCCCG
307	C215T	EF	GACGATGCCTTCAGCACAGTTACTGCCTCTCTGACC
307	C215T	ER	AGTGTGACCTGCTCTCTT
307	C215T	TR	gctggctcggtcaagaGAGTGGGTGCTGTTCCCA
411	A369T	ER	gacgatgccttcagcacaAACACATTCCCCCTCTAC
411	A369T	EF	GTCTCTATTCCAAGCCAAG
411	A369T	AF	gggacggtcggtagatCCCGCTCCAGCTCCTCA
411	A369T	TF	gctggctcggtcaagaCCCGCTCCAGCTCCTCT
449	C323G	CR	gggacggtcggtagatCCGCTTCTGCTTCTGCTG
449	C323G	EF	GACGATGCCTTCAGCACAAAGGAGAAGAGGGAGGAGA
449	C323G	ER	GGAGCACGTAAGGAGAAA
449	C323G	GR	gctggctcggtcaagaCCGCTTCTGCTTCTGCTC
466	C123T	CF	gggacggtcggtagatGGCCAGGGGCTGGAGGGC
466	C123T	EF	TCTTCAGTTCTCTCAGCTTC
466	C123T	ER	GACGATGCCTTCAGCACATCACTAGGGGCTCTTACC
466	C123T	TF	gctggctcggtcaagaGGCCAGGGGCTGGAGGGT
472	A497G	AR	gggacggtcggtagatTCCTCCCGCTGCTTCAGT
472	A497G	EF	GACGATGCCTTCAGCACATCACTTACCCATCATACTTCTTT TTC
472	A497G	ER	AATCCTGCCTCCACCTT
472	A497G	GR	gctggctcggtcaagaTCCTCCCGCTGCTTCAGC
542	A402G	AR	gggacggtcggtagatAGAAATTCCCTCCCAACT
542	A402G	EF	GACGATGCCTTCAGCACATGATTGAGCCAGTTGTTT

baySNP	SNP	Name	Sequence
542	A402G	ER	GGGGTGTATTTTGAGAGTG
542	A402G	GR	gctggctcggtcaagaAGAAATTCCTCCCAACC
739	C87G	CR	gggacggtcggtagatGCTGGTTTGACTGGACGG
739	C87G	EF	GACGATGCCTTCAGCACAACTTGGTATAATCCTTTCC
739	C87G	ER	AGGCAACCTAATCCACTT
739	C87G	GR	gctggctcggtcaagaGCTGGTTTGACTGGACGC
821	A140C	AF	gggacggtcggtagatAGTGCTGTGATACCTGGA
821	A140C	CF	gctggctcggtcaagaAGTGCTGTGATACCTGGC
821	A140C	EF	ACACCCACAAAACAAGAA
821	A140C	ER	GACGATGCCTTCAGCACAGGAACAAGGACATAAAAGAG
1005	A257G	AR	gggacggtcggtagatAGGAAATGTTAGCCCTGT
1005	A257G	EF	GACGATGCCTTCAGCACACTCCACTTCTCTATGCCTC
1005	A257G	ER	GTCCCCAGCTATGTATTGT
1005	A257G	GR	gctggctcggtcaagaAGGAAATGTTAGCCCTGC
1055	A287T	AF	gggacggtcggtagatCTCAGGGAGGGAGAGAGA
1055	A287T	EF	GGGACAGACAGACAGACA
1055	A287T	ER	GACGATGCCTTCAGCACACAACCTCCTTCTTCAGCAC
1055	A287T	TF	gctggctcggtcaagaCTCAGGGAGGGAGAGAGT
1056	A354G	AR	gggacggtcggtagatGCGGCTGCCCCGTCCTGT
1056	A354G	EF	GACGATGCCTTCAGCACAGTGTGTCTATGTGTCTGTGTG
1056	A354G	ER	CGGACTTCTCCTTCTTGT
1056	A354G	GR	gctggctcggtcaagaGCGGCTGCCCCGTCCTGC
1085	A251G	EF	TAGGGTAAGCAGCAAGAG
1085	A251G	ER	CACAAGGCAAGAGATAACA
1085	A251G	AF	gggacggtcggtagatCAGGCAAGATAGACAGCA
1085	A251G	GF	gctggctcggtcaagaCAGGCAAGATAGACAGCG
1086	A104G	EF	GTGCCCATACGAACAGAATAG
1086	A104G	ER	TGCCAAGTACCCCAAGAG
1086	A104G	AR	gggacggtcggtagatCCATTCCTCCCCAGACAT
1086	A104G	GR	gctggctcggtcaagaCCATTCCTCCCCAGACAC
1092	C1687	CF	gggacggtcggtagatCGTGCGAGCAGCGAAAGC

baySNP	SNP	Name	Sequence
	G		
1092	C1687	EF	CCAGAGAGAAGTCGAGGAAGAGA
	G		
1092	C1687	ER	GACGATGCCTTCAGCACAGTCACCCCCAAAAGCAGG
	G		
1092	C1687	GF	gctggctcggtcaagaCGTGCGAGCAGCGAAAGG
	G		
1096	G454T	EF	GACGATGCCTTCAGCACACTTTTCCTCCTAGCCCAC
1096	G454T	ER	AAGTGATGTAACCCTCCTCTC
1096	G454T	GR	gggacggtcggtagatTCAGCTATAAATAGGGCC
1096	G454T	TR	gctggctcggtcaagaTCAGCTATAAATAGGGCA
1101	C249T	CR	gggacggtcggtagatTGATGGCGGGTGCCAAGG
1101	C249T	EF	GACGATGCCTTCAGCACAGCTCTTTCCTTTGCTTCC
1101	C249T	ER	CACTGGGGGTCCTCTTAC
1101	C249T	TR	gctggctcggtcaagaTGATGGCGGGTGCCAAGA
1204	A307G	AR	gggacggtcggtagatCAAGGGCACTCACATTAT
1204	A307G	EF	GACGATGCCTTCAGCACAGCTCTTGCGTCTGTTTCC
1204	A307G	ER	TTTCCCTTCTGTCCCCTT
1204	A307G	GR	gctggctcggtcaagaCAAGGGCACTCACATTAC
1504	C180T	CF	gggacggtcggtagatGTGACTTTTGTTCCAC
1504	C180T	EF	AACTCGGGGTCACTGGTCT
1504	C180T	ER	GACGATGCCTTCAGCACACAGCGGGTATGGAGGATG
1504	C180T	TF	gctggctcggtcaagaGTGACTTTTGTTCCCAT
1511	G153T	EF	ACACCAGTTCTCCCTCCT
1511	G153T	ER	GACGATGCCTTCAGCACACCCACCTTTCCTAATCCT
1511	G153T	GF	gggacggtcggtagatTTGGGACTCTGCGTCAAG
1511	G153T	TF	gctggctcggtcaagaTTGGGACTCTGCGTCAAT
1524	A284C	AF	gggacggtcggtagatCTCTCAAAGCCCACACAA
1524	A284C	CF	gctggctcggtcaagaCTCTCAAAGCCCACACAC
1524	A284C	EF	AGAAAAAGAAAAGGAAAAAGA
1524	A284C	ER	GACGATGCCTTCAGCACAGGAAAGTTACAAGGCTATGA

baySNP	SNP	Name	Sequence
1556	C367G	CR	gggacggtcggtagatACCTGCCTCTAAGGTCTG
1556	C367G	EF	GACGATGCCTTCAGCACAAAGGAGAAGACAGTTCAAGG
1556	C367G	ER	ACAGTTGCCAGAGAAAAG
1556	C367G	GR	gctggctcggtcaagaACCTGCCTCTAAGGTCTC
1561	A251C	EF	TCACTTGCCTCTACTCCA
1561	A251C	ER	ATACCAGAAAGACTAAGCTCC
1561	A251C	AF	gggacggtcggtagatGGGTGAGCTCTGTGGGCA
1561	A251C	CF	gctggctcggtcaagaGGGTGAGCTCTGTGGGCC
1582	C389T	CR	gggacggtcggtagatCCAAGGGTTATGGCAGGG
1582	C389T	EF	GACGATGCCTTCAGCACACCTGACTATTTGGGGTTGTG
1582	C389T	ER	ATCGCTCTCTGCTTCTGCT
1582	C389T	TR	gctggctcggtcaagaCCAAGGGTTATGGCAGGA
1638	A443G	AR	gggacggtcggtagatCCAAAACCCCAGCGCTGT
1638	A443G	EF	GACGATGCCTTCAGCACACTCTTTATCCTGCTTATGGT
1638	A443G	ER	CCAAGCTCACTCTGTAGG
1638	A443G	GR	gctggctcggtcaagaCCAAAACCCCAGCGCTGC
1662	C251T	EF	AATACAATGGAAGCCAAG
1662	C251T	ER	CCTAATCGAACAGAAAGG
1662	C251T	CF	gggacggtcggtagatCCAGTCTCCATCCACTTC
1662	C251T	TF	gctggctcggtcaagaCCAGTCTCCATCCACTTT
1714	A376G	AF	gggacggtcggtagatTGAACGGCATGACGGGGA
1714	A376G	EF	AAGTGTTTCTGCTGTGCCT
1714	A376G	ER	GACGATGCCTTCAGCACACAAGTCCTGGTTTTCCATC
1714	A376G	GF	gctggctcggtcaagaTGAACGGCATGACGGGGG
1722	C89T	CF	gggacggtcggtagatACCCCAGGATGCCCACAC
1722	C89T	EF	GTTTATCCTCCTCATGTCC
1722	C89T	ER	GACGATGCCTTCAGCACAGTTACCTTTTCCACCTCTC
1722	C89T	TF	gctggctcggtcaagaACCCCAGGATGCCCACAT
1757	A210G	AF	gggacggtcggtagatGGAAACAAACCAAAATGA
1757	A210G	EF	CCAGCACCCAAAATAAGA
1757	A210G	ER	GACGATGCCTTCAGCACATAAGTTGAAGCCCTCCC

baySNP	SNP	Name	Sequence
1757	A210G	GF	gctggctcgggtcaagaGGAAACAAACCAAAATGG
1765	A240G	AF	gggacgggtcggtagatGGCTTCACGGAGGAAGAA
1765	A240G	EF	TTAGGAGCTGTGAGGTATG
1765	A240G	ER	GACGATGCCTTCAGCACATAAGATGGAGCAGGGTAG
1765	A240G	GF	gctggctcgggtcaagaGGCTTCACGGAGGAAGAG
1776	A200G	AF	gggacgggtcggtagatAAAGGGCTCCCAACACCA
1776	A200G	EF	TGAGCACAAGATCAGAGAGG
1776	A200G	ER	GACGATGCCTTCAGCACAAAGACAGAGACGCAGGAATG
1776	A200G	GF	gctggctcgggtcaagaAAAGGGCTCCCAACACCG
1799	C370T	CF	gggacgggtcggtagatAGGGACAACCAAGTGAC
1799	C370T	EF	ATCATCAGAACAGCCCTAC
1799	C370T	ER	GACGATGCCTTCAGCACACAAGCCCACCTACTTACTC
1799	C370T	TF	gctggctcgggtcaagaAGGGACAACCAAGTGAT
1806	A201G	AF	gggacgggtcggtagatTGGGCGTCCTGGTGGGCA
1806	A201G	EF	TCTTCGGGCTAACTCTTT
1806	A201G	ER	GACGATGCCTTCAGCACACTGTCACTCCAAACCTTCT
1806	A201G	GF	gctggctcgggtcaagaTGGGCGTCCTGGTGGGCG
1837	C413T	CF	gggacgggtcggtagatCTCAGCTTCATGCAGGGC
1837	C413T	EF	CCCACTCAGCCCTGCTCTT
1837	C413T	ER	GACGATGCCTTCAGCACAGCATCCTTGGCGGTCTTG
1837	C413T	TF	gctggctcgggtcaagaCTCAGCTTCATGCAGGGT
1870	C323T	CF	gggacgggtcggtagatCTCCTCATTCGCTCCTTC
1870	C323T	EF	CACCTCTTTTCTCCTTCTCTT
1870	C323T	ER	GACGATGCCTTCAGCACACCCACCCCTCTATCTAC
1870	C323T	TF	gctggctcgggtcaagaCTCCTCATTCGCTCCTTT
1882	C115T	CR	gggacgggtcggtagatGTCCCCACAAGTCCTCG
1882	C115T	EF	GACGATGCCTTCAGCACAGACCTGTACCCTTTACCC
1882	C115T	ER	TGTTTCCCTGTCTGTTTC
1882	C115T	TR	gctggctcgggtcaagaGTCCCCACAAGTCCTCA
1988	C214T	CF	gggacgggtcggtagatGTGACTCGGTCTATACC
1988	C214T	EF	GTGGGCTGTGATTGTGTT

baySNP	SNP	Name	Sequence
1988	C214T	ER	GACGATGCCTTCAGCACATCTCGTCGTCGTAGTAGTTGT
1988	C214T	TF	gctggctcggtcaagaGTGACTCGGTCTTATACT
2000	C349T	CR	gggacggtcggtagatAGTATGGTAATTAGGAAG
2000	C349T	EF	GACGATGCCTTCAGCACACTGACACTGAGCCACAAC
2000	C349T	ER	AACTGATGAGCAAGAAGGA
2000	C349T	TR	gctggctcggtcaagaAGTATGGTAATTAGGAAA
2071	A338G	AR	gggacggtccgtagatAAAATTGTTTCCTGTGAT
2071	A338G	EF	GACGATGCCTTCAGCACACATTGCTATTCTCAGGCTATA
2071	A338G	ER	CCCATTCTCTGCTTGACAGT
2071	A338G	GR	gctggctcggtcaagaAAAATTGTTTCCTGTGAC
2078	G876T	EF	CCAGAGAGGGGATAAAGA
2078	G876T	ER	GACGATGCCTTCAGCACAGAGTGTCAAGAGGAACAGG
2078	G876T	GF	gggacggtcggtagatTGGCTGCTGAGGTCTGAG
2078	G876T	TF	gctggctcggtcaagaTGGCTGCTGAGGTCTGAT
2085	G415T	EF	GCTTTTCTTTTCATTACATC
2085	G415T	ER	GACGATGCCTTCAGCACACCTCTTTTAGAATCAGAGACA
2085	G415T	GF	gggacggtcggtagatGGTAGTGTTACCAGAAAG
2085	G415T	TF	gctggctcggtcaagaGGTAGTGTTACCAGAAAT
2095	A406G	AR	gggacggtcggtagatTGTGCACCGGGATATTTT
2095	A406G	EF	GACGATGCCTTCAGCACAATGTGTGCTTGGGTTCTT
2095	A406G	ER	GGTGTTCCTCCTCCTCTCT
2095	A406G	GR	gctggctcggtcaagaTGTGCACCGGGATATTTT
2119	A67G	AR	gggacggtcggtagatGTGGGCACCAAACGCTAT
2119	A67G	EF	GACGATGCCTTCAGCACAGATGTAGGGCTGGAAGTG
2119	A67G	ER	TCAAGAAAAATGGGAGTTG
2119	A67G	GR	gctggctcggtcaagaGTGGGCACCAAACGCTAC
2141	A176G	EF	TGTAGCATCGGTAGGTTC
2141	A176G	ER	CAACATCAGACTTTCTTTTTC
2141	A176G	AR	gggacggtcggtagatTGGTACAGGGCTAGTTTT
2141	A176G	GR	gctggctcggtcaagaTGGTACAGGGCTAGTTTC
2182	A318G	AF	gggacggtcggtagatAGGCGGGCCAAGGGTGAA

baySNP	SNP	Name	Sequence
2182	A318G	EF	TTCTCTCTCCCCTTCTGT
2182	A318G	ER	GACGATGCCTTCAGCACATAAATGTTCACTCTTCTTGCT
2182	A318G	GF	gctggctcggtcaagaAGGCGGGCCAAGGGTGAG
2234	G296T	EF	GGGTTGTTCCAGGGCGCTATT
2234	G296T	ER	GACGATGCCTTCAGCACATGTGGAGAGGCCGGGTGC
2234	G296T	GF	gggacggtcggtagatGAACCAGCCCCCTGGAAG
2234	G296T	TF	gctggctcggtcaagaGAACCAGCCCCCTGGAAT
2281	A227C	AR	gggacggtcggtagatCAGGCTTGGAGACCTGGT
2281	A227C	CR	gctggctcggtcaagaCAGGCTTGGAGACCTGGG
2281	A227C	EF	GACGATGCCTTCAGCACAGGGTATTAGTTGGAAGG
2281	A227C	ER	AAGGCAAGGTTCTTAGTTG
2298	A77C	AR	gggacggtcggtagatTCTAAAAGCACTTGAAAT
2298	A77C	CR	gctggctcggtcaagaTCTAAAAGCACTTGAAAG
2298	A77C	EF	GACGATGCCTTCAGCACACCTGCTAGTGTCTTCTGG
2298	A77C	ER	TGTAAGTATAGGTGGTGG
2341	C286T	CR	gggacggtccgtagatTGAAGATTCTGCTCAGCG
2341	C286T	EF	GACGATGCCTTCAGCACAAAGGGCCCGGGACTCAT
2341	C286T	ER	TTTGGGGTCCTGCGGATG
2341	C286T	TR	gctggctcggtcaagaTGAAGATTCTGCTCAGCA
2357	A165G	AF	gggacggtcggtagatCAAAGAAGACGAAAATGA
2357	A165G	EF	CTCAAGTTTGTTACTGATTTCTC
2357	A165G	ER	GACGATGCCTTCAGCACAGGGTTACGTCTGCTCTTC
2357	A165G	GF	gctggctcggtcaagaCAAAGAAGACGAAAATGG
2366	G50T	EF	GACGATGCCTTCAGCACACTGCTCCGAAACACGGTC
2366	G50T	ER	GCATCTTCAGCCCTTCTTACTCT
2366	G50T	GR	gggacggtcggtagatCTCCTGGGCACCACGGGC
2366	G50T	TR	gctggctcggtcaagaCTCCTGGGCACCACGGGA
2995	A299C	ER	gacgatgccttcagcacatGGGATTAGACACGAGAG
2995	A299C	EF	AAAGAACTGGAAGAAGGAA
2995	A299C	AF	gggacggtcggtagatGTCACCTCCTTTCCACTA
2995	A299C	CF	gctggctcggtcaagaGTCACCTCCTTTCCACTC

baySNP	SNP	Name	Sequence
3360	G777T	ER	gacgatgccttcagcacaAGAAAAATGAGAGGGAAAAAC
3360	G777T	EF	GATGAAGGGAAATGGAAC
3360	G777T	GF	gggacggtcggtagatCCAACCTATATAGGAGCCG
3360	G777T	TF	gctggctcggtcaagaCCAACCTATATAGGAGCCT
3464	A110G	EF	CTGAACCGAGGAGATTTTT
3464	A110G	ER	TGATGCTTACAGAACTGGG
3464	A110G	AF	gggacggtcggtagatGTGTAGTGGGCAGGGTTA
3464	A110G	GF	gctggctcggtcaagaGTGTAGTGGGCAGGGTTG
3975	A65C	EF	gacgatgccttcagcacaAAAAGAACCCTGGTGAAG
3975	A65C	ER	CCCTGATAAAAGAGATGGA
3975	A65C	AR	gggacggtcggtagatCGCATGGGAGTCAGGGAT
3975	A65C	CR	gctggctcggtcaagaCGCATGGGAGTCAGGGAG
3976	A239G	EF	gacgatgccttcagcacaATGAGGGAGCAAGACAAG
3976	A239G	ER	TGATAAAAGAGATGGAAGGAG
3976	A239G	AR	gggacggtcggtagatGTCACTGTTTGTCACTGT
3976	A239G	GR	gctggctcggtcaagaGTCACTGTTTGTCACTGC
4206	A304T	EF	gacgatgccttcagcacaCTTTTATAGCCAAGTGGAG
4206	A304T	ER	GGATCTGAGGAATCTGTG
4206	A304T	AR	gggacggtcggtagatACCAGGCAGAGAGAAAAAT
4206	A304T	TR	gctggctcggtcaagaACCAGGCAGAGAGAAAAA
4912	A74G	EF	CTTCACTGAGCGTCCGCAGAG
4912	A74G	ER	CCGTCGGCCCGATTCA
4912	A74G	AR	CAGGCGAGCCTCAGCCCT
4912	A74G	GR	CAGGCGAGCCTCAGCCCC
4925	A251C	EF	TCATTTCCTAATTACCTCC
4925	A251C	ER	CCTCTTTCCCATCTCCCT
4925	A251C	AF	gggacggtcggtagatAGCCAGGAGCCTGCGTCA
4925	A251C	CF	gctggctcggtcaagaAGCCAGGAGCCTGCGTCC
4966	A251G	EF	CATTGCTCTTCTCTCTGT
4966	A251G	ER	GTGTCATCATTCCTTTCTTG
4966	A251G	AR	gggacggtcggtagatTCAGAGACATGAGTCCAT

baySNP	SNP	Name	Sequence
4966	A251G	GR	gctggctcggtagatTCAGAGACATGAGTCCAC
5014	A2057 G	ER	gacgatgccttcagcacaCACCTGTCCCACCCTATTT
5014	A2057 G	EF	GTCCTGAACCCCCATTCT
5014	A2057 G	AF	gggacggtagatGCCTGCACTGCGTTCCTA
5014	A2057 G	GF	gctggctcggtagatGCCTGCACTGCGTTCCTG
5296	A251G	EF	GTCCTCTGCCTTCTGCTT
5296	A251G	ER	ATTTGCCCACTGCCCTTC
5296	A251G	AF	gggacggtagatTGGCTGCAGGTGCGTCCA
5296	A251G	GF	gctggctcggtagatTGGCTGCAGGTGCGTCCG
5298	C172T	EF	GCCACACACCTTAACA
5298	C172T	ER	AAAGTTCTCTGCCTCCAA
5298	C172T	CF	gggacggtagatAGCTCTCAGCTGGGGTGC
5298	C172T	TF	gctggctcggtagatAGCTCTCAGCTGGGGTGT
5457	A134G	EF	AGCAGAATGGGCAATAGA
5457	A134G	ER	AGAGATGTGGGCAGAGAA
5457	A134G	AF	gggacggtagatGGAAAGCCTACTTTCTTA
5457	A134G	GF	gctggctcggtagatGGAAAGCCTACTTTCTTG
5704	C61T	EF	ACAGCCATAACAGGAGTG
5704	C61T	ER	GGGTTACTCAACCTAAGAGA
5704	C61T	CR	gggacggtagatGTTCTCTTTGGGAAAACG
5704	C61T	TR	gctggctcggtagatGTTCTCTTTGGGAAAACA
5717	A1960 G	EF	gacgatgccttcagcacaGAACAGAAACCACAGAACC
5717	A1960 G	ER	GTCCCACCCTATTTTGAG
5717	A1960 G	AR	gggacggtagatCACTGGCCCACCTCCCTT
5717	A1960	GR	gctggctcggtagatCACTGGCCCACCTCCCTC

baySNP	SNP	Name	Sequence
	G		
5959	A71G	EF	gacgatgccttcagcacaACCATGCCTGACTTAACC
5959	A71G	ER	TTGTTTCCTGTCTCTTTC
5959	A71G	AR	gggacggctcggtagatGTTAAGAGGCTGGGCAGT
5959	A71G	GR	gctggctcggtcaagaGTTAAGAGGCTGGGCAGC
6162	C340G	EF	gacgatgccttcagcacaAGTGTTGTTAGGAGCAAAG
6162	C340G	ER	CTTAGGAAACTGAGGTGG
6162	C340G	CR	gggacggctcggtagatCTGCAGCCTGGGCAACAG
6162	C340G	GR	gctggctcggtcaagaCTGCAGCCTGGGCAACAC
6236	C906T	ER	gacgatgccttcagcacaTGGACACATTTGAGCTTT
6236	C906T	EF	CTTCCCCAGAGATGACTAC
6236	C906T	CF	gggacggctcggtagatCCCCATCCTACTCAGCAC
6236	C906T	TF	gctggctcggtcaagaCCCCATCCTACTCAGCAT
6744	C348T	ER	gacgatgccttcagcacaAGTTACAGTGAGCCAAGA
6744	C348T	EF	AGGTGAAGAAAGCAAATAAC
6744	C348T	CF	gggacggctcggtagatTGGTGTGTGTTTTGTTC
6744	C348T	TF	gctggctcggtcaagaTGGTGTGTGTTTTGTTC
7133	C63G	EF	TTGAGACCCTACAGAGCCA
7133	C63G	ER	GGCAAGCTGAGGTGAAAG
7133	C63G	CR	gggacggctcggtagataATAAGGTAAGAAATGAG
7133	C63G	GR	gctggctcggtcaagaATAAGGTAAGAAATGAC
8210	A251G	EF	TAATTTCTAATGGCCTTCC
8210	A251G	ER	TCACTTACTCCCTGATGTCT
8210	A251G	AR	gggacggctcggtagatCATTGGGTTTTCCCTCAT
8210	A251G	GR	gctggctcggtcaagaCATTGGGTTTTCCCTCAC
8592	C46T	ER	gacgatgccttcagcacaACATTTAGTGCCAACATCAC
8592	C46T	EF	CTCTTCCCTGAGACACCA
8592	C46T	CF	gggacggctcggtagatGAAGGTGAAGGCCAGAGC
8592	C46T	TF	gctggctcggtcaagaGAAGGTGAAGGCCAGAGT
8943	A251C	EF	GAGGCTGAGACAGAAGAA
8943	A251C	ER	GTTTGACATTAAAGAAAATGAG

baySNP	SNP	Name	Sequence
8943	A251C	AR	gggacggtcggtagatGGCTGGAGTGCAGTGATT
8943	A251C	CR	gctggctcggtcaagaGGCTGGAGTGCAGTGATG
9193	C88G	EF	CACGCTGTTGAGTGGG
9193	C88G	ER	CGCAGGTCTACGGTCA
9193	C88G	CR	gggacggtcggtagatCCCGGGTCTGAGGCTGCG
9193	C88G	GR	gctggctcggtcaagaCCCGGGTCTGAGGCTGCC
9516	A187G	EF	CACACACACACACACAC
9516	A187G	ER	GGTCCCTTACTTTCCTCTT
9516	A187G	AR	gggacggtcggtagatCCTATCCCTACTTCCCCT
9516	A187G	GR	gctggctcggtcaagaCCTATCCCTACTTCCCCC
9698	A251G	EF	GTGACCCCAAAGAGAGA
9698	A251G	ER	CTAGCTTGTTACTGCCTCC
9698	A251G	AF	gggacggtcggtagatGGCACGACCCCGCCCCCA
9698	A251G	GF	gctggctcggtcaagaGGCACGACCCCGCCCCCG
9883	A249G	EF	TCCACAACCTCAAACAC
9883	A249G	ER	CACAGTCCTGCAAGCTCA
9883	A249G	AR	gggacggtcggtagatCCGTGGCCGTGGCTCACT
9883	A249G	GR	gctggctcggtcaagaCCGTGGCCGTGGCTCACC
10481	A107T	ER	gacgatgccttcagcacaGTTGCGGGCTCCACTT
10481	A107T	EF	TAGCGGGACAGCGCTG
10481	A107T	AF	gggacggtcggtagatCCCGGCGCGCCTCGGAGA
10481	A107T	TF	gctggctcggtcaagaCCCGGCGCGCCTCGGAGT
10542	C367T	EF	gacgatgccttcagcacaAATACACTGGGTCTGCT
10542	C367T	ER	ATACTGCTGGCCTTTCTC
10542	C367T	CR	gggacggtcggtagatGGTCAGGGGAGCCCAGAG
10542	C367T	TR	gctggctcggtcaagaGGTCAGGGGAGCCCAGAA
10600	A251G	EF	CCTGGCAACTAACCTCTT
10600	A251G	ER	AGGCAGTCTCTGTCTACTC
10600	A251G	AR	gggacggtcggtagatATTGGCCCTGCTCAGGAT
10600	A251G	GR	gctggctcggtcaagaATTGGCCCTGCTCAGGAC
10621	C402T	EF	CCAGCCCTAAACCTAAA

baySNP	SNP	Name	Sequence
10621	C402T	ER	AACCTCTCAAGATCAGACAC
10621	C402T	CF	gggacggtcggtagatTTAGCACTTAATAAGTAC
10621	C402T	TF	gctggctcggtcaagaTTAGCACTTAATAAGTAT
10745	A251G	EF	CCCCACAACAAAGAAAGA
10745	A251G	ER	GAAGCCAACCTCTCCAACA
10745	A251G	AF	gggacggtcggtagatCAAGGATTTCAAAAACCA
10745	A251G	GF	gctggctcggtcaagaCAAGGATTTCAAAAACCG
10771	C64G	EF	gacgatgccttcagcacaCCAGGGAAGAGCAGAACC
10771	C64G	ER	TGTACGGGAAGAGGCAGA
10771	C64G	CR	gggacggtcggtagatAGGGTGACACAGGCCACG
10771	C64G	GR	gctggctcggtcaagaAGGGTGACACAGGCCACC
10870	A251G	EF	ATCCCATCCCAACACACA
10870	A251G	ER	CCGAGACCAAACCTCATTCAC
10870	A251G	AR	gggacggtcggtagatGGCAGAGCCTGAGTCACT
10870	A251G	GR	gctggctcggtcaagaGGCAGAGCCTGAGTCACC
10877	A251C	EF	CCTGTTTCTCAACCTTCTC
10877	A251C	ER	ATGGTCTATGGAACCTAATCT
10877	A251C	AF	gggacggtcggtagatGCACTGATTCTGCTTCCA
10877	A251C	CF	gctggctcggtcaagaGCACTGATTCTGCTTCCC
10948	G140T	EF	AAGGACAGGGTCAGGAAAG
10948	G140T	ER	CAGAGGGAGGAAGGAGGT
10948	G140T	GF	gggacggtcggtagatATGGAGGAGGGTGTCTGG
10948	G140T	TF	gctggctcggtcaagaATGGAGGAGGGTGTCTGT
11001	C286T	EF	gacgatgccttcagcacaTTCCCAAAGACCCACA
11001	C286T	ER	CCTCCACCGCTATCAC
11001	C286T	CR	gggacggtcggtagatTGGCTGCAGGACGTCCAG
11001	C286T	TR	gctggctcggtcaagaTGGCTGCAGGACGTCCAA
11001	C286T	EF	TTCCCAAAGACCCACA
11001	C286T	ER	CCTCCACCGCTATCAC
11001	C286T	CR	gggacggtcggtagatTGGCTGCAGGACGTCCAG
11001	C286T	TR	gctggctcggtcaagaTGGCTGCAGGACGTCCAA

baySNP	SNP	Name	S quence
11073	C215G	EF	CCCAACCACCCGTTCC
11073	C215G	ER	GCGCGGGAGCTAGAGA
11073	C215G	CF	gggacggtcggtagatGAAGCTGCGGGCCGGACC
11073	C215G	GF	gctggctcggtcaagaGAAGCTGCGGGCCGGACG
11153	C116T	EF	CGAGTGGAAGAAAAGTAGA
11153	C116T	ER	ATGACTGCCTGCCTAGAA
11153	C116T	CR	gggacggtcggtagataAAGATAGGGTAGAGGCCG
11153	C116T	TR	gctggctcggtcaagaAAGATAGGGTAGAGGCCA
11210	C194T	EF	GAGGAGTGAGGGAAAGTAAG
11210	C194T	ER	AAATGGAGAGAGATGGGA
11210	C194T	CF	gggacggtcggtagatCCAGGAAATGACATGATC
11210	C194T	TF	gctggctcggtcaagaCCAGGAAATGACATGATT
11248	C225T	EF	TGAGTTGAACAGCACTTGG
11248	C225T	ER	AGGGTAAGGGAGGGAAAA
11248	C225T	CR	gggacggtcggtagatTGATTCTTTTCGCTTGGCG
11248	C225T	TR	gctggctcggtcaagaTGATTCTTTTCGCTTGGCA
11372	A251G	EF	TAGAAAAGAAGAAAAATCAA
11372	A251G	ER	ACACACACACACACACAC
11372	A251G	AR	gggacggtcggtagatCATCACCTTTTAGTTTCT
11372	A251G	GR	gctggctcggtcaagaCATCACCTTTTAGTTTCC
11449	C251G	EF	ACAGAAGAACAACAACAAAC
11449	C251G	ER	TGCGTATGAGGTAAAGAGA
11449	C251G	CF	gggacggtcggtagatATGAGTGAAGCCTGTCTC
11449	C251G	GF	gctggctcggtcaagaATGAGTGAAGCCTGTCTG
11450	A251T	EF	ACAGAAGAACAACAACAAAC
11450	A251T	ER	TGCGTATGAGGTAAAGAGA
11450	A251T	AR	gggacggtcggtagatGGACCATAATCTTGAAGT
11450	A251T	TR	gctggctcggtcaagaGGACCATAATCTTGAAGA
11470	C251T	EF	GCTTGTCTTGTCTGATAGGTG
11470	C251T	ER	CAACGTGAGAATTTCCAAAAT
11470	C251T	CR	gggacggtcggtagatTGAGAATTTCCAAAATAG

baySNP	SNP	Name	Sequence
11470	C251T	TR	gctggctcggtcaagaTGAGAATTTCCAAAATAA
11472	A251T	EF	TACATTCAAGGCAAGAAAA
11472	A251T	ER	TGATTAGTTACAATTACCTCTAGTATC
11472	A251T	AF	gggacggctcggtagatAGTTTGTCTAGTAAATGTA
11472	A251T	TF	gctggctcggtcaagaAGTTTGTCTAGTAAATGTT
11487	A485T	EF	gacgatgccttcagcacaAGAGAGCAGCTAGACTGAGA
11487	A485T	ER	TTCCTGCAAACAGTTGAG
11487	A485T	AR	gggacggctcggtagatAGTTGAGGGCTCAGGATT
11487	A485T	TR	gctggctcggtcaagaAGTTGAGGGCTCAGGATA
11488	C533G	EF	gacgatgccttcagcacaAGAGAGCAGCTAGACTGAGA
11488	C533G	ER	GTAAATAAAATGGGATGGTG
11488	C533G	CR	gggacggctcggtagatGCCCCAGCAAGCTGCATG
11488	C533G	GR	gctggctcggtcaagaGCCCCAGCAAGCTGCATC
11493	A171G	EF	CCTTTTGTGTTTGTGTTTGT
11493	A171G	ER	CTTCTCCACCTTCCATTC
11493	A171G	AF	gggacggctcggtagatGGGAACTCCTAAATCAAA
11493	A171G	GF	gctggctcggtcaagaGGGAACTCCTAAATCAAG
11502	C455T	EF	gacgatgccttcagcacaACGATGGGGTCAGAGTCA
11502	C455T	ER	CCTACATTTACACACGAACA
11502	C455T	CR	gggacggctcggtagatACACACTCCTCTCTCAAG
11502	C455T	TR	gctggctcggtcaagaACACACTCCTCTCTCAAA
11534	G258T	EF	GCCATCGTCTTTCCCT
11534	G258T	ER	TCCTCCCTCCTTCTCTCT
11534	G258T	GR	gggacggctcggtagatCCTCCACCCACCAGGGCC
11534	G258T	TR	gctggctcggtcaagaCCTCCACCCACCAGGGCA
11537	A251G	EF	CCTCTTTCTCCTCCTCTTC
11537	A251G	ER	CTCTTCCTGTCTTCTCCTCT
11537	A251G	AF	gggacggctcggtagatAGATGGACCTCTACAGGA
11537	A251G	GF	gctggctcggtcaagaAGATGGACCTCTACAGGG
11560	A185G	EF	CTCCTCCAACCTCCTTTAC
11560	A185G	ER	ATACTTCTCACTGCATCCT

baySNP	SNP	Name	Sequence
11560	A185G	AR	gggacggtcggtagatCCTGTCCCCTCCCTAGTT
11560	A185G	GR	gctggctcggtcaagaCCTGTCCCCTCCCTAGTC
11594	C251T	EF	CACCTTCCTGAACTCACTC
11594	C251T	ER	TGATGTCTGTGCTGTCCT
11594	C251T	CR	gggacggtcggtagatTCTGGTCCACTCAAGGAG
11594	C251T	TR	gctggctcggtcaagaTCTGGTCCACTCAAGGAA
11624	C251T	EF	TCGGGAGGTGTAAGTAAG
11624	C251T	ER	CCACAGTCAGAAGAGACAA
11624	C251T	CR	gggacggtcggtagatAGAGACCCTGGTCCCAAG
11624	C251T	TR	gctggctcggtcaagaAGAGACCCTGGTCCCAA
11627	C251T	EF	TTTATCACTACACCCCCTACTC
11627	C251T	ER	GACAGACCGACCAATCAC
11627	C251T	CR	gggacggtcggtagatCCCTGGGAAGGTTGAGAG
11627	C251T	TR	gctggctcggtcaagaCCCTGGGAAGGTTGAGAA
11650	A146G	EF	CTGTCTGTTTGGGTCTTC
11650	A146G	ER	CGTTGTTCTCTGTCCACT
11650	A146G	AR	gggacggtcggtagatGGCCAAATGTCTAAAAGT
11650	A146G	GR	gctggctcggtcaagaGGCCAAATGTCTAAAAGC
11654	A251G	EF	CGTATCTCTTGCCTTTCTT
11654	A251G	ER	CTTCTCTTATGCCTTCCC
11654	A251G	AF	gggacggtcggtagatTTACTTGAAAGGACACCA
11654	A251G	GF	gctggctcggtcaagaTTACTTGAAAGGACACCG
11655	A251C	EF	CGTATCTCTTGCCTTTCTT
11655	A251C	ER	CTTCTCTTATGCCTTCCC
11655	A251C	AF	gggacggtcggtagatTTCTGCACTAAAGCTGTA
11655	A251C	CF	gctggctcggtcaagaTTCTGCACTAAAGCTGTC
11656	C251T	EF	TGGGAAGAAAAGAGAAG
11656	C251T	ER	GTTGAAACACTGCACAAG
11656	C251T	CR	gggacggtcggtagatCAGGGCTGTTGGGTGAAG
11656	C251T	TR	gctggctcggtcaagaCAGGGCTGTTGGGTGAAA
11825	A277G	ER	gacgatgccttcagcacatGAATAGACAGGGACGAA

baySNP	SNP	Name	Sequence
11825	A277G	EF	GACCTTGAAATAATGGAG
11825	A277G	AF	gggacggctcggtagatCAACCCAGCAAAAATGGA
11825	A277G	GF	gctggctcggtcaagaCAACCCAGCAAAAATGGG
11914	A246T	EF	gacgatgccttcagcacaTTGGAAGTGAGATAAGATAGGT
11914	A246T	ER	ACGGTGAGAATGAGAGGT
11914	A246T	AR	gggacggctcggtagatAAAACAGACATCAGAGGT
11914	A246T	TR	gctggctcggtcaagaAAAACAGACATCAGAGGA
12097	A411G	ER	gacgatgccttcagcacaGATGAAACCCTGTCTCTACT
12097	A411G	EF	TTATCAACCTTAGTCTCCCT
12097	A411G	AF	gggacggctcggtagatACCTGCCACCACACCCAA
12097	A411G	GF	gctggctcggtcaagaACCTGCCACCACACCCAG
12366	A412G	ER	gacgatgccttcagcacaGCTGATGTGGTTGTGAG
12366	A412G	EF	GTTCTGTAGCTCGTGTAG
12366	A412G	AF	gggacggctcggtagatCTCCCCGCCCTGCAGCAA
12366	A412G	GF	gctggctcggtcaagaCTCCCCGCCCTGCAGCAG
12619	A25G	ER	gacgatgccttcagcacaTGGCTGGACTTTGACTGATA
12619	A25G	EF	TCTTGTTTGTGTACAGTGC
12619	A25G	AF	gggacggctcggtagatTGTGTCACAGTGCTCTGA
12619	A25G	GF	gctggctcggtcaagaTGTGTCACAGTGCTCTGG
13025	A585C	EF	gacgatgccttcagcacaTTTAAGTAACATGACAAACTC
13025	A585C	ER	ATCTGATAACTGAGCAGG
13025	A585C	AR	gggacggctcggtagatCTATTAAGTAACTGGTGT
13025	A585C	CR	gctggctcggtcaagaCTATTAAGTAACTGGTGG
13191	A504G	ER	gacgatgccttcagcacaATTCTCCCATTCTCCTGT
13191	A504G	EF	TGCCTCTTCTCCTCATTC
13191	A504G	AF	gggacggctcggtagatCCCTAATGTCTTCCTCTGA
13191	A504G	GF	gctggctcggtcaagaCCCTAATGTCTTCCTCTGG
900045	C116T	EF	ATCTCCTGATCCAAGTCC
900045	C116T	ER	CACACTGTGCCCATCTAC
900045	C116T	CR	gggacggctcggtagatCTGACTGATTACCTCATG
900045	C116T	TR	gctggctcggtcaagaCTGACTGATTACCTCATA

baySNP	SNP	Name	Sequence
900078	A251G	EF	CATAGGTAAAGATCTGTAGGTG
900078	A251G	ER	CCACCTTGGAAGTTGGCAA
900078	A251G	AR	gggacggtcggtagatattaaatcgctctctcT
900078	A251G	GR	gctggctcggtcaagaattaaatcgctctctcC
900107	C426T	ER	gacgatgccttcagcacaAGGGCTTTTTCAGGTAGA
900107	C426T	EF	GACCTTTCCTGGGTAGAA
900107	C426T	CF	gggacggtcggtagatACTCTGAACCTGGGGGAC
900107	C426T	TF	gctggctcggtcaagaACTCTGAACCTGGGGGAT
10000002	A103G	AF	gggacggtcggtagatGATCAACACAATCTTCAA
10000002	A103G	EF	CAGCTGAAAGAGATGAAATTTACT
10000002	A103G	ER	GACGATGCCTTCAGCACAACTTATGAAGATTAAGGCATAG G
10000002	A103G	GF	gctggctcggtcaagaGATCAACACAATCTTCAG
10000006	G107A	AF	gctggctcggtcaagaGGGCTGGGCTGCTAGGGA
10000006	G107A	EF	AGACGAGTTCAAGGTGAGTG
10000006	G107A	ER	GACGATGCCTTCAGCACACCAAGTTTCCGAGTTTCC
10000006	G107A	GF	gggacggtcggtagatGGGCTGGGCTGCTAGGGG
10000014	A153C	AF	gggacggtcggtagatGTACCAATACATCCTGCA
10000014	A153C	CF	gctggctcggtcaagaGTACCAATACATCCTGCC
10000014	A153C	EF	CTGCTGATGTCTCTGTTG
10000014	A153C	ER	GACGATGCCTTCAGCACAGACTTACTTTGCTCACACTT
10000025	C291T	CF	gggacggtcggtagatCCTCACTTCCTCAACGCC
10000025	C291T	EF	CCTCTCTGTCTGGTTATCTTG
10000025	C291T	ER	GACGATGCCTTCAGCACAAAGTGTGCCTCCTGGTTAG
10000025	C291T	TF	gctggctcggtcaagaCCTCACTTCCTCAACGCT

Table 2b Oligonucleotide primers used for genotyping using Pyrosequencing

5 The baySNP number refers to an internal numbering of the PA SNPs. Primer sequences are listed for preamplification of the genomic fragments and for sequencing of the SNP using the pyrosequencing method. Bio: Biotinylated Oligonucleotide.

BaySNP	Name	Sequence
2995	Primer F	GCCAAGACTAGGAAGTAAGTGT
2995	Primer R	Bio- CCCAGAACCACAAAGCTAGTAA
2995	Seq.	TGCCCTGGTCACCTCCTTTCC
3689	Primer F	BIO-CTGACCCTGACCTTCATACTCAA
3689	Primer R	AGAAGAAAGAAGCCTCTCTACAGTT
3689	Seq.	AACAGATCAGGTTGGTG
4838	Primer F	Bio-CAAAGATGACCTTATGGCTCTGA
4838	Primer R	GTCTCGGAACATGACCTTTAGT
4838	Seq.	TGACTAAGAATGTAATGGGGAAGA
6498	Primer F	CTTTGTGGATCTTTCTGCGGTGT
6498	Primer R	Bio-CCATGTTGAGGAGCCAGAGTGA
6498	Seq.	ATTACAGTTGTGAGATTGTGC
8021	Primer F	GGCCTTCTATGTACTAGGCG
8021	Primer R	Bio-CTCTTTCTGGAGGCATCAATC
8021	Seq.	CACAGGGAGACCCC
8060	Primer F	Bio-GCCTTATTTTCCACTCCACCT
8060	Primer R	TACCTTTCCCATCCCAACTG
8060	Seq.	TCAGCATATGTTTGGATT
8846	Primer F	ATTTGAGAGAAGGTAGGGT
8846	Primer R	BIO-TTTGTTACTCTGTAGCCA
8846	Seq.	AAATATTCAGTAACTTGTTT
9849	Primer F	AAG CAG CAA TCG AAT CCC TT
9849	Primer R	TGT TGT TGT TTG GCT AGC TCC
9849	Seq.	CCT GCC TTA CTG AGA GCC AAA

BaySNP	Name	Sequence
10079	Primer F	Bio-CACGCCAATTCCCACCATCCT
10079	Primer R	GTCCGTCGAGGGGGAATGTGTTT
10079	Seq.	AATGTGTTTCTTGGGGGT
10747	Primer F	CTAACCATCTTCCAAATGCTTAATC
10747	Primer R	BIO-TCCTTGAGTCTGAGTTTCCC
10747	Seq.	CACAAGAAACCCTGAAA
11578	Primer F	CTC GGC GTG CTT GGT AAT AA
11578	Primer R	CGG AGC CGA ACT CTG GAG GAA TCT
11578	Seq.	GGC TGG CAA GTT GTT CCA TCC CAC
11644	Primer F	TGA GCA GCG CAT CCT
11644	Primer R	TGC AGC CCA CTG ACT CAA
11644	Seq.	GCT GTT ACT CAG TAT GAT
12008	Primer F	CCGAAGACCAAGACGC
12008	Primer R	Bio-TCTTCCATAAAAACAAGGCTC
12008	Seq.	AAACAAGAAATTCTGTTTA
13937	Primer F	TGA CAG CTC CCA TTG GAA
13937	Primer R	AAT TAA TGC GAT CCC TC
13937	Seq.	GAC AGC TCC CAT TGG AAG
900002	Primer F	ATTGGGCAGGGATAAGAGAAAAG
900002	Primer R	Bio-GATGAATCACAGAATGCGGTAT
900002	Seq.	CACACAGCAGTTCACGCA
900013	Primer F	GCCAAGACTAGGAAGTAAGTGT
900013	Primer R	Bio- CCCAGAACCACAAAGCTAGTAA
900013	Seq.	TGCCCTGGTCACCTCCTTTCC
900025	Primer F	Bio-AGTGGCTCACTTGCTAACG
900025	Primer R	CTGGGGAAGAAAATAAATGAA
900025	Seq.	CTTGCTCTTAGGATACACGT
900032	Primer F	AGCGTCTTCACCATCTGCT
900032	Primer R	Bio-GGGAAGGAGGAAGCCAAACA
900032	Seq.	ACATGTCTGATGATACCTGG
900045	Primer F	BIO-GCCATGCACGATTTCCC

BaySNP	Name	Sequence
900045	Primer R	CACTGTGCCCATCTACGAG
900045	Seq.	GGACCTGACTGATTACCT
900065	Primer F	GAGTAGCTAGGATCACAGGTGCGT
900065	Primer R	BIO-TGTTTCGAGATTTAAGAAAGTTGGC
900065	Seq.	CAGGTGCGTGCCACCATGCCC
900082	Primer F	CAC ACA ATT TTC CAC TTA
900082	Primer R	GAC TCC AGT TTT CTA TCA
900082	Seq.	ATG TTG ATG TAA TCT ACT
900096	Primer F	TGGGGCAAGCAACAGTGGT
900096	Primer R	Bio-TAGGCAGGGCAAGGGATTAGG
900096	Seq.	TTTAAATTCTCTGACAGAGAC
900107	Primer F	BIO-GCCACCAGCCCACACTCTGAACCTG
900107	Primer R	CCATCAGCCTTCACCCACGTGCCA
900107	Seq.	GCCTCAGCTTGACCT
900115	Primer F	Bio-GGTAAGTGCGTGCCTGGGAGATGC
900115	Primer R	CGGGGTGGGGAGGACAGAGC
900115	Seq.	GAGGACAGAGCAAAAGGAT
900121	Primer F	Bio-TGCCTTACAATATACAATGG
900121	Primer R	CAATGGGTAAGGAGTAAAGTT
900121	Seq.	TTCCAGCTGCTTTTA

Table 2c Oligonucleotide primers used for genotyping using Restriction Fragment Length Polymorphism (RFLP)

- 5 The baySNP number refers to an internal numbering of the PA SNPs. Primer sequences are listed for preamplification of the genomic fragments. The restriction enzyme used for RFPL is indicated.

baySNP	Name	Sequence	Enzyme
900173	Primer F	GAACAAACCTCCGAGATGCTAC	Hind III
900173	Primer R	GTCTTATGTTACTGGGCTTTCACC	Hind III

Table 2d Oligonucleotide primers used for genotyping using TaqMan

The baySNP number refers to an internal numbering of the PA SNPs. Primer sequences are listed for amplification of the genomic fragments. In addition the respective fluorescent hybridisation probes are listed. If not otherwise stated, all fluorescent probes have a 'minor groove binder' (MGB) attached (Kutyavin et al., Nucleic Acids Research 2000, 28:655-661).

baySNP	F-Sequence	R-Sequence	VIC-MGB	FAM-MGB
52	CACCCCTAGAAATTCACATTAATTTTCAA C	GGCCTTGAAGAAGATTTTATATTGAGAA	CTATGCATACCTTTTGC	ATGCATAGTTTTTGCATTAT
542	TTTGGCTCCATCAACCAAGTC	GATGGTGATCAGCCGAATC	CAATTGGGATTGGGAGG	AATTGGGTTGGGAGG
821	GCCAGTTATACCTCAGTGTGTGAAC	AGGTCAGTACAGAGGGTATCATGAGA	TGTGATACCTGGaACAG	CTGTGATACCTGGCACA
1056	TGTATGCACGTGCGTGATCTG	CGCCCTCGGCACCTCTTG	CCAAACaACAGGACGG	AAACaGcAGGACGGG
1204	CTGTAAGCAATCTGGAATGTGATGA	GGCTCAGTCTTTGATCTTTAGCAAG	CACACATTAATAATTAG	ACTCATTACAAATTAGT
1722	GGACCCTAAGAACCCAGGAT	ATGGCTTAACACAGGAGATGATG	TGGCCTGGCGGTG	TGGCCTGGCGaTGT
1757	ACAGGGCTGCAGCCAC	AGCCTCTGCCCTCCTCCA	AACCAATGAAGGAGAG	ACCAATGAAGGAGAG
1765	GGAGCTGTGAGGTATGGGCTT	TGTCAAGATGCAGCTGAAGTC	ACGGAGGAAGAGT	ACGGAGGAAGaGT
1799	TTTGGTGGTGTGTCATTGACA	TGGACATATGGCGGACTCT	AGTGTGATCaTCACTTT	CAGTGTGATCgTCACt
1837	CACTCAGCCCTGCTCTTTCC	CATCCTTGGCGGTCTTTGGT	TGCAGGGCTACATGA	TCATGCAGGGTtACAT
1870	CTGGCTCCTGACCCCTTGCT	GGAGGATGCCATCTGAACA	TGCCTCCTTCTCACAC	CCTCCTTtTCACACCGA
1988	CCGTGGCTTCATGGTGACT	CTACCTGTCCGGTGATCATC	TCCTAFAcCGTGGGTGT	CTATACtGTGGGtGTcAT
2000	TTCTCACTGTGATATATAAACTCAGAC CC	CGATGAACAGTTGGAATAGTTGT	TACTCATCTTCCTAATTAC	CAATATCTACTCATtTTC
2085	TCATTACATCAGGTATATTGCCTGTA AA	TCAGAGACACTGAAGAACTTAAAGAATC	TGTTACCAGAAAGAAA	TGTTACCAGAAALAAA
2281	GCTGCATTGAGAGGACTGATC	CGGTTAACTTATAAAGAAACGAGTGTTC	CATACCACAAaCCA	ACCACAAaCCAGGTC
2298	TGCTAGTGTTTCTGGTGTGCAATT	GGCACCGTGTAGACTTGAATCAA	TCATGGCaTTTCA	TATCATGGGcTTTCA
2357	GCGAAGTGTGGACACCAA	GGTTACTCTCTGCTCTTCGATCCT	AAGACGAaAATGaATC	AAGACGAaAATGaATC
4838	AAGATGACCTTATGGCTCTGAGATG	TCTCGGAACATGACCTTTAGTCTGT	AAGAAcTGCCCTGCCT	AAGAAcTGCCCTGCC
5320	GGGATATATAGTAGAATAAACAAGCCTG	CAACTTAATCACTACTACTCTCATCTGTAAGCA	AAGGAAGCTGGaTATG	AGGAAGCTGGgTATGT

baySNP	F-Sequence	R-Sequence	VIC-MGB	FAM-MGB
	TCT			
5717	GGCCGGCTCCTGGCT	AACCCACACCTTCAGTCTAGAAA	Vic-CCACCTCCCTCTAGCCTCAGTTGC-TAMRA	Fam-CCACCTCCCTCCTAGCCTCAGTT-TAMRA
5959	ACCAGAAACAATGCCAACCA	CAGTGTGAAACCAAGGATGTC	Vic-CGAATGTGTGCCCCAGCC-TAMRA	Fam-TCGAATGTGaCTGCCAGCCTC-TAMRA
6482	CATAGTTTAGGATAAACAAAGGGATT CA	TGTCATGGAACGCCCAAC	AACAGATCTGGTCTaCCT	AGATCTGGTCTGCTC
8060	GCTATTGAATGGATGTGCCCTTATT	TGCATGGCATCAGCATATGTT	CCCACCTGGaGAAT	TCCCACCTGGGGA
8816	CAGCCCTCTGCTCCAAG	TCCCCCTCTGTCCAGGC	TGAGAAAAAAGgTTCCG	CTGAGAAAAAAGCTTC
10600	GGTGACGTTTGGCCTCTC	AGTTTAATCAAGCCTTTTCAATTGG	TGCTCAGGATAGCC	TGCTCAGGACAGCC
10771	CTGGGCCCAACCGAGTTAC	GATCTCTGTGAGTGTGCTCTGT	AGGAAGCgGTGGCCT	CAAGGAAGgGTGGC
10948	ACATTTCCCTTCCAGCTT	GCAAGGCAGAGGGAGGA	CGCCACAGTAATaCAGA	CCCAGTAATCCAGACAC
11001	GCCATCCTTGTGAACGTGAA	ACATGACAGGGGCCACTT	TCGTTCACCTGGACGT	TTCCATYGGACGTCTT
11073	GAGCAACAGCCGCTGAG	GCGGAGCTAGAGAGCAGTG	TCGGCGCTgGTC	TCTCGGGCTcGT
11248	GAAAGCTAACTCCCTGACG	TGAAGGGTAAGGGAGGAAA	CTTGGGCTCGCGTC	TTGGCaTCGCGTCAG
11654	AGTTTGTTTCCATTAGAGGTTTCCA	CTCTTATGCCCTTCCCCACCA	TTGAAAGGACACCaTATT	ACACCGTATTTTTTCAC
11655	CATATTCAGAAAGATTATCTCCAAC	TGGAACCTCTAATAGGAAAAACAACCT	CACCTAAAGCTGTaATATTA	CTAAAGCTGTcATATTAC
	CTT			
13191	GAGTTGGTGGCAFAAAACCTAA	CCCTGCCCACTTCTCTCTCT	TCTTCCTCTGgGTAAACA	TCTTCTGaGTAAACAAC

Table 3 PA SNPs, SNP classes and putative PA genes

The baySNP number refers to an internal numbering of the PA SNPs. Listed are the different polymorphisms found in our association study. Also from the association study we defined SNP classes; with ADR being adverse drug reaction related, with EFF being drug efficacy related and CVD being cardiovascular disease related. ADR3 and ADR5 relate to advanced and severe ADR, whereas VEFF and UEFF relate to very high/low and ultra high/low drug efficacy (see table 1b). Also accession numbers and descriptions of those gene loci are given that are most homologous to the PA genes as listed in the sequences section (see below). Homologous genes and their accession numbers could be found by those skilled in the art in the Genbank database. Null: not defined.

BAYSNP	SNP class	GTYPE1	GTYPE1	GTYPE1	GTYPE2	NCBI	DESCRIPTION
28	EFF	CC	CT	TT		U15552	Human acidic 82 kDa protein mRNA, complete cds.
29	CVD	AA	AG	GG		HS162961	Human T-lymphoma invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA, complete cds.
29	ADR3	AA	AG	GG		HS162961	Human T-lymphoma invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA, complete cds.
29	ADR5	AA	AG	GG		HS162961	Human T-lymphoma invasion and metastasis inducing TIAM1 protein (TIAM1) mRNA, complete cds.
52	EFF	CC	CG	GG		X69907	H.sapiens gene for mitochondrial ATP synthase c subunit (P1 form)

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE2	NCBI	DESCRIPTION
56	EFF	AA	AG	GG	M92357	Homo sapiens B94 protein mRNA, complete cds.
89	CVD	AA	AG	null	L23982	Homo sapiens (clones: CW52-2, CW27-6, CW15-2, CW26-5, 11-67) collagen type VII intergenic region and (COL7A1) gene, complete cds.
90	CVD	CC	CT	TT	M65212	Homo sapiens catechol-O-methyltransferase (COMT) mRNA, complete cds.
99	CVD	CC	CT	TT	X96698	H.sapiens mRNA for D1075-like gene
140	EFF	CC	CT	TT	M14335	Human coagulation factor V mRNA, complete cds.
152	EFF	AA	AG	GG	M32670	Homo sapiens ITGB3 gene, intron 2, fragment C, partial sequence.
214	CVD	AA	AG	GG	X66957	H. sapiens hexokinase I (MK-16)
221	CVD	CC	CG	GG	X76732	H.sapiens mRNA for NEFA protein
224	CVD	CC	CT	TT	M14764	Human nerve growth factor receptor mRNA, complete cds.
294	CVD	CC	CT	TT	P02568	ACTIN, ALPHA SKELETAL MUSCLE (ALPHA-ACTIN 1).
307	CVD	CC	CT	TT	X63546	H.sapiens mRNA for tre oncogene (clone 210)
411	CVD	AA	AT	TT	HS34804	Human thermostable phenol sulfotransferase (STP2) gene, partial cds.
449	CVD	CC	CG	GG	M36341	Human ADP-ribosylation factor 4 (ARF4) mRNA, complete cds.

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
466	CVD	CC	CT	TT	AF129756		Homo sapiens MSH55 gene, partial cds; and CLIC1, DDAH, G6b, G6c, G6d, G6e, G6f, BAT5, G5b, CSK2B, BAT4, G4, Apo M, BAT3, BAT2, AIF-1, IC7, LST-1, LTB, TNF, and LTA genes, complete cds.
472	EFF	AA	AG	GG	M57965		Homo sapiens (clones lambda gMHC 1,2,3 and 4) beta-myosin heavy chain (MYH7) gene, complete cds.
542	CVD	AA	AG	GG	M64082		Human flavin-containing monooxygenase (FMO1) mRNA, complete cds.
542	ADR	AA	AG	GG	M64082		Human flavin-containing monooxygenase (FMO1) mRNA, complete cds.
739	CVD	CC	CG	GG	L43509		Homo sapiens methionine adenosyltransferase alpha subunit gene fragment.
821	CVD	AA	AC	CC	X80507		H.sapiens YAP65 mRNA
821	VEFF	AA	AC	CC	X80507		H.sapiens YAP65 mRNA
1005	CVD	AA	AG	GG	M81357		Human coagulation factor VII (F7) gene exon 1 and factor X (F10) gene, exon 1.
1055	CVD	AA	AT	TT	J02758		Human apolipoprotein A-IV gene, complete cds.
1056	EFF	AA	AG	GG	Q16720		CALCIUM-TRANSPORTING ATPASE PLASMA MEMBRANE, ISOFORMS 3A/3B (EC 3.6.1.38) (CALCIUM

BAYSNP	SNP class	GTTYPE1	GTTYPE1	GTTYPE1	GTTYPE2	NCBI	DESCRIPTION
							PUMP) (PMCA3).
1085	CVD	AA	AG	GG	M14564		Human cytochrome P450c17 (steroid 17-alpha-hydroxylase/17,20 lyase) mRNA, complete cds.
1086	CVD	AA	AG	GG	M14564		Human cytochrome P450c17 (steroid 17-alpha-hydroxylase/17,20 lyase) mRNA, complete cds.
1092	CVD	CC	CG	GG	AF022375		Homo sapiens vascular endothelial growth factor mRNA, complete cds.
1096	CVD	GG	GT	TT	X15323		H.sapiens angiotensinogen gene 5' region and exon 1
1101	EFF	CC	CT	TT	AL031005		Homo sapiens DNA sequence from PAC 329E20 on chromosome 1p34.4-36.13. Contains endothelin-converting-enzyme 1 (ECE-1), EST, STS, CA repeat
1204	CVD	AA	AG	GG	AC004264		Homo sapiens PAC clone RP1-102K2 from 22q12.1-qter, complete sequence:
1504	CVD	CC	CT	TT	AC005175		Homo sapiens chromosome 19, cosmid R31449, complete sequence.
1511	EFF	GG	GT	TT	AF009674		Homo sapiens axin (AXIN) mRNA, partial cds.
1524	ADR3	AA	AC	CC	AF223404		Homo sapiens WNT1 inducible signaling pathway protein 1 (WISP1) gene, promoter and partial cds.
1556	EFF	CC	CG	GG	L34058		Homo sapiens cadherin-13 mRNA, complete cds.

BA5NP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 AC	GTTYPE1 CT	GTTYPE1 AG	GTTYPE1 GT	GTTYPE2	NCBI	DESCRIPTION
1561	CVD	AA	CC	AC	CT	AG	GT	CC	M31664	Human cytochrome P450 (CYP1A2) gene, exons 1 and 2.
1582	CVD	CC	CC	CT	CT	AG	GT	TT	AF050163	Homo sapiens lipoprotein lipase precursor, gene, partial cds.
1638	CVD	AA	CC	AC	CT	AG	GT	GG	AF090318	Homo sapiens sterol 12-alpha hydroxylase CYP8B1 (Cyp8b1) mRNA, partial cds.
1653	CVD	GG	CC	GT	CT	AG	GT	TT	J02846	Human tissue factor gene, complete cds.
1662	CVD	CC	CC	CT	CT	AG	GT	TT	K02402	Human coagulation factor IX gene, complete cds.
1714	CVD	AA	CC	AC	CT	AG	GT	GG	D50857	Human DOCK180 protein mRNA, complete cds.
1722	ADR5	CC	CC	CT	CT	AG	GT	TT	D73409	Homo sapiens mRNA for diacylglycerol kinase delta, complete cds.
1757	EFF	AA	CC	AC	CT	AG	GT	GG	J04046	Human calmodulin mRNA, complete cds.
1765	ADR3	AA	CC	AC	CT	AG	GT	GG	J05096	Human Na,K-ATPase subunit alpha 2 (ATP1A2) gene, complete cds.
1765	ADR5	AA	CC	AC	CT	AG	GT	GG	J05096	Human Na,K-ATPase subunit alpha 2 (ATP1A2) gene, complete cds.
1776	CVD	AA	CC	AC	CT	AG	GT	GG	L22569	Homo sapiens cathepsin B mRNA, 3' UTR with a stem-loop structure providing mRNA stability.
1799	CVD	CC	CC	CT	CT	AG	GT	TT	D21255	Human mRNA for OB-cadherin-2, complete cds.
1806	EFF	AA	CC	AC	CT	AG	GT	GG	AF106202	Homo sapiens endothelial cell protein C receptor precursor

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
						(EPCR) gene, complete cds.
1837	CVD	CC	CT	TT	J00098	Human apolipoprotein A-I and C-III genes, complete cds.
1837	ADR5	CC	CT	TT	X00566	Human mRNA for lipoprotein apoAI Human apolipoprotein A-I and C-III genes, complete cds.
1837	ADR	CC	CT	TT	J00098	Human apolipoprotein A-I and C-III genes, complete cds.
1870	CVD	CC	CT	TT	M84820	Human retinoid X receptor beta (RXR-beta) mRNA, complete cds.
1882	CVD	CC	CT	TT	U06643	Human keratinocyte lectin 14 (HKL-14) mRNA, complete cds.
1988	CVD	CC	CT	TT	X61598	H.sapiens mRNA for colligin (a collagen-binding protein)
2000	CVD	CC	TT	null	P03915	NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 5 (EC 1.6.5.3).
2000	ADR	CC	TT	null	P03915	NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 5 (EC 1.6.5.3).
2071	CVD	AA	AG	GG	L04143	Human c-kit gene.
2078	CVD	GG	GT	TT	X77584	H.sapiens mRNA for ATL-derived factor/thiredoxin.
2085	VEFF	GG	GT	TT	X82540	H.sapiens mRNA for activin beta-C chain
2095	CVD	AG	GG	null	L34155	Homo sapiens laminin-related protein (LamA3) mRNA, complete cds.

BAYSNP	SNP class	GTYPE1	GTYPE1	GTYPE1	GTYPE2	NCBI	DESCRIPTION
2119	CVD	AA	AG	AG	null	Z22535	H.sapiens ALK-3 mRNA.
2119	EFF	AA	AG	AG	null	Z22535	H.sapiens ALK-3 mRNA.
2141	EFF	AA	AG	AG	GG	AB035073	Homo sapiens mRNA for platelet glycoprotein VI, complete cds.
2141	CVD	AA	AG	AG	GG	AB035073	Homo sapiens mRNA for platelet glycoprotein VI, complete cds.
2182	EFF	AA	AG	AG	GG	D32046	Human gene for thrombopoietin, exon1-exon6, complete cds.
2234	CVD	GG	GT	GT	TT	AC004264	Homo sapiens PAC clone RP1-102K2 from 22q12.1-qter, complete sequence.
2281	VEFF	AA	AC	AC	CC	X87872	H.sapiens mRNA for hepatocyte nuclear factor 4c
2298	CVD	AA	AC	AC	CC	V01511	H.sapiens gene for beta-nerve growth factor (beta-NGF)
2341	CVD	CC	CT	CT	TT	J03280	Human phenylethanolamine N-methyltransferase gene, complete cds.
2357	CVD	AA	AG	AG	GG	O15055	PERIOD CIRCADIAN PROTEIN 2 (KIAA0347).
2366	CVD	GG	GT	GT	TT	P35414	PROBABLE G PROTEIN-COUPLED RECEPTOR APJ.
2423	CVD	AA	AG	AG	GG	AF000571	Homo sapiens kidney and cardiac voltage dependent K+ channel (KvLQT1) mRNA, complete cds.
2708	CVD	CC	CT	CT	TT	AL031005	Homo sapiens DNA sequence from PAC 329E20 on chromosome 1p34.4-36.13. Contains endothelin-converting-enzyme 1 (ECE-1), EST, STS, CA repeat

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
2995	ADR5	AA	AC	CC	ABCC1	ABCC1: ATP-binding cassette, sub-family C (CFTR/MRP), member 1
2995	UEFF	AA	AC	CC	ABCC1	ABCC1: ATP-binding cassette, sub-family C (CFTR/MRP), member 1
3360	ADR5	GG	GT	TT	ABCB4	ABCB4: ATP-binding cassette, sub-family B (MDR/TAP), member 4
3464	CVD	AA	AG	GG	M34668	Human protein tyrosine phosphatase (PTPase-alpha) mRNA.
3689	EFF	CC	CG	GG	M95724	H.sapiens centromere autoantigen C (CENPC) mRNA, complete cds.
3975	UEFF	AA	AC	CC	U43368	Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds.
3976	UEFF	AA	AG	GG	U43368	Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds.
4206	ADR3	AA	AT	TT	BC000006	Homo sapiens, ATPase, Na+/K+ transporting, beta 1 polypeptide
4838	VEFF	AA	AG	GG	L08246	Human myeloid cell differentiation protein (MCL1) mRNA.
4912	EFF	AA	AG	GG	AF022375	Homo sapiens vascular endothelial growth factor mRNA, complete cds.
4925	CVD	AA	AC	CC	AF036365	Homo sapiens caveolin-3 (CAV3) mRNA, complete cds.

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 AG	GTYPE2 GG	NCBI	DESCRIPTION
4966	ADR3	AA	AG	AG	GG	AF133298	Homo sapiens cytochrome P450 (CYP4F8) mRNA, complete cds.
5014	ADR5	AA	AG	AG	GG	AL008637	Human DNA sequence from clone CTA-833B7 on chromosome 22q12.3-13.2 Contains the NCF4 gene for cytosolic neutrophil factor 4 (40kD), the 5' part of the CSF2RB gene for granulocyte-macrophage low-affinity colony stimulating factor 2 receptor beta, ESTs, STS
5296	CVD	AA	AG	AG	GG	J02933	Human blood coagulation factor VII gene, complete cds.
5296	EFF	AA	AG	AG	GG	J02933	Human blood coagulation factor VII gene, complete cds.
5298	EFF	CC	CT	CT	TT	J02933	Human blood coagulation factor VII gene, complete cds.
5298	CVD	CC	CT	CT	TT	J02933	Human blood coagulation factor VII gene, complete cds.
5320	EFF	AA	AG	AG	GG	J03799	Human colon carcinoma laminin-binding protein mRNA, complete cds.
5361	CVD	AA	AC	AC	CC	L02932	Human peroxisome proliferator activated receptor mRNA, complete cds.
5457	EFF	AA	AG	AG	GG	L29529	Homo sapiens (clone HHT-1 variant harboring HH-05) cardiac L-type voltage dependent calcium channel alpha 1 subunit (CACNL1A1) mRNA, complete cds.
5704	CVD	CC	CT	CT	TT	M58050	Human membrane cofactor protein (MCP) mRNA, complete cds.

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 2	NCBI	DESCRIPTION
5717	ADR3	AA	AG	GG	AL008637	Human DNA sequence from clone CTA-833B7 on chromosome 22q12.3-13.2 Contains the NCF4 gene for cytosolic neutrophil factor 4 (40kD), the 5' part of the CSF2RB gene for granulocyte-macrophage low-affinity colony stimulating factor 2 receptor beta, ESTs, STS
5959	CVD	AA	AG	GG	HSHMGCOA S	H.sapiens mRNA for 3-hydroxy-3-methylglutaryl coenzyme A synthase
5959	ADR5	AA	AG	GG	HSHMGCOA S	H.sapiens mRNA for 3-hydroxy-3-methylglutaryl coenzyme A synthase
5959	ADR	AA	AG	GG	HSHMGCOA S	H.sapiens mRNA for 3-hydroxy-3-methylglutaryl coenzyme A synthase
6162	ADR3	CC	CG	GG	AF005896	Homo sapiens Na K-ATPase beta-3 subunit (atp1b3) gene, exon 7 and complete cds.
6162	ADR	CC	CG	GG	AF005896	Homo sapiens Na K-ATPase beta-3 subunit (atp1b3) gene, exon 7 and complete cds.
6162	ADR5	CC	CG	GG	AF005896	Homo sapiens Na K-ATPase beta-3 subunit (atp1b3) gene, exon 7 and complete cds.
6236	ADR5	CC	CT	TT	HSU62961	Human succinyl CoA:3-oxoacid CoA transferase precursor (OXCT) mRNA, complete cds.

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 CT	GTYPE2 2	NCBI	DESCRIPTION
6236	ADR3	CC	CT	CT	TT	HSU62961	Human succinyl CoA:3-oxoacid CoA transferase precursor (OXCT) mRNA, complete cds.
6482	CVD	AA	AG	AG	GG	X69086	H.sapiens mRNA for utrophin
6498	CVD	AA	AG	AG	GG	X71348	Homo sapiens vHNF1-C mRNA
6744	ADR5	CC	CT	CT	TT	AC002310	Human Chromosome 16 BAC clone CIT987SK-A-635H12, complete sequence.
7133	CVD	CC	CG	CG	GG	K02402	Human coagulation factor IX gene, complete cds.
8021	CVD	AA	AG	AG	GG	Z13009	H.sapiens mRNA for E-cadherin
8060	CVD	AA	AG	AG	GG	Z99572	Human DNA sequence from PAC 86F14 on chromosome 1q23-1q24. Contains coagulation factor V, ESTs and STS.
8210	EFF	AA	AG	AG	GG	ABCB11	ABCB11: ATP-binding cassette, sub-family B (MDR/TAP), member 11
8592	VEFF	CC	CT	CT	TT	J04038	Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, complete cds.
8816	EFF	CC	CG	CG	GG	L36033	Human pre-B cell stimulating factor homologue (SDF1b) mRNA, complete cds.
8846	CVD	AA	AG	AG	GG	L41162	Homo sapiens collagen alpha 3 type IX (COL9A3) mRNA, complete cds.

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 AC	GTYPE1 CC	GTYPE2	NCBI	DESCRIPTION
8943	CVD	AA	AC	CC	CC	AF050163		Homo sapiens lipoprotein lipase precursor, gene, partial cds.
9193	CVD	CC	CG	GG	GG	M12674		Human estrogen receptor mRNA, complete cds.
9443	CVD	CC	CT	TT	TT	U09587		Human glycyl-tRNA synthetase mRNA, complete cds.
9516	CVD	AA	AG	GG	GG	U16720		Human interleukin 10 (IL10) gene, complete cds.
9698	ADR	AA	AG	GG	GG	HS5211110		Homo sapiens X28 region near ALD locus containing dual specificity phosphatase 9 (DUSP9), ribosomal protein L18a (RPL18a), Ca2+/Calmodulin-dependent protein kinase I (CAMKI), creatine transporter (CRTR), CDM protein (CDM), adrenoleukodystrophy protein (AL
9698	ADR3	AA	AG	GG	GG	HS5211110		Homo sapiens X28 region near ALD locus containing dual specificity phosphatase 9 (DUSP9), ribosomal protein L18a (RPL18a), Ca2+/Calmodulin-dependent protein kinase I (CAMKI), creatine transporter (CRTR), CDM protein (CDM), adrenoleukodystrophy protein (AL
9698	EFF	AA	AG	GG	GG	HS5211110		Homo sapiens X28 region near ALD locus containing dual specificity phosphatase 9 (DUSP9), ribosomal protein L18a (RPL18a), Ca2+/Calmodulin-dependent protein kinase I (CAMKI), creatine transporter (CRTR), CDM protein (CDM), adrenoleukodystrophy protein (AL

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
9698	ADR5	AA	AG	AG	GG	HS5211110	Homo sapiens X28 region near ALD locus containing dual specificity phosphatase 9 (DUSP9), ribosomal protein L18a (RPL18a), Ca2+/Calmodulin-dependent protein kinase I (CAMKI), creatine transporter (CRTR), CDM protein (CDM), adrenoleukodystrophy protein (AL)
9698	CVD	AA	AG	AG	GG	HS5211110	Homo sapiens X28 region near ALD locus containing dual specificity phosphatase 9 (DUSP9), ribosomal protein L18a (RPL18a), Ca2+/Calmodulin-dependent protein kinase I (CAMKI), creatine transporter (CRTR), CDM protein (CDM), adrenoleukodystrophy protein (AL)
9849	CVD	CC	CT	CT	null	X04588	Human 2.5 kb mRNA for cytoskeletal tropomyosin TM30(nm)
9883	CVD	AA	AG	AG	GG	BC000140	PCCA: propionyl Coenzyme A carboxylase, alpha polypeptide
10079	CVD	AA	AG	AG	GG	X77197	H.sapiens mRNA for chloride channel
10481	ADR5	AA	AT	AT	TT	AF023268	Homo sapiens clk2 kinase (CLK2), propin1, cotel1, glucocerebrosidase (GBA), and metaxin genes, complete cds; metaxin pseudogene and glucocerebrosidase pseudogene; and thrombospondin3 (THBS3) gene, partial cds.
10542	UEFF	CC	CT	CT	TT	AF066859	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds.

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 2	GTYPE2	NCBI	DESCRIPTION
10542	ADR5	CC	CT	TT	TT	AF066859	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds.
10600	EFF	AA	AG	GG	GG	AF129756	Homo sapiens MSH55 gene, partial cds; and CLIC1, DDAH, G6b, G6c, G5b, G6d, G6e, G6f, BAT5, G5b, CSK2B, BAT4, G4, Apo M, BAT3, BAT2, AIF-1, IC7, LST-1, LTB, TNF, and LTA genes, complete cds.
10621	CVD	CC	CT	TT	TT	AF220490	Homo sapiens group III secreted phospholipase A2 mRNA, complete cds.
10745	ADR5	AA	AG	GG	GG	D11456	Human mRNA for Xanthine dehydrogenase, complete cds.
10745	VEFF	AA	AG	GG	GG	D11456	Human mRNA for Xanthine dehydrogenase, complete cds.
10747	ADR	CC	CT	TT	TT	D11456	Human mRNA for Xanthine dehydrogenase, complete cds.
10747	CVD	CC	CT	TT	TT	D11456	Human mRNA for Xanthine dehydrogenase, complete cds.
10747	ADR3	CC	CT	TT	TT	D11456	Human mRNA for Xanthine dehydrogenase, complete cds.
10771	ADR5	CC	CG	GG	GG	D37932	Human mRNA for HPC-1, partial cds.
10771	EFF	CC	CG	GG	GG	D37932	Human mRNA for HPC-1, partial cds.
10870	CVD	AA	AG	GG	GG	AH002776	LDLR: low density lipoprotein receptor (familial hypercholesterolemia)
10877	CVD	AA	AC	CC	CC	AC005832	Homo sapiens 12p13.3 BAC RPC111-500M8 (Roswell Park

BAYSNP	SNP.class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
							Cancer Institute Human BAC Library) complete sequence.
10948	CVD	GG	GT	TT	TT	M10065	Human apolipoprotein E (epsilon-4 allele) gene, complete cds.
11001	ADR5	CC	CT	TT	TT	M34424	Human acid alpha-glucosidase (GAA) mRNA, complete cds.
11073	ADR5	CC	CG	GG	GG	AF070670	Homo sapiens protein phosphatase 2C alpha 2 mRNA, complete cds.
11153	CVD	CC	CT	TT	TT	U57623	Human fatty acid binding protein FABP gene, complete cds.
11210	CVD	CC	CT	TT	TT	AB014460	Homo sapiens TSC2, NTHL1/NTH1 and SLC9A3R2/E3KARP genes, partial and complete cds.
11210	ADR3	CC	CT	TT	TT	AB014460	Homo sapiens TSC2, NTHL1/NTH1 and SLC9A3R2/E3KARP genes, partial and complete cds.
11210	ADR	CC	CT	TT	TT	AB014460	Homo sapiens TSC2, NTHL1/NTH1 and SLC9A3R2/E3KARP genes, partial and complete cds.
11248	ADR	CC	CT	TT	TT	X60435	H.sapiens gene PACAP for pituitary adenylate cyclase activating polypeptide
11248	CVD	CC	CT	TT	TT	X60435	H.sapiens gene PACAP for pituitary adenylate cyclase activating polypeptide
11372	CVD	AA	AG	GG	GG	Z82215	Human DNA sequence from clone RP1-68O2 on chromosome 22 Contains the 5' end of the APOL2 gene for apolipoprotein L 2, the APOL gene for apolipoprotein L, the MYH9 gene for

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 1	GTYPE1 2	NCBI	DESCRIPTION
							nonmuscle type myosin heavy chain 9. ESTs, STSs and GSSs.
11449	CVD	CC	CG	CG	GG	AF050163	Homo sapiens lipoprotein lipase precursor, gene, partial cds.
11450	EFF	AA	AT	AT	TT	AF050163	Homo sapiens lipoprotein lipase precursor, gene, partial cds.
11470	CVD	CC	CT	CT	null	AJ006945	Human P2Y1 gene
11472	CVD	AA	AT	AT	null	AJ006945	Human P2Y1 gene
11487	ADR5	AT	TT	TT	null	M75106	Human prepro-plasma carboxypeptidase B mRNA, complete cds.
11487	ADR3	AT	TT	TT	null	M75106	Human prepro-plasma carboxypeptidase B mRNA, complete cds.
11488	ADR5	CC	CG	CG	GG	M75106	Human prepro-plasma carboxypeptidase B mRNA, complete cds.
11488	UEFF	CC	CG	CG	GG	M75106	Human prepro-plasma carboxypeptidase B mRNA, complete cds.
11488	ADR3	CC	CG	CG	GG	M75106	Human prepro-plasma carboxypeptidase B mRNA, complete cds.
11493	CVD	AA	AG	AG	GG	U03882	Human monocyte chemoattractant protein 1 receptor (MCP-1RA) alternatively spliced mRNA, complete cds.
11502	ADR3	CC	CT	CT	TT	U58917	Homo sapiens IL-17 receptor mRNA, complete cds.
11502	ADR5	CC	CT	CT	TT	U58917	Homo sapiens IL-17 receptor mRNA, complete cds.
11534	CVD	GG	GT	GT	null	AJ276102	Homo sapiens mRNA for GPRC5C protein

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 2	GTYPE2	NCBI	DESCRIPTION
11537	CVD	AA	AG	GG	GG	AL022721	Human DNA sequence from clone 109F14 on chromosome 6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferato
11537	EFF	AA	AG	GG	GG	AL022721	Human DNA sequence from clone 109F14 on chromosome 6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferato
11560	EFF	AA	AG	GG	GG	AC006312	Homo sapiens chromosome 9, clone hRPK.401_G_18, complete sequence.
11578	CVD	CC	CT	CT	null	AC073593	Homo sapiens 12 BAC RP11-13J12 (Roswell Park Cancer Institute Human BAC Library) complete sequence.
11594	ADR3	CC	CT	CT	TT	AF026069	Homo sapiens phosphomevalonate kinase (HUMPMKI) gene, partial cds.
11594	ADR5	CC	CT	CT	TT	AF026069	Homo sapiens phosphomevalonate kinase (HUMPMKI) gene, partial cds.
11594	CVD	CC	CT	CT	TT	AF026069	Homo sapiens phosphomevalonate kinase (HUMPMKI) gene,

BAYSNP	SNP class	GTYPE1 1	GTYPE1 2	GTYPE1 2	GTYPE2 2	NCBI	DESCRIPTION
							partial cds.
11594	ADR	CC	CT	CT	TT	AF026069	Homo sapiens phosphomevalonate kinase (HUMPMKI) gene, partial cds.
11624	CVD	CC	CT	CT	TT	AL022721	Human DNA sequence from clone 109F14 on chromosome 6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferato
11624	EFF	CC	CT	CT	TT	AL022721	Human DNA sequence from clone 109F14 on chromosome 6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferato
11627	CVD	CC	CT	CT	TT	AL022721	Human DNA sequence from clone 109F14 on chromosome 6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferator
11627	EFF	CC	CT	CT	TT	AL022721	Human DNA sequence from clone 109F14 on chromosome

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
							6p21.2-21.3. Contains the alternatively spliced gene for Transcriptional Enhancer Factor TEF-5, the 60S Ribosomal Protein RPL10A gene, a PUTATIVE ZNF127 LIKE gene, and the PPARD for Peroxisome Proliferato
11644	ADR5	AA	AG	AG	GG	D84371	Homo sapiens mRNA for serum arylalkylphosphatase, complete cds.
11650	EFF	AA	AG	AG	GG	X56668	Human DNA for calretinin exon 1
11654	ADR5	AA	AG	AG	GG	AJ276180	Homo sapiens partial ZNF202 gene for zinc finger protein homolog, exon 4
11654	ADR3	AA	AG	AG	GG	AJ276180	Homo sapiens partial ZNF202 gene for zinc finger protein homolog, exon 4
11655	ADR5	AA	AC	AC	CC	AJ276180	Homo sapiens partial ZNF202 gene for zinc finger protein homolog, exon 4
11655	ADR3	AA	AC	AC	CC	AJ276180	Homo sapiens partial ZNF202 gene for zinc finger protein homolog, exon 4
11656	CVD	CC	CT	CT	TT	NM_001081	CUBN: cubilin (intrinsic factor-cobalamin receptor)
11656	EFF	CC	CT	CT	TT	NM_001081	CUBN: cubilin (intrinsic factor-cobalamin receptor)
11825	ADR5	AA	AG	AG	null	AC008897	Homo sapiens chromosome 5 clone CTD-2235C13, WORKING DRAFT SEQUENCE, 6 ordered pieces.

BAYSNP	SNP class	GTTYPE1 1	GTTYPE1 2	GTTYPE2	NCBI	DESCRIPTION
11914	ADR5	AA	AT	TT	AF030555	Homo sapiens acyl-CoA synthetase 4 (ACS4) mRNA, complete cds.
12008	EFF	CC	CT	null	AF107885	Homo sapiens chromosome 14q24.3 clone BAC270M14 transforming growth factor-beta 3 (TGF-beta 3) gene, complete cds; and unknown genes.
12008	ADR5	CC	CT	null	AF107885	Homo sapiens chromosome 14q24.3 clone BAC270M14 transforming growth factor-beta 3 (TGF-beta 3) gene, complete cds; and unknown genes.
12097	ADR5	AG	GG	null	AF280107	Homo sapiens cytochrome P450 polypeptide 43 (CYP3A43) gene, partial cds; cytochrome P450 polypeptide 4 (CYP3A4) and cytochrome P450 polypeptide 7 (CYP3A7) genes, complete cds; and cytochrome P450 polypeptide 5 (CYP3A5) gene, partial cds.
12097	ADR3	AG	GG	null	AF280107	Homo sapiens cytochrome P450 polypeptide 43 (CYP3A43) gene, partial cds; cytochrome P450 polypeptide 4 (CYP3A4) and cytochrome P450 polypeptide 7 (CYP3A7) genes, complete cds; and cytochrome P450 polypeptide 5 (CYP3A5) gene, partial cds.
12366	UEFF	AA	AG	GG	D63807	Human mRNA for lanosterol synthase, complete cds.
12366	ADR5	AA	AG	GG	D63807	Human mRNA for lanosterol synthase, complete cds.
12619	ADR5	AG	GG	null	L13744	Human AF-9 mRNA, complete cds.

Table 4 Cohorts

Given are names (as used in table 5) and formations of the various cohorts that were used for genotyping

COHORT	Definition
HELD_ALL_GOOD/BAD	Healthy elderly individuals of both genders with good or bad serum lipid profiles (as defined in table 1a)
HELD_FEM_GOOD/BAD	Healthy elderly individuals (female) with good or bad serum lipid profiles (as defined in table 1a)
HELD_MAL_GOOD/BAD	Healthy elderly individuals (male) with good or bad serum lipid profiles (as defined in table 1a)
CVD_ALL_CASE/CTRL	Individuals with diagnosis of cardiovascular disease and healthy controls (both genders)
CVD_FEM_CASE/CTRL	Individuals with diagnosis of cardiovascular disease and healthy controls (female)
CVD_MAL_CASE/CTRL	Individuals with diagnosis of cardiovascular disease and healthy controls (male)
HELD_FEM_ADRCTRL	Female individuals that tolerate administration of cerivastatin without exhibiting signs of ADR (as defined in table 1b)
HELD_FEM_ADRCASE	Female individuals that exhibited ADR (as defined in table 1b) upon administration of cerivastatin
HELD_MAL_ADRCTRL	Male individuals that tolerate administration of cerivastatin without exhibiting signs of ADR (as defined in table 1b)
HELD_MAL_ADRCASE	Male individuals that exhibited ADR (as defined in table 1b) upon administration of cerivastatin
HELD_ALL_ADRCTRL	Individuals of both genders that tolerate administration of cerivastatin without exhibiting signs

COHORT	Definition
	of ADR (as defined in table 1b)
HELD_ALL_ADRCASE	Individuals of both genders that exhibited ADR (as defined in table 1b) upon administration of cerivastatin
HELD_FEM_LORESP	Female individuals with a minor response to cerivastatin administration (as defined in table 1b)
HELD_FEM_HIRES	Female individuals with a high response to cerivastatin administration (as defined in table 1b)
HELD_FEM_HIHDL/LOHDL	Healthy elderly individuals (female) with high or low serum HDL cholesterol levels (as defined in table 1c)
HELD_MAL_HIHDL/LOHDL	Healthy elderly individuals (male) with high or low serum HDL cholesterol levels (as defined in table 1c)
HELD_ALL_HIHDL/LOHDL	Healthy elderly individuals of both genders with high or low serum HDL cholesterol levels (as defined in table 1c)
HELD_FEM_ADR3CASE	Female individuals that exhibited advanced ADR (as defined in table 1b) upon administration of cerivastatin
HELD_MAL_ADR3CASE	Male individuals that exhibited advanced ADR (as defined in table 1b) upon administration of cerivastatin
HELD_ALL_ADR3CASE	Individuals of both genders that exhibited advanced ADR (as defined in table 1b) upon administration of cerivastatin
HELD_FEM_VLORESP	Female individuals with a very low response to cerivastatin administration (as defined in table 1b)

COHORT	Definition
HELD_FEM_VHIRESP	Female individuals with a very high response to cerivastatin administration (as defined in table 1b)
HELD_FEM_ADR5CASE	Female individuals that exhibited severe ADR (as defined in table 1b) upon administration of cerivastatin
HELD_MAL_ADR5CASE	Male individuals that exhibited severe ADR (as defined in table 1b) upon administration of cerivastatin
HELD_ALL_ADR5CASE	Individuals of both genders that exhibited severe ADR (as defined in table 1b) upon administration of cerivastatin
HELD_FEM_ULORESP	Female individuals with a ultra low response to cerivastatin administration (as defined in table 1b)
HELD_FEM_UHIRESP	Female individuals with a ultra high response to to cerivastatin administration (as defined in table 1b)

Table 5a and 5b Cohort sizes and p-values of PA SNPs

The baySNP number refers to an internal numbering of the PA SNPs. Cpval denotes the classical Pearson chi-squared test, Xpval denotes the exact version of Pearson's chi-squared test, LRpval denotes the likelihood-ratio chi-squared test, Cpvalue, Xpvalue, and LRpvalue are calculated as described in (SAS/STAT User's Guide of the SAS OnlineDoc, Version 8), (L. D. Fisher and G. van Belle, Biostatistics, Wiley Interscience 1993), and (A. Agresti, Statistical Science 7, 131 (1992)). The GTYPE and Allele p values were obtained through the respective chi square tests when comparing COHORTs A and B. For GTYPE p value the number of patients in cohort A carrying genotypes 11, 12 or 22 (FQ11 A, FQ 12 A, FQ 22 A; genotypes as defined in table 3) were compared with the respective patients in cohort B (FQ11 B, FQ 12 B, FQ 22 B; genotypes as defined in table 3) resulting in the respective chi square test with a 3x2 matrix. For Allele p values we compared the allele count of alleles 1 and 2 (A1 and A2) in cohorts A and B, respectively (chi square test with a 2x2 matrix). SIZE A and B: Number of patients in cohorts A and B, respectively. See table 4 for definition of COHORTs A and B.

Table 5a Cohort sizes and frequency of alleles and genotypes

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
28	C	T	HELD_FEM_HIRES	12	4	20	1	2	9	HELD_FEM_LORESP	22	18	26	3	12	7
29	A	G	HELD_ALL_LOHDL	10	12	8	4	4	2	HELD_ALL_HIHDL	15	7	23	0	7	8
29	A	G	HELD_MAL_ADRCASE3 ULN	26	33	19	13	7	6	HELD_MAL_ADRCTRL	72	68	76	18	32	22
29	A	G	HELD_MAL_ADRCASE5 ULN	9	13	5	5	3	1	HELD_MAL_ADRCTRL	72	68	76	18	32	22
52	C	G	HELD_FEM_HIRES	18	24	12	7	10	1	HELD_FEM_LORESP	31	27	35	5	17	9

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
56	A	G	HELD_FEM_HIRES	12	5	19	0	5	7	HELD_FEM_LORESP	22	2	42	0	2	20
89	A	G	HELD_ALL_CASE	45	90	0	45	0	0	HELD_ALL_CTRL	40	77	3	37	3	0
90	C	T	HELD_FEM_CASE	31	29	33	8	13	10	HELD_FEM_CTRL	22	27	17	6	15	1
99	C	T	HELD_FEM_BAD	82	54	110	13	28	41	HELD_FEM_GOOD	80	51	109	5	41	34
140	C	T	HELD_FEM_HIRES	12	24	0	0	0	12	HELD_FEM_LORESP	21	4	38	1	2	18
152	A	G	HELD_FEM_HIRES	12	12	12	3	6	3	HELD_FEM_LORESP	22	33	11	12	9	1
214	A	G	HELD_ALL_BAD	97	156	38	59	38	0	HELD_ALL_GOOD	113	182	44	73	36	4
214	A	G	HELD_FEM_BAD	81	131	31	50	31	0	HELD_FEM_GOOD	78	122	34	48	26	4
221	C	G	HELD_ALL_CASE	45	26	64	7	12	26	HELD_ALL_CTRL	39	27	51	3	21	15
221	C	G	HELD_FEM_CASE	31	17	45	4	9	18	HELD_FEM_CTRL	22	18	26	2	14	6
224	C	T	HELD_FEM_BAD	79	110	48	51	8	20	HELD_FEM_GOOD	79	125	33	60	5	14
224	C	T	HELD_MAL_BAD	20	35	5	17	1	2	HELD_MAL_GOOD	37	51	23	25	1	11
294	C	T	HELD_ALL_CASE	45	56	34	16	24	5	HELD_ALL_CTRL	40	58	22	18	22	0
307	C	T	CVD_FEM_CASE	36	19	53	2	15	19	CVD_FEM_CTRL	38	38	38	9	20	9
307	C	T	HELD_ALL_BAD	102	70	134	0	70	32	HELD_ALL_GOOD	117	63	171	0	63	54
411	A	T	HELD_ALL_LOHDL	10	17	3	7	3	0	HELD_ALL_HIHDL	15	18	12	5	8	2
449	C	G	HELD_MAL_BAD	20	3	37	0	3	17	HELD_MAL_GOOD	37	16	58	1	14	22
466	C	T	CVD_FEM_CASE	35	27	43	6	15	14	CVD_FEM_CTRL	40	44	36	12	20	8
472	A	G	HELD_FEM_HIRES	11	22	0	0	0	11	HELD_FEM_LORESP	22	12	32	3	6	13
542	A	G	HELD_MAL_CASE	14	12	16	2	8	4	HELD_MAL_CTRL	19	2	36	0	2	17
542	A	G	HELD_MAL_LOHDL	21	14	28	3	8	10	HELD_MAL_HIHDL	27	3	51	0	3	24
542	A	G	HELD_ALL_ADRCASE	159	53	265	0	53	106	HELD_ALL_ADRCtrl	154	37	271	2	33	119

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
542	A	G	HELD_FEM_LOHDL	23	2	44	0	2	21	HELD_FEM_HIHDL	32	10	54	1	8	23
739	C	G	HELD_ALL_CASE	45	39	51	9	21	15	HELD_ALL_CTRL	40	48	32	14	20	6
821	A	C	HELD_MAL_BAD2	309	180	438	32	116	161	HELD_MAL_GOOD2	349	174	524	18	138	193
821	A	C	HELD_FEM_VHIRESP	10	4	16	0	4	6	HELD_FEM_VLORESP	14	14	14	4	6	4
1005	A	G	HELD_MAL_CASE	14	26	2	12	2	0	HELD_MAL_CTRL	18	27	9	11	5	2
1055	A	T	HELD_MAL_CASE	9	3	15	0	3	6	HELD_MAL_CTRL	12	8	16	4	0	8
1056	A	G	HELD_FEM_HIRES	24	30	18	12	6	6	HELD_FEM_LORESP	33	41	25	10	21	2
1085	A	G	HELD_MAL_BAD	20	17	23	3	11	6	HELD_MAL_GOOD	36	46	26	15	16	5
1085	A	G	CVD_FEM_CASE	34	51	17	20	11	3	CVD_FEM_CTRL	40	47	33	16	15	9
1086	A	G	HELD_MAL_BAD	20	24	16	7	10	3	HELD_MAL_GOOD	36	28	44	5	18	13
1092	C	G	HELD_MAL_BAD	20	9	31	2	5	13	HELD_MAL_GOOD	37	29	45	4	21	12
1096	G	T	HELD_MAL_CASE	14	7	21	0	7	7	HELD_MAL_CTRL	18	3	33	0	3	15
1096	G	T	CVD_MAL_CASE	69	21	117	4	13	52	CVD_MAL_CTRL	33	12	54	0	12	21
1101	C	T	HELD_FEM_HIRES	12	24	0	12	0	0	HELD_FEM_LORESP	22	40	4	18	4	0
1204	A	G	HELD_MAL_BAD	19	12	26	2	8	9	HELD_MAL_GOOD	35	9	61	0	9	26
1204	A	G	HELD_ALL_BAD	99	62	136	12	38	49	HELD_ALL_GOOD	115	52	178	8	36	71
1504	C	T	HELD_ALL_CASE	44	37	51	5	27	12	HELD_ALL_CTRL	39	36	42	12	12	15
1504	C	T	HELD_MAL_BAD	19	12	26	0	12	7	HELD_MAL_GOOD	37	33	41	8	17	12
1504	C	T	HELD_MAL_CASE	14	13	15	2	9	3	HELD_MAL_CTRL	18	12	24	4	4	10
1504	C	T	HELD_FEM_CASE	30	24	36	3	18	9	HELD_FEM_CTRL	21	24	18	8	8	5
1511	G	T	HELD_FEM_HIRES	12	15	9	3	9	0	HELD_FEM_LORESP	22	35	9	14	7	1
1524	A	C	HELD_FEM_ADRCASE3	38	16	60	0	16	22	HELD_FEM_ADRCTRL	82	39	125	8	23	51

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
			ULN													
1765	A	G	HELD_MAL_ADRCASE5	10	20	0	0	0	10	HELD_MAL_ADRCTRL	70	25	115	2	21	47
			ULN													
1765	A	G	HELD_MAL_ADRCASE5	10	20	0	0	0	10	HELD_MAL_ADRCTRL	70	25	115	2	21	47
			ULN													
1765	A	G	HELD_FEM_ADRCASE3	37	7	67	1	5	31	HELD_FEM_ADRCTRL	79	31	127	2	27	50
			ULN													
1765	A	G	HELD_FEM_ADRCASE3	37	7	67	1	5	31	HELD_FEM_ADRCTRL	79	31	127	2	27	50
			ULN													
1776	A	G	HELD_ALL_CASE	45	90	0	45	0	0	HELD_ALL_CTRL	40	74	6	37	0	3
1776	A	G	HELD_FEM_CASE	31	62	0	31	0	0	HELD_FEM_CTRL	22	40	4	20	0	2
1799	C	T	HELD_FEM_BAD2	291	365	217	123	119	49	HELD_FEM_GOOD2	356	468	244	145	178	33
1799	C	T	HELD_MAL_CASE	14	15	13	4	7	3	HELD_MAL_CTRL	18	28	8	11	6	1
1806	A	G	HELD_FEM_HIRES	12	23	1	11	1	0	HELD_FEM_LORESP	22	34	10	14	6	2
1837	C	T	HELD_FEM_BAD2	304	436	172	164	108	32	HELD_FEM_GOOD2	355	499	211	166	167	22
1837	C	T	HELD_ALL_BAD2	607	891	323	334	223	50	HELD_ALL_GOOD2	682	952	412	322	308	52
1837	C	T	HELD_ALL_ADRCASE5	28	46	10	20	6	2	HELD_ALL_ADRCTRL	155	208	102	66	76	13
			ULN													
1837	C	T	HELD_MAL_ADRCASE	77	107	47	37	33	7	HELD_MAL_ADRCTRL	72	86	58	21	44	7
1837	C	T	HELD_MAL_BAD2	303	455	151	170	115	18	HELD_MAL_GOOD2	327	453	201	156	141	30
1870	C	T	HELD_ALL_CASE	45	29	61	2	25	18	HELD_ALL_CTRL	39	16	62	3	10	26
1870	C	T	HELD_FEM_CASE	31	22	40	1	20	10	HELD_FEM_CTRL	22	9	35	1	7	14

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
1882	C	T	CVD_MAL_CASE	69	79	59	21	37	11	CVD_MAL_CTRL	34	43	25	9	25	0
1988	C	T	HELD_ALL_BAD	100	143	57	52	39	9	HELD_ALL_GOOD	116	144	88	48	48	20
2000	C	T	CVD_MAL_CASE	70	136	4	68	2	0	CVD_MAL_CTRL	34	58	10	29	5	0
2000	C	T	CVD_ALL_CASE	105	202	8	101	4	0	CVD_ALL_CTRL	74	130	18	65	9	0
2000	C	T	HELD_FEM_CASE2	46	90	2	45	1	0	HELD_FEM_CTRL2	42	74	10	37	5	0
2000	C	T	HELD_MAL_LOHDL	20	40	0	20	0	0	HELD_MAL_HIHDL	22	40	4	20	2	0
2000	C	T	HELD_FEM_ADRCASE	79	154	4	77	2	0	HELD_FEM_ADRCtrl	82	152	12	76	6	0
2000	C	T	HELD_MAL_CASE	14	22	6	11	3	0	HELD_MAL_CTRL	19	36	2	18	1	0
2071	A	G	CVD_ALL_CASE	102	80	124	14	52	36	CVD_ALL_CTRL	74	42	106	4	34	36
2078	G	T	HELD_MAL_BAD	18	13	23	1	11	6	HELD_MAL_GOOD	35	13	57	0	13	22
2085	G	T	HELD_FEM_VHIRESP	10	16	4	6	4	0	HELD_FEM_VLORESP	14	13	15	3	7	4
2095	A	G	CVD_ALL_CASE	105	4	206	4	101	0	CVD_ALL_CTRL	73	146	0	0	73	0
2119	A	G	HELD_MAL_BAD	20	23	17	3	17	0	HELD_MAL_GOOD	37	53	21	16	21	0
2119	A	G	HELD_ALL_BAD	102	131	73	29	73	0	HELD_ALL_GOOD	117	166	68	49	68	0
2119	A	G	HELD_FEM_HIRES	12	15	9	3	9	0	HELD_FEM_LORESP	22	35	9	13	9	0
2141	A	G	HELD_FEM_HIRES	12	6	18	0	6	6	HELD_FEM_LORESP	22	6	38	2	2	18
2141	A	G	HELD_ALL_CASE	45	17	73	0	17	28	HELD_ALL_CTRL	39	15	63	3	9	27
2182	A	G	HELD_FEM_HIRES	12	18	6	6	6	0	HELD_FEM_LORESP	21	16	26	1	14	6
2234	G	T	HELD_MAL_BAD	20	10	30	0	10	10	HELD_MAL_GOOD	35	32	38	7	18	10
2281	A	C	HELD_FEM_VHIRESP	9	5	13	0	5	4	HELD_FEM_VLORESP	13	15	11	4	7	2
2298	A	C	CVD_FEM_CASE	35	18	52	4	10	21	CVD_FEM_CTRL	38	20	56	0	20	18
2298	A	C	HELD_MAL_CASE2	29	8	50	0	8	21	HELD_MAL_CTRL2	28	16	40	2	12	14

daySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
2341	C	T	HELD_FEM_CASE	31	6	56	0	6	25	HELD_FEM_CTRL	22	44	0	0	0	22
2357	A	G	HELD_ALL_CASE2	74	28	120	5	18	51	HELD_ALL_CTRL2	71	25	117	0	25	46
2357	A	G	HELD_ALL_CASE	45	16	74	4	8	33	HELD_ALL_CTRL	40	14	66	0	14	26
2357	A	G	HELD_MAL_BAD	20	4	36	0	4	16	HELD_MAL_GOOD	36	17	55	0	17	19
2357	A	G	HELD_FEM_CASE	31	12	50	4	4	23	HELD_FEM_CTRL	22	7	37	0	7	15
2366	G	T	CVD_FEM_CASE	33	38	28	12	14	7	CVD_FEM_CTRL	40	31	49	8	15	17
2423	A	G	CVD_FEM_CASE	33	45	21	16	13	4	CVD_FEM_CTRL	39	38	40	12	14	13
2708	C	T	CVD_FEM_CASE	29	57	1	28	1	0	CVD_FEM_CTRL	40	73	7	33	7	0
2995	A	C	HELD_FEM_ADRCASE5 ULN	18	16	20	3	10	5	HELD_FEM_ADRCTRL	82	45	119	4	37	41
2995	A	C	HELD_FEM_UHRESP	54	24	84	2	20	32	HELD_FEM_ULORESP	75	50	100	5	40	30
3360	G	T	HELD_MAL_ADRCASE5 ULN	10	20	0	10	0	0	HELD_MAL_ADRCTRL	73	122	24	50	22	1
3464	A	G	HELD_ALL_CASE	45	21	69	3	15	27	HELD_ALL_CTRL	40	35	45	9	17	14
3464	A	G	HELD_FEM_CASE	31	13	49	3	7	21	HELD_FEM_CTRL	22	19	25	5	9	8
3689	C	G	HELD_FEM_HIRES	6	9	3	3	3	0	HELD_FEM_LORESP	14	10	18	1	8	5
3975	A	C	HELD_FEM_UHRESP	56	28	84	2	24	30	HELD_FEM_ULORESP	75	58	92	10	38	27
3976	A	G	HELD_FEM_UHRESP	56	28	84	2	24	30	HELD_FEM_ULORESP	75	57	93	11	35	29
4206	A	T	HELD_FEM_ADRCASE3 ULN	37	36	38	8	20	9	HELD_FEM_ADRCTRL	83	103	63	31	41	11
4838	A	G	HELD_FEM_VHRESP	10	16	4	7	2	1	HELD_FEM_VLORESP	14	14	14	3	8	3
4838	A	G	HELD_FEM_VHRESP	10	16	4	7	2	1	HELD_FEM_VLORESP	14	14	14	3	8	3

daySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
4838	A	G	HELD_FEM_VHRESP	10	16	4	7	2	1	HELD_FEM_VLORESP	14	14	14	3	8	3
4912	A	G	HELD_FEM_HIRES	12	14	10	7	0	5	HELD_FEM_LORESP	20	12	28	5	2	13
4925	A	C	HELD_MAL_CASE	14	21	7	7	7	0	HELD_MAL_CTRL	18	33	3	15	3	0
4966	A	G	HELD_MAL_ADRCASE3 ULN	26	22	30	7	8	11	HELD_MAL_ADRCTRL	72	77	67	18	41	13
5014	A	G	HELD_ALL_ADRCASE5 ULN	28	8	48	3	2	23	HELD_ALL_ADRCTRL	152	77	227	10	57	85
5014	A	G	HELD_FEM_ADRCASE5 ULN	18	5	31	2	1	15	HELD_FEM_ADRCTRL	81	37	125	5	27	49
5296	A	G	CVD_FEM_CASE	36	10	62	0	10	26	CVD_FEM_CTRL	40	4	76	0	4	36
5296	A	G	HELD_FEM_HIRES	12	3	21	1	1	10	HELD_FEM_LORESP	22	9	35	0	9	13
5296	A	G	CVD_ALL_CASE	104	27	181	1	25	78	CVD_ALL_CTRL	74	10	138	0	10	64
5298	C	T	HELD_FEM_HIRES	11	3	19	1	1	9	HELD_FEM_LORESP	22	9	35	0	9	13
5298	C	T	CVD_ALL_CASE	101	28	174	3	22	76	CVD_ALL_CTRL	74	10	138	0	10	64
5298	C	T	CVD_FEM_CASE	35	10	60	1	8	26	CVD_FEM_CTRL	40	4	76	0	4	36
5320	A	G	HELD_FEM_HIRES	19	12	26	1	10	8	HELD_FEM_LORESP	33	37	29	9	19	5
5361	A	C	CVD_MAL_CASE	64	53	75	24	5	35	CVD_MAL_CTRL	32	36	28	18	0	14
5457	A	G	HELD_FEM_HIRES	12	2	22	1	0	11	HELD_FEM_LORESP	21	8	34	1	6	14
5704	C	T	HELD_MAL_BAD	20	10	30	1	8	11	HELD_MAL_GOOD	37	32	42	3	26	8
5704	C	T	CVD_MAL_CASE	68	40	96	5	30	33	CVD_MAL_CTRL	33	30	36	6	18	9
5717	A	G	HELD_FEM_ADRCASE3 ULN	38	50	26	17	16	5	HELD_FEM_ADRCTRL	83	83	83	21	41	21

DaySNP	AI	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
5717	A	G	HELD_ALL_ADRCASE3 ULN	65	74	56	21	32	12	HELD_ALL_ADRCTRL	156	144	168	34	76	46
5959	A	G	HELD_ALL_CASE	43	52	34	16	20	7	HELD_ALL_CTRL	38	29	47	4	21	13
5959	A	G	CVD_FEM_CASE	9	12	6	4	4	1	CVD_FEM_CTRL	13	7	19	0	7	6
5959	A	G	HELD_MAL_CASE	14	15	13	4	7	3	HELD_MAL_CTRL	17	10	24	0	10	7
5959	A	G	HELD_MAL_ADRCASE5 ULN	9	6	12	2	2	5	HELD_MAL_ADRCTRL	67	67	67	13	41	13
5959	A	G	HELD_FEM_ADRCASE	72	71	73	15	41	16	HELD_FEM_ADRCTRL	68	51	85	11	29	28
6162	C	G	HELD_ALL_ADRCASE3 ULN	64	37	91	1	35	28	HELD_ALL_ADRCTRL	151	90	212	19	52	80
6162	C	G	HELD_ALL_ADRCASE	156	88	224	6	76	74	HELD_ALL_ADRCTRL	151	90	212	19	52	80
6162	C	G	HELD_ALL_ADRCASE5 ULN	27	16	38	0	16	11	HELD_ALL_ADRCTRL	151	90	212	19	52	80
6162	C	G	HELD_MAL_ADRCASE3 ULN	26	13	39	0	13	13	HELD_MAL_ADRCTRL	71	43	99	11	21	39
6162	C	G	HELD_FEM_ADRCASE5 ULN	18	13	23	0	13	5	HELD_FEM_ADRCTRL	80	47	113	8	31	41
6162	C	G	HELD_MAL_ADRCASE	74	40	108	3	34	37	HELD_MAL_ADRCTRL	71	43	99	11	21	39
6236	C	T	HELD_ALL_ADRCASE5 ULN	27	24	30	6	12	9	HELD_ALL_ADRCTRL	152	84	220	13	58	81
6236	C	T	HELD_MAL_ADRCASE3 ULN	27	23	31	4	15	8	HELD_MAL_ADRCTRL	72	38	106	5	28	39

daySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
6236	C	T	HELD_MAL_ADRCASE5 ULN	10	10	10	2	6	2	HELD_MAL_ADRCTRL	72	38	106	5	28	39
6236	C	T	HELD_ALL_ADRCASE3 ULN	63	47	79	10	27	26	HELD_ALL_ADRCTRL	152	84	220	13	58	81
6482	A	G	HELD_MAL_LOHDL	17	18	16	5	8	4	HELD_MAL_HIHDL	21	34	8	15	4	2
6482	A	G	HELD_ALL_BAD2	619	918	320	340	238	41	HELD_ALL_GOOD2	709	1098	320	436	226	47
6482	A	G	HELD_MAL_CASE2	27	43	11	18	7	2	HELD_MAL_CTRL2	28	32	24	10	12	6
6482	A	G	HELD_MAL_BAD2	309	461	157	173	115	21	HELD_MAL_GOOD2	339	539	139	220	99	20
6498	A	G	CVD_FEM_CASE	32	60	4	28	4	0	CVD_FEM_CTRL	35	57	13	25	7	3
6744	C	T	HELD_ALL_ADRCASE5 ULN	26	21	31	4	13	9	HELD_ALL_ADRCTRL	149	74	224	9	56	84
7133	C	G	HELD_MAL_CASE	14	20	8	10	0	4	HELD_MAL_CTRL	18	36	0	18	0	0
8021	A	G	CVD_FEM_CASE	28	35	21	8	19	1	CVD_FEM_CTRL	36	44	28	15	14	7
8060	A	G	CVD_FEM_CASE	35	65	5	31	3	1	CVD_FEM_CTRL	40	68	12	28	12	0
8060	A	G	HELD_FEM_LOHDL	18	29	7	11	7	0	HELD_FEM_HIHDL	23	43	3	20	3	0
8210	A	G	HELD_FEM_HIRES	12	9	15	1	7	4	HELD_FEM_LORESP	22	22	22	9	4	9
8592	C	T	HELD_FEM_VHIRES	150	122	178	15	92	43	HELD_FEM_VLORESP	143	118	168	25	68	50
8816	C	G	HELD_FEM_HIRES	13	15	11	4	7	2	HELD_FEM_LORESP	11	5	17	0	5	6
8846	A	G	HELD_ALL_BAD	107	161	53	57	47	3	HELD_ALL_GOOD	116	166	66	62	42	12
8943	A	C	HELD_MAL_BAD	20	35	5	15	5	0	HELD_MAL_GOOD	37	52	22	20	12	5
9193	C	G	HELD_FEM_BAD	83	155	11	72	11	0	HELD_FEM_GOOD	80	140	20	60	20	0
9193	C	G	CVD_FEM_CASE	36	63	9	28	7	1	CVD_FEM_CTRL	40	77	3	37	3	0

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
9443	C	T	CVD_MAL_CASE	69	43	95	9	25	35	CVD_MAL_CTRL	33	12	54	0	12	21
9516	A	G	HELD_MAL_CASE	14	17	11	7	3	4	HELD_MAL_CTRL	18	12	24	2	8	8
9698	A	G	HELD_MAL_ADRCASE	74	8	140	4	0	70	HELD_MAL_ADRCTRL	72	30	114	14	2	56
9698	A	G	HELD_MAL_ADRCASE3 ULN	27	54	0	0	0	27	HELD_MAL_ADRCTRL	72	30	114	14	2	56
9698	A	G	HELD_FEM_HIRES	294	105	483	5	95	194	HELD_FEM_LORESP	298	123	473	16	91	191
9698	A	G	HELD_MAL_ADRCASE5 ULN	10	20	0	0	0	10	HELD_MAL_ADRCTRL	72	30	114	14	2	56
9698	A	G	CVD_ALL_CASE	102	46	158	17	12	73	CVD_ALL_CTRL	72	19	125	6	7	59
9849	C	T	HELD_FEM_CASE	31	62	0	31	0	0	HELD_FEM_CTRL	21	39	3	18	3	0
9849	C	T	HELD_MAL_BAD	20	35	5	15	5	0	HELD_MAL_GOOD	37	72	2	35	2	0
9883	A	G	HELD_FEM_CASE	31	23	39	7	9	15	HELD_FEM_CTRL	22	18	26	1	16	5
9883	A	G	HELD_ALL_CASE	45	33	57	9	15	21	HELD_ALL_CTRL	39	32	46	4	24	11
10079	A	G	CVD_ALL_CASE	103	8	198	4	0	99	CVD_ALL_CTRL	73	1	145	0	1	72
10079	A	G	CVD_MAL_CASE	68	8	128	4	0	64	CVD_MAL_CTRL	34	68	0	0	0	34
10481	A	T	HELD_FEM_ADRCASE5 ULN	17	12	22	3	6	8	HELD_FEM_ADRCTRL	83	97	69	32	33	18
10542	C	T	HELD_FEM_UHRES	54	8	100	1	6	47	HELD_FEM_ULORESP	75	21	129	0	21	54
10542	C	T	HELD_MAL_ADRCASE5 ULN	10	20	0	0	0	10	HELD_MAL_ADRCTRL	69	14	124	0	14	55
10600	A	G	HELD_FEM_HIRES	21	42	0	0	0	21	HELD_FEM_LORESP	33	4	62	0	4	29
10621	C	T	HELD_FEM_CASE	30	52	8	24	4	2	HELD_FEM_CTRL	20	32	8	12	8	0

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
10745	A	G	HELD_ALL_ADRCASE5 ULN	27	20	34	5	10	12	HELD_ALL_ADRCTRL	148	75	221	7	61	80
10745	A	G	HELD_FEM_VHRESP	153	90	216	11	68	74	HELD_FEM_VLORESP	150	77	223	16	45	89
10747	C	T	HELD_MAL_ADRCASE	76	74	78	14	46	16	HELD_MAL_ADRCTRL	70	64	76	3	58	9
10747	C	T	CVD_ALL_CASE	62	54	70	15	24	23	CVD_ALL_CTRL	74	51	97	6	39	29
10747	C	T	HELD_MAL_ADRCASE3 ULN	27	24	30	4	16	7	HELD_MAL_ADRCTRL	70	64	76	3	58	9
10771	C	G	HELD_MAL_ADRCASE5 ULN	10	12	8	4	4	2	HELD_MAL_ADRCTRL	70	48	92	6	36	28
10771	C	G	HELD_FEM_HRESP	284	222	346	52	118	114	HELD_FEM_LORESP	276	185	367	40	105	131
10870	A	G	HELD_MAL_BAD	20	11	29	0	11	9	HELD_MAL_GOOD	37	19	55	5	9	23
10870	A	G	HELD_FEM_BAD	82	32	132	7	18	57	HELD_FEM_GOOD	77	46	108	8	30	39
10870	A	G	HELD_MAL_CASE	14	3	25	0	3	11	HELD_MAL_CTRL	18	12	24	2	8	8
10870	A	G	HELD_ALL_CASE	45	17	73	2	13	30	HELD_ALL_CTRL	40	27	53	6	15	19
10877	A	C	HELD_ALL_LOHDL	9	18	0	0	0	9	HELD_ALL_HHDL	15	7	23	1	5	9
10948	G	T	HELD_FEM_BAD	84	83	85	16	51	17	HELD_FEM_GOOD	79	95	63	31	33	15
10948	G	T	HELD_ALL_BAD	104	104	104	22	60	22	HELD_ALL_GOOD	115	138	92	44	50	21
10948	G	T	HELD_FEM_CASE2	44	46	42	9	28	7	HELD_FEM_CTRL2	42	50	34	17	16	9
10948	G	T	CVD_MAL_CASE	69	63	75	12	39	18	CVD_MAL_CTRL	34	41	27	12	17	5
11001	C	T	HELD_MAL_ADRCASE5 ULN	10	9	11	2	5	3	HELD_MAL_ADRCTRL	75	41	109	2	37	36
11073	C	G	HELD_MAL_ADRCASE5	9	10	8	3	4	2	HELD_MAL_ADRCTRL	68	43	93	9	25	34

baySNP	A1	A2	COHORT A	SIZE	FQ1A	FQ2A	FQ11	FQ12	COHORT B	SIZE	FQ1B	FQ2B	FQ11	FQ12	FQ22
			U1N												
11153	C	T	HELD_FEM_CASE	31	55	7	24	7	0	22	33	11	11	11	0
11210	C	T	HELD_MAL_CASE	14	23	5	9	5	0	19	37	1	18	1	0
11210	C	T	HELD_ALL_ADRCASE3	63	110	16	47	16	0	144	267	21	125	17	2
			U1N												
11210	C	T	HELD_ALL_ADRCASE	153	275	31	122	31	0	144	267	21	125	17	2
11248	C	T	HELD_FEM_ADRCASE	81	131	31	56	19	6	79	112	46	38	36	5
11248	C	T	HELD_MAL_BAD	18	33	3	15	3	0	34	53	15	19	15	0
11248	C	T	HELD_ALL_CASE	41	68	14	27	14	0	31	44	18	13	18	0
11372	A	G	HELD_MAL_BAD	20	25	15	10	5	5	36	31	41	10	11	15
11449	C	G	HELD_FEM_CASE	31	6	56	1	4	26	22	10	34	0	10	12
11450	A	T	HELD_FEM_HIRES	289	170	408	28	114	147	290	139	441	16	107	167
11470	C	T	HELD_MAL_BAD	20	40	0	20	0	0	36	67	5	31	5	0
11472	A	T	HELD_MAL_BAD	20	40	0	20	0	0	35	65	5	30	5	0
11472	A	T	HELD_FEM_BAD	83	158	8	75	8	0	80	158	2	78	2	0
11487	A	T	HELD_MAL_ADRCASE5	10	20	0	0	10	0	69	34	104	34	35	0
			U1N												
11487	A	T	HELD_MAL_ADRCASE3	27	6	48	6	21	0	69	34	104	34	35	0
			U1N												
11488	C	G	HELD_MAL_ADRCASE5	10	20	0	10	0	0	70	102	38	35	32	3
			U1N												
11488	C	G	HELD_FEM_UHRES	54	78	30	29	20	5	77	126	28	49	28	0

- 170 -

baySNP	AI	A2	COHORT A	SIZE	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
11488	C	G	HELD_MAL_ADRCASE3 ULN	26	44	8	20	4	2	HELD_MAL_ADRCTRL	70	102	38	35	32	3
11493	A	G	HELD_MAL_CASE	14	6	22	0	6	8	HELD_MAL_CTRL	18	6	30	2	2	14
11502	C	T	HELD_MAL_ADRCASE3 ULN	27	8	46	0	8	19	HELD_MAL_ADRCTRL	73	44	102	7	30	36
11502	C	T	HELD_MAL_ADRCASE5 ULN	10	2	18	0	2	8	HELD_MAL_ADRCTRL	73	44	102	7	30	36
11534	G	T	HELD_ALL_BAD	102	204	0	102	0	0	HELD_ALL_GOOD	117	231	3	114	3	0
11537	A	G	CVD_FEM_CASE	36	52	20	20	12	4	CVD_FEM_CTRL	39	68	10	30	8	1
11537	A	G	HELD_FEM_HIRES	12	22	2	10	2	0	HELD_FEM_LORESP	22	31	13	12	7	3
11560	A	G	HELD_FEM_HIRES	12	2	22	1	0	11	HELD_FEM_LORESP	22	44	0	0	0	22
11578	C	T	HELD_FEM_BAD	61	121	1	60	1	0	HELD_FEM_GOOD	65	122	8	57	8	0
11578	C	T	CVD_FEM_CASE	30	57	3	27	3	0	CVD_FEM_CTRL	39	78	0	39	0	0
11594	C	T	HELD_FEM_ADRCASE3 ULN	37	74	0	0	0	37	HELD_FEM_ADRCTRL	80	10	150	2	6	72
11594	C	T	HELD_ALL_ADRCASE5 ULN	27	54	0	0	0	27	HELD_ALL_ADRCTRL	151	20	282	2	16	133
11594	C	T	HELD_ALL_CASE	45	10	80	0	10	35	HELD_ALL_CTRL	41	3	79	0	3	38
11594	C	T	HELD_ALL_ADRCASE	155	9	301	1	7	147	HELD_ALL_ADRCTRL	151	20	282	2	16	133
11594	C	T	HELD_FEM_ADRCASE5 ULN	18	36	0	0	0	18	HELD_FEM_ADRCTRL	80	10	150	2	6	72
11624	C	T	HELD_ALL_CASE	42	57	27	21	15	6	HELD_ALL_CTRL	40	60	20	20	20	0

daySNP	AI	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
1111624	C	T	HELD_MAL_CASE	13	18	8	8	2	3	HELD_MAL_CTRL	18	27	9	9	9	0
1111624	C	T	HELD_FEM_HIRES	12	22	2	10	2	0	HELD_FEM_LORESP	21	30	12	12	6	3
1111627	C	T	HELD_ALL_CASE	45	58	32	20	18	7	HELD_ALL_CTRL	40	61	19	21	19	0
1111627	C	T	HELD_MAL_CASE	14	18	10	7	4	3	HELD_MAL_CTRL	18	27	9	9	9	0
1111627	C	T	HELD_FEM_HIRES	12	22	2	10	2	0	HELD_FEM_LORESP	22	31	13	12	7	3
1111644	A	G	HELD_MAL_ADRCASES	10	2	18	0	2	8	HELD_MAL_ADRCTRL	68	40	96	7	26	35
1111650	A	G	HELD_FEM_HIRES	291	157	425	26	105	160	HELD_FEM_LORESP	290	181	399	23	135	132
1111654	A	G	HELD_ALL_ADRCASES	25	17	33	7	3	15	HELD_ALL_ADRCTRL	136	84	188	14	56	66
1111654	A	G	HELD_FEM_ADRCASES	15	11	19	5	1	9	HELD_FEM_ADRCTRL	71	47	95	8	31	32
1111654	A	G	HELD_FEM_ADRCASE3	32	23	41	8	7	17	HELD_FEM_ADRCTRL	71	47	95	8	31	32
1111654	A	G	HELD_ALL_ADRCASE3	53	39	67	12	15	26	HELD_ALL_ADRCTRL	136	84	188	14	56	66
1111655	A	C	HELD_ALL_ADRCASES	26	35	17	16	3	7	HELD_ALL_ADRCTRL	148	203	93	72	59	17
1111655	A	C	HELD_FEM_ADRCASES	17	23	11	11	1	5	HELD_FEM_ADRCTRL	80	104	56	35	34	11
1111655	A	C	HELD_FEM_ADRCASE3	35	45	25	19	7	9	HELD_FEM_ADRCTRL	80	104	56	35	34	11

daySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B
11656	C	T	HELD_MAL_BAD	20	20	20	6	8	HELD_MAL_GOOD	36	53	19	19	2
11656	C	T	HELD_FEM_HIRES	12	19	5	7	5	HELD_FEM_LORESP	22	24	20	5	3
11656	C	T	HELD_ALL_BAD	102	119	85	35	49	HELD_ALL_GOOD	114	156	72	51	9
11825	A	G	HELD_MAL_ADRCASE5 ULN	9	15	3	6	3	HELD_MAL_ADRCTRL	63	121	5	58	0
11914	A	T	HELD_MAL_ADRCASE5 ULN	9	2	16	1	0	HELD_MAL_ADRCTRL	69	83	55	41	27
11914	A	T	HELD_ALL_ADRCASE5 ULN	27	24	30	6	12	HELD_ALL_ADRCTRL	151	178	124	63	36
12008	C	T	HELD_FEM_HIRES	278	529	27	251	27	HELD_FEM_LORESP	277	541	13	264	0
12008	C	T	HELD_ALL_ADRCASE5 ULN	24	48	0	24	0	HELD_ALL_ADRCTRL	134	256	12	122	0
12097	A	G	HELD_ALL_ADRCASE5 ULN	28	6	50	6	22	HELD_ALL_ADRCTRL	155	11	299	11	0
12097	A	G	HELD_FEM_ADRCASE3 ULN	38	7	69	7	31	HELD_FEM_ADRCTRL	83	5	161	5	0
12097	A	G	HELD_MAL_ADRCASE5 ULN	10	3	17	3	7	HELD_MAL_ADRCTRL	72	6	138	6	0
12097	A	G	HELD_ALL_ADRCASE3 ULN	63	10	116	10	53	HELD_ALL_ADRCTRL	155	11	299	11	0
12366	A	G	HELD_FEM_UHIRES	50	82	18	32	18	HELD_FEM_ULORESP	74	104	44	39	9
12366	A	G	HELD_ALL_ADRCASE5	25	40	10	18	4	HELD_ALL_ADRCTRL	151	229	73	85	7

baySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	FQ22 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
			ULN													
12619	A	G	HELD_MAL_ADRCASE5	10	1	19	1	9	0	HELD_MAL_ADRCTRL	71	142	0	0	71	0
			ULN													
12619	A	G	HELD_ALL_ADRCASE5	27	2	52	2	25	0	HELD_ALL_ADRCTRL	151	1	301	1	150	0
			ULN													
13025	A	C	HELD_ALL_ADRCASE5	28	34	22	13	8	7	HELD_ALL_ADRCTRL	151	201	101	65	71	15
			ULN													
13191	A	G	HELD_FEM_BAD	83	42	124	6	30	47	HELD_FEM_GOOD	79	62	96	10	42	27
13191	A	G	HELD_MAL_CASE	14	11	17	2	7	5	HELD_MAL_CTRL	18	5	31	0	5	13
13191	A	G	HELD_ALL_BAD	101	51	151	6	39	56	HELD_ALL_GOOD	114	81	147	13	55	46
13937	A	C	HELD_FEM_ADRCASE5	17	19	15	4	11	2	HELD_FEM_ADRCTRL	83	122	44	42	38	3
			ULN													
900002	G	T	CVD_FEM_CASE	34	23	45	5	13	16	CVD_FEM_CTRL	40	15	65	2	11	27
900013	C	G	CVD_FEM_CASE	35	49	21	20	9	6	CVD_FEM_CTRL	40	49	31	13	23	4
900013	C	G	CVD_ALL_CASE	104	150	58	58	34	12	CVD_ALL_CTRL	74	97	51	29	39	6
900025	G	T	CVD_MAL_CASE	66	41	91	7	27	32	CVD_MAL_CTRL	34	31	37	7	17	10
900032	C	T	CVD_FEM_CASE	25	47	3	23	1	1	CVD_FEM_CTRL	37	65	9	28	9	0
900045	C	T	HELD_FEM_HIRES	12	4	20	1	2	9	HELD_FEM_LORESP	22	18	26	5	8	9
900065	A	C	CVD_FEM_CASE	32	54	10	22	10	0	CVD_FEM_CTRL	39	50	28	16	18	5
900065	A	C	CVD_MAL_CASE	59	80	38	25	30	4	CVD_MAL_CTRL	29	36	22	7	22	0
900065	A	C	CVD_ALL_CASE	91	134	48	47	40	4	CVD_ALL_CTRL	68	86	50	23	40	5
900078	A	G	HELD_ALL_ADRCASE3	64	116	12	52	12	0	HELD_ALL_ADRCTRL	155	297	13	142	13	0

BaySNP	A1	A2	COHORT A	SIZE A	FQ1 A	FQ2 A	FQ11 A	FQ12 A	COHORT B	SIZE B	FQ1 B	FQ2 B	FQ11 B	FQ12 B	FQ22 B
			ULN												
900078	A	G	HELD_ALL_ADRCASE5	27	48	6	21	6	0	155	297	13	142	13	0
			ULN												
900078	A	G	HELD_FEM_ADRCASE3	38	69	7	31	7	0	83	161	5	78	5	0
			ULN												
900082	A	G	HELD_FEM_ADRCASE3	35	25	45	8	9	18	74	70	78	17	36	21
			ULN												
900082	A	G	HELD_FEM_ADRCASE5	17	10	24	3	4	10	74	70	78	17	36	21
			ULN												
900096	A	G	CVD_ALL_CASE	101	157	45	60	37	4	72	125	19	55	15	2
900107	C	T	HELD_MAL_ADRCASE5	10	2	18	0	2	8	73	43	103	9	25	39
			ULN												
900115	A	G	HELD_MAL_ADRCASE5	9	6	12	1	4	4	72	91	53	27	37	8
			ULN												
900115	A	G	HELD_FEM_HIRES	40	58	22	22	14	4	46	62	30	17	28	1
900121	G	T	HELD_MAL_ADRCASE	66	47	85	5	37	24	67	56	78	15	26	26
900173	G	T	CVD_ALL_CASE	23	17	29	5	7	11	22	26	18	11	4	7
1000002	A	G	HELD_FEM_HIRES	12	21	3	9	3	0	22	25	19	9	7	6
1000006	A	G	HELD_FEM_CASE	31	58	4	28	2	1	22	31	13	11	9	2

baySNP	AI	A2	COHORT A	SIZE	FQ1 A	FQ2 A	FQ11	FQ12	FQ22	COHORT B	SIZE	FQ1 B	FQ2 B	FQ11	FQ12	FQ22
				A			A	A	A		B			B	B	B
10000006	A	G	HELD_ALL_CASE	44	82	6	39	4	1	HELD_ALL_CTRL	38	58	18	23	12	3
10000014	A	C	HELD_ALL_CASE	45	83	7	40	3	2	HELD_ALL_CTRL	39	64	14	26	12	1
10000014	A	C	HELD_FEM_CASE	31	58	4	28	2	1	HELD_FEM_CTRL	22	37	7	15	7	0
10000025	C	T	HELD_MAL_BAD	20	29	11	9	11	0	HELD_MAL_GOOD	36	43	29	14	15	7

Table 5b p-values of PA SNPs. A SNP is considered as associated to cardiovascular disease, adverse statin response or to efficacy of statin treatment, respectively, when one of the p values is equal or below 0.05.

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
28	HELD_FEM_EFF	0,0506	0,0508	0,0442	0,0411	0,0579	0,0349
29	HELD_ALL_HDL	0,021	0,0227	0,0099	0,0089	0,0164	0,0087
29	HELD_MAL_ADR3ULN	0,0602	0,0582	0,0664	0,0446	0,0526	0,0435
29	HELD_MAL_ADR5ULN	0,1406	0,1835	0,1554	0,0455	0,0778	0,0422
52	HELD_FEM_EFF	0,0644	0,0861	0,0488	0,0272	0,0362	0,0261
56	HELD_FEM_EFF	0,0248	0,0379	0,0273	0,0347	0,0479	0,0393
89	HELD_ALL_CC	0,0614	0,1	0,0311	0,0638	0,1021	0,0323
90	HELD_FEM_CC	0,0398	0,0424	0,0242	0,1382	0,1687	0,137
99	HELD_FEM_LIP	0,0363	0,0366	0,0338	0,8397	0,9056	0,8397
140	HELD_FEM_EFF	0,3895	0,6921	0,2368	0,1188	0,288	0,0524
152	HELD_FEM_EFF	0,1084	0,1216	0,1082	0,0373	0,0595	0,0389
214	HELD_ALL_LIP	0,1139	0,1152	0,0532	0,9756	1	0,9756

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
214	HELD_FEM_LIP	0,1095	0,1196	0,0506	0,5567	0,5803	0,5567
221	HELD_ALL_CC	0,0367	0,0359	0,0353	0,4257	0,506	0,426
221	HELD_FEM_CC	0,0406	0,0424	0,0384	0,1456	0,2083	0,1469
224	HELD_FEM_LIP	0,2893	0,3016	0,2874	0,0533	0,0709	0,0527
224	HELD_MAL_LIP	0,2292	0,2815	0,1975	0,0278	0,0392	0,0221
294	HELD_ALL_CC	0,0851	0,1041	0,0327	0,1547	0,1913	0,1534
307	CVD_FEM	0,013	0,0118	0,0104	0,0032	0,004	0,003
307	HELD_ALL_LIP	0,0255	0,0273	0,0249	0,0934	0,0968	0,0936
411	HELD_ALL_HDL	0,1529	0,2195	0,1076	0,0588	0,1136	0,0513
449	HELD_MAL_LIP	0,1321	0,0942	0,1001	0,0535	0,0667	0,0416
466	CVD_FEM	0,133	0,1439	0,1301	0,0444	0,0505	0,0438
472	HELD_FEM_EFF	0,0453	0,0626	0,0116	0,0068	0,0146	0,0009
542	HELD_MAL_CC	0,0014	0,0009	0,0007	0,0002	0,0003	0,0002
542	HELD_MAL_HDL	0,0054	0,0028	0,0029	0,0004	0,0005	0,0003
542	HELD_ALL_ADR	0,0257	0,0152	0,0171	0,0971	0,1108	0,0962
542	HELD_FEM_HDL	0,1914	0,1661	0,1457	0,0613	0,0709	0,0487
739	HELD_ALL_CC	0,0958	0,0983	0,0902	0,03	0,0327	0,0296
821	HELD_MAL_LIP2	0,0426	0,0436	0,0419	0,0865	0,0927	0,0867
821	HELD_FEM_VEFF	0,1193	0,1222	0,0584	0,0343	0,0681	0,0306
1005	HELD_MAL_CC	0,2376	0,3423	0,1618	0,0603	0,0946	0,0502
1055	HELD_MAL_CC	0,0302	0,0328	0,0084	0,2241	0,2988	0,216

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
1056	HELD_FEM_EFF	0,0094	0,0085	0,0079	0,9671	1	0,9671
1085	HELD_MAL_LIP	0,0889	0,0964	0,0773	0,0288	0,0462	0,0288
1085	CVD_FEM	0,1655	0,1833	0,156	0,0373	0,0546	0,0359
1086	HELD_MAL_LIP	0,0963	0,1125	0,0928	0,0318	0,0475	0,0315
1092	HELD_MAL_LIP	0,0493	0,0492	0,046	0,0712	0,0958	0,0663
1096	HELD_MAL_CC	0,0436	0,0623	0,0423	0,0685	0,0895	0,0679
1096	CVD_MAL	0,0766	0,0645	0,0452	0,5906	0,6848	0,5936
1101	HELD_FEM_EFF	0,1158	0,2728	0,0522	0,1279	0,2891	0,0572
1204	HELD_MAL_LIP	0,0471	0,0447	0,0362	0,0189	0,0238	0,0214
1204	HELD_ALL_LIP	0,1563	0,1592	0,1558	0,0422	0,0485	0,0424
1504	HELD_ALL_CC	0,0128	0,0133	0,0115	0,5946	0,64	0,5946
1504	HELD_MAL_LIP	0,0864	0,087	0,0247	0,1834	0,2241	0,1799
1504	HELD_MAL_CC	0,051	0,0757	0,0467	0,2868	0,3134	0,2871
1504	HELD_FEM_CC	0,0535	0,0663	0,0532	0,0878	0,1084	0,0873
1511	HELD_FEM_EFF	0,0513	0,0299	0,0413	0,1279	0,1563	0,1329
1524	HELD_FEM_ADR3ULN	0,0684	0,0673	0,0215	0,64	0,7419	0,6382
1556	HELD_FEM_EFF	0,0063	0,0151	0,0066	0,0129	0,0269	0,015
1561	CVD_FEM	0,1299	0,1484	0,1216	0,0472	0,0666	0,0456
1582	HELD_MAL_LIP	0,1444	0,1408	0,0649	0,0389	0,0633	0,0319
1638	HELD_FEM_CC	0,0876	0,0903	0,0861	0,0318	0,0385	0,0328
1653	CVD_MAL	0,0269	0,0234	0,0255	0,4812	0,5499	0,4809

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
1662	HELD_MAL_CC	0,0153	0,0278	0,0067	0,0006	0,0007	0,0001
1714	CVD_MAL	0,0716	0,0776	0,0817	0,0388	0,0484	0,041
1722	HELD_FEM_ADR5ULN	0,0325	0,0304	0,0429	0,1144	0,1401	0,1146
1757	HELD_FEM_EFF	0,0289	0,0296	0,0153	0,1752	0,1926	0,1779
1765	HELD_ALL_ADR3ULN	0,0044	0,0049	0,0024	0,0023	0,0029	0,0012
1765	HELD_ALL_ADR3ULN	0,0044	0,0049	0,0024	0,0023	0,0029	0,0012
1765	HELD_ALL_ADR5ULN	0,0469	0,0457	0,0235	0,0166	0,0163	0,0077
1765	HELD_ALL_ADR5ULN	0,0469	0,0457	0,0235	0,0166	0,0163	0,0077
1765	HELD_MAL_ADR3ULN	0,0428	0,0505	0,0211	0,0131	0,0174	0,0058
1765	HELD_MAL_ADR3ULN	0,0428	0,0505	0,0211	0,0131	0,0174	0,0058
1765	HELD_MAL_ADR5ULN	0,0997	0,0786	0,0255	0,0396	0,0451	0,0069
1765	HELD_MAL_ADR5ULN	0,0997	0,0786	0,0255	0,0396	0,0451	0,0069
1765	HELD_FEM_ADR3ULN	0,0666	0,0733	0,0522	0,0513	0,0579	0,0423
1765	HELD_FEM_ADR3ULN	0,0666	0,0733	0,0522	0,0513	0,0579	0,0423
1776	HELD_ALL_CC	0,0614	0,1	0,0311	0,0082	0,0098	0,0023
1776	HELD_FEM_CC	0,087	0,1676	0,0568	0,0155	0,0273	0,0071
1799	HELD_FEM_LIP2	0,006	0,0058	0,0061	0,2598	0,268	0,2601
1799	HELD_MAL_CC	0,1419	0,1545	0,134	0,0408	0,0604	0,0406
1806	HELD_FEM_EFF	0,1946	0,236	0,128	0,047	0,0817	0,0299
1837	HELD_FEM_LIP2	0,0049	0,0047	0,0048	0,569	0,5843	0,5688
1837	HELD_ALL_LIP2	0,0085	0,0085	0,0084	0,0433	0,0445	0,0431

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
1837	HELD_ALL_ADR5ULN	0,0159	0,015	0,0135	0,0245	0,0271	0,019
1837	HELD_MAL_ADR	0,0544	0,0558	0,0529	0,078	0,0897	0,0779
1837	HELD_MAL_LIP2	0,0694	0,0696	0,0684	0,0215	0,0237	0,0213
1870	HELD_ALL_CC	0,0213	0,018	0,0195	0,0874	0,1157	0,0854
1870	HELD_FEM_CC	0,0621	0,0435	0,059	0,0937	0,1293	0,0894
1882	CVD_MAL	0,0296	0,028	0,0055	0,4108	0,4529	0,4093
1988	HELD_ALL_LIP	0,1287	0,1307	0,1234	0,0385	0,0414	0,0379
2000	CVD_MAL	0,0237	0,0363	0,0295	0,0014	0,0025	0,0021
2000	CVD_ALL	0,034	0,0425	0,035	0,0027	0,0035	0,0029
2000	HELD_FEM_CC2	0,0705	0,0992	0,061	0,0105	0,0145	0,0081
2000	HELD_MAL_HDL	0,1671	0,489	0,1018	0,0507	0,1177	0,0207
2000	HELD_FEM_ADR	0,1624	0,2773	0,1528	0,0482	0,0704	0,0432
2000	HELD_MAL_CC	0,1597	0,2882	0,1581	0,0467	0,063	0,0459
2071	CVD_ALL	0,0823	0,09	0,0741	0,0349	0,0411	0,0339
2078	HELD_MAL_LIP	0,0667	0,0395	0,0572	0,0468	0,0583	0,0507
2085	HELD_FEM_VEFF	0,0707	0,0839	0,0347	0,019	0,0349	0,0165
2095	CVD_ALL	0,0917	0,1451	0,0384	0,0935	0,1473	0,0392
2119	HELD_MAL_LIP	0,0309	0,0409	0,0248	0,1269	0,148	0,1297
2119	HELD_ALL_LIP	0,0382	0,0476	0,0373	0,133	0,1514	0,1332
2119	HELD_FEM_EFF	0,057	0,0796	0,0527	0,1279	0,1563	0,1329
2141	HELD_FEM_EFF	0,021	0,0256	0,0169	0,2401	0,3207	0,2483

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
2141	HELD_ALL_CC	0,079	0,0695	0,0439	0,9551	1	0,9551
2182	HELD_FEM_EFF	0,0038	0,0027	0,0014	0,0039	0,0051	0,0033
2234	HELD_MAL_LIP	0,0604	0,0581	0,0195	0,0315	0,0414	0,0289
2281	HELD_FEM_VEFF	0,1098	0,1234	0,0542	0,0501	0,0685	0,0472
2298	CVD_FEM	0,0241	0,0171	0,0108	0,9341	1	0,934
2298	HELD_MAL_CC2	0,1235	0,1076	0,0833	0,053	0,0671	0,0514
2341	HELD_FEM_CC	0,0284	0,0709	0,0083	0,0336	0,0796	0,0097
2357	HELD_ALL_CC2	0,042	0,0374	0,016	0,7724	0,8793	0,7723
2357	HELD_ALL_CC	0,0452	0,0325	0,0209	0,9622	1	0,9622
2357	HELD_MAL_LIP	0,0438	0,0824	0,0385	0,077	0,1278	0,0657
2357	HELD_FEM_CC	0,0772	0,0829	0,0381	0,6486	0,7985	0,6469
2366	CVD_FEM	0,1125	0,1171	0,1073	0,0234	0,0304	0,023
2423	CVD_FEM	0,086	0,0888	0,077	0,0185	0,0274	0,0179
2708	CVD_FEM	0,0719	0,1262	0,054	0,0813	0,1384	0,0609
2995	HELD_FEM_ADR5ULN	0,0882	0,0827	0,1088	0,0448	0,0488	0,0503
2995	HELD_FEM_UEFF	0,0943	0,0942	0,0928	0,0516	0,0693	0,0495
3360	HELD_MAL_ADR5ULN	0,1131	0,1691	0,0302	0,0499	0,0819	0,0097
3464	HELD_ALL_CC	0,0305	0,0331	0,0278	0,0047	0,0056	0,0046
3464	HELD_FEM_CC	0,0743	0,0777	0,0721	0,0141	0,0184	0,0144
3689	HELD_FEM_EFF	0,0488	0,0584	0,0295	0,0226	0,0378	0,0206
3975	HELD_FEM_UEFF	0,0492	0,0474	0,0407	0,0198	0,0237	0,0188

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
3976	HELD_FEM_UEFF	0,059	0,0605	0,0456	0,0262	0,0327	0,025
4206	HELD_FEM_ADR3ULN	0,1395	0,1496	0,1372	0,0522	0,0655	0,0529
4838	HELD_FEM_VEFF	0,0581	0,0772	0,0529	0,0343	0,0681	0,0306
4838	HELD_FEM_VEFF	0,0581	0,0772	0,0529	0,0343	0,0681	0,0306
4838	HELD_FEM_VEFF	0,0581	0,0772	0,0529	0,0343	0,0681	0,0306
4912	HELD_FEM_EFF	0,1257	0,1748	0,0921	0,0255	0,0361	0,0255
4925	HELD_MAL_CC	0,0436	0,0623	0,0423	0,0685	0,0895	0,0679
4966	HELD_MAL_ADR3ULN	0,0269	0,0282	0,0298	0,1675	0,1966	0,1669
5014	HELD_ALL_ADR5ULN	0,007	0,0104	0,0022	0,0738	0,0869	0,0611
5014	HELD_FEM_ADR5ULN	0,0574	0,0604	0,0276	0,2347	0,2691	0,2164
5296	CVD_FEM	0,0459	0,0738	0,0438	0,0585	0,0899	0,0558
5296	HELD_FEM_EFF	0,0703	0,0489	0,0461	0,4109	0,5177	0,4006
5296	CVD_ALL	0,145	0,1027	0,1148	0,0579	0,0771	0,0523
5298	HELD_FEM_EFF	0,0813	0,0465	0,0567	0,4984	0,7366	0,49
5298	CVD_ALL	0,107	0,1065	0,0603	0,0348	0,0376	0,0306
5298	CVD_FEM	0,1629	0,1593	0,1332	0,0511	0,0885	0,049
5320	HELD_FEM_EFF	0,037	0,0397	0,029	0,016	0,0243	0,0151
5361	CVD_MAL	0,0947	0,1065	0,0447	0,0519	0,0654	0,0518
5457	HELD_FEM_EFF	0,1213	0,134	0,0452	0,2429	0,3056	0,2246
5704	HELD_MAL_LIP	0,0385	0,0334	0,0406	0,054	0,0678	0,0503
5704	CVD_MAL	0,0701	0,0755	0,07	0,0246	0,0281	0,0259

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
5717	HELD_FEM_ADR3ULN	0,0736	0,0775	0,0739	0,0219	0,026	0,021
5717	HELD_ALL_ADR3ULN	0,1246	0,1264	0,1214	0,0391	0,0471	0,0389
5959	HELD_ALL_CC	0,0126	0,0122	0,0098	0,0046	0,0073	0,0044
5959	CVD_FEM	0,019	0,0225	0,0082	0,0089	0,0137	0,0083
5959	HELD_MAL_CC	0,0525	0,0589	0,0243	0,0536	0,0708	0,053
5959	HELD_MAL_ADR5ULN	0,038	0,0364	0,0482	0,1839	0,2158	0,1795
5959	HELD_FEM_ADR	0,054	0,0574	0,0527	0,0465	0,0539	0,0461
6162	HELD_ALL_ADR3ULN	0,0037	0,0034	0,0015	0,8524	0,9082	0,8522
6162	HELD_ALL_ADR	0,0033	0,003	0,0028	0,663	0,722	0,663
6162	HELD_ALL_ADR5ULN	0,0206	0,0248	0,006	0,9797	1	0,9797
6162	HELD_MAL_ADR3ULN	0,0412	0,0352	0,0108	0,4721	0,4836	0,468
6162	HELD_FEM_ADR5ULN	0,0274	0,0257	0,0147	0,4282	0,5487	0,4335
6162	HELD_MAL_ADR	0,0219	0,0217	0,0188	0,5399	0,6036	0,5399
6236	HELD_ALL_ADR5ULN	0,0477	0,0396	0,0641	0,0131	0,016	0,0158
6236	HELD_MAL_ADR3ULN	0,0787	0,0734	0,0762	0,0279	0,0376	0,0305
6236	HELD_MAL_ADR5ULN	0,0932	0,0861	0,0924	0,0297	0,0375	0,0368
6236	HELD_ALL_ADR3ULN	0,1516	0,1516	0,1604	0,0474	0,051	0,0497
6482	HELD_MAL_HDL	0,0359	0,0402	0,0326	0,009	0,013	0,0087
6482	HELD_ALL_LIP2	0,0383	0,0381	0,0383	0,0486	0,0506	0,0487
6482	HELD_MAL_CC2	0,0613	0,0667	0,0572	0,0114	0,0142	0,0106
6482	HELD_MAL_LIP2	0,0651	0,0662	0,065	0,0357	0,04	0,0358

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
6498	CVD_FEM	0,145	0,1987	0,0811	0,0323	0,0389	0,0281
6744	HELD_ALL_ADR5ULN	0,0659	0,07	0,0775	0,02	0,0273	0,0243
7133	HELD_MAL_CC	0,0153	0,0278	0,0067	0,0006	0,0007	0,0001
8021	CVD_FEM	0,039	0,0422	0,0304	0,8726	1	0,8726
8060	CVD_FEM	0,044	0,0304	0,0304	0,1299	0,1961	0,1237
8060	HELD_FEM_HDL	0,0558	0,0753	0,0549	0,0759	0,0965	0,0753
8210	HELD_FEM_EFF	0,0336	0,0396	0,0276	0,3226	0,4454	0,3207
8592	HELD_FEM_VEFF	0,0395	0,0432	0,0388	0,8842	0,9331	0,8842
8816	HELD_FEM_EFF	0,0448	0,0448	0,0202	0,0144	0,0199	0,0128
8846	HELD_ALL_LIP	0,0628	0,0654	0,0521	0,3798	0,3932	0,3794
8943	HELD_MAL_LIP	0,1444	0,1408	0,0649	0,0389	0,0633	0,0319
9193	HELD_FEM_LIP	0,0561	0,0723	0,0548	0,0707	0,0889	0,0691
9193	CVD_FEM	0,1616	0,1289	0,1306	0,0458	0,0687	0,0424
9443	CVD_MAL	0,0828	0,0869	0,0213	0,0507	0,0634	0,0455
9516	HELD_MAL_CC	0,0504	0,0583	0,046	0,029	0,043	0,0283
9698	HELD_MAL_ADR	0,0106	0,0048	0,0061	0,0001	0,0001	0,0001
9698	HELD_MAL_ADR3ULN	0,0279	0,0274	0,0035	0,0003	0,0002	0
9698	HELD_FEM_EFF	0,0538	0,0557	0,0464	0,2251	0,2386	0,2249
9698	HELD_MAL_ADR5ULN	0,2515	0,3809	0,097	0,0239	0,0263	0,0032
9698	CVD_ALL	0,2256	0,2237	0,2119	0,0274	0,0357	0,025

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
9849	HELD_FEM_CC	0,0302	0,0602	0,0168	0,0327	0,063	0,0182
9849	HELD_MAL_LIP	0,0315	0,0448	0,0358	0,0376	0,0505	0,043
9883	HELD_FEM_CC	0,006	0,0053	0,0046	0,6913	0,8398	0,6915
9883	HELD_ALL_CC	0,0345	0,035	0,0331	0,5629	0,6344	0,563
10079	CVD_ALL	0,118	0,0767	0,048	0,0611	0,0864	0,0418
10079	CVD_MAL	0,1491	0,2983	0,0682	0,0413	0,054	0,0099
10481	HELD_FEM_ADR5ULN	0,0697	0,0667	0,0774	0,0136	0,0149	0,0135
10542	HELD_FEM_VEFF	0,0374	0,0214	0,0265	0,0981	0,1126	0,0911
10542	HELD_MAL_ADR5ULN	0,1163	0,1946	0,0404	0,1357	0,2186	0,046
10600	HELD_FEM_EFF	0,0973	0,1483	0,0418	0,104	0,1554	0,0445
10621	HELD_FEM_CC	0,0622	0,0649	0,0451	0,373	0,4126	0,3769
10745	HELD_ALL_ADR5ULN	0,0329	0,0356	0,0723	0,0754	0,0953	0,0832
10745	HELD_FEM_VEFF	0,0308	0,0308	0,0302	0,3022	0,3181	0,302
10747	HELD_MAL_ADR	0,006	0,0053	0,0044	0,6116	0,64	0,6115
10747	CVD_ALL	0,0285	0,0292	0,027	0,1252	0,1349	0,1253
10747	HELD_MAL_ADR3ULN	0,0401	0,0412	0,0505	0,8735	1	0,8734
10771	HELD_MAL_ADR5ULN	0,0176	0,0191	0,0469	0,0263	0,0458	0,0291
10771	HELD_FEM_EFF	0,1837	0,1844	0,1832	0,0527	0,0543	0,0525
10870	HELD_MAL_LIP	0,0323	0,0272	0,0156	0,8328	1	0,8332
10870	HELD_FEM_LIP	0,0431	0,0412	0,0421	0,0319	0,037	0,0317
10870	HELD_MAL_CC	0,1157	0,0954	0,0779	0,0341	0,0413	0,0285

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
10870	HELD_ALL_CC	0,1146	0,1205	0,109	0,0272	0,0351	0,027
10877	HELD_ALL_HDL	0,0907	0,1181	0,0333	0,0266	0,0356	0,007
10948	HELD_FEM_LIP	0,0134	0,0136	0,0127	0,052	0,0588	0,0517
10948	HELD_ALL_LIP	0,0209	0,0207	0,0197	0,0356	0,0432	0,0355
10948	HELD_FEM_CC2	0,0513	0,0521	0,0493	0,3385	0,3602	0,3382
10948	CVD_MAL	0,0986	0,0986	0,103	0,0481	0,0548	0,0475
11001	HELD_MAL_ADR5ULN	0,0438	0,0618	0,1215	0,1034	0,1201	0,1152
11073	HELD_MAL_ADR5ULN	0,1741	0,1866	0,1892	0,0446	0,0632	0,0503
11153	HELD_FEM_CC	0,0378	0,0459	0,038	0,064	0,0726	0,0658
11210	HELD_MAL_CC	0,025	0,0616	0,0225	0,0335	0,0756	0,0304
11210	HELD_ALL_ADR3ULN	0,0344	0,027	0,0311	0,076	0,0917	0,0844
11210	HELD_ALL_ADR	0,0536	0,038	0,0354	0,2211	0,2468	0,2195
11248	HELD_FEM_ADR	0,0125	0,0119	0,0118	0,0368	0,0494	0,0364
11248	HELD_MAL_LIP	0,0478	0,0677	0,0404	0,0784	0,1038	0,0644
11248	HELD_ALL_CC	0,0431	0,0567	0,0425	0,0874	0,1066	0,0887
11372	HELD_MAL_LIP	0,2326	0,2665	0,2343	0,0486	0,0753	0,0477
11449	HELD_FEM_CC	0,0245	0,0119	0,0204	0,0644	0,0971	0,0663
11450	HELD_FEM_EFF	0,0922	0,0949	0,0903	0,0362	0,0394	0,036
11470	HELD_MAL_LIP	0,0807	0,1484	0,0304	0,0882	0,1582	0,033
11472	HELD_MAL_LIP	0,0763	0,1465	0,0284	0,0836	0,1565	0,031
11472	HELD_FEM_LIP	0,0576	0,0991	0,0495	0,0617	0,1046	0,053

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
11487	HELD_MAL_ADR5ULN	0,0033	0,0039	0,0004	0,0122	0,0159	0,0012
11487	HELD_MAL_ADR3ULN	0,0156	0,021	0,0131	0,038	0,0474	0,0295
11488	HELD_MAL_ADR5ULN	0,0117	0,0227	0,0018	0,0076	0,0087	0,0006
11488	HELD_FEM_UEFF	0,0217	0,021	0,0091	0,0655	0,0713	0,0672
11488	HELD_MAL_ADR3ULN	0,0239	0,0311	0,0166	0,0898	0,127	0,0797
11493	HELD_MAL_CC	0,0736	0,0542	0,0493	0,6283	0,7502	0,6293
11502	HELD_MAL_ADR3ULN	0,0881	0,0865	0,0363	0,0283	0,0301	0,0225
11502	HELD_MAL_ADR5ULN	0,1706	0,154	0,1118	0,0592	0,0659	0,0396
11534	HELD_ALL_LP	0,1034	0,2501	0,0513	0,1046	0,2518	0,0519
11537	CVD_FEM	0,1061	0,1119	0,0989	0,0221	0,0256	0,0214
11537	HELD_FEM_EFF	0,1916	0,2436	0,1166	0,0438	0,0655	0,0324
11560	HELD_FEM_EFF	0,1693	0,3529	0,1436	0,0519	0,1212	0,0386
11578	HELD_FEM_LP	0,0201	0,0333	0,0132	0,0226	0,0366	0,0147
11578	CVD_FEM	0,0435	0,0775	0,0229	0,0459	0,0799	0,0241
11594	HELD_FEM_ADR3ULN	0,1373	0,2125	0,0418	0,0279	0,0331	0,0052
11594	HELD_ALL_ADR5ULN	0,1669	0,1552	0,0434	0,0516	0,0536	0,0092
11594	HELD_ALL_CC	0,0539	0,0724	0,0479	0,0648	0,0846	0,0574
11594	HELD_ALL_ADR	0,1052	0,0878	0,1	0,0304	0,036	0,0286
11594	HELD_FEM_ADR5ULN	0,3753	0,4458	0,1824	0,1236	0,213	0,0409
11624	HELD_ALL_CC	0,0352	0,0383	0,0111	0,3119	0,388	0,3111
11624	HELD_MAL_CC	0,032	0,0313	0,0164	0,6153	0,7739	0,6163

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
11624	HELD_FEM_EFF	0,2292	0,244	0,1389	0,053	0,0656	0,0407
11627	HELD_ALL_CC	0,0337	0,0316	0,0088	0,0936	0,1309	0,0921
11627	HELD_MAL_CC	0,0931	0,0933	0,0528	0,352	0,4146	0,3531
11627	HELD_FEM_EFF	0,1916	0,2436	0,1166	0,0438	0,0655	0,0324
11644	HELD_MAL_ADR5ULN	0,2097	0,2525	0,1344	0,0676	0,1027	0,0467
11650	HELD_FEM_EFF	0,0366	0,0361	0,0363	0,1123	0,1212	0,1122
11654	HELD_ALL_ADR5ULN	0,0052	0,0046	0,0042	0,6623	0,7404	0,6642
11654	HELD_FEM_ADR5ULN	0,0104	0,0096	0,006	0,7072	0,832	0,7087
11654	HELD_FEM_ADR3ULN	0,0546	0,0592	0,0524	0,6906	0,7512	0,6913
11654	HELD_ALL_ADR3ULN	0,052	0,0518	0,0601	0,2706	0,2742	0,2735
11655	HELD_ALL_ADR5ULN	0,0085	0,0074	0,0058	0,8555	0,8723	0,8558
11655	HELD_FEM_ADR5ULN	0,0136	0,0138	0,0053	0,7681	0,8443	0,7672
11655	HELD_FEM_ADR3ULN	0,0489	0,048	0,0432	0,9169	1	0,9169
11656	HELD_MAL_LIP	0,0321	0,0317	0,0346	0,012	0,0141	0,0126
11656	HELD_FEM_EFF	0,0782	0,0909	0,0511	0,0442	0,0652	0,0393
11656	HELD_ALL_LIP	0,0617	0,0646	0,06	0,0295	0,0353	0,0295
11825	HELD_MAL_ADR5ULN	0,0233	0,056	0,0499	0,0278	0,0619	0,0612
11914	HELD_MAL_ADR5ULN	0,0186	0,0915	0,0128	0,0001	0,0001	0
11914	HELD_ALL_ADR5ULN	0,1572	0,1781	0,1391	0,0477	0,0533	0,0487
12008	HELD_FEM_EFF	0,0222	0,0317	0,0209	0,0249	0,0351	0,0234
12008	HELD_ALL_ADR5ULN	0,1272	0,2155	0,0422	0,135	0,225	0,0445

BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
12097	HELD_ALL_ADR5ULN	0,0162	0,0277	0,0308	0,019	0,0313	0,0367
12097	HELD_FEM_ADR3ULN	0,0342	0,0487	0,042	0,0392	0,0543	0,0484
12097	HELD_MAL_ADR5ULN	0,04	0,0749	0,0726	0,0462	0,081	0,0857
12097	HELD_ALL_ADR3ULN	0,0465	0,073	0,056	0,0524	0,0805	0,0633
12366	HELD_FEM_UEFF	0,0342	0,0313	0,0069	0,0364	0,0514	0,0338
12366	HELD_ALL_ADR5ULN	0,0464	0,0391	0,0411	0,5197	0,5929	0,5131
12619	HELD_MAL_ADR5ULN	0,0073	0,1235	0,0387	0,0075	0,1235	0,0398
12619	HELD_ALL_ADR5ULN	0,0121	0,0605	0,0414	0,0125	0,0613	0,0427
13025	HELD_ALL_ADR5ULN	0,044	0,0399	0,0593	0,3978	0,4443	0,4018
13191	HELD_FEM_LIP	0,0157	0,0149	0,015	0,0072	0,0088	0,0071
13191	HELD_MAL_CC	0,0648	0,0601	0,0431	0,0199	0,0396	0,0196
13191	HELD_ALL_LIP	0,0634	0,0669	0,0616	0,0211	0,0217	0,0206
13937	HELD_FEM_ADR5ULN	0,076	0,0835	0,0789	0,0402	0,0615	0,0462
900002	CVD_FEM	0,1492	0,1674	0,1456	0,0364	0,04	0,0364
900013	CVD_FEM	0,0212	0,022	0,0192	0,2613	0,3039	0,2602
900013	CVD_ALL	0,0279	0,0289	0,0279	0,1847	0,2004	0,1858
900025	CVD_MAL	0,1379	0,1533	0,1361	0,0426	0,0452	0,0439
900032	CVD_FEM	0,0555	0,036	0,0317	0,2549	0,3578	0,2418
900045	HELD_FEM_EFF	0,162	0,2388	0,151	0,0411	0,0579	0,0349
900065	CVD_FEM	0,0222	0,0175	0,0086	0,0066	0,0077	0,0057
900065	CVD_MAL	0,0549	0,0421	0,0289	0,4512	0,5001	0,453


BAYSNP	COMPARISON	GTYPE CPVAL	GTYPE XPVAL	GTYPE LRPVAL	ALLELE CPVAL	ALLELE XPVAL	ALLELE LRPVAL
900065	CVD_ALL	0,0773	0,0753	0,0754	0,0471	0,0505	0,0477
900078	HELD_ALL_ADR3ULN	0,0283	0,036	0,0348	0,0335	0,0417	0,0415
900078	HELD_ALL_ADR5ULN	0,03	0,0417	0,0487	0,0349	0,0466	0,0574
900078	HELD_FEM_ADR3ULN	0,0342	0,0487	0,042	0,0392	0,0543	0,0484
900082	HELD_FEM_ADR3ULN	0,0377	0,0378	0,0364	0,1073	0,111	0,1055
900082	HELD_FEM_ADR5ULN	0,0517	0,0587	0,0566	0,0581	0,0837	0,0542
900096	CVD_ALL	0,0644	0,0622	0,0602	0,032	0,0354	0,0294
900107	HELD_MAL_ADR3ULN	0,2371	0,2767	0,1405	0,0665	0,1045	0,0455
900115	HELD_MAL_ADR5ULN	0,0214	0,02	0,0409	0,0148	0,0208	0,0158
900115	HELD_FEM_EFF	0,0347	0,0338	0,0316	0,4668	0,5083	0,4661
900121	HELD_MAL_ADR	0,0303	0,0297	0,0268	0,3005	0,3162	0,3003
900173	CVD_ALL	0,1397	0,146	0,1347	0,0356	0,0569	0,0349
10000002	HELD_FEM_EFF	0,0781	0,0766	0,0305	0,0098	0,0139	0,0067
10000006	HELD_FEM_CC	0,0041	0,0018	0,0035	0,0014	0,0024	0,0014
10000006	HELD_ALL_CC	0,0127	0,0087	0,0113	0,0023	0,0034	0,002
10000014	HELD_ALL_CC	0,0156	0,0099	0,013	0,0468	0,0612	0,046
10000014	HELD_FEM_CC	0,0415	0,0248	0,0336	0,1157	0,1943	0,1184
10000025	HELD_MAL_LIP	0,1055	0,1309	0,0337	0,1763	0,2188	0,1719

Table 6a Correlation of genotypes of PA SNPs to relative risk

For diagnostic conclusions to be drawn from genotyping a particular patient we calculated the relative risk RR_1 , RR_2 , RR_3 for the three possible genotypes of each SNP. Given the genotype frequencies as

	gtype1	gtype2	gtype3
case	N11	N12	N13
control	N21	N22	N23

we calculate



- 190 -

Here, the *case* and *control* populations represent any case-control-group pair, or bad(case)-good(control)-group pair, respectively (due to their increased response to statins, 'high responders' are treated as a case cohort, whereas 'low responders' are treated as the respective control cohort). A value $RR_1 > 1$, $RR_2 > 1$, and $RR_3 > 1$ indicates an increased risk for individuals carrying genotype 1, genotype 2, and genotype 3, respectively. For example, $RR_1 = 3$ indicates a 3-fold risk of an individual carrying genotype 1 as compared to individuals carrying genotype 2 or 3 (a detailed description of relative risk calculation and statistics can be found in (Biostatistics, L. D. Fisher and G. van Belle, Wiley Interscience 1993)). The baySNP number refers to an internal numbering of the PA SNPs and can be found in the sequence listing. null: not defined.

In cases where a relative risk is not given in the table (three times zero or null) the informative genotype can be drawn from the right part of the table where the frequencies of genotypes are given in the cases and control cohorts. For example BaySNP 3360 gave the following results:

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3
3360	HELD_MAL_ADRSULN	GG	GT	TT	null	0	0

FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
10	0	0	50	22	1

It can be concluded that a GT or TT genotype is only present in the control cohort; these genotypes are somehow protective against ADR. An analogous proceeding can be used to determine protective alleles if no relative risk is given (table 6b).

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
28	HELD_FEM_EFF	CC	CT	TT	0,68	0,29	3,38	1	2	9	3	12	7
29	HELD_ALL_HDL	AA	AG	GG	0	0,90	0,58	4	4	2	0	7	8
29	HELD_MAL_ADR3ULN	AA	AG	GG	2,16	0,56	0,75	13	7	6	18	32	22
29	HELD_MAL_ADR5ULN	AA	AG	GG	3,15	0,66	0,32	5	3	1	18	32	22
52	HELD_FEM_EFF	CC	CG	GG	1,96	1,02	0,23	7	10	1	5	17	9
56	HELD_FEM_EFF	AA	AG	GG	null	2,76	0,36	0	5	7	0	2	20
89	HELD_ALL_CC	AA	AG	null	null	0	null	45	0	0	37	3	0
90	HELD_FEM_CC	CC	CT	TT	0,97	0,64	1,82	8	13	10	6	15	1
99	HELD_FEM_LIP	CC	CT	TT	1,51	0,7	1,16	13	28	41	5	41	34
140	HELD_FEM_EFF	CC	CT	TT	0	0	null	0	0	12	1	2	18
152	HELD_FEM_EFF	AA	AG	GG	0,42	1,27	2,5	3	6	3	12	9	1
214	HELD_ALL_LIP	AA	AG	GG	0,92	1,18	0	59	38	0	73	36	4
214	HELD_FEM_LIP	AA	AG	GG	1	1,11	0	50	31	0	48	26	4
221	HELD_ALL_CC	CC	CG	GG	1,36	0,56	1,44	7	12	26	3	21	15
221	HELD_FEM_CC	CC	CG	GG	1,16	0,53	1,67	4	9	18	2	14	6
224	HELD_FEM_LIP	CC	CT	TT	0,77	1,26	1,24	51	8	20	60	5	14
224	HELD_MAL_LIP	CC	CT	TT	2,02	1,45	0,38	17	1	2	25	1	11
294	HELD_ALL_CC	CC	CT	TT	0,83	0,97	2	16	24	5	18	22	0
307	CVD_FEM	CC	CT	TT	0,34	0,8	1,84	2	15	19	9	20	9
307	HELD_ALL_LIP	CC	CT	TT	null	1,41	0,71	0	70	32	0	63	54
411	HELD_ALL_HDL	AA	AT	TT	1,85	0,69	0,56	7	3	0	5	8	2

BAYSNP	COMPARISON	GTYPE1	GTTYPE2	GTTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
449	HELD_MAL_LIP	CC	CG	GG	0	0,42	2,62	0	3	17	1	14	22
466	CVD_FEM	CC	CT	TT	0,66	0,86	1,61	6	15	14	12	20	8
472	HELD_FEM_EFF	AA	AG	GG	0	0	null	0	0	11	3	6	13
542	HELD_MAL_CC	AA	AG	GG	2,58	3,07	0,23	2	8	4	0	2	17
542	HELD_MAL_HDL	AA	AG	GG	0	2,38	0,30	3	8	10	0	3	24
542	HELD_ALL_ADR	AA	AG	GG	0	1,32	0,78	0	53	106	2	33	119
542	HELD_FEM_HDL	AA	AG	GG	0,57	0,67	1,56	0	2	21	1	8	23
739	HELD_ALL_CC	CC	CG	GG	0,67	0,94	1,52	9	21	15	14	20	6
821	HELD_MAL_LIP2	AA	AC	CC	1,4	0,96	0,93	32	116	161	18	138	193
821	HELD_FEM_VEFF	AA	AC	CC	0	0,93	2,1	0	4	6	4	6	4
1005	HELD_MAL_CC	AA	AG	GG	2,35	0,6	0	12	2	0	11	5	2
1055	HELD_MAL_CC	AA	AT	TT	0	3	1	0	3	6	4	0	8
1056	HELD_FEM_EFF	AA	AG	GG	1,59	0,37	2,04	12	6	6	10	21	2
1085	HELD_MAL_LIP	AA	AG	GG	0,37	1,31	1,75	3	11	6	15	16	5
1085	CVD_FEM	AA	AG	GG	1,51	0,88	0,5	20	11	3	16	15	9
1086	HELD_MAL_LIP	AA	AG	GG	1,97	1	0,44	7	10	3	5	18	13
1092	HELD_MAL_LIP	CC	CG	GG	0,94	0,4	2,38	2	5	13	4	21	12
1096	HELD_MAL_CC	GG	GT	TT	null	2,2	0,45	0	7	7	0	3	15
1096	CVD_MAL	GG	GT	TT	1,51	0,72	1,22	4	13	52	0	12	21
1101	HELD_FEM_EFF	CC	CT	TT	null	0	null	12	0	0	18	4	0
1204	HELD_MAL_LIP	AA	AG	GG	3,06	1,58	0,49	2	8	9	0	9	26
1204	HELD_ALL_LIP	AA	AG	GG	1,34	1,18	0,77	12	38	49	8	36	71

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
1504	HELD_ALL_CC	CC	CT	TT	0,5	1,79	0,78	5	27	12	12	12	15
1504	HELD_MAL_LIP	CC	CT	TT	0	1,6	1,14	0	12	7	8	17	12
1504	HELD_MAL_CC	CC	CT	TT	0,72	2,63	0,4	2	9	3	4	4	10
1504	HELD_FEM_CC	CC	CT	TT	0,4	1,44	1,13	3	18	9	8	8	5
1511	HELD_FEM_EFF	GG	GT	TT	0,33	3,38	0	3	9	0	14	7	1
1524	HELD_FEM_ADR3ULN	AA	AC	CC	0	1,51	0,89	0	16	22	8	23	51
1556	HELD_FEM_EFF	CC	CG	GG	null	3,36	0,3	0	7	5	0	3	19
1561	CVD_FEM	AA	AC	CC	1,59	0,73	0,41	23	12	1	17	19	4
1582	HELD_MAL_LIP	CC	CT	TT	0	0,78	1,89	0	5	15	5	12	20
1638	HELD_FEM_CC	AA	AG	GG	0,56	0,62	1,73	1	8	22	2	11	9
1653	CVD_MAL	GG	GT	TT	0,86	1,43	0,71	15	40	14	10	10	13
1662	HELD_MAL_CC	CC	CT	TT	2,8	null	0,36	4	0	10	0	0	18
1714	CVD_MAL	AA	AG	GG	0,48	0,98	1,23	3	26	37	6	14	14
1722	HELD_FEM_ADR5ULN	CC	CT	TT	2,8	0,41	0,93	8	5	5	14	43	24
1757	HELD_FEM_EFF	AA	AG	GG	3	0,68	0,88	4	7	9	0	16	16
1765	HELD_ALL_ADR3ULN	AA	AG	GG	0,67	0,36	2,71	1	7	55	4	48	97
1765	HELD_ALL_ADR3ULN	AA	AG	GG	0,67	0,36	2,71	1	7	55	4	48	97
1765	HELD_ALL_ADR5ULN	AA	AG	GG	null	0,31	3,64	0	3	24	4	48	97
1765	HELD_ALL_ADR5ULN	AA	AG	GG	null	0,31	3,64	0	3	24	4	48	97
1765	HELD_MAL_ADR3ULN	AA	AG	GG	0	0,26	4,23	0	2	24	2	21	47
1765	HELD_MAL_ADR3ULN	AA	AG	GG	0	0,26	4,23	0	2	24	2	21	47
1765	HELD_MAL_ADR5ULN	AA	AG	GG	0	0	null	0	0	10	2	21	47

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
1765	HELD_MAL_ADR5ULN	AA	AG	GG	0	0	null	0	0	10	2	21	47
1765	HELD_FEM_ADR3ULN	AA	AG	GG	1,05	0,41	2,23	1	5	31	2	27	50
1765	HELD_FEM_ADR3ULN	AA	AG	GG	1,05	0,41	2,23	1	5	31	2	27	50
1776	HELD_ALL_CC	AA	AG	GG	null	null	0	45	0	0	37	0	3
1776	HELD_FEM_CC	AA	AG	GG	null	null	0	31	0	0	20	0	2
1799	HELD_FEM_LIP2	CC	CT	TT	1,04	0,82	1,4	123	119	49	145	178	33
1799	HELD_MAL_CC	CC	CT	TT	0,45	1,46	1,91	4	7	3	11	6	1
1806	HELD_FEM_EFF	AA	AG	GG	3,96	0,35	0	11	1	0	14	6	2
1837	HELD_FEM_LIP2	CC	CT	TT	1,17	0,77	1,32	164	108	32	166	167	22
1837	HELD_ALL_LIP2	CC	CT	TT	1,18	0,83	1,04	334	223	50	322	308	52
1837	HELD_ALL_ADR5ULN	CC	CT	TT	2,82	0,34	0,86	20	6	2	66	76	13
1837	HELD_MAL_ADR	CC	CT	TT	1,45	0,7	0,96	37	33	7	21	44	7
1837	HELD_MAL_LIP2	CC	CT	TT	1,19	0,89	0,77	170	115	18	156	141	30
1870	HELD_ALL_CC	CC	CT	TT	0,73	1,75	0,61	2	25	18	3	10	26
1870	HELD_FEM_CC	CC	CT	TT	0,85	1,75	0,58	1	20	10	1	7	14
1882	CVD_MAL	CC	CT	TT	1,06	0,76	1,59	21	37	11	9	25	0
1988	HELD_ALL_LIP	CC	CT	TT	1,26	0,95	0,64	52	39	9	48	48	20
2000	CVD_MAL	CC	TT	null	2,45	0,41	null	68	2	0	29	5	0
2000	CVD_ALL	CC	TT	null	1,98	0,51	null	101	4	0	65	9	0
2000	HELD_FEM_CC2	CC	TT	null	3,29	0,3	null	45	1	0	37	5	0
2000	HELD_MAL_HDL	CC	TT	null	2,00	0,50	0	20	0	0	20	2	0
2000	HELD_FEM_ADR	CC	TT	null	2,01	0,5	null	77	2	0	76	6	0

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
2000	HELD_MAL_CC	CC	TT	null	0,51	1,98	null	11	3	0	18	1	0
2071	CVD_ALL	AA	AG	GG	1,4	1,09	0,79	14	52	36	4	34	36
2078	HELD_MAL_LIP	GG	GT	TT	3,06	1,9	0,45	1	11	6	0	13	22
2085	HELD_FEM_VEFF	GG	GT	TT	2,5	0,79	0	6	4	0	3	7	4
2095	CVD_ALL	AG	GG	null	1,72	0,58	null	4	101	0	0	73	0
2119	HELD_MAL_LIP	AA	AG	null	0,35	2,83	null	3	17	0	16	21	0
2119	HELD_ALL_LIP	AA	AG	null	0,72	1,39	null	29	73	0	49	68	0
2119	HELD_FEM_EFF	AA	AG	null	0,38	2,67	null	3	9	0	13	9	0
2141	HELD_FEM_EFF	AA	AG	GG	0	3,25	0,42	0	6	6	2	2	18
2141	HELD_ALL_CC	AA	AG	GG	0	1,35	0,87	0	17	28	3	9	27
2182	HELD_FEM_EFF	AA	AG	GG	3,71	0,65	0	6	6	0	1	14	6
2234	HELD_MAL_LIP	GG	GT	TT	0	0,96	1,75	0	10	10	7	18	10
2281	HELD_FEM_VEFF	AA	AC	CC	0	1,04	2,13	0	5	4	4	7	2
2298	CVD_FEM	AA	AC	CC	2,23	0,57	1,31	4	10	21	0	20	18
2298	HELD_MAL_CC2	AA	AC	CC	0	0,7	1,65	0	8	21	2	12	14
2341	HELD_FEM_CC	CC	CT	TT	null	1,88	0,53	0	6	25	0	0	22
2357	HELD_ALL_CC2	AA	AG	GG	2,03	0,76	1,1	5	18	51	0	25	46
2357	HELD_ALL_CC	AA	AG	GG	1,98	0,62	1,21	4	8	33	0	14	26
2357	HELD_MAL_LIP	AA	AG	GG		0,42	2,4	0	4	16	0	17	19
2357	HELD_FEM_CC	AA	AG	GG	1,81	0,57	1,13	4	4	23	0	7	15
2366	CVD_FEM	GG	GT	TT	1,51	1,12	0,55	12	14	7	8	15	17
2423	CVD_FEM	AA	AG	GG	1,48	1,08	0,45	16	13	4	12	14	13

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
2708	CVD_FEM	CC	CT	TT	3,67	0,27	null	28	1	0	33	7	0
2995	HELD_FEM_ADR5ULN	AA	AC	CC	2,66	1,41	0,45	3	10	5	4	37	41
2995	HELD_FEM_UEFF	AA	AC	CC	0,67	0,68	1,57	2	20	32	5	40	30
3360	HELD_MAL_ADR5ULN	GG	GT	TT	null	0	0	10	0	0	50	22	1
3464	HELD_ALL_CC	AA	AG	GG	0,43	0,83	1,61	3	15	27	9	17	14
3464	HELD_FEM_CC	AA	AG	GG	0,6	0,67	1,74	3	7	21	5	9	8
3689	HELD_FEM_EFF	CC	CG	GG	4	0,82	0	3	3	0	1	8	5
3975	HELD_FEM_UEFF	AA	AC	CC	0,37	0,83	1,5	2	24	30	10	38	27
3976	HELD_FEM_UEFF	AA	AG	GG	0,34	0,92	1,41	2	24	30	11	35	29
4206	HELD_FEM_ADR3ULN	AA	AT	TT	0,57	1,14	1,61	8	20	9	31	41	11
4838	HELD_FEM_VEFF	AA	AG	GG	3,27	0,35	0,56	7	2	1	3	8	3
4838	HELD_FEM_VEFF	AA	AG	GG	3,27	0,35	0,56	7	2	1	3	8	3
4838	HELD_FEM_VEFF	AA	AG	GG	3,27	0,35	0,56	7	2	1	3	8	3
4912	HELD_FEM_EFF	AA	AG	GG	2,33	0	0,56	7	0	5	5	2	13
4925	HELD_MAL_CC	AA	AC	CC	0,45	2,2	null	7	7	0	15	3	0
4966	HELD_MAL_ADR3ULN	AA	AG	GG	1,08	0,44	2,26	7	8	11	18	41	13
5014	HELD_ALL_ADR5ULN	AA	AG	GG	1,54	0,16	3,07	3	2	23	10	57	85
5014	HELD_FEM_ADR5ULN	AA	AG	GG	1,64	0,15	2,73	2	1	15	5	27	49
5296	CVD_FEM	AA	AG	GG	null	1,7	0,59	0	10	26	0	4	36
5296	HELD_FEM_EFF	AA	AG	GG	3	0,22	2,39	1	1	10	0	9	13
5296	CVD_ALL	AA	AG	GG	1,72	1,29	0,76	1	25	78	0	10	64
5298	HELD_FEM_EFF	CC	CT	TT	3,2	0,23	2,25	1	1	9	0	9	13

BAYSNP	COMPARISON	GTYP1	GTYP2	GTYP3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
5298	CVD_ALL	CC	CT	TT	1,76	1,24	0,76	3	22	76	0	10	64
5298	CVD_FEM	CC	CT	TT	2,18	1,56	0,61	1	8	26	0	4	36
5320	HELD_FEM_EFF	AA	AG	GG	0,23	0,88	2,18	1	10	8	9	19	5
5361	CVD_MAL	AA	AC	CC	0,77	1,54	1,16	24	5	35	18	0	14
5457	HELD_FEM_EFF	AA	AG	GG	1,41	0	3,52	1	0	11	1	6	14
5704	HELD_MAL_LIP	CC	CT	TT	0,7	0,45	2,44	1	8	11	3	26	8
5704	CVD_MAL	CC	CT	TT	0,65	0,87	1,32	5	30	33	6	18	9
5717	HELD_FEM_ADR3ULN	AA	AG	GG	1,77	0,82	0,55	17	16	5	21	41	21
5717	HELD_ALL_ADR3ULN	AA	AG	GG	1,44	1,01	0,64	21	32	12	34	76	46
5959	HELD_ALL_CC	AA	AG	GG	1,81	0,85	0,59	16	20	7	4	21	13
5959	CVD_FEM	AA	AG	GG	3,6	0,8	0,27	4	4	1	0	7	6
5959	HELD_MAL_CC	AA	AG	GG	2,7	0,82	0,57	4	7	3	0	10	7
5959	HELD_MAL_ADR3ULN	AA	AG	GG	1,16	0,22	4,03	2	2	5	13	41	13
5959	HELD_FEM_ADR	AA	AG	GG	1,15	1,32	0,62	15	41	16	11	29	28
6162	HELD_ALL_ADR3ULN	CC	CG	GG	0,15	1,78	0,77	1	35	28	19	52	80
6162	HELD_ALL_ADR	CC	CG	GG	0,45	1,33	0,9	6	76	74	19	52	80
6162	HELD_ALL_ADR3ULN	CC	CG	GG	0	2,35	0,66	0	16	11	19	52	80
6162	HELD_MAL_ADR3ULN	CC	CG	GG	0	1,85	0,87	0	13	13	11	21	39
6162	HELD_FEM_ADR3ULN	CC	CG	GG	0	3,19	0,43	0	13	5	8	31	41
6162	HELD_MAL_ADR	CC	CG	GG	0,4	1,39	0,91	3	34	37	11	21	39
6236	HELD_ALL_ADR3ULN	CC	CT	TT	2,41	1,25	0,49	6	12	9	13	58	81
6236	HELD_MAL_ADR3ULN	CC	CT	TT	1,74	1,63	0,47	4	15	8	5	28	39

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
6236	HELD_MAL_ADR5ULN	CC	CT	TT	2,68	2,12	0,25	2	6	2	5	28	39
6236	HELD_ALL_ADR3ULN	CC	CT	TT	1,58	1,15	0,71	10	27	26	13	58	81
6482	HELD_MAL_HDL	AA	AG	GG	0,44	1,96	1,79	5	8	4	15	4	2
6482	HELD_ALL_LIP2	AA	AG	GG	0,87	1,16	1	340	238	41	436	226	47
6482	HELD_MAL_CC2	AA	AG	GG	1,93	0,66	0,47	18	7	2	10	12	6
6482	HELD_MAL_LIP2	AA	AG	GG	0,83	1,2	1,08	173	115	21	220	99	20
6498	CVD_FEM	AA	AG	GG	1,85	0,73	0	28	4	0	25	7	3
6744	HELD_ALL_ADR5ULN	CC	CT	TT	2,27	1,54	0,47	4	13	9	9	56	84
7133	HELD_MAL_CC	CC	CG	GG	0,36	null	2,8	10	0	4	18	0	0
8021	CVD_FEM	AA	AG	GG	0,71	1,98	0,26	8	19	1	15	14	7
8060	CVD_FEM	AA	AG	GG	2,1	0,38	2,18	31	3	1	28	12	0
8060	HELD_FEM_HDL	AA	AG	GG	0,47	2,13	0	11	7	0	20	3	0
8210	HELD_FEM_EFF	AA	AG	GG	0,22	2,93	0,81	1	7	4	9	4	9
8592	HELD_FEM_VEFF	CC	CT	TT	0,7	1,32	0,86	15	92	43	25	68	50
8816	HELD_FEM_EFF	CC	CG	GG	2,22	1,17	0,36	4	7	2	0	5	6
8846	HELD_ALL_LIP	AA	AG	GG	1	1,18	0,4	57	47	3	62	42	12
8943	HELD_MAL_LIP	AA	AC	CC	1,89	0,78	0	15	5	0	20	12	5
9193	HELD_FEM_LIP	CC	CG	GG	1,54	0,65	null	72	11	0	60	20	0
9193	CVD_FEM	CC	CG	GG	0,59	1,59	2,14	28	7	1	37	3	0
9443	CVD_MAL	CC	CT	TT	1,55	1	0,85	9	25	35	0	12	21
9516	HELD_MAL_CC	AA	AG	GG	2,56	0,52	0,67	7	3	4	2	8	8
9698	HELD_MAL_ADR	AA	AG	GG	0,41	0	2,78	4	0	70	14	2	56

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
9698	HELD_MAL_ADR3ULN	AA	AG	GG	0	0		0	0	27	14	2	56
9698	HELD_FEM_EFF	AA	AG	GG	0,47	1,04	1,04	5	95	194	16	91	191
9698	HELD_MAL_ADR5ULN	AA	AG	GG	0	0	null	0	0	10	14	2	56
9698	CVD_ALL	AA	AG	GG	1,31	1,09	0,8	17	12	73	6	7	59
9849	HELD_FEM_CC	CC	CT	null	null	0	null	31	0	0	18	3	0
9849	HELD_MAL_LIP	CC	CT	null	0,42	2,38	null	15	5	0	35	2	0
9883	HELD_FEM_CC	AA	AG	GG	1,64	0,46	1,55	7	9	15	1	16	5
9883	HELD_ALL_CC	AA	AG	GG	1,37	0,58	1,42	9	15	21	4	24	11
10079	CVD_ALL	AA	AG	GG	1,74	0	0,72	4	0	99	0	1	72
10079	CVD_MAL	AA	AG	GG	1,53	null	0,65	4	0	64	0	0	34
10481	HELD_FEM_ADR5ULN	AA	AT	TT	0,4	0,85	2,53	3	6	8	32	33	18
10542	HELD_FEM_UEFF	CC	CT	TT	2,42	0,47	1,86	1	6	47	0	21	54
10542	HELD_MAL_ADR5ULN	CC	CT	TT	null	0	null	0	0	10	0	14	55
10600	HELD_FEM_EFF	AA	AG	GG	null	0	null	0	0	21	0	4	29
10621	HELD_FEM_CC	CC	CT	TT	1,56	0,49	1,71	24	4	2	12	8	0
10745	HELD_ALL_ADR5ULN	AA	AG	GG	3,09	0,86	0,72	5	10	12	7	61	80
10745	HELD_FEM_VEFF	AA	AG	GG	0,79	1,35	0,8	11	68	74	16	45	89
10747	HELD_MAL_ADR	CC	CT	TT	1,71	0,62	1,29	14	46	16	3	58	9
10747	CVD_ALL	CC	CT	TT	1,75	0,73	0,95	15	24	23	6	39	29
10747	HELD_MAL_ADR3ULN	CC	CT	TT	2,24	0,45	1,77	4	16	7	3	58	9
10771	HELD_MAL_ADR5ULN	CC	CG	GG	4,67	0,67	0,42	4	4	2	6	36	28
10771	HELD_FEM_EFF	CC	CG	GG	1,14	1,07	0,86	52	118	114	40	105	131

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
10870	HELD_MAL_LP	AA	AG	GG	0	2,26	0,64	0	11	9	5	9	23
10870	HELD_FEM_LP	AA	AG	GG	0,9	0,65	1,5	7	18	57	8	30	39
10870	HELD_MAL_CC	AA	AG	GG	0	0,52	2,51	0	3	11	2	8	8
10870	HELD_ALL_CC	AA	AG	GG	0,45	0,83	1,47	2	13	30	6	15	19
10877	HELD_ALL_HDL	AA	AC	CC	0,61	0,53	2,00	0	0	9	1	5	9
10948	HELD_FEM_LP	GG	GT	TT	0,58	1,45	1,04	16	51	17	31	33	15
10948	HELD_ALL_LP	GG	GT	TT	0,62	1,35	1,1	22	60	22	44	50	21
10948	HELD_FEM_CC2	GG	GT	TT	0,59	1,67	0,83	9	28	7	17	16	9
10948	CVD_MAL	GG	GT	TT	0,69	1,09	1,23	12	39	18	12	17	5
11001	HELD_MAL_ADRSULN	CC	CT	TT	5,06	1,02	0,51	2	5	3	2	37	36
11073	HELD_MAL_ADRSULN	CC	CG	GG	2,71	1,32	0,33	3	4	2	9	25	34
11153	HELD_FEM_CC	CC	CT	TT	1,76	0,57	null	24	7	0	11	11	0
11210	HELD_MAL_CC	CC	CT	TT	0,4	2,5	null	9	5	0	18	1	0
11210	HELD_ALL_ADR3ULN	CC	CT	TT	0,6	1,79	0	47	16	0	125	17	2
11210	HELD_ALL_ADR	CC	CT	TT	0,8	1,32	0	122	31	0	125	17	2
11248	HELD_FEM_ADR	CC	CT	TT	1,57	0,59	1,08	56	19	6	38	36	5
11248	HELD_MAL_LP	CC	CT	TT	2,65	0,38	null	15	3	0	19	15	0
11248	HELD_ALL_CC	CC	CT	TT	1,54	0,65	null	27	14	0	13	18	0
11372	HELD_MAL_LP	AA	AG	GG	1,8	0,83	0,6	10	5	5	10	11	15
11449	HELD_FEM_CC	CC	CG	GG	1,73	0,41	2,05	1	4	26	0	10	12
11450	HELD_FEM_EFF	AA	AT	TT	1,3	1,06	0,87	28	114	147	16	107	167
11470	HELD_MAL_LP	CC	CT	null	null	0	null	20	0	0	31	5	0

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
11472	HELD_MAL_LIP	AA	AT	null	null	0	null	20	0	0	30	5	0
11472	HELD_FEM_LIP	AA	AT	null	0,61	1,63	null	75	8	0	78	2	0
11487	HELD_MAL_ADR3ULN	AT	TT	null	0	null	null	0	10	0	34	35	0
11487	HELD_MAL_ADR3ULN	AT	TT	null	0,4	2,5	null	6	21	0	34	35	0
11488	HELD_MAL_ADR3ULN	CC	CG	GG	null	0	0	10	0	0	35	32	3
11488	HELD_FEM_UFFF	CC	CG	GG	0,79	1,02	2,57	29	20	5	49	28	0
11488	HELD_MAL_ADR3ULN	CC	CG	GG	2,48	0,3	1,52	20	4	2	35	32	3
11493	HELD_MAL_CC	AA	AG	GG	0	2,25	0,61	0	6	8	2	2	14
11502	HELD_MAL_ADR3ULN	CC	CT	TT	0	0,69	1,94	0	8	19	7	30	36
11502	HELD_MAL_ADR3ULN	CC	CT	TT	0	0,4	3,55	0	2	8	7	30	36
11534	HELD_ALL_LIP	GG	GT	null	null	0	null	102	0	0	114	3	0
11537	CVD_FEM	AA	AG	GG	0,63	1,38	1,75	20	12	4	30	8	1
11537	HELD_FEM_UFFF	AA	AG	GG	2,73	0,56	0	10	2	0	12	7	3
11560	HELD_FEM_UFFF	AA	AG	GG	3		0,33	1	0	11	0	0	22
11578	HELD_FEM_LIP	CC	CT	null	4,62	0,22	null	60	1	0	57	8	0
11578	CVD_FEM	CC	CT	null	0,41	2,44	null	27	3	0	39	0	0
11594	HELD_FEM_ADR3ULN	CC	CT	TT	0	0	null	0	0	37	2	6	72
11594	HELD_ALL_ADR3ULN	CC	CT	TT	0	0	null	0	0	27	2	16	133
11594	HELD_ALL_CC	CC	CT	TT	null	1,6	0,62	0	10	35	0	3	38
11594	HELD_ALL_ADR	CC	CT	TT	0,66	0,58	1,71	1	7	147	2	16	133
11594	HELD_FEM_ADR3ULN	CC	CT	TT	0	0	null	0	0	18	2	6	72
11624	HELD_ALL_CC	CC	CT	TT	1	0,75	2,11	21	15	6	20	20	0

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
11624	HELD_MAL_CC	CC	CT	TT	1,32	0,33	2,8	8	2	3	9	9	0
11624	HELD_FEM_EFF	CC	CT	TT	2,5	0,63	0	10	2	0	12	6	3
11627	HELD_ALL_CC	CC	CT	TT	0,86	0,86	2,05	20	18	7	21	19	0
11627	HELD_MAL_CC	CC	CT	TT	1	0,58	2,64	7	4	3	9	9	0
11627	HELD_FEM_EFF	CC	CT	TT	2,73	0,56	0	10	2	0	12	7	3
11644	HELD_MAL_ADR5ULN	AA	AG	GG	0	0,45	3,26	0	2	8	7	26	35
11650	HELD_FEM_EFF	AA	AG	GG	1,07	0,8	1,21	26	105	160	23	135	132
11654	HELD_ALL_ADR5ULN	AA	AG	GG	2,59	0,24	1,48	7	3	15	14	56	66
11654	HELD_FEM_ADR5ULN	AA	AG	GG	2,81	0,12	1,65	5	1	9	8	31	32
11654	HELD_FEM_ADR3ULN	AA	AG	GG	1,81	0,48	1,25	8	7	17	8	31	32
11654	HELD_ALL_ADR3ULN	AA	AG	GG	1,83	0,66	1,02	12	15	26	14	56	66
11655	HELD_ALL_ADR5ULN	AA	AC	CC	1,56	0,24	2,3	16	3	7	72	59	17
11655	HELD_FEM_ADR5ULN	AA	AC	CC	2,03	0,11	2,11	11	1	5	35	34	11
11655	HELD_FEM_ADR3ULN	AA	AC	CC	1,34	0,45	1,64	19	7	9	35	34	11
11656	HELD_MAL_LIP	CC	CT	TT	0,53	0,96	2,57	6	8	6	19	15	2
11656	HELD_FEM_EFF	CC	CT	TT	2,57	0,56	0	7	5	0	5	14	3
11656	HELD_ALL_LIP	CC	CT	TT	0,79	1,01	1,5	35	49	18	51	54	9
11825	HELD_MAL_ADR5ULN	AA	AG	null	0,25	4	null	6	3	0	58	5	0
11914	HELD_MAL_ADR5ULN	AA	AT	TT	0,11	0	9,83	1	0	8	41	1	27
11914	HELD_ALL_ADR5ULN	AA	AT	TT	0,45	1,43	1,48	6	12	9	63	52	36
12008	HELD_FEM_EFF	CC	CT	null	0,72	1,38	null	251	27	0	264	13	0
12008	HELD_ALL_ADR5ULN	CC	CT	null	null	0	null	24	0	0	122	12	0

BAYSNP	COMPARISON	GTTYPE1	GTTYPE2	GTTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
12097	HELD_ALL_ADR5ULN	AG	GG	null	2,66	0,38	null	6	22	0	11	144	0
12097	HELD_FEM_ADR3ULN	AG	GG	null	2,05	0,49	null	7	31	0	5	78	0
12097	HELD_MAL_ADR5ULN	AG	GG	null	3,48	0,29	null	3	7	0	6	66	0
12097	HELD_ALL_ADR3ULN	AG	GG	null	1,77	0,56	null	10	53	0	11	144	0
12366	HELD_FEM_UEFF	AA	AG	GG	1,33	1,02	0	32	18	0	39	26	9
12366	HELD_ALL_ADR5ULN	AA	AG	GG	1,82	0,34	2,26	18	4	3	85	59	7
12619	HELD_MAL_ADR5ULN	AG	GG	null	8,89	0,11	null	1	9	0	0	71	0
12619	HELD_ALL_ADR5ULN	AG	GG	null	4,67	0,21	null	2	25	0	1	150	0
13025	HELD_ALL_ADR5ULN	AA	AC	CC	1,12	0,51	2,38	13	8	7	65	71	15
13191	HELD_FEM_LIP	AA	AG	GG	0,71	0,71	1,55	6	30	47	10	42	27
13191	HELD_MAL_CC	AA	AG	GG	2,5	1,67	0,43	2	7	5	0	5	13
13191	HELD_ALL_LIP	AA	AG	GG	0,65	0,81	1,38	6	39	56	13	55	46
13937	HELD_FEM_ADR5ULN	AA	AC	CC	0,36	1,91	2,53	4	11	2	42	38	3
900002	CVD_FEM	GG	GT	TT	1,65	1,29	0,64	5	13	16	2	11	27
900013	CVD_FEM	CC	CG	GG	1,7	0,47	1,34	20	9	6	13	23	4
900013	CVD_ALL	CC	CG	GG	1,32	0,7	1,16	58	34	12	29	39	6
900025	CVD_MAL	GG	GT	TT	0,73	0,88	1,3	7	27	32	7	17	10
900032	CVD_FEM	CC	CT	TT	2,48	0,22	2,54	23	1	1	28	9	0
900045	HELD_FEM_EFF	CC	CT	TT	0,42	0,48	2,67	1	2	9	5	8	9
900065	CVD_FEM	AA	AC	CC	1,91	0,7	0	22	10	0	16	18	5
900065	CVD_MAL	AA	AC	CC	1,29	0,72	1,53	25	30	4	7	22	0
900065	CVD_ALL	AA	AC	CC	1,36	0,77	0,77	47	40	4	23	40	5

BAYSNP	COMPARISON	GTYPE1	GTYPE2	GTYPE3	RR1	RR2	RR3	FQ1_A	FQ2_A	FQ3_A	FQ1_B	FQ2_B	FQ3_B
900078	HELD_ALL_ADR3ULN	AA	AG	GG	0,56	1,79	null	52	12	0	142	13	0
900078	HELD_ALL_ADR5ULN	AA	AG	GG	0,41	2,45	null	21	6	0	142	13	0
900078	HELD_FEM_ADR3ULN	AA	AG	GG	0,49	2,05	null	31	7	0	78	5	0
900082	HELD_FEM_ADR3ULN	AA	AG	GG	1	0,49	1,9	8	9	18	17	36	21
900082	HELD_FEM_ADR5ULN	AA	AG	GG	0,76	0,39	2,76	3	4	10	17	36	21
900096	CVD_ALL	AA	AG	GG	0,74	1,35	1,15	60	37	4	55	15	2
900107	HELD_MAL_ADR5ULN	CC	CT	TT	0	0,52	3,06	0	2	8	9	25	39
900115	HELD_MAL_ADR5ULN	AA	AG	GG	0,24	0,78	4,6	1	4	4	27	37	8
900115	HELD_FEM_EFF	AA	AG	GG	1,47	0,56	1,8	22	14	4	17	28	1
900121	HELD_MAL_ADR	GG	GT	TT	0,46	1,42	0,95	5	37	24	15	26	26
900173	CVD_ALL	GG	GT	TT	0,5	1,35	1,38	5	7	11	11	4	7
10000002	HELD_FEM_EFF	AA	AG	GG	2,67	0,8	0	9	3	0	9	7	6
10000006	HELD_FEM_CC	AA	AG	GG	3,35	0,26	0,56	28	2	1	11	9	2
10000006	HELD_ALL_CC	AA	AG	GG	2,52	0,41	0,45	39	4	1	23	12	3
10000014	HELD_ALL_CC	AA	AC	CC	2,18	0,33	1,26	40	3	2	26	12	1
10000014	HELD_FEM_CC	AA	AC	CC	2,17	0,34	1,73	28	2	1	15	7	0
10000025	HELD_MAL_LIP	CC	CT	TT	1,17	1,41	0	9	11	0	14	15	7

Table 6b: Correlation of PA SNP alleles to relative risk

For diagnostic conclusions to be drawn from genotyping a particular patient we calculated the relative risks RR_1 , and RR_2 for the two possible alleles of each SNP. Given the allele frequencies as

	allele1	allele2
case	N11	N12
control	N21	N22

we calculate

$$\frac{N11 \cdot N22}{N21 \cdot N12}$$

- 206 -

Here, the *case* and *control* populations represent any case-control-group pair, or bad(case)-good(control)-group pair, respectively (due to their increased response to statins, 'high responders' are treated as a case cohort, whereas 'low responders' are treated as the respective control cohort). A value $RR_1 > 1$, and $RR_2 > 1$ indicates an increased risk for individuals carrying allele 1, and allele2, respectively. For example, $RR_1 = 3$ indicates a 3-fold risk of an individual carrying allele 1 as compared to individuals not carrying allele 1 (a detailed description of relative risk calculation and statistics can be found in (Biostatistics, L. D. Fisher and G. van Belle, Wiley Interscience 1993)). The baySNP number refers to an internal numbering of the PA SNPs and can be found in the sequence listing. null: not defined.

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
28	C	T	HELD_FEM_EFF	0,42	2,39	12	4	20	22	18	26
29	A	G	HELD_ALL_HDL	2,01	0,5	10	12	8	15	7	23
29	A	G	HELD_MAL_ADR3ULN	1,63	0,61	26	33	19	72	68	76
29	A	G	HELD_MAL_ADR5ULN	2,6	0,38	9	13	5	72	68	76
52	C	G	HELD_FEM_EFF	1,84	0,54	18	24	12	31	27	35
56	A	G	HELD_FEM_EFF	2,29	0,44	12	5	19	22	2	42
89	A	G	HELD_ALL_CC	null	0	45	90	0	40	77	3
90	C	T	HELD_FEM_CC	0,78	1,27	31	29	33	22	27	17
99	C	T	HELD_FEM_LIP	1,02	0,98	82	54	110	80	51	109
140	C	T	HELD_FEM_EFF	null	0	12	24	0	21	4	38
152	A	G	HELD_FEM_EFF	0,51	1,96	12	12	12	22	33	11
214	A	G	HELD_ALL_LIP	1	1	97	156	38	113	182	44
214	A	G	HELD_FEM_LIP	1,09	0,92	81	131	31	78	122	34
221	C	G	HELD_ALL_CC	0,88	1,13	45	26	64	39	27	51
221	C	G	HELD_FEM_CC	0,77	1,3	31	17	45	22	18	26
224	C	T	HELD_FEM_LIP	0,79	1,27	79	110	48	79	125	33
224	C	T	HELD_MAL_LIP	2,28	0,44	20	35	5	37	51	23
294	C	T	HELD_ALL_CC	0,81	1,24	45	56	34	40	58	22
307	C	T	CVD_FEM	0,57	1,75	36	19	53	38	38	38
307	C	T	HELD_ALL_LIP	1,2	0,83	102	70	134	117	63	171
411	A	T	HELD_ALL_HDL	1,56	0,64	10	17	3	15	18	12
449	C	G	HELD_MAL_LIP	0,41	2,47	20	3	37	37	16	58
466	C	T	CVD_FEM	0,7	1,43	35	27	43	40	44	36

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
472	A	G	HELD_FEM_EFF	null	0	11	22	0	22	12	32
542	A	G	HELD_MAL_CC	2,79	0,36	14	12	16	19	2	36
542	A	G	HELD_MAL_HDL	3,66	0,27	21	14	28	27	3	51
542	A	G	HELD_ALL_ADR	1,19	0,84	159	53	265	154	37	271
542	A	G	HELD_FEM_HDL	0,66	1,51	23	2	44	32	10	54
739	C	G	HELD_ALL_CC	0,73	1,37	45	39	51	40	48	32
821	A	C	HELD_MAL_LIP2	1,12	0,9	309	180	438	349	174	524
821	A	C	HELD_FEM_VEFF	0,42	2,4	10	4	16	14	14	14
1005	A	G	HELD_MAL_CC	2,7	0,37	14	26	2	18	27	9
1055	A	T	HELD_MAL_CC	0,56	1,77	9	3	15	12	8	16
1056	A	G	HELD_FEM_EFF	1,01	0,99	24	30	18	33	41	25
1085	A	G	HELD_MAL_LIP	0,57	1,74	20	17	23	36	46	26
1085	A	G	CVD_FEM	1,53	0,65	34	51	17	40	47	33
1086	A	G	HELD_MAL_LIP	1,73	0,58	20	24	16	36	28	44
1092	C	G	HELD_MAL_LIP	0,58	1,72	20	9	31	37	29	45
1096	G	T	HELD_MAL_CC	1,8	0,56	14	7	21	18	3	33
1096	G	T	CVD_MAL	0,93	1,08	69	21	117	33	12	54
1101	C	T	HELD_FEM_EFF	null	0	12	24	0	22	40	4
1204	A	G	HELD_MAL_LIP	1,91	0,52	19	12	26	35	9	61
1204	A	G	HELD_ALL_LIP	1,26	0,8	99	62	136	115	52	178
1504	C	T	HELD_ALL_CC	0,92	1,08	44	37	51	39	36	42
1504	C	T	HELD_MAL_LIP	0,69	1,46	19	12	26	37	33	41
1504	C	T	HELD_MAL_CC	1,35	0,74	14	13	15	18	12	24

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
1504	C	T	HELD_FEM_CC	0,75	1,33	30	24	36	21	24	18
1511	G	T	HELD_FEM_EFF	0,6	1,67	12	15	9	22	35	9
1524	A	C	HELD_FEM_ADR3ULN	0,9	1,11	38	16	60	82	39	125
1556	C	G	HELD_FEM_EFF	2,39	0,42	12	7	17	22	3	41
1561	A	C	CVD_FEM	1,53	0,65	36	58	14	40	53	27
1582	C	T	HELD_MAL_LIP	0,46	2,17	20	5	35	37	22	52
1638	A	G	HELD_FEM_CC	0,62	1,6	31	10	52	22	15	29
1653	G	T	CVD_MAL	1,07	0,93	69	70	68	33	30	36
1662	C	T	HELD_MAL_CC	0,18	5,5	14	8	20	18	36	0
1714	A	G	CVD_MAL	0,78	1,28	66	32	100	34	26	42
1722	C	T	HELD_FEM_ADR5ULN	1,61	0,62	18	21	15	81	71	91
1757	A	G	HELD_FEM_EFF	1,41	0,71	20	15	25	32	16	48
1765	A	G	HELD_ALL_ADR3ULN	0,42	2,35	63	9	117	149	56	242
1765	A	G	HELD_ALL_ADR3ULN	0,42	2,35	63	9	117	149	56	242
1765	A	G	HELD_ALL_ADR5ULN	0,29	3,42	27	3	51	149	56	242
1765	A	G	HELD_ALL_ADR5ULN	0,29	3,42	27	3	51	149	56	242
1765	A	G	HELD_MAL_ADR3ULN	0,24	4,09	26	2	50	70	25	115
1765	A	G	HELD_MAL_ADR3ULN	0,24	4,09	26	2	50	70	25	115
1765	A	G	HELD_MAL_ADR5ULN	null	0	10	20	0	70	25	115
1765	A	G	HELD_MAL_ADR5ULN	null	0	10	20	0	70	25	115
1765	A	G	HELD_FEM_ADR3ULN	0,53	1,87	37	7	67	79	31	127
1765	A	G	HELD_FEM_ADR3ULN	0,53	1,87	37	7	67	79	31	127
1776	A	G	HELD_ALL_CC	null	0	45	90	0	40	74	6

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
1776	A	G	HELD_FEM_CC	null	0	31	62	0	22	40	4
1799	C	T	HELD_FEM_LIP2	0,93	1,07	291	365	217	356	468	244
1799	C	T	HELD_MAL_CC	0,56	1,77	14	15	13	18	28	8
1806	A	G	HELD_FEM_VEFF	4,44	0,23	12	23	1	22	34	10
1837	C	T	HELD_FEM_LIP2	1,04	0,96	304	436	172	355	499	211
1837	C	T	HELD_ALL_LIP2	1,1	0,91	607	891	323	682	952	412
1837	C	T	HELD_ALL_ADR5ULN	2,03	0,49	28	46	10	155	208	102
1837	C	T	HELD_MAL_ADR	1,24	0,81	77	107	47	72	86	58
1837	C	T	HELD_MAL_LIP2	1,17	0,86	303	455	151	327	453	201
1870	C	T	HELD_ALL_CC	1,3	0,77	45	29	61	39	16	62
1870	C	T	HELD_FEM_CC	1,33	0,75	31	22	40	22	9	35
1882	C	T	CVD_MAL	0,92	1,08	69	79	59	34	43	25
1988	C	T	HELD_ALL_LIP	1,27	0,79	100	143	57	116	144	88
2000	C	T	CVD_MAL	2,45	0,41	70	136	4	34	58	10
2000	C	T	CVD_ALL	1,98	0,51	105	202	8	74	130	18
2000	C	T	HELD_FEM_CC2	3,29	0,3	46	90	2	42	74	10
2000	C	T	HELD_MAL_HDL	2	0,5	20	40	0	22	40	4
2000	C	T	HELD_FEM_ADR	2,01	0,5	79	154	4	82	152	12
2000	C	T	HELD_MAL_CC	0,51	1,98	14	22	6	19	36	2
2071	A	G	CVD_ALL	1,22	0,82	102	80	124	74	42	106
2078	G	T	HELD_MAL_LIP	1,74	0,58	18	13	23	35	13	57
2085	G	T	HELD_FEM_VEFF	2,62	0,38	10	16	4	14	13	15
2095	A	G	CVD_ALL	0,03	37,5	105	4	206	73	146	0

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
2119	A	G	HELD_MAL_LIP	0,68	1,48	20	23	17	37	53	21
2119	A	G	HELD_ALL_LIP	0,85	1,17	102	131	73	117	166	68
2119	A	G	HELD_FEM_EFF	0,6	1,67	12	15	9	22	35	9
2141	A	G	HELD_FEM_EFF	1,56	0,64	12	6	18	22	6	38
2141	A	G	HELD_ALL_CC	0,99	1,01	45	17	73	39	15	63
2182	A	G	HELD_FEM_EFF	2,82	0,35	12	18	6	21	16	26
2234	G	T	HELD_MAL_LIP	0,54	1,85	20	10	30	35	32	38
2281	A	C	HELD_FEM_VEFF	0,46	2,17	9	5	13	13	15	11
2298	A	C	CVD_FEM	0,98	1,02	35	18	52	38	20	56
2298	A	C	HELD_MAL_CC2	0,6	1,67	29	8	50	28	16	40
2341	C	T	HELD_FEM_CC	0,12	8,33	31	6	56	22	44	0
2357	A	G	HELD_ALL_CC2	1,04	0,96	74	28	120	71	25	117
2357	A	G	HELD_ALL_CC	1,01	0,99	45	16	74	40	14	66
2357	A	G	HELD_MAL_LIP	0,48	2,08	20	4	36	36	17	55
2357	A	G	HELD_FEM_CC	1,1	0,91	31	12	50	22	7	37
2366	G	T	CVD_FEM	1,51	0,66	33	38	28	40	31	49
2423	A	G	CVD_FEM	1,57	0,63	33	45	21	39	38	40
2708	C	T	CVD_FEM	3,51	0,29	29	57	1	40	73	7
2995	A	C	HELD_FEM_ADRSULN	1,82	0,55	18	16	20	82	45	119
2995	A	C	HELD_FEM_UEFF	0,71	1,41	54	24	84	75	50	100
3360	G	T	HELD_MAL_ADR5ULN	null	0	10	20	0	73	122	24
3464	A	G	HELD_ALL_CC	0,62	1,61	45	21	69	40	35	45
3464	A	G	HELD_FEM_CC	0,61	1,63	31	13	49	22	19	25

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
3689	C	G	HELD_FEM_EFF	3,32	0,3	6	9	3	14	10	18
3975	A	C	HELD_FEM_UEFF	0,68	1,47	56	28	84	75	58	92
3976	A	G	HELD_FEM_UEFF	0,69	1,44	56	28	84	75	57	93
4206	A	T	HELD_FEM_ADR3ULN	0,69	1,45	37	36	38	83	103	63
4838	A	G	HELD_FEM_VEFF	2,4	0,42	10	16	4	14	14	14
4838	A	G	HELD_FEM_VEFF	2,4	0,42	10	16	4	14	14	14
4838	A	G	HELD_FEM_VEFF	2,4	0,42	10	16	4	14	14	14
4912	A	G	HELD_FEM_EFF	2,05	0,49	12	14	10	20	12	28
4925	A	C	HELD_MAL_CC	0,56	1,8	14	21	7	18	33	3
4966	A	G	HELD_MAL_ADR3ULN	0,72	1,39	26	22	30	72	77	67
5014	A	G	HELD_ALL_ADR5ULN	0,54	1,85	28	8	48	152	77	227
5014	A	G	HELD_FEM_ADR5ULN	0,6	1,67	18	5	31	81	37...	125
5296	A	G	CVD_FEM	1,59	0,63	36	10	62	40	4	76
5296	A	G	HELD_FEM_EFF	0,67	1,5	12	3	21	22	9	35
5296	A	G	CVD_ALL	1,29	0,78	104	27	181	74	10	138
5298	C	T	HELD_FEM_EFF	0,71	1,41	11	3	19	22	9	35
5298	C	T	CVD_ALL	1,32	0,76	101	28	174	74	10	138
5298	C	T	CVD_FEM	1,62	0,62	35	10	60	40	4	76
5320	A	G	HELD_FEM_EFF	0,52	1,93	19	12	26	33	37	29
5361	A	C	CVD_MAL	0,82	1,22	64	53	75	32	36	28
5457	A	G	HELD_FEM_EFF	0,51	1,96	12	2	22	21	8	34
5704	C	T	HELD_MAL_LIP	0,57	1,75	20	10	30	37	32	42
5704	C	T	CVD_MAL	0,79	1,27	68	40	96	33	30	36

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
5717	A	G	HELD_FEM_ADR3ULN	1,58	0,63	38	50	26	83	83	83
5717	A	G	HELD_ALL_ADR3ULN	1,36	0,74	65	74	56	156	144	168
5959	A	G	HELD_ALL_CC	1,53	0,65	43	52	34	38	29	47
5959	A	G	CVD_FEM	2,63	0,38	9	12	6	13	7	19
5959	A	G	HELD_MAL_CC	1,71	0,59	14	15	13	17	10	24
5959	A	G	HELD_MAL_ADR5ULN	0,54	1,85	9	6	12	67	67	67
5959	A	G	HELD_FEM_ADR	1,26	0,79	72	71	73	68	51	85
6162	C	G	HELD_ALL_ADR3ULN	0,97	1,03	64	37	91	151	90	212
6162	C	G	HELD_ALL_ADR	0,96	1,04	156	88	224	151	90	212
6162	C	G	HELD_ALL_ADR5ULN	0,99	1,01	27	16	38	151	90	212
6162	C	G	HELD_MAL_ADR3ULN	0,82	1,22	26	13	39	71	43	99
6162	C	G	HELD_FEM_ADR5ULN	1,28	0,78	18	13	23	80	47	113
6162	C	G	HELD_MAL_ADR	0,92	1,08	74	40	108	71	43	99
6236	C	T	HELD_ALL_ADR5ULN	1,85	0,54	27	24	30	152	84	220
6236	C	T	HELD_MAL_ADR3ULN	1,67	0,6	27	23	31	72	38	106
6236	C	T	HELD_MAL_ADR5ULN	2,42	0,41	10	10	10	72	38	106
6236	C	T	HELD_ALL_ADR3ULN	1,36	0,74	63	47	79	152	84	220
6482	A	G	HELD_MAL_HDL	0,51	1,96	17	18	16	21	34	8
6482	A	G	HELD_ALL_LIP2	0,91	1,1	619	918	320	709	1098	320
6482	A	G	HELD_MAL_CC2	1,82	0,55	27	43	11	28	32	24
6482	A	G	HELD_MAL_LIP2	0,87	1,15	309	461	157	339	539	139
6498	A	G	CVD_FEM	2,18	0,46	32	60	4	35	57	13
6744	C	T	HELD_ALL_ADR5ULN	1,82	0,55	26	21	31	149	74	224

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
7133	C	G	HELD_MAL_CC	0,36	2,8	14	20	8	18	36	0
8021	A	G	CVD_FEM	1,03	0,97	28	35	21	36	44	28
8060	A	G	CVD_FEM	1,66	0,6	35	65	5	40	68	12
8060	A	G	HELD_FEM_HDL	0,5	1,99	18	29	7	23	43	3
8210	A	G	HELD_FEM_EFF	0,72	1,4	12	9	15	22	22	22
8592	C	T	HELD_FEM_VEFF	0,99	1,01	150	122	178	143	118	168
8816	C	G	HELD_FEM_EFF	1,91	0,52	13	15	11	11	5	17
8846	A	G	HELD_ALL_LIP	1,11	0,9	107	161	53	116	166	66
8943	A	C	HELD_MAL_LIP	2,17	0,46	20	35	5	37	52	22
9193	C	G	HELD_FEM_LIP	1,48	0,68	83	155	11	80	140	20
9193	C	G	CVD_FEM	0,6	1,67	36	63	9	40	77	3
9443	C	T	CVD_MAL	1,23	0,82	69	43	95	33	12	54
9516	A	G	HELD_MAL_CC	1,87	0,54	14	17	11	18	12	24
9698	A	G	HELD_MAL_ADR	0,38	2,62	74	8	140	72	30	114
9698	A	G	HELD_MAL_ADR3ULN	null	0	27	54	0	72	30	114
9698	A	G	HELD_FEM_EFF	0,91	1,1	294	105	483	298	123	473
9698	A	G	HELD_MAL_ADR5ULN		0	10	20	0	72	30	114
9698	A	G	CVD_ALL	1,27	0,79	102	46	158	72	19	125
9849	C	T	HELD_FEM_CC	null	0	31	62	0	21	39	3
9849	C	T	HELD_MAL_LIP	0,46	2,18	20	35	5	37	72	2
9883	A	G	HELD_FEM_CC	0,93	1,07	31	23	39	22	18	26
9883	A	G	HELD_ALL_CC	0,92	1,09	45	33	57	39	32	46
10079	A	G	CVD_ALL	1,54	0,65	103	8	198	73	1	145

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
10079	A	G	CVD_MAL	0,11	9,5	68	8	128	34	68	0
10481	A	T	HELD_FEM_ADR5ULN	0,46	2,2	17	12	22	83	97	69
10542	C	T	HELD_FEM_VEFF	0,63	1,58	54	8	100	75	21	129
10542	C	T	HELD_MAL_ADR5ULN	null	0	10	20	0	69	14	124
10600	A	G	HELD_FEM_VEFF	null	0	21	42	0	33	4	62
10621	C	T	HELD_FEM_CC	1,24	0,81	30	52	8	20	32	8
10745	A	G	HELD_ALL_ADR5ULN	1,58	0,63	27	20	34	148	75	221
10745	A	G	HELD_FEM_VEFF	1,1	0,91	153	90	216	150	77	223
10747	C	T	HELD_MAL_ADR	1,06	0,94	76	74	78	70	64	76
10747	C	T	CVD_ALL	1,23	0,82	62	54	70	74	51	97
10747	C	T	HELD_MAL_ADR3ULN	0,96	1,04	27	24	30	70	64	76
10771	C	G	HELD_MAL_ADR5ULN	2,5	0,4	10	12	8	70	48	92
10771	C	G	HELD_FEM_VEFF	1,12	0,89	284	222	346	276	185	367
10870	A	G	HELD_MAL_LIP	1,06	0,94	20	11	29	37	19	55
10870	A	G	HELD_FEM_LIP	0,75	1,34	82	32	132	77	46	108
10870	A	G	HELD_MAL_CC	0,39	2,55	14	3	25	18	12	24
10870	A	G	HELD_ALL_CC	0,67	1,5	45	17	73	40	27	53
10877	A	C	HELD_ALL_HDL	3,57	0,28	9	18	0	15	7	23
10948	G	T	HELD_FEM_LIP	0,81	1,23	84	83	85	79	95	63
10948	G	T	HELD_ALL_LIP	0,81	1,23	104	104	104	115	138	92
10948	G	T	HELD_FEM_CC2	0,87	1,15	44	46	42	42	50	34
10948	G	T	CVD_MAL	0,82	1,21	69	63	75	34	41	27
11001	C	T	HELD_MAL_ADR5ULN	1,96	0,51	10	9	11	75	41	109

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
11073	C	G	HELD_MAL_ADR5ULN	2,38	0,42	9	10	8	68	43	93
11153	C	T	HELD_FEM_CC	1,61	0,62	31	55	7	22	33	11
11210	C	T	HELD_MAL_CC	0,46	2,17	14	23	5	19	37	1
11210	C	T	HELD_ALL_ADR3ULN	0,67	1,48	63	110	16	144	267	21
11210	C	T	HELD_ALL_ADR	0,85	1,17	153	275	31	144	267	21
11248	C	T	HELD_FEM_ADR	1,34	0,75	81	131	31	79	112	46
11248	C	T	HELD_MAL_LIP	2,3	0,43	18	33	3	34	53	15
11248	C	T	HELD_ALL_CC	1,39	0,72	41	68	14	31	44	18
11372	A	G	HELD_MAL_LIP	1,67	0,6	20	25	15	36	31	41
11449	C	G	HELD_FEM_CC	0,6	1,66	31	6	56	22	10	34
11450	A	T	HELD_FEM_EFF	1,14	0,87	289	170	408	290	139	441
11470	C	T	HELD_MAL_LIP	null	0	20	40	0	36	67	5
11472	A	T	HELD_MAL_LIP	null	0	20	40	0	35	65	5
11472	A	T	HELD_FEM_LIP	0,63	1,6	83	158	8	80	158	2
11487	A	T	HELD_MAL_ADR5ULN	null	0	10	20	0	69	34	104
11487	A	T	HELD_MAL_ADR3ULN	0,48	2,11	27	6	48	69	34	104
11488	C	G	HELD_MAL_ADR5ULN	null	0	10	20	0	70	102	38
11488	C	G	HELD_FEM_UEFF	0,74	1,35	54	78	30	77	126	28
11488	C	G	HELD_MAL_ADR3ULN	1,73	0,58	26	44	8	70	102	38
11493	A	G	HELD_MAL_CC	1,18	0,85	14	6	22	18	6	30
11502	C	T	HELD_MAL_ADR3ULN	0,49	2,02	27	8	46	73	44	102
11502	C	T	HELD_MAL_ADR5ULN	0,29	3,45	10	2	18	73	44	102
11534	G	T	HELD_ALL_LIP	null	0	102	204	0	117	231	3

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
11537	A	G	CVD_FEM	0,65	1,54	36	52	20	39	68	10
11537	A	G	HELD_FEM_EFF	3,11	0,32	12	22	2	22	31	13
11560	A	G	HELD_FEM_EFF	0,04	23	12	2	22	22	44	0
11578	C	T	HELD_FEM_LIP	4,48	0,22	61	121	1	65	122	8
11578	C	T	CVD_FEM	0,42	2,37	30	57	3	39	78	0
11594	C	T	HELD_FEM_ADR3ULN	null	0	37	74	0	80	10	150
11594	C	T	HELD_ALL_ADR5ULN	null	0	27	54	0	151	20	282
11594	C	T	HELD_ALL_CC	1,53	0,65	45	10	80	41	3	79
11594	C	T	HELD_ALL_ADR	0,6	1,66	155	9	301	151	20	282
11594	C	T	HELD_FEM_ADR5ULN	null	0	18	36	0	80	10	150
11624	C	T	HELD_ALL_CC	0,85	1,18	42	57	27	40	60	20
11624	C	T	HELD_MAL_CC	0,85	1,18	13	18	8	18	27	9
11624	C	T	HELD_FEM_EFF	2,96	0,34	12	22	2	21	30	12
11627	C	T	HELD_ALL_CC	0,78	1,29	45	58	32	40	61	19
11627	C	T	HELD_MAL_CC	0,76	1,32	14	18	10	18	27	9
11627	C	T	HELD_FEM_EFF	3,11	0,32	12	22	2	22	31	13
11644	A	G	HELD_MAL_ADR5ULN	0,3	3,32	10	2	18	68	40	96
11650	A	G	HELD_FEM_EFF	0,9	1,11	291	157	425	290	181	399
11654	A	G	HELD_ALL_ADR5ULN	1,13	0,89	25	17	33	136	84	188
11654	A	G	HELD_FEM_ADR5ULN	1,14	0,88	15	11	19	71	47	95
11654	A	G	HELD_FEM_ADR3ULN	1,09	0,92	32	23	41	71	47	95
11654	A	G	HELD_ALL_ADR3ULN	1,21	0,83	53	39	67	136	84	188
11655	A	C	HELD_ALL_ADR5ULN	0,95	1,05	26	35	17	148	203	93

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
11655	A	C	HELD_FEM_ADR5ULN	1,1	0,91	17	23	11	80	104	56
11655	A	C	HELD_FEM_ADR3ULN	0,98	1,02	35	45	25	80	104	56
11656	C	T	HELD_MAL_LIP	0,53	1,87	20	20	20	36	53	19
11656	C	T	HELD_FEM_EFF	2,21	0,45	12	19	5	22	24	20
11656	C	T	HELD_ALL_LIP	0,8	1,25	102	119	85	114	156	72
11825	A	G	HELD_MAL_ADR5ULN	0,29	3,4	9	15	3	63	121	5
11914	A	T	HELD_MAL_ADR5ULN	0,1	9,58	9	2	16	69	83	55
11914	A	T	HELD_ALL_ADR5ULN	0,61	1,64	27	24	30	151	178	124
12008	C	T	HELD_FEM_EFF	0,73	1,37	278	529	27	277	541	13
12008	C	T	HELD_ALL_ADR5ULN	null	0	24	48	0	134	256	12
12097	A	G	HELD_ALL_ADR5ULN	2,46	0,41	28	6	50	155	11	299
12097	A	G	HELD_FEM_ADR3ULN	1,94	0,51	38	7	69	83	5	161
12097	A	G	HELD_MAL_ADR5ULN	3,04	0,33	10	3	17	72	6	138
12097	A	G	HELD_ALL_ADR3ULN	1,7	0,59	63	10	116	155	11	299
12366	A	G	HELD_FEM_UEFF	1,52	0,66	50	82	18	74	104	44
12366	A	G	HELD_ALL_ADR5ULN	1,23	0,81	25	40	10	151	229	73
12619	A	G	HELD_MAL_ADR5ULN	0,01	143	10	1	19	71	142	0
12619	A	G	HELD_ALL_ADR5ULN	4,53	0,22	27	2	52	151	1	301
13025	A	C	HELD_ALL_ADR5ULN	0,81	1,24	28	34	22	151	201	101
13191	A	G	HELD_FEM_LIP	0,72	1,4	83	42	124	79	62	96
13191	A	G	HELD_MAL_CC	1,94	0,52	14	11	17	18	5	31
13191	A	G	HELD_ALL_LIP	0,76	1,31	101	51	151	114	81	147
13937	A	C	HELD_FEM_ADR5ULN	0,53	1,89	17	19	15	83	122	44

BRAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
900002	G	T	CVD_FEM	1,48	0,68	34	23	45	40	15	65
900013	C	G	CVD_FEM	1,24	0,81	35	49	21	40	49	31
900013	C	G	CVD_ALL	1,14	0,88	104	150	58	74	97	51
900025	G	T	CVD_MAL	0,8	1,25	66	41	91	34	31	37
900032	C	T	CVD_FEM	1,68	0,6	25	47	3	37	65	9
900045	C	T	HELD_FEM_EFF	0,42	2,39	12	4	20	22	18	26
900065	A	C	CVD_FEM	1,97	0,51	32	54	10	39	50	28
900065	A	C	CVD_MAL	1,09	0,92	59	80	38	29	36	22
900065	A	C	CVD_ALL	1,24	0,8	91	134	48	68	86	50
900078	A	G	HELD_ALL_ADR3ULN	0,59	1,71	64	116	12	155	297	13
900078	A	G	HELD_ALL_ADR5ULN	0,44	2,27	27	48	6	155	297	13
900078	A	G	HELD_FEM_ADR3ULN	0,51	1,94	38	69	7	83	161	5
900082	A	G	HELD_FEM_ADR3ULN	0,72	1,39	35	25	45	74	70	78
900082	A	G	HELD_FEM_ADR5ULN	0,53	1,88	17	10	24	74	70	78
900096	A	G	CVD_ALL	0,79	1,26	101	157	45	72	125	19
900107	C	T	HELD_MAL_ADR5ULN	0,3	3,35	10	2	18	73	43	103
900115	A	G	HELD_MAL_ADR5ULN	0,34	2,98	9	6	12	72	91	53
900115	A	G	HELD_FEM_EFF	1,14	0,88	40	58	22	46	62	30
900121	G	T	HELD_MAL_ADR	0,88	1,14	66	47	85	67	56	78
900173	G	T	CVD_ALL	0,64	1,56	23	17	29	22	26	18
10000002	A	G	HELD_FEM_EFF	3,35	0,3	12	21	3	22	25	19
10000006	A	G	HELD_FEM_CC	2,77	0,36	31	58	4	22	31	13
10000006	A	G	HELD_ALL_CC	2,34	0,43	44	82	6	38	58	18

BAYSNP	ALLELE1	ALLELE2	COMPARISON	RR1	RR2	SIZE A	FREQ1 A	FREQ2 A	SIZE B	FREQ1 B	FREQ2 B
10000014	A	C	HELD_ALL_CC	1,69	0,59	45	83	7	39	64	14
10000014	A	C	HELD_FEM_CC	1,68	0,6	31	58	4	22	37	7
10000025	C	T	HELD_MAL_LIP	1,46	0,68	20	29	11	36	43	29

19 Aug. 2002

Claims

1. An isolated polynucleotide encoded by a phenotype associated (PA) gene; the polynucleotide is selected from the group comprising
5 SEQ ID 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103,
10 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168 with allelic variation as indicated in the sequences
15 section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.
2. An expression vector containing one or more of the polynucleotides of claim 1.
20
3. A host cell containing the expression vector of claim 2.
4. A substantially purified PA gene polypeptide encoded by a polynucleotide of claim 1.
25
5. A method for producing a PA gene polypeptide, wherein the method comprises the following steps:
30
 - a) culturing the host cell of claim 3 under conditions suitable for the expression of the PA gene polypeptide; and
 - b) recovering the PA gene polypeptide from the host cell culture.

6. A method for the detection of a polynucleotide of claim 1 or a PA gene polypeptide of claim 4 comprising the steps of:
contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the PA gene polypeptide.
7. A method of screening for agents which regulate the activity of a PA gene comprising the steps of:
contacting a test compound with a PA gene polypeptide encoded by any polynucleotide of claim 1; and detecting PA gene activity of the polypeptide, wherein a test compound which increases the PA gene polypeptide activity is identified as a potential therapeutic agent for increasing the activity of the PA gene polypeptide and wherein a test compound which decreases the PA activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the PA gene polypeptide.
8. A reagent that modulates the activity of a PA polypeptide or a polynucleotide wherein said reagent is identified by the method of the claim 7.
9. A pharmaceutical composition, comprising:
the expression vector of claim 2 or the reagent of claim 8 and a pharmaceutically acceptable carrier.
10. Use of the reagent according to claim 8 for the preparation of a medicament.
11. A method for determining whether a human subject has, or is at risk of developing a cardiovascular disease, comprising determining the identity of nucleotide variations as indicated in the sequences section of SEQ ID 1-168 of the PA gene locus of the subject and where the SNP class of the SNP is "CVD" as can be seen from table 3; whereas a "risk" genotype has a risk ratio of greater than 1 as can be seen from table 6.

12. A method for determining a patient's individual response to statin therapy, including drug efficacy and adverse drug reactions, comprising determining the identity of nucleotide variations as indicated in the sequences section of SEQ ID 1-168 of the PA gene locus of the subject and where the SNP class of the SNP is "ADR", "EFF" or both as can be seen from table 3; whereas the probability for such response can be seen from table 6.
13. Use of the method according to claim 12 for the preparation of a medicament tailored to suit a patient's individual response to statin therapy.
14. A kit for assessing cardiovascular status or statin response, said kit comprising
- a) sequence determination primers and
 - b) sequence determination reagents
- wherein said primers are selected from the group comprising primers that hybridize to polymorphic positions in human PA genes according to claim 1; and primers that hybridize immediately adjacent to polymorphic positions in human PA genes according to claim 1.
15. A kit as defined in claims 12 detecting a combination of two or more, up to all, polymorphic sites selected from the groups of sequences as defined in claim 1.
16. A kit for assessing cardiovascular status or statin response, said kit comprising one or more antibodies specific for a polymorphic position defined in claim 1 within the human PA gene polypeptides and combinations of any of the foregoing.

Single Nucleotide Polymorphisms sensitively predicting Adverse Drug Reactions (ADR) and Drug Efficacy

Abstract

EPO - Munich
67
19. Aug. 2002

The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes.

The present invention further relates to isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response, the polynucleotide is selected from the group comprising:

SEQ ID 1-168 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for PA gene polypeptide and with or without the PA gene promoter sequence.

EPO - Munich
67
19. Aug. 2002

Sequences:

SEQUENCE LISTING

<110> Bayer AG

<120> Single Nucleotide Polymorphisms sensitively predicting ADR and Drug Efficacy

<130> LeA

<160> 168

<170> PatentIn version 3.1

<210> 1

<211> 414

<212> DNA

<213> Homo Sapiens

<220>

- 2 -

<221> variation

<222> (137) .. (137)

<223> baySNP28_C137T

<220>

<221> misc_feature

<222> (229) .. (229)

<223> Unsure

<220>

<221> misc_feature

<222> (233) .. (233)

<223> Unsure

<400> 1

ggatcttaat tgcattgtcc ccagtgtcca gtgttaggaa aaagccgaaa gtaactccaa 60

caaaggagtc ttacactgaa gaaatagtgt ctgaagcaga atctcatggt tcaggtatctt 120

ctagaattgt gcttccyaca gaaaaaacta caggagccag aagaagtaag gctaaatctc 180

tgacagatcc aagccaagaa tctcatacag aagccacatc tgatgctgng acntaaagct 240

cagacatttc attctctgga attgcaacta gaagaaccag gagtatgcag aggaaattaa 300

aggcacaaaac tgaaaagaaa gatagtaaga ttgtaccagg aaatgagaaa cagatcgtgg 360

- 3 -

gtacacctgt gattcagagg attcagaaac cagacaaact tcccatttac aagc 414

<210> 2

<211> 641

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (464) .. (464)

<223> baySNP29_A464G

<400> 2

caaaaccgtg tgtgcaagag cgcgacctaa ggggacattc ttgtcgacgg tacaggaggg 60

tgggcagagt tagggcagga agtatctaca cacattctct acggggcagg tgacgcagtc 120

agatctcagt gttcagtttc ctggaggggg caaagtcttc acgcctaacc caaatgactt 180

cctcgcttgc gctctccagg cctccattga tccccgacag ggcagcttgc ttcttgagct 240

gtgccatgcg ggacgcgtga ctatccaggg ttttccggcc tctttcccgc tgactgatgg 300

aggtggcctg aagccgctcc tgcaggtctc tgtccactga ggcacccttc acggactcac 360

agaactcacc atcgctcactg aggatgtctg tctccttgat gtcactcttgc tcctcactac 420

gagcaagatc aaactgctcc tctacccacc ggtcagtgtc ccccccaccg gggggctgct 480

gggactcttt ctccgggctg cttgcggaga cggcatcaga atcaatggta aacctgtttc 540

gagccagccg ccgcctcctc ctcccaagag acttgcttgg ggcagacact gcacacacac 600

acaaaaatat aaaaataaaa cccccacatg ctttacgtga g 641

<210> 3

<211> 606

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (397) .. (397)

<223> baySNP_C397G

<220>

<221> misc_feature

<222> (513) .. (513)

<223> Unsure

<400> 3

ttgaggccag gagtttgaga ccagcctgga caacatagca agatcccacc ttagtccta 60

gatacttggg agagtgagga gggaggggta cttgagccca ggagattaag gctataatag 120

```

tgagggatga ttgcaccact gcactccagc ctgggcaaca gagtgagacc ctgtctctaa 180
aaaaaaaaaa aaattattaa aaaaaaaaaa gttttcttaa gagtccagac ttgtgaattg 240
ccagattagt gtaattttta aaatatgttt ctattataaa ttaccatac tcataaaaat 300
ataaatcaat ttattacacc ctctagaatt cactattaat tttcaacatt tttttcattc 360
tttttccatg catatttttt cacaattcta tgcatasttt tgcattataa aatatttttc 420
aatataaaat cttcttcaag gccaggcgca gtggctcatg cctgcaatcc cagcacttta 480
gaaggccaag gcgagcagat cacttgaggt cangaattca agaccagcct gaccaacatg 540
gtgaaacccc ttctctacta aaaatacaaa aattagccgg gcatgggtgg ggcgcctgt 600
aatccc 606

```

<210> 4

<211> 746

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (429) .. (429)

<223> baySNP56_A429G

<400> 4

```

tgattagcca ccttagttcc atctgcaact ttagttccca ctggctgtgt aacctaacat 60

```


agtcacaggc tctggggact gtcacgtgga catctttggg aggccgttat tctgcccacc	120
gcacctccg ttcaccccct gccctgccg gcacctcgct ctaccccagg aaaatgtgag	180
ctcgttttcc tgctcgcat gtgctcccc taaggctctg ctctccctg ggctgaaag	240
ttccttctca gcctgagagg gggcccttcg atctcaggca tgactcagcc cggctgatgc	300
ctctgcagtg ctgagtcagg atttggggcc ggctctcttg ggtctgtccc cttttccag	360
gtactgcctt acaaagctgt ggccaggaag tggccggtat aaaggatgcc caaggctctt	420
gtacgtgtrt aggagttagc gtgtttgata ttggtaatat aataataatt attttttaga	480
gtactgcttt tgtatgtatg ttgaacagga tccaggtttt tatagcttga tataaaacag	540
aattcaaagt ggctgtggag tgatttattt tgggagctgc acaatgatgg ggggcccagc	600
caggcagcct tagcagcttt ctgagcctct aggggtaccg gcaaacctac ctaaggctctt	660
tgtaatcccc agactgtcca agcccagagc acctcatgtg gttcagcagg agattgccc	720
catcctcaact ggagcagagc ttttga	746

<210> 5

<211> 1936

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (159) .. (159)

<223> baySNP89_A159G

<400> 5

tagttcaagg gtaaaggatc agaaaccaca gtgggaagga gtctcaccgg aggaccctcg	60
tcacctttct ctccaacttc accctgtgaa acatgagagt cagccctggg tccaagaacc	120
cccatgatgc tggcaacagc cctactccct taccgcctt gactcccccg actccagcct	180
cttacatctc gtccctgggg gccaacaggt cctggggggc caggccgccc agggctctcc	240
ttctctccag gaggccctga gtcaccctgt ggaggaggca agaggagggt gatgcaggac	300
gctcgaagca agcagttctc aaggggaggg gacccagaa gccttgaggt tgcccagggt	360
aacgggtact cactgggggt cctgctctgc cagtaaggcc aatgggaccc tgaaggggca	420
cagaaggggg gcaggactta gtcagggtcc caccacctca tctccctctg tcacactccc	480
cattcccaca ttgattcacc cggctctccag ggtctccctt ggggccaggg tctccaggaa	540
gaaccaagcc ggggtgggccc tgtggatgga aggataagaa gtcaggaaga caaccttcac	600
caactgcccc ctaaagagtc tgcttcactt acccggtccc cttggactcc ggtagctcct	660
ctgggcccag cgggccccac atctccctgg aggtgacaaa gaccatcagt gctagtccca	720
ggctccagtt aacccctgg cccagcaagt ctgtagcccc ccaagcccat agataggcct	780
atgaccatag cctcaaccct gtagaaacct cccctgcccc ataccaggct taccttttct	840
cctttgggtc cagcaacagc aggtccctga aaacaaacag ggacagatac agcttgagac	900
tgcttgagggt gtatggatca aagtcttctt ggaatggagg tcacatggaa ttggaagtca	960
tacagctcag tcccctccca gaagtcacag agtcaccgct gacagcaggg aaggggttat	1020

acaaaatgga ctgacacaaa gagctcatga cctgcatggc ggtcttgggg tcacaggatc 1080
 atagccaaga gtctgggggc aggttctagc agaaggagag gccagagctc cgcacctgct 1140
 cacgggcca gcaactgtgga atcacagccc agatagtgtt ctataggagg gtcactgctc 1200
 aagggtgtg ctgtgctcag agcgccatcc tcccgtcact caccaccact gcaggggtccc 1260
 cagggcgacc aggtccccc tgtggagaga ggataggagc agggacaggt cagggagtca 1320
 cctaggagcc caaaatccca gtgtcccatc tgccacatcc ctagtaccag acagtgccac 1380
 cccagccga ggaccacact tctctccttg gcggccagtg ggtcctgggtg gcccctgaat 1440
 gtagagaaag tgtgagcca ggaggggaag ggaaagggga gggacacaca aaagtccac 1500
 tcctgggtccc accacagtca cagactcact tcaggaccct tggctccagg acgtccagca 1560
 acccctggca gcccctggag gagaggaagg gaagagctgt gcaggtgggt ggggacgggg 1620
 gatatggaca gacagggtta gaggtctggg tgggggctgg agaggggtca gggaagattg 1680
 ggatttaggt tggcaggggt aagacttggc aggagaacag agaccaggtc agtgaaaatc 1740
 aaggtcagtt cagcagggtc agaggttcaa agccaggtcc ctggggctga gggtagagc 1800
 ctgtatcagc agggataagt ggtcattgag gaggggtgag gagcaggggt agcaggggtc 1860
 aagggaaga agtcagaacc agaaaggga cagccaggtc agctggtatg agcattgcag 1920
 ccagtgggtt tacccg 1936

<210> 6

<211> 578

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (154)..(154)

<223> baySNP90_C154T

<400> 6

tgtgttgctg ggccctgggtgc tgctgggtggt gctgctgctg cttctgaggc actggggctg. 60
 gggcctgtgc cttatcggtt ggaacgagtt catcctgcag cccatccaca acctgctcat. 120
 gggtgacacc aaggagcagc gcctcctgaa ccaygtgctg cagcatgcgg agagcccggg. 180
 aacgcacaaa gcgtgctgga ggccattgac acctactgcg agcagaagga gtggggccatg. 240
 aacgtgggcg acaagaaagg tgggggccgg gccagcaggt gctcagctct gggacaggga 300
 cccaggacca ggcaccaaag cccttacagg agaagctggt atcaccccggt ttccaggggg. 360
 ctgggaaccc tgggatatgc ccagataggg ctggggggct cctctggagt cccaggggtgc. 420
 cagggtcctt gatgaccctt gcaggccctg ctgcctgctg cccaagaca acaggccccc. 480
 aactcacag ggtctgacgg tgggtgcagtt ccccttgaac tctgttctgg gcaccatgga 540
 acctgcttgg ggaccagtca gacaggttct cctggggcc 578

<210> 7

<211> 224

<212> DNA

- 10 -

<213> Homo Sapiens

<220>

<221> variation

<222> (58) .. (58)

<223> baySNP99_C58T

<400> 7

agcctgcctg gtcactgact gcttactcta ccttagctgg acctcgtctc ccagggayta 60

gagaaaagag caggagtcct gggctcttccc agttgagact gctggagctg agacacagta 120

ctctcttaaa gaaggtgggg agctgcccag ggcagaaccc actgggtgttc atgactaccc 180

ctggctcctc tcaccttgtc cctccactgc caacagaaaa caaa 224

<210> 8

<211> 630

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (468) .. (468)

<223> baySNP140_C468T

<400> 8

ggatcttcac atcaggataa atggtgcttt cttttttag atgatgtaaa cttcacccctg	60
acatatctcc ttttttacac tgactgccat aaagcttagg acaaaatttg aagacagcct	120
tacaggggtca catgggtatct acttatctgt ggctttatct tctttgtccc catattctat	180
cccaattaca tagactcctt gttttatgcc ttataactt gagaaactgt ctcagatcct	240
ttgtattact gagtaagctg taaataaata caaatactaa ataaaaacta aaagttgcat	300
ttgaatttaa aattatatga gcatcttttt cttttaaaat taaaaaataa ccaggtactc	360
cataatattt tactatgtaa tttctcccat gattctgtat ttgtgttact tactttgagt	420
gtgtctctga cctgggctct gataatagga cccaaaatcc catcttcytc catattggga	480
ttcactgtat gtttggtgaa ggactcatct tcgtactgtg tgtacataac tttcttataa	540
tgttttccaa tttggtttga gaaattatcc aaatgctgag acctgtattt tcttaaagtg	600
aagtaaaaaa aaattaaacc actttctcaa	630

<210> 9

<211> 968

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (587) .. (587)

<223> baySNP152_A587G

<400> 9

```

tttccaggac ccaagacaga tgctgaagaa gacagcaggg accggagccc agcaaactgg      60
atgagagcag caaggccttc atgcatcttc aggtccatc agcagagggg gagaatgcat      120
tagacgggag tttcctgact cctatcttct aatgtggcag tcctaataag aagaggggtt      180
gaagcgctaa gatgtgctga cagtcctaata ggtttggtat gagtttctct agaaaaatta      240
aacactgaaa aacaaaactg cctccctccc tccctttgtg gttgctgaca tcagagggtca      300
ggaatataac aggctgctc gtcagccaag ctctccacga gagccctctg ttccagaaga      360
gcaccaaggc agtgacctca acatacttgg gcaacattcc ctttcttggt aaccagggt      420
gagaaggtag aaagaatgtc tccaggttat gcaggaagaa agctagaagg gggaggggtg      480
gatattaaag tttcagttcc cagggaaacc ggatgttaca caaaaagggc aaaaatagcc      540
aagaccaggg ggaagggcct gagcacagag gtgggagggt ccagccrgcg cctgcgagc      600
tggtgaatt acctccctct cctgggaggg tgacacacgc tcttggtacc attctccatt      660
aatcccattt tggaaattgg gaaagtacaa catgaatagt tgtcattatc ctgcctattt      720
cacagggttg gtcaggaagt aaaagaagac tgtgaatgtg aaatgctttc aaaatataaa      780
aatctcaaca taagttaact atactgaaat ccattaggac agaggttccc aaccttttag      840
gcaccaggga ctgggtttcag ggaagacaat ttttccatgg acaggagggt ggggatggtt      900
tcagaatgaa actgttccac cccagatcat caggcattag tttgatctc ataaggagt      960
aacaacct                                         968

```

<210> 10

<211> 709

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (209) .. (209)

<223> baySNP214_A209G

<400> 10

tggtgtggaa tgtccccct gccccataa ggtattcccg gcgtttccac aagactctaa	60
ggcgcttggg gccagactcc gatgtgcgct tcctcctctc ggagagtggc agcggcaagg	120
gggctgccat ggtgacggcg gtggcctacc gcttggccga gcagcaccgg cagatagagg	180
agaccctggc tcatttccac ctcaccaarg acatgctgct ggaggtgaag aagaggatgc	240
gggccgagat ggagctgggg ctgaggaagc agacgcacaa caatgccgtg gttaagatgc	300
tgccctcctt cgtccggaga actcccgacg ggaccggtga gggcctgctg ggggctgaca	360
tgctgtcct gtcctgcca ggaactgagc cgcagtgggg gaggttgat tcgccagtgg	420
atgccttcac actggtgatg cacgattttg ccagagctag aaactccctc acatctctgt	480
tttccatttt tattaactga tttgtcatgt gtgtgactca gggcagttta attttcttg	540
tcagacctcc caagcaagtg ctatctctaa aaccacagcc ctgctcagaa cagtgtctct	600

- 14 -

agctgggcaa ggtgacacac gcctgtcatc cagctactta aaaggctgag gtgggaggac 660

tgcttgagcc caagagttca agaacagtct gggcacatag caagaccct 709

<210> 11

<211> 674

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (339)..(339)

<223> baySNP221_C339G

<400> 11

aaaataaaat ttagattaat attccacaaa acagttttta agtattaaaa tttaaaatac 60

tatagtatag ctatagcagt gtactatata gtacaatgaa atatgttaca aaaacacagg 120

cttttaacaa agcacctaaa atctttttta tgccataatc ttttgacaaa atgccacctg 180

atgatattcc agcttctgag cctccagttg atcatgctga cggtgtagct cttctttttg 240

tttctgaagc tcattctgct tcttcttaag ttcattttct tgtaaagcaa taatattttc 300

atattctttt agttcttcct ctgtgaagaa ctgttgctsa tctaattgtct aaaagaaaaa 360

aaatgaggaa agaataatct caaaactaca acaataaagt ctgatttagc tttaaaattc 420

tatggttagc aaagtataaa agagtatcta taggattacg cctttggagg taagaaggaa 480
 ggggaaataa gtaatataa tttatgtact catttgaaca aaaggaaaaa caggaagaaa 540
 aactcaagag attctcttctt gggattgaca actaaaggca aagagtgaga actgggtaga 600
 agaggcaaag agaacgtggg aagagaaata aaatttgtca ttccccccaa ccctcactga 660
 aacatgaaat tttta 674

<210> 12

<211> 811

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (189) .. (189)

<223> baySNP224_C189T

<400> 12

ctgccagaga agcatcggag ggaattgagg tctgctcggc cgtcttcaact cgcccccgagg 60
 tttggcgggc caaggactgc cgaccgaggc tggagctggc gtctgtcttc aagggttac 120
 acgtggagga atgctcccc atcctcccct tcctgcaaa catgggggttg gctgggcca 180
 gaaggttgyg atgaagaaaa gcgggccagt gtgggaatgc ggcaagaagg aattgacttc 240
 gactgtgacc tgtggggatt tctcccagct ctagacaacc ctgcaaagga ctgttttttc 300

```

ctgagcttgg ccagaagggg gccatgaggc ctcagtggac ttccacccc ctccctggcc 360
tggtctgttt tgccctgaagt tggaatgagt gtggctcccc tctatttagc atgacaagcc 420
ccaggcaggc tgtgcgctga caaccacgc tccccagccc aggggtcccc cagccctgtg 480
gaagggacta ggagcactgt agtaaatggc aattctttga cctcaacctg tgatgagggg 540
aggaaactca cctgctggcc cctcacctgg gcacctgggg agtgggacag agtctgggtg 600
tatttatttt cctccccaca ggtggggagg gggtttgggg ggcttgcaag tatgttttag 660
catgtgtttg gttctggggc ccctttttac tccccttgag ctgaaaggaa ccccttttgg 720
ccccgagct gggggccatg agctcagacc ccacaaccc tcctataacc tcccctcctt 780
gccttctgtg taatcatttc ttgggcctc c 811

```

<210> 13

<211> 776

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (465) .. (465)

<223> baySNP294_C465T

<400> 13

tccatttgat tcttctgagc aggagcctct gccagacccc agcttttccc tacctcccct 60
 gaagtcagaa aaggaatgga ttacaggatt actcacctgt cgtgcggcca gaggcataga 120
 gggagagcac agcttgaatg ggcacgtaca tggcaggac attgaagggt tcaaacaatga 180
 tcttaaagga caatgaagaa taaaagatta tttggcaaaa atcacagcac ttcttggcct 240
 gtagaatggt ttgtaatctc attaagggca ggaactatgc cagtttgata gttcattatt 300
 ccacacccac tccccaggg cctggcatgg accacagaca tagcaggtcc tcagagagtt 360
 ctgttgcaact gatgtttgaa ggggagaaaag tatctggcca agcatccatg ttgcattctt 420
 atgccagtgt tcaagtcttc ctggcttctt acctgggtca tcttytccct gttggccttg 480
 ggatttaggg gagcctctgt gagcaggggtg ggggtgctctt caggtgctac acgcagctca 540
 ttgtagaagg agtggtgcca gatctagtgg agacaaaagc catatgagcc tggcagactc 600
 ccaatggctg gaaaattctc attgacattc ccatgctggg agagtgtggc accatgttac 660
 acaggatggg atggatctgg agaggagaat ggtcagccct ggaaatttct gattgacatt 720
 taaaggttat actccttctc acagggcccc agtaggactc agactggaac agtatt 776

<210> 14

<211> 1920

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (215) .. (215)

<223> baySNP307_C215T

<400> 14

atcccagtgt ctctgccagg gccaggctct gcccattgg gatcggaaat ctgggcagat	60
ttgggatcta gagcagggaa gtctcagggt tgaggcctga agtctagcat ggcacacagc	120
agggctgaga gcaaaaccca gggctctgtc tggattccca ggccagttac tgccctctctg	180
acccagacg gctcacctgt cgaatgggta cattygggaa cagcaccac tctacgaagc	240
caccatgaag acgaaagaga aaatcgtcta catgggcagt gtagaacggg cgcccggtga	300
gtgctcaggg atgacctcc tctgtagctg ccagaggcc aacaccgcc ataccatagc	360
cactgtcccc aagtcagcct ggagggaaga gagcaggta cactcacctg attctgatga	420
atcagctggc ctgggttatg cctctcaggg agaaaacctt tgagtccaca aaaccgcttg	480
tgaataccac tgcgtgtgtg taactgccgt agaacacaga cgcagtctgg agagcggata	540
ggtgctaagc accagtgaca ttctgaggtc atggcacgca tcacaatggg gccttgcccc	600
ggtcagcagg gccagagtc agggctcctc gctgcctgag gcgtcaacat gcctgcctgc	660
aatgtgtttg tgcacatgcg tgcacatgtg tatgtggata aacatgtctg tgcacgtgtg	720
tgttgcttct ctggccaggc ccggctgccc cactcatgtg tgcaccagc tcctcatcac	780
tgtaccccc ggagcccagg accagcttca gacctcctg acctcagccc tccccccca	840
gggtggctct gggatacaca taggagtgga gggaagtgac tgetgctgtt gaatctcaga	900
atacaaaagc taatactatt acttaatggg attttttagta tctctaatac tctttttagt	960
gtctctaata gttacacttt ttcatttctg atattttaac tgggtatttc tctccatgac	1020

ccttggatat tctagctaga ggatcatgtg cggaaatgcc aggcacacag taggggccca 1080
 ctctagacat gttatctaaa cctggctcag ctgtcccacc cagggcctag gggatgccaa 1140
 attccagggg ccagaagagc ttgggataaa atgaacatcc aaggggaggg ctttgacctg 1200
 ggtagtctg cctgtgccat ccaaacggag tctcaagtcc tgagacaggg cgtccagatg 1260
 cccagtgcag ggtccccctg atcaacacct gctccccctg actcattagc aacctcacc 1320
 acctactct caaagcactt ggccctcgta tctgggagct ctgcaactgt ggattcagcc 1380
 aacagcagat ggaaaatatt cagaaaacaa atcggatggg tgtctctact gaacatgtgc 1440
 agacgttggt cttgtcatca ttccctaaat acagtatcac aaccatttat atagcatctg 1500
 cattgtatta cacataatga ataatctaga gatgggtctaa tgtatacggg agaatgtgca 1560
 tagcttatat gtaaatacta ggtcatgtta tgtcagcgac ttgagcatcc atggattttg 1620
 gcatccccgg ggaccctaga actaatcctc catggatacc aagggatgac tatataaact 1680
 cactcaggaa ggcttctcac tggaggaagg gccagttca ggacacacag ggacatctcc 1740
 ctggactgct gtccattcat ccatccattc atccattgtc tccccgact ccccatctca 1800
 gactgtccca atgacagccc tagcaagaag agacaagaaa caagacaagt tcacgttgtc 1860
 cagttttgag gtcttgggaag aagttgcacc agtatgagaa tagtgggtca gttttctcca 1920

<210> 15

<211> 587

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (369)..(369)

<223> baySNP411_A397T

<400> 15

tggagcctcc ccataggcac tcggggcctc ccctgggatg agactccagc tttgctccct	60
gccttcctcc cccaggcatg gctggggact ggaagaccac cttcaccgtg gcgcagaatg	120
agcgcttcga tgcggactat gcggagaaga tggcaggctg cagcctcagc ttccgctctg	180
agctgtgaga ggggttcctg gagtcactgc agagggagtg tgcgaaatcaa gcctgaccaa	240
gaggctccag aataaagtat gatttgtgtt caatgcagag tctctattcc aagccaagag	300
aaaccctgag ctgaaagagt gatcgccac tggggccaaa tacggccacc tccccgctcc	360
agctcctcwa cttgccctgt ttggagaggg gagagggctc ggagaagtaa aaccaggag	420
acgagtagag ggggaatgtg tttaatccca gcacgtcctc tgctgtcctg ccctgtgtcg	480
ttgggggatg gcgagtctgc caggcggcat cactttttct tgggttcctt acaagccacc	540
acgtatctct gagccacatt gaggggaggg gaatagccat ctgcata	587

<210> 16

<211> 478

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (323) .. (323)

<223> baySNP449_C323G

<400> 16

gaattcttcc acgatcattg ctatctacca caaaaataag accctgggta ttctggaagt	60
aatgcttcca gagaggccta attctgtctt gaccaccaac atcccgtact gtgaaacaag	120
tggtcttata ctctactggt tccacgttaa aaccagtggg aggaatgggt gtgactatct	180
cccctaactt cagtttatac agaatgggtca tcttgccagc agcatccaat ccaaatagca	240
aaatgtgcat ttacttcttg ccaaagaagc aggagaagag ggaggagatg gtgaggccca	300
tggtggtagt gccacttgca atsagcagaa gcagaagcgg tttggggcag cccctgctt	360
tctccttacg tgctccaggc aaactgaaca agagagaaga gaaagagcgg aggaagaaag	420
agggaggcag gaacatctca ctggccgctg tgctaataa gctccaggac acgaattc	478

<210> 17

<211> 844

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (123)..(123)

<223> baySNP466_C123T

<400> 17

ctggccccgc tcttgggggg cctgcccagc ctccacccac ccctcaacc tccatggctg	60
atcttcagtt ctctcagctt ctgggggaacc tgctagggcc tgcagggcca ggggctggag	120
ggyctgggtgt ggcttctccc accatcactg tggcgatgcc tgggtgtccct gcctttctcc	180
aaggcatgac tgacttcttg caggtgagtg gctggcttgc cattcacctc atcttctgt	240
cccccgccc agccaggcag tggtagcttc ttgccattac ataaccactg ggtaagagcc	300
cctagtgaca tgtagggga aggggccctg ggaattcatt gactctgaac ctttcatttt	360
aaagatgaag aaaatgaggt ttagaaaaag aaagtatagt aattagtgtc actgctttct	420
gacaacctgt tcagaggaag aggtaggtaa gttgtgctgc ctgactctgt taaataccta	480
ccatacttct gctttaagca gtgaagatca gaatgtaact cccatcttc ccagaccgt	540
tggtttgtgc cctcttgatg cgtattatt tccgtgtgtc ttcattctca cctcactttc	600
tgttctttgt tctttcttta ttgcccaggc accaaaaaca ggccctttca ccaaccccaa	660
cctttttcac cccaccacc tgccccaga gcagcagaac catgccccca ccaggtccc	720
ctttttggtg gcgcagggga gtccctggagg cctgggtctt gaaaacctgt caccggagtt	780
ttttacttca gtggtgcaag ggtggcctca acttcctgct gggctccctg ggggcccggg	840
ctgg	844

<210> 18

<211> 561

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (497)..(497)

<223> baySNP472_A497G

<400> 18

```
ccaagaaaca agcatcaccg agggagcagg acgaggaggg aaggccatgc agacggcatg . 60
gggctggagg ggctgttagg tgaacagatg cagacaggta tggaaggcca ggcaggaagc .. 120
aagtgtaggg ccaggaagca taagtgggta actcagaaaa gctgtggcca ctgacactgg . 180
ggctgcggcc aactgacgtc tgctctgctc ttgcatctta catcctttgt tttggagttc . 240
cctgcatctt acatcctttg ttttggagct cccactggg tatgggagtc tcagaaccca . 300
cagggattaa ggagacaagt tttctctcca acttacaagg gatctcactt acccatcata . 360
cttctttttc tgggggtccgc caatatgggg cctccctaca gaacgctttt gatgtgctgg . 420
gcttcacttc agaggagaaa aactccatgt ataagctgac aggcgccatc atgcactttg . 480
gaaacatgaa gttcaarctg aagcagcggg aggagcaggc ggagccagac ggcactgaag . 540
gtgggaggca ggattcttgg g . 561
```

<210> 19

<211> 832

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (402)..(402)

<223> baysNP542_A402G

<400> 19

tgaggatcaa gtaacttgcc aagggtcacag agttcactta ctactcagtg agcttgggta	60
aatggctgaa ttttgctggt tcagttttctc cataataaaa ggattattat aataatacgt	120
aaagtgttgc tgacaagggtg aaatacataa tttcactttc tgagtactta agaacagtta	180
gctgttatta tcaagcaaatt ttgtatcaag tgttcccaca cattcagcca tgttgctgtg	240
gtactgcctg gcttgtatag gctgctggac aggcagaggc tcctttcttc taaaagccct	300
tggcagtcac attatattta cctgtcttct ggtattaagc cgtaatttgc atgattgagc	360
cagttgttta tctttcgtct catcaaccaa gtcacaattg grgttgggag ggaatttctc	420
aacatgttct gaaagcgtgt catgaacacc atgtcccatg ggtagcccgga gtcaaagatt	480
cggctgatca cccatccccc tccggtggtg ctgaggaaca cctggaagca atcaaagaca	540

- 25 -

```

tcccttcatt tgacactgtg aacacggctg gctgggttctg ccagagattc aagaagtgtc   600
atgaatggaa aggcactgaa aagtctgcac totcaaaata caccctgac aagatagtct   660
tggttcttct aacttctatt ttaaagttaa tccttttgag attaggattc agagcatcta   720
gagtattaaa atgccttaag acatattatt gatacttatt atctgccagc ctttagtaaa   780
ccatagggac cttaagtcta cgtaagaaac aatgaacagt gattgctact tg           832

```

<210> 20

<211> 988

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (87)..(87)

<223> baySNP739_C87G

<400> 20

```

ctgacggtcg accttggtat aatcctttcc tgaaaggcac ctcctccatg agcaccceaa   60
ccgccataag tgtccacaat gatttttscgt ccagtcaaac cagcatcacc ctgaaattac   120
aggatttaag ttactttacg cctagtgtt tccaagtgga ttaggttgcc tattctgaat   180
tcattcagca aatatcctcc gatgattcac atgtagggtt cagaaagcct gaaaaaaatg   240
tagtagccaa aattttaagt aaccatcaaa aatccagaaa aatgcaacaa aatgacatta   300

```

cctgaggccc accaataaca aaatctgcc	cttggctgta ggtggtagat tgtatcctca	360
tcaaggtatt tcgcaggcac aactgctttg	atgactttct ccttagggc atccctcatt	420
tcataagac aaacctcttc atcatgctga	acagatataa caattgtgtg gactctgatg	480
ggaagcacag cacctcgatc ctgcatatac	tgcacagtaa ccttgaaggc aacacaggtc	540
atcagaacat cacaccaaac aataactttg	tatttgtttc tctacctgaa gttacaatat	600
aggaaaacaa atgctatttt ttccagttag	ctattatcaa aattatggat cttctgtgct	660
gatgtaataa atgagacaac cagctttatg	atcatcactt acttgagttt tagaatcagg	720
gcgtacccaa ggcaaagtgc attacggcgt	aattctgcc gtttggcatt tagcttgtgt	780
gccaaagacat ggtaaaagca tacactcctc	agttcatcag tggcatagcc caacattaag	840
cctaagaaag aagtcaccat gtgatcaagc	tcgatttatg ttgagagatt aaacagcttt	900
acacaagaac tgcttcagac catgtctctt	attttgtcag atgacctgg gcaattttgt	960
gatgtggtcc aggtaccacg tacagctg		988

<210> 21

<211> 851

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (140) .. (140)

<223> baySNP821_A140C

<400> 21

tgtttctaga atttcaatca tttaagtaca cccacaaaac aagaatatgg agatcttctt	60
ttccctccaa tcttcttttc cctcgaactt taatttgccc agttataoct cagtgttgta	120
acagtgtctgt gatacctggm acagtgtttt aatctcatga taccctctgt actgacctga	180
aggagaccta agagtccttt ctctttttga gtttgaatca tagccttgat gtggtctctc	240
ttttatgtcc ttgttcctaa tgtgaaagtg ctttaactgct tcttccttgt attaggtagc	300
actgggataa gattttaact ggggtattctt gaattacttt tacaataaac caagtctata	360
atattaaaaa taaaaaagaa agaaaacaaa gccttattgc tgggtatggag aaagtttaag	420
tgggtctggac agaagaccag gccaaaccaca acattccctt aagccaaagc ctaatccgta	480
gcaaagccct aattctcttc aattttatga aggccgagag agataaggaa gctacagaag	540
aaaagtctga agtttagcata gggttggttca tgagggttaa gaaagaagac atctctatga	600
tataatagca caagatgaag ctgcaagttc tgatgtagaa gcttcagcaa gttatccaga	660
aaatctggct tagatcattg atgaaagtgg ctatgctgaa caatggactg tcaatgtagg	720
tgaaacagcc ttctattgga aaaagatgcc atctggactt tggatagaga ggataagtca	780
tgcttggtt aaagctcaaa ggaggcagta cagtggctca tgctgttat ccacactttg	840
aagatgaagc t	851

<210> 22

<211> 880

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (257)..(257)

<223> baySNP1005_A257G

<400> 22

tgaatggagc tgactccatc cttgaaatgt gtgagcctct cccctcccc actctaccag	60
cccttgccctc ttcttgccct gggcagcttt tgtgtcttgg gagccaacca gaactcaggc	120
taggtgctaa ttaaaagcta cctacctcct ttctgcagag gctgagcccc tccatttgca	180
cacagccctt gtctaccatt gctagcctca ggcaaagac tccacttctc tatgcctcag	240
tttcttcac tgtaaaarcag ggctaacatt tcctgtcttg cctcccttct ggggtgtcac	300
aaggtttaaa ggacacatgc tgtgtatatg tagggctgca gacatgagga gtccctggacg	360
atgggcaata gctgccctcc tcagaggctg tggggcacta tcctgggatg ggtagaagtt	420
gacaatacat agctggggac agcttgcatg gatgggggca gaacgaggag aggaatgggg	480
ggagcatgtg ggcccaagtg tctgttttgc tgattgctcc ttttgctttc aaggagatta	540
aactatTTTT agtctgcgct actgctgggtg agacgccgga ggaagccttt ccatcgctga	600
gatcttctgg aagctgccaa gtgtgggtctt cagctcgatt ctgggagcct ccagagcag	660

gcgggagggg tgtcaccatc tgggggctgt ggggacaggc tgggtgtgtgc ttgctccctg 720
aggtcctttt gtgcgctggc ctccctgagc cgtgtggccc tggcctgcag agaacagaat 780
ctgatcaccg gatgttggac gctgtgttaa aaaaagaatt atttctaata ttccttgctg 840
cataccggca tcgcaagtgt cgctattaat attatctctc 880

<210> 23

<211> 550

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (287)..(287)

<223> baySNP1055_A287T

<400> 23

tgcaaggagg attcatccgg caaccagttg aggctagatt ctcagcagct ttattgaata 60
ttgagaggtg gtctcacctc cactggaca tgtgtcctca agttcatacc agaacttctt 120
tgggacagac agacagacag gtggcagggc agggcaggtg tccacgaggg tggggccagt 180
gcaccagggg cagctcagct ctccaaaggg gccagcatct gcacctgctc ctgctgctgc 240
tcctgctgct gttcctgctg ttgctccagc tcaggagagg agagagwctt gtcctggctc 300
tctttctcct tgaagggtgct gaagaaggag ttgacctgtt ccctcaggtc cttctccagg 360


```

aagctcaagt ggccttccac gtcccccgca tgggggcccc gtttctgcct gagctgttcc 420
atctgctgca ccagggcctt gttgaagttt tccccgtagg gctccaccg gcgtcggaac 480
tcctccacct gctgggccag gtgcccaccc agctctgcca gtgacttctg cagcccctcg 540
gtgttgcccc 550

```

<210> 24

<211> 668

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (354)..(354)

<223> baySNP1056_A354G

<400> 24

```

agcctgtctg tcttgtctga atgtgggaaa ggacaaggga ccacctaggg taggactcac 60
aggcttggtc aggccgagag ggggatccag ggtaacagca tcagtcctg ctgtgtccca 120
gattccaggt ctgaggcagc gagtaccact gggatccata gctccggctg gaagaggcag 180
gccccatca caggacttct gcaccagcca tgcggggctc agtccaggca gtcagcacct 240
accctgggca ggcaggggtg ggtgccagcg tctccaccct gtgggctgac ctgcatgtgt 300

```

gtctatgtgt ctgtgtgtat gcacgtgcgt gatctgcccc ctgcagccaa acarcaggac 360
 ggggcagccg ccatggagat gcagcccctc aagagtgccg agggcggcga cgctgacgac 420
 aggaagaagg ccagcatgca caagaaggag aagtccgtgc tgcagggcaa gctcaccaag 480
 ctggctgtgc agatcgggaa ggcgggtgag tgcagcatgt gggaggcagg ggacagggct 540
 cacaggggga ccccaggcag agccctgccc catgctcggc ctcagttacc tcatctgcaa 600
 agtggggggc ttgaatgagt gcctgaagcc cacctttttt taccacagca ccagttctga 660
 gtcctgtg 668

<210> 25

<211> 789

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (257) .. (257)

<223> baySNP1085_A257G

<400> 25

ctggtggtgg ccgacaatca ctgtagtctt ggtgcccata cgaacagaat agatggggcc 60
 atatTTTTTt tgcaggcttg aagaagttgt tatgcatatg gccatgtctg gggaggaatg 120
 gcaggctgcc caccaggggc agggacagga ggctcttggg gtacttggca ccagggcacc 180

```

ttctcttggg ccaaaacaaa taagctaggg taagcagcaa gagagccacg agctcccaca 240
tggtggctgg gtgccggcag gcaagataga cagcrgtgga gtagaagagc tgtggcaact 300
ctagggcaca aggaggcctt ttaaagggtt accctgatct tcaccttgac tttgtgttat 360
ctcttgccct gtggaaagat tctcctggag ccagccagg cctgagctca tatccagaag 420
ggagagaggc ggtgggagtg aaggcctcct caagggtctg ctcaactcca gggcaaact 480
ccggaggagg agctaggtaa gggaggtcag ttgatcacc cctgaggagc tccccatgct 540
tgaatgactc cagagtgcga atggtatctg ggctcaagag tcaaggcttg gaactttcca 600
tgctgcaaaa tcaaaatcac tggacagatg acagattcag gagggtcaca agtagcaggg 660
actgttaaag gacttttatg cttctttttt tttttttcag agtctgctcc atcaccaggc 720
ttgtgtgcag tggtgtgact gtccatgcag ccctgaccct ccagcccatt gtggttttgc 780
agcgataag 789

```

<210> 26

<211> 789

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (104) .. (104)

<223> baySNP1086_A104G

<400> 26

ctggtggtgg ccgacaatca ctgtagtctt ggtgcccata cgaacagaat agatggggcc	60
atatttttttc tgcaggcttg aagaagttgt tatgcatatg gcortgtctg gggaggaatg	120
gcaggctgcc caccaggggc agggacagga ggctcttggg gtacttggca ccagggcacc	180
ttctcttggg caaaacaaa taagctaggg taagcagcaa gagagccacg agtccccaca	240
tggtggctgg gtgccggcag gcaagataga cagcagtgga gtagaagagc tgtggcaact	300
ctagggcaca aggaggcctt ttaaagggt accctgatct tcaccttgac tttgtgttat	360
ctcttgctt gtggaaagat tctcctggag ccagccagg cctgagctca tatccagaag	420
ggagagaggc ggtgggagtg aaggcctcct caagggtgg ctcaactcca gggcaaacct	480
ccggaggagg agctaggtaa gggaggtcag ttgatcacc tctgaggagc tccccatgct	540
tgaatgactc cagagtgcga atggtatctg ggctcaagag tcaaggcttg gaactttcca	600
tgctgcaaaa tcaaaatcac tggacagatg acagattcag gagggtcaca agtagcaggg	660
actgttaaag gacttttatg cttctttttt tttttttcag agtctgctcc atcaccaggg	720
ttgtgtgcag tggtgtgact gtccatgcag ccctgaccct ccagcccatt gtggttttgc	780
agcgataag	789

<210> 27

<211> 1756

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1687)..(1687)

<223> baySNP1092_C1687G

<400> 27

tgagggaatg ggggagctga gacgaaaccc ccatttctat tcagaagatg agctatgagt	60
ctgggcttgg gctgatagaa gccttggccc ctggcctggt gggagctctg ggcagctggc	120
ctacagacgt tccttagtgc tggcgggtag gtttgaatca tcacgcaggc cctggcctcc	180
accgcccc accagcccc tggcctcagt tccctggcaa catctggggg tgggggggca	240
gcaggaacaa gggcctctgt ctgccagct gcctccccct ttgggttttg ccagactcca	300
cagtgcatac gtgggctcca acaggtcctc ttccctccca gtcactgact aaccccgga	360
ccacacagct tcccgttctc agctccacaa acttgggtgcc aaattcttct cccctgggaa	420
gcatccctgg acaattccca aaggaccca gtcactccag cctgttggct gccgctcact	480
ttgatgtctg caggccagat gagggctcca gatggcacat tgtcagaggg acacactgtg	540
gcccctgtgc ccagccctgg gctctctgta catgaagcaa ctccagtccc aaatatgtag	600
ctgtttggga ggtcagaaat agggggctcca ggagcaaact cccccaccc cctttccaaa	660
gccattccc tcttttagcca gagccggggg gtgcagacgg cagtactag ggggcgctcg	720
gccaccacag ggaagctggg tgaatggagc gagcagcgtc ttcgagagtg aggacgtgtg	780
tgtctgtgtg ggtgagtgag tgtgtgcgtg tggggttgag ggtgttggag cggggagaag	840

gccaggggtc actccaggat tccaacagat ctgtgtgtcc ctctccccac ccgtccctgt 900
 ccggctctcc gccttccccct gcccccttca atattcctag caaagaggga acggctctca 960
 ggccctgtcc gcacgtaacc tcactttcct gctccctcct cgccaatgcc ccgcggggcg 1020
 gtgtctctgg acagagtttc cggggggcgga tgggtaattt tcaggctgtg aaccttggtg 1080
 ggggtcgagc ttcccccttca ttgcggcggg ctgcggggcca ggcttcactg ggcgccgca 1140
 gagcccgggc ccgagccgcg tgtggagggg ctgaggctcg cctgtccccg cccccgggg 1200
 cgggcccggg gcgggggtccc ggcgggggcg agccatgcgc ccccccttt tttttttaa 1260
 agtcggctgg tagcggggag gatcgcgag gcttggggca gccgggtagc tcggaggtcg 1320
 tggcgctggg ggctagcacc agcgctctgt cgggaggcgc agcggttagg tggaccggtc 1380
 agcggactca ccggccaggg cgctcggtgc tggaaattga tattcattga tccgggtttt 1440
 atccctcttc ttttttctta aacatttttt tttaaaactg tattgtttct cgttttaatt 1500
 tatttttgct tgccattccc cacttgaatc gggccgacgg cttggggaga ttgctctact 1560
 tccccaaatc actgtggatt ttggaaacca gcagaaagag gaaagaggta gcaagagctc 1620
 cagagagaag tcgaggaaga gagagacggg gtcagagaga gcgcgcgggc gtgcgagcag 1680
 cgaaagsgac agggggcaaag tgagtgcct gcttttgggg gtgaccgccg gagcgcggcg 1740
 tgagccctcc cccttg 1756

<210> 28

<211> 565

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (454)..(454)

<223> baySNP1096_G454T

<400> 28

cagctggaga ctgaccgagc cgggcccttc cctccagccc caattcctgc acaagccctg	60
ctattcctcc tgatggcaag aggaccgggt ggactcttgg ccatgatgac tctgttctctg	120
taccagtctg ctccgttccct gaggacccta actttttctca gcggaagcag gaagacctga	180
ccatcttctg ctattgctga ggaggagcag ctctctctgt aagaccccag gtgggcaccg	240
agtgggggaa agcccgcgtc cggatgactg gtcttatgag aggggagagg tttttcagtc	300
atcacctgctc ctctctcccg cctttttcttc ctagcccaaca gctcagttac atctgagaga	360
gacaaggccg agaaggagct gagggggccc ccggcttacc ttctgctgta gtaccagaa	420
caacggcagc ttcttccccc ggccgggtca cgakgcccta tttatagctg aggggtgggg	480
atggagctgt tcccaggctg cctgtgcaca ggctggagag gagggttaca tcaottggcc	540
agaccacagg ctggccagaa ggaca	565

<210> 29

<211> 842

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (249) .. (249)

<223> baySNP1101_C249T

<400> 29

ctgctgcatc ttctcattgc atcctcattc catttcaggt taaatTTtTgg tgttggactc	60
cttagaattc tacctacagc atctctgaca aaagcccgcc aggetccgct tgactctctg	120
cccggTgcgc tgtcagatgg cgccaagccc aagctctttc ctttgcTtcc tgtagaagcc	180
cgtcctagag ccctgggctg tgaggaggag cagccccaca gggTcacact gTccttttcc	240
cttgCagayc ttggcaccg ccatcaactg gttgcTttt ctcaacacca tcttctaccc	300
cgtggagatc aatgaatccg agcctattgt ggtctatgac aaggaatacc ttgagcagat	360
ctccactctc atcaacacca ccgacagatg gtaagaggac cccagTggc ctggggcagc	420
cctctcacag acagccctct tcttgggcag gtgggcaggg gtggggatga cagtctgact	480
caggagagtg ggacctgggc gggctttttac gagaggcagc aggacatcct ggTtacaggc	540
acaggTttaa atcccagcct ctttcaaact accagctttg tagccttggg caaatttcgt	600
aacctttctt aagttcattc tcctccttca taaaatggtg atacaaatat cacctgtggc	660
cgggcatgaa cgcccgtaat gcgggacttt tgggagacag aggcaggagg atcccttgag	720
tcctctgcgt ttgagacca gcctgggcaa catggcgaga cgtgtctcta caaaaaataa	780

aaaatagcca gacatggtgt cgcgtgcctg tcacccagct cttgagagag gaagctgaag 840

tg 842

<210> 30

<211> 656

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (307)..(307)

<223> baySNP1204_A307G

<400> 30

gtgccaaagg acacgactat gcggtacagc tccaccagct tggccttctc cgtgccgttg 60

gcgtggaagg gcgggaagtc cgtcacgttg gggccacata gcttgctccag gttgttgggg 120

aacggctccc cctgggctgt gtactgaggg gcagaagggg ggtgacgtgg gagtcagggg 180

tcagtgtccc agccctgccg ccaacccttt gggcaagctc ttgcgtctgt ttccccatct 240

agcgcatgag gacccaactc cttgcctgt aagcatctgg aattgtcatg agagccaaaa 300

ctaattrtaa tgtgagtgcc cttgctaaag atcaaagact gagccatgca cgcagtcac 360

attatcatca tcatcatcat caccacccta aggggacaga agggaaaact cgggtgtctag 420

ccctagctgg ggcaccacac acaagtactt ccatccctgc actcacaatg ttccgggacg 480

ccccctccatg cccagcaccc acagcccact gcctctcaac cgcctctccc tggcgcctca 540
cgcccatctc cctccatcc ctgctccct gcagcaggac aatcacaaga taagaagtgc 600
caggtcccca cctttgcaact cagttctccc cttgctaact gggcaccctg gggaag 656

<210> 31

<211> 615

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (180)..(180)

<223> baySNP1504_C180T

<400> 31

atgggcaaaa ctgggggtca ctggtctcat gctccaaggc cccgtgagca ggccaggtgg 60
ggggatccct gggggaagcc cctcaccctt ctccaacccc cagccttcgg ggagcccctg 120
ccctccaggc cctgtgctca gaggtggggg gaggacggct cagtgacttt tggttcccay 180
gaccttgaca gagacaggga cctcgacgca tcctccatac ccgctgcggg gaaatggacc 240
ccaccagcca gcacgggggtg agttgggggc cagtccctgc agagtgtggg tgtccacaga 300
gggtctcttc tgcagtggcg gatcggggcg cagcagggtc ccggcctcag tgetgcctgt 360

gcgggagagg gtggcctgtg ggcagggctg gagctgcccc acagccgcgg gctctgcctc 420
 acgcccagtg ggtgccccgt gatgtggcag ggctggcctt gagtttcctg cttctcacga 480
 gcctggcacc gccaaagcca ggccccctctg gcccatctcc acaacaccct gtgtggccgc 540
 cacttggggc aggccctgtg ggccccaccc agcctggctg aggggcggtg gagagtgtcc 600
 gcctggacgg tgagg 615

<210> 32

<211> 527

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (153) .. (153)

<223> baySNP1511_G153T

<400> 32

cagaaactgt agctggcggg cctcgggtct gtggacacca gttctccctc ctcaccagga 60
 actgggggtc ggggagcatc ttcggtgaaa cttgctccga ggtccaaggg gaaaccctgc 120
 tcttgatat tcattttggg actctgcgtc aakgaacaat gagcgctgca ccctaataca 180
 tcagtactta cagctccaaa gtgaatcaat ctgtcctgtt gaaaccatta agaggacaag 240
 gattaggaaa ggtgggtcca tgaaacacga ccagaggttt tctcaagaca agactcacga 300

tgacgcctc ccgctcaaac tcaaagcaag aaactcagtt taaatgttca atcaagatat 360
 attttggcca caagcatagt tctactttaa agcaatttct ggaaactttt acaactacag 420
 gaatgcctct catgctaaga agggatgccc aggacatggg aatgccactc cccacaagtc 480
 tcaactgcaca aacatcacgg aggctggcag cttgagcacc tcccacc 527

<210> 33

<211> 663

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (284)..(284)

<223> baySNP1524_A284C

<400> 33

ggtgtggtgg cacatgcctg taatctcagc tattcaggag gctgaggcag gagaattgct 60
 tgagcctggg agacagaggt tgcagtgagc agagatcgcg ccactgcact ccagcctggc 120
 cgacagagcg agactctgtc tcaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agaaaagaaa 180
 agaaaagaaa aaagaaaagg aaaaagaaaa ccagaagtag gagcagcctg aagaaatgac 240
 agggagttga tttcccactg ggagccctct caaagcccac acamccgcct gcctggggta 300

- 42 -

```

acagtatctc ctcggacatc ctgcacctc ccacgctccc cctccctac agtagtgaaa 360
gacctaggca ggatgacccc agctcctctg tgagaatttc acaccctagt gtgaagtcac 420
agccttgtaa ctttcccttt aagaactgtc agagctgggg aggctggcca agctcaggct 480
ggaggtgggg acagagggaa gaaagaaaaa aaaaaaagag agagaggcag gaaaagtttt 540
ttcagaggaa aatgcagggt ttgtccttca cctgacgtc agatcttgct ttataaaaac 600
ccccaaggct gcggagaagc atatctggtg ctctgatgg gcggccagtc tgggccagc 660
tcc 663

```

<210> 34

<211> 609

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (367)..(367)

<223> baySNP1556_C367G

<400> 34

```

ctttagatca gagtattcag aagggttata actccgtcag tcatttacat gttagtagta 60
taaattatct gagcttcctg ttctaacttt tagctcttct agcataaact cttctgtgca 120
atttagctgc accgaggaaa cgggagtttt tctggaaggg acttttgatc tctttagact 180

```

gagggaaacgt cctttgggag tagaggggca gggagcatac gcaagggatt ccaggtgcag . 240
 gtaaaaggtg gcactagttc aaggttttgc tgactcagtc tggtagtcag agtctgcagg 300
 agaagacagt tcaaggcagg gcctggagga ttggatcagt ttagggacag gtcaaaggct . 360
 ggcttasaga ccttagaggc aggttgcttg ggtcgttgaa tgctagtctg gtgctgagag . 420
 cccttttctc tggcaactgt ggactcagag ctaaccaatt gtagttggca gtgggggtga 480
 agggatgatcc agaggcctga gctgcagagg gcacaagaga gaaaagatgt cttagaaaga 540
 gctttgagaa catgccttgg ctgctggcag ggaccttgga tggggtagtc tacacccgga . 600
 agtgccctgc 609

<210> 35

<211> 740

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (699) .. (699)

<223> baySNP1561_A699C

<400> 35

tcaagcacct gcctctacag gtacctttct tgggaccaat ttacaatctc tgggatcccc 60

aactatagaa cctggaagct agtggggaca gaaagacggg gagcctgggc taggtgtagg	120
ggtcctgagt tccgggcttt gctacccagc tcttgacttc tgtttcccga ttttaaata	180
gcagtttgga ctaagccatt ttttaaggaga gcgatgggga gggcttcccc cttagcacia	240
gggcagccct ggccctggct gaagcccaac cccaacctcc aagactgtga gaggatgggg	300
actcatccct ggaggaggtg cccctcctgg tattgataaa gaatgccctg gggagggggc	360
atcacaggct atttgaacca gccctgggac cttggccacc tcagtgtcac tgggtagggg	420
gaactcctgg tcccttgggt atatggaagg tatcagcaga aagccagcac tggcagggac	480
tctttggtac aataccagc atgcatgctg tgccaggggc tgacaagggt gctgtccttg	540
gcttccccat tttggagtgg tcacttgccct ctactccagc ccagaagtg gaaactgaga	600
tgatgtgtgg aggagagagc cagcgttcat gttgggaatc ttgaggctcc tttccagctc	660
tcagattctg tgatgctcaa aggggtgagct ctgtgggcmc aggacgcatg gtagatggag	720
cttagtcttt ctggtatcca	740

<210> 36

<211> 1181

<212> DNA

<213> Homo. Sapiens

<220>

<221> variation

<222> (389) .. (389)

<223> baySNP1582_C389T

<400> 36

ataaccacac ttttctgaaa gggagtagaa ttcaaggtct gcattttcta ggtatgaaca	60
ctgtgcatga tgaagtcttt ccaagccaca ccagtgggtc catgtgtgtg cacttccggt	120
ttgagtgcta gtgagatact tctgtgggtc tgaattgcct gactatttgg ggttgtgata	180
ttttcataaa gattgatcaa catgttcgaa tttcctcccc aacagtcttc cattaccaag	240
taaagattca ttttctctggg actgagagtg aaaccctaac caatcaggcc tttgagattt	300
ctctgtatgg caccgtggcc gagagtgaga acatcccatt cactctgtga gtagcacagg	360
ggggcggtca tcatggcacc agtccctcyc ctgccataac ccttgggtctg agcagcagaa	420
gcagagagcg atgcctagaa aacaagtctt tagttaaaaa aatcagaatt tcaaaattga	480
ggtcttttct ctatttgata ttgagaaaaa aatgcttcaa attggccatt ttattttcac	540
ttactagtta tattttttta tttatcatct tatactctgtt tatttctttt ataaagctgc	600
tggttaaaca tataattaaa ctatctcaaa aggtttgaca ttaaagaaaa tgagcaatgg	660
taacaggaaa ccactctata gatgtacata taatatgtac agaaaatata agtagtaaga	720
agtccatgac aaagtgttag ctcttttttt tttttttttt tttttttttt ttgagatgga	780
gtctctctcc tattgcccag gctggagtgc agtgattcga tctcagctca ctgcaacctc	840
tacctcccg gttcaaaca ttcttctgtc tcagcctccc gagtagctgg ggctgcaggt	900
gcccaccacc atgcccagct aatttttgta tttttagtag cgacagggtc tcaccatggt	960
ggccaagctg gtcttgaatt cctgatctca ggtgatccac ccgcctcggc ctcccaaagt	1020
gctgggatta caggtgtgag ccaccatgcc cagcctaccc tttactacta atcaaagaaa	1080

- 46 -

taaaagtaag gcaacttgat actttttacaa ttactagatg aacaaatctt taaaaatagc 1140

cagtgcagac aaggtggtga agcagaacat gcgaacctac c 1181

<210> 37

<211> 531

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (443) .. (443)

<223> baySNP1638_A443G

<400> 37

aactcggtgc cctgcaacac accccagttc tagacagcgt ggtggaggag acgctgcggc 60

tgagggctgc acccaccctc ctcaggttgg ttcatagaaga ctataccctg aagatgtcca 120

gtgggcagga gtatctgttc cgccatggag acatcctggc cctctttccc tacctctcag 180

tgcacatgga ccctgacatc caccctgagc ccaccgtctt caagtacgat cgcttctca 240

accctaattg cagccggaag gtggacttct tcaagacagg caagaagatc caccactaca 300

ccatgccctg ggggttcgggc gtttccatct gccctgggag gttctttgca ctcagtggag 360

tgaagctctt tatcctgctt atgggtcacac actttgactt agagttggtg gaccctgaca 420

caccactacc ccatgttgac ccrcagcgct ggggttttgg caccatgcag ccagccacg 480

atgtgcgctt ccgctaccgc ctgcaccta cagagtgagc ttggccaagc c 531

<210> 38

<211> 711

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (648)..(648)

<223> baySNP1653_G648T

<400> 38

ttcagatttc accaattgag aattagtaag taattttctt gatacaggcc tgaagtttac 60

cttagtaaac actttacttc catatggtaa aaattagatt ttgggaggaa tgcttacctc 120

ctaaatatat tcaatctaata atttgaggac acatgggaat atatttatga ttcattctgct 180

ttttaaacat aagcctttgt taactgtaag ttcttgaact ttataaggct gctgttattt 240

aaatgagcac agctcctgat ctgcaaacag cagagcgcag ggctacagct tgggggatgc 300

cagccgactc aggggtgtcc tgtggactga acaatctctt gctgctgtac tggagggcct 360

gggagctttt ccattcagcct cggcctgagg tgtgcactct tctcctgccc accccaggaa 420

taaatgagat tcttggttaa aaaggaccag agcagtcatt ttacagttga ggaaactgtt 480

gctctgagaa gtgagggatt tattcatgac tacactgatg gtgagtgcc atgtcaggtc 540
 tggaaccaaa gtctaccag tatccacaca ccaccatccc tcaggtggct ctgccacagt 600
 ctgatgggag gctccaaagc gggaggaaga aggaaagtct tgcccackgc atctcctcag 660
 ttggccttcc tctctgcctg ttttccctcc ctacagttag catcttaagc a 711

<210> 39

<211> 2438

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (398)..(398)

<223> baySNP1662_C398T

<400> 39

catgcccattg accctgccag ctgacaattc taagcatgcg caaactggcc ccaaaaattc 60
 ctcccacatt tccgaagaac tatttggccc tttatgtgaa gtacctggtt tttccatttt 120
 ctgttttacc ataggcctca gttcgggtgtg tggcgtatatt attctacatt taacaatttg 180
 aagatcattc tattagatta aaaaaaaga atacaatgga agccaagtga ttaagctttc 240
 cttatgctta tattaagttg tagcatatgc atttaccgat agttaaccgt attaacctac 300
 agaaaatgtc cagggaaatg gtctattttct tattctatatt ttgacctaaa gaaaatcttt 360

aaaatgtctt agcattttcc ccagttctcca tccacttycc tcagcttttg cctgaagcta	420
tcttttaaagg taccctgtac agctcttgcc ctgtacagct agctacagag attcaatcct	480
ttctgttcga ttaggcacaca tctcagtggc agataacatg caaagttatt atatgtatga	540
accagaactt gtttttcctt agggggccagg atgttacact aaggtcttaa gactatagta	600
atatcttcac ttgaaaaagc cctctattat tcctatctca gatgataaaa attcaattaa	660
gagaaataag aacgtgacat gtgtaatcgc acctggctct acaaagctag tctggacaga	720
catttaaaca attatcctct aagattatct gatgaaatgc atttcaatga ctagttaacc	780
attaaaaacc aaagtgcgca tcccatctgt tcccagtcga atgacctaga gcaaaggact	840
aggcaaacca catctgtggg catagcaagc tgtacatcac aaacaaatga atttgctttg	900
tatatgagtg agagcaaaca ctctttattg tacaacttgg gtgggtaagt agggagaata	960
atggttttac tgaaatcgca ggtaacgggt acgttggagt taaaggttag gaagaaaacc	1020
aaagggtgag agctgttggt ctgggctggc attgtcaatg aagagcataa attcagatgt	1080
gaatgtatat tttgtagaag catgtgtggt gttggttttt gtgtatgtgt gagtctgaaa	1140
gagggaaaac aggctcccat tagactatga ctaacaaaaa tgtttgacag attataactc	1200
agatgtctta ctcagagcat atgccttccc attttccca ttattccca acatgatgtc	1260
tttaagaact tgtccttgac cgagcagaca tctcatccc caaatagcta atattttgat	1320
agctatgatc ctgaacggcc aaacattcca aaaccaagta gtttgtaata tctttaaatg	1380
caaatatatt ttaggccttt tccttgcaa ggatgtttg tcaggggttg gcaaaaataa	1440
tgctcttcag acttaaaaga acacaacat atttcttagc catccaccag aaagtagtag	1500
aacgtctcag gaagcaagtc tttgtcagga gtcagactag ctacatcata atctctctgc	1560

ccaggggctg tggatgtcat ccacctggc ctaactagcc tactgagctg agagatgtcc 1620
 aatttcccc caatacacta accagaggag aaggaccgtg atatcattgc atgtgaattc 1680
 ttaattccaa ttgcttaaac aaatatgttc agttgtaact atcaatacca gtatataaca 1740
 gtgttggcca agttttattg atgctgacaa tcaattggag ttacagccag acacatggtc 1800
 ttatgaccgg cgtacttacg cagggtttg cactgagaca ggtcgtgcat ctgaggttta 1860
 ctgctttgca tttttgtttt gtaactgaag tctgatgaga cagccagagc atgtgctacc 1920
 tagggacttg aatccctgca gcccatttc acttctcacc accttccggg gtgggtttctc 1980
 gacctccac tcccctacca cctgggtgct tagccagccc tggctctccc tccaaacacc 2040
 tgcccaatga gcactgccac cccatgggtg ccagacatgc tctccctcct catccctacc 2100
 tagctaccat tgccactccc ctccccagc ggggacatgg gcataggagc agggagagtt 2160
 aagggttggtc aggtgcacgt gccctatgct atcttgggaag ggggcttggc catgtggcat 2220
 ctctggacca agaatgcgc acagcacatt tggaggggtga atggtggggg cacaccctt 2280
 gtccacctct atttcaggca tggaacacat cctggcatga aagttgcagt cccttgggaa 2340
 tcacctctcc accttgattg ccacagtagg ccagtgacaa gggaagattg acacatcatc 2400
 ccctgctggg gccagtgct ctgtggctgg caggcagg 2438

<210> 40

<211> 794

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (376) .. (376)

<223> baySNP1714_A376G

<400> 40

tcggtacccc tgtttaactt ccaccgaggc agggggcccg agcagggaca gaagaggccg	60
gggtgaacat caccctttct acagtggctc gatgccttgc ttcacactcc agttttaatg	120
ttcgtgtgat acttgctatt ctctttctag aacattgccg ttaggagagg gtcccaccct	180
tttgtttcgc tccctccctg ccctcatctg ctctgttgac aaacgttttc tgccagatga	240
agtgtttctg ctgtgectgc ctctctggga gggaaacgtgg agcagctccc tgagcattca	300
ggctccgtgg ggaagtcgga ctgattttaa atagatcccg gttttccagg cttggagctg	360
aacggcatga cggggrcgga cgtggccgat gtcccacccc ctctgcctct caaagcagcg	420
tggcagatta cgggaatttg atggaaaacc aggacttgct gggctcgcca acaccttcac	480
ctccccctcc acaccagagg gtaagtcggc aatctgaaac acaggctttc attgcttcgc	540
ctccacaaag taggacgagt ccctcattcc agatactagc aggtttactt cgggctagtg	600
agcacatgag gaaaaccatg tatgatgggc cccgggtttg attttgcaaa aagatatcga	660
agcagtaagg actccagtgg gtaagatctg tggctctgcg tcattatcaa taactgcac	720
aaaaagcaca ttttgatata atgcctcaga acgaggaaga ggatagacat ttccaggttg	780
tcatcggtta tcat	794

<210> 41

<211> 813

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (89)..(89)

<223> baySNP1722_C89T

<400> 41

tgtttatcct cctcatgtcc cctccccacc caagttccag cttgcctggg gcttggtctg	60
ggaccctaag aaccccagga tgcccacayc gccaggccag cagggccaat ggtcatgcag	120
ggactgcggg acaggttccc atcatctcct gtgttagccc attccacctg ggaaaccaag	180
cgactgccgt ggctggctta tttctccctc tgccaacccc catctacaat gttctgggga	240
aaacaatgag aggtggaaaa ggtaacatac aaccaccttc caccacatc acttccagtg	300
aggcagctaa gtccaccaac agagcgtggg agagtctttc atccaaaaat cccaacacgt	360
cgcatgcagc gacaggaggc tgtgctgggg aaaccaagg cctggctcag cctccatact	420
ctaagggcct cgggccagaa cgaccacgag aggggagcac ccaaaggcac gcagaggggc	480
ccacctgggt gcactgcaga ggggacagag gggctgtgag tgggaggtgg gccagtgctg	540
ttcactgccg cctgctcagg accaggggct gctgcagacc cagcccggtc tatgccacc	600

cccgaggtg cagcccagct tctgcacatc agatggagtg acgtgacta aaggacctgg	660
acagcgccgg cagatactcc caacactgtc cttctctttg ggagccaaag agaagccacg	720
cagatactcc caacactgtc cttttttttg ggagccaaaa gaaaaccccg gccaggcagc	780
caggcgagcc atttctcta caccaggcag ggg	813

<210> 42

<211> 524

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (210)..(210)

<223> baySNP1757_A210G

<400> 42

ttctggaatg cctctcttgg caccctgcc ccaacaggct gctgggatct gcacgtggaa	60
tcacagggct ggttgcattc aacggcaaag ggcattctct tctgcctggg ggagggcctc	120
ttgtccctcc cagcaggctc cgggacaggg ctggcagcca cccagcacc caaaataaga	180
tgacaaacaa gaggaacaaa accaaaatgr aggagagcca tccgggctgg aggagggcag	240
aggtcccca aggggatctg gggagggctt caacttatga atgcatcagg ccttggaaga	300
cgtggatgga agaggcgagg gcaaaaggaa gagatgaggg gcatggagag agactcaggg	360

aagaaggaga aagagcaatc atgcagcttg ggacaaatct tttgttgctt tatcagattc 420
 tcagtcaatc aattggtggt tgctagaacc ggggtacgca ggggagtggt gaagagagag 480
 tgcgcgcgcg agaagagaga gatcaagaga acgggcatcg ccag 524

<210> 43

<211> 1279

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (240)..(240)

<223> baySNP1765_A240G

<400> 43

gtatctgtgt gtctgtgtct gtgtgtgtgt gagtgtgtgt ccttgaccac gtgttctcca 60
 taggcgggga gtcctgcagt tactcatgga tgagtacctg tgtttgtgtc tcagcaggca 120
 aatttgtaaa tgtacaagcc ttcaagcctg cacaagcata aatgtcactg tgtgggggtg 180
 cttgagagtc tgtgagcctg cccttaggag ctgtgaggta tgggcttcac ggaggaagar 240
 gtcatagctg caggaagata tactgtcttg ggaccttcag ctgcattctg acatctctgg 300
 ctcccatgg aaagggcatc cctagctgag atgcaggacc tctgagaaga ggcaggggtt 360

aaaggatcag ataagccctc catttcccc atccaagtga agagagaagg aggggaggta 420
 gccccctacc ctgctccatc ttagagcaag gtagaccag ctcaggaggt cttgcttggg 480
 aagtgatgag accttgactt ttccagtctg tctttttccc ctagcacccc caaactcccc 540
 ttaatcacca tcctaagttg ctgtgggtga tgcaatagca agatgaggag cagatctggg 600
 ctgttttaac taagaggctg ggtgagggtg gggatatttag ggctggagc ttagagttca 660
 acctaccaac gacccctgaa gagggaaggc atctgacacc cacaacctgt tctagggatg 720
 atttttctc caatcccttc tcccctgcat ctccactgca gaggcaggct tcaactgtccc 780
 cccattaccc agtggctgtg aagggcagcg tgggagttgg ggaagggac gacactgggtg 840
 ggaggagacc cagcctgctc cagctaccac ggagaggctg agatgggggg agcgttggcg 900
 gattcccagc tgccccact ctgtcccagc ctctggcttt ctcaaaaagg actctctgtt 960
 ctcttcagc attcaagacc cagagagggg gacttgtggt tgggggaggg aggagtggag 1020
 ggagggtggg ggggtccttg cttcctctct ttctttcttg cctgggcagc cgctggcccc 1080
 aaatctctgc aggctcctgg ctgcagagcc tgagatcttt gccaggacag gaggaggggg 1140
 aaggggcagt gtgtctcaag ctctaagcct gctggagagc agggcgggag cttgggaaaa 1200
 ggaggcactg cgtggagctg cttagctcag ccacaatcca gcatgccaaa gtgcatggac 1260
 cagcaagttt ttaaaaagc 1279

<210> 44

<211> 359

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (200)..(200)

<223> baySNP1776_A200G

<400> 44

taaggaggca atctgtaaaa ctagcacagg tctcccgctg ttccactggc tcaccacat	60
gattagcaga gtgcacgaaa aaataaaact tctattaaag aatcatgctg agcacaagat	120
cagagagggt gtgacattgc aaactcgata gatgcagggg gcctgggaga ctggcgttct	180
ccaaagggct cccaacaccr tctctcctct gatttctgtg acaaatgtgg aaagctactt	240
gcttggaggt actgggggaa ctgatggggg aactttcatc ctgttaggaa ctccgcttct	300
cattcctgcg tctctgtctt gctccctgga gatggatgga tcacggaggg ggccacagt	359

<210> 45

<211> 437

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (127) .. (127)

<223> baySNP1799_A127G

<400> 45

taaagcagga atagggttaga ggagggagag agctggctgt gtcaccatgg aaaagtgaaa	60
gccaagtcca cctacttact ctgcggaaac tttggtgggt tgcattgac atcggtcagt	120
gtgatcrtca ctttggttgt ccctgagagt ccgccatat gtccacccat gtccttggcc	180
tggatcacca cgtggtactc ctcccttgcc tccctgtcca tgttgggtag ggctgttctg	240
atgatacctg gacaggtaag caggcaacat cacagatatt cgtttataac attatgacaa	300
caagaaagtt ctgagcactg aggaagcaat gctgaataaa atatcccatg ccctcagcaa	360
gaatcatttc aacatggtaa ttacaaccaa aggcagccat actgaagcat cattatgtct	420
tttcaagcaa atcataa	437

<210> 46

<211> 752

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (201) .. (201)

<223> baySNP1806_A201G

<400> 46

ctggggggttt gggacagaac acacgcagct tcagtcagtt ggtaaacggg tccctttcct	60
ctgggggcaga aacgcttttg ggtttgactc aaatcatgga ctcttgggg gcctattctt	120
cgggctaact ctttgcatgt tctgcaggga gccaaacaag ccgctcctac acttcgctgg	180
tcctgggcgt cctgggtgggc rgtttcatca ttgctggtgt ggctgtaggc atcttcctgt	240
gcacaggttg acggcgatgt taattactct ccagccccgt cagaaggggc tggattgatg	300
gaggctggca agggaaagtt tcagctcact gtgaagccag actccccaac tgaaacacca	360
gaaggtttgg agtgacagct cctttcttct ccacatctg ccactgaag atttgaggga	420
ggggagatgg agaggagagg tggacaaagt acttggtttg ctaagaacct aagaacgtgt	480
atgctttgct gaattagtct gataagtga tgtttatcta tctttgtgga aaacagataa	540
tggagttggg gcaggaagcc tatggcccat cctccaaaga cagacagaat cacctgagcg	600
ttcaaaagat ataaccaaata aaacaagtca tccacaatca aaatacaaca ttcaatactt	660
ccaggtgtgt cagacttggg atgggacgct gatataatag ggtagaaagg agtaacacga	720
agaagtgggtg gaatgtaaaa tccagtcata tg	752

<210> 47

<211> 527

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (413)..(413)

<223> baySNP1837_C413T

<400> 47

ctcaccagtc ccccttctga gagcccgat gagcagggag cgggcccta ctccttctgg 60

cagaccagc taaggttcta ccttaggggc cagccacct cccagggag gggccacag 120

gcatggggac ctggggtgcc cctcacagga cacttccttg caggaacaga ggtgccatgc 180

agccccgggt actccttggt gttgccctcc tggcgctcct ggcctctgcc cgtaagcact 240

tggtgggact gggctggggg cagggaggag gcaacttggg gatcccagtc ccaatgggtg 300

gtcaagcagg agcccagggc tcgtccagag gccgatccac cccactcagc cctgctcttt 360

cctcaggagc ttcagaggcc gaggatgcct cccttctcag cttcatgcag ggytacatga 420

agcagccac caagaccgcc aaggatgcac tgagcagcgt gcaggagtcc caggtggccc 480

agcaggccag gtacaccgc tggcctccct ccccatcccc cctgcca 527

<210> 48

<211> 600

<212> DNA

<213> Homo Sapiens

- 60 -

<220>

<221> variation

<222> (323)..(323)

<223> baySNP1870_C323T

<400> 48

```

aacagctatt cacgcttggt gagtggggcga agaggatccc acacttttcc tccttgccctc      60
tggatgatca ggtcatattg ctgcggggcag gtcagtgacc ttggatccct ttgacttctt      120
gacatttgac ccctctttga cttcccgatc tttagtgacc ccagtggcct taccttgcggt      180
accaggggag ccaaacttgc tgacctcgcc acctcttttc tccttctctt ccactgatgt      240
gctttgaate ccttggcctg atttctgggt cctgaccctt gctgccccac ccaggctgga      300
atgaactcct cattgcctcc ttytcacacc gatccattga tgttcgagat ggcatcctcc      360
ttgccacagg tcttcacgtg caccgcaact cagcccatc agcaggagta ggagccatct      420
ttgatcggtc agtggccctc ggctaggctg gcatgtagat agaggggggtg gggctatagg      480
ctggtccgtg tccaaggctg gctgagctgt gacctttgag tgacctgcag gtcctctctc      540
agggtgctga cagagctagt gtccaaaatg cgtgacatga ggatggacaa gacagagctt      600

```

<210> 49

<211> 725

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (115) .. (115)

<223> baySNP1882_C115T

<400> 49

tgatcctgag acctgtaccc tttaacctta gggcctgggg cctcacctgc tggcattggg	60
aggaaccaag ccgcgaattc tcagcacctg gccagggagg atgccctcgg gcagyagga	120
cttgtggggg acgttctgca agagtggggg gcaggggcca ctgtgagccg gtgagaccga	180
aggagggagg cagaagggtg gtcacccctc agaggagccg accagggctg agactgacag	240
aaatcagtgg aagaggaaa ggtggcggag aggcaggaaa gagaccagaa acagacaggg	300
aaacagatgg ggagagcaac aaagacaaac agaaagatcc tcaaagaggg cccagagga	360
agccacaaag aggtagaggg gacagtcggg atgggggtta cccggaggcc acagcccagg	420
ccagtccgtg gcacactcac tgcccacttg ctcctttgaa agaggagccc ccagccccct	480
ccctgcttgg ccccgccccg ggccctgga gcactcacgg acatggctgg gaccgggttg	540
ggcagccgtg gtggtggggc ctgctgggga ccttaaaata aaagcagggc ggggctggcc	600
ctgatgactt accccacctt ttccaccac caccctaaac tggcacgacc ctggccctgg	660
ggcaagcctg gcgaaacggg agtgggactt ttttgggggc ctgatcccc atcaccagg	720
cccg	725

- 62 -

<210> 50

<211> 493

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (214)..(214)

<223> baySNP1988_C214T

<400> 50

tgctctatag ctgggccctg aagaatggag caaagacctg tggcaaggat aaatcaaggt	60
ctgcagccgg gggctggctgt gggctgtgat tgtgtttggg ggcggccatg tgtctctgac	120
cctgtgtttt gcccctaacta cagcacactg ggatgagaaa ttccaccaca agatgggtgga	180
caaccgtggc ttcattggtga ctcggtccta tacygtgggt gtcattgatga tgcaccggac	240
aggtagggtgc tgtgaggagc aggggtgtcaa ggtgggtggg ggtccaaggg tagttggtct	300
gaccaccccc tgcacacagg gtgcccagtg tcctttccgc tcctctccca ggcctctaca	360
actactacga cgacgagaag gaaaagctgc aaatcgtgga gatgccctg gccacaagc	420
tctccagcct catcatcctc atgccccatc acgtggagcc tctcgagcgc cttgaaaagc	480
tgctaaccac aga	493

<210> 51

<211> 1161

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (349)..(349)

<223> baySNP2000_C349T

<400> 51

```

aaccacccta accctgactt ccctaattcc ccccatcctt accaccctcg ttaaccctaa      60
caaaaaaaaaac tcataccccc attatgtaaa atccattgtc gcatccacct ttattatcag      120
tctcttcccc acaacaatat tcatgtgcct agaccaagaa gttattatct cgaactgaca      180
ctgagccaca acccaaaca cccagctctc cctaagcttc aaactagact acttctccat      240
aatattcatc cctgtagcat tgttcgttac atggtccatc atagaattct cactgtgata      300
tataaactca gacccaaaca ttaatcagtt cttcaaatat ctactcatyt tcctaattac      360
catactaata ttagttaccg ctaacaacct attccaactg ttcatcggct gagagggcgt      420
aggaattata tccttcttgc tcatcagttg atgatacgcc cgagcagatg ccaacacagc      480
agccattcaa gcaatcctat acaacogtat cggcgatatc ggtttcatcc tcgccttagc      540
atgatttata ctacactcca actcatgaga cccacaacaa atagcccttc taaacgctaa      600

```

- 64 -

```

tccaagcctc accccactac taggcctcct cctagcagca gcaggcaaat cagcccaatt    660
aggtctccac ccctgactcc cctcagccat agaaggcccc accccagtct cagccctact    720
ccactcaagc actatagttg tagcaggaat cttcttactc atccgcttcc accccctagc    780
agaaaatagc ccactaatcc aaactetaac actatgctta ggcgctatca ccactctggt    840
cgcagcagtc tgcgccctta cacaaaatga catcaaaaaa atcgtagcct tctccacttc    900
aagtcaacta ggactcataa tagttacaat cggcatcaac caaccacacc tagcattcct    960
gcacatctgt acccagcctc tcttcaaagc catactattt atgtgctccg ggtccatcat   1020
ccacaacctt aacaatgaac aagatattcg aaaaatagga ggactactca aaaccatacc   1080
tctcacttca acctccctca ccattggcag cctagcatta gcaggaatac ctttcctcac   1140
aggtttctac tccaaagacc a                                         1161

```

<210> .52.

<211> 2915

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (338)..(338)

<223> baySNP2071_A338G

<400> 52

aacattctat atggetaact ctgaatatga tcttagattt taatattttt cacacggcat	60
gccaatcccc ccaaaatttc tcttgctgtg accttcaatg acctacattt gttacacttg	120
agcaaatca agttcattgc tattctcagg ctataatgaa aattaaggct atttctgttt	180
ccttcacatg ccccaaaatt acacaattag aattaggact tctattattg aatgttagtt	240
gtagtaatgt tcagcatacc atgcaaattt tgctgaagta tacttaattt gactgctaaa	300
atgtgtgata tccctagaca ggatttacat tatgaaartc acaggaaaca atttttatcg	360
aaagttgaaa ctaaaaatcc tttgcaggac tgtcaagcag agaatgggta ctcacgtttc	420
ctttaaccac ataattagaa tcattcttga tgtctctggc tagaccaaaa tcacaaatct	480
ttgtgatccg accatgagta aggaggatat ttctggctgc caagtctctg tgaatacact	540
attaggttgg aggagaaaag aaaaccattt aaattcattt taacttgtaa agagtgaaaa	600
ctaacttttt aatactatag tgttgcttat attataaaaa atccaatact tttgttttaa	660
agtattcagt acaccaaaaa taaaaatcaa aagtacgcct tgaatgatgt tcacataatc	720
aagagtctaa ttattataat ctctttttaa agcaattcta ataaatgctg ttttcttctc	780
aggactgctt tcattcatag ggaaatacat aagaaatagt catatcatat tgtttaaact	840
gaaaattcat tttgcatgca tctctttgaa tgtcctttca cagagttcct aatatgcctt	900
tgcaaattca atctgacatc tccaaggac acacggaaga aggtctttat ttcagccatc	960
ttatatcctt tcttagtttg gtaattgttg ggaaatgtca cccatgacat ttaagggtag	1020
gactggtaac tcattctggt cggttaatct tacttcttaa ggaactcctt tcacccttcc	1080
acagaccatg ctcttctgtt tggttccatc attctttcca ttcctaacct tctcccaagt	1140
gtttattact cctctgacc ccttatttcc tgacacttca taagccacac atataatatt	1200

tggatctaac ttcaataaaa ctcaagtcta tgcttcaccc caagccttgt aactatgagg	1260
tgccctctgc ttttactgat aaaatgattc tgttctctag gaacatatcc tatatcctaa	1320
aagccaaaag ttttaaaaga atttcactgc atataaaaga atattcatag aaaaactcat	1380
ttagacaggc ttgtacttta cagcttataa attagaacag gaattccaaa gagacagcag	1440
ttggaacatg aagaaactaa atttcctctg cttttggtta ccacacttca aaatgacatt	1500
ctgcatttta actatggctc taaaatgctc tgttctcaa aaaaaaaaaa aaaaaaaaaa	1560
aatcaaaaa aacaaaacac aaaactcttt agagaatcac tcccacttac attcttggag	1620
gcgaggaaag ccatgccctt tgccacctgg taagaaaagc tcagcaagtc ttctaagtct	1680
agggccaact cgtcatcctc catgatggcg ggagtcacat ctctttctat gtatgagcct	1740
gtgaggaaga gaggattttt cttagcaatt acaaccataa aggtcaggaa aggaaaagac	1800
agtggcaatg acataccaaa ggctggtaat gaatgaacta atgtgaactt gcaggcagat	1860
cacttccctg gtgtccagga aaggtagatg ctgaatcaca aagttaatat ttaacaatcc	1920
taggctgggt tacaaaatcc atagaggaga gggatggcga attaaagcaa agatcccata	1980
tctatagaaa gatactcagg cacaaaaaca tatgctctga ccccaaacac ccacttgcaa	2040
ccctaactgc cattgaccat tggcactgct accataaagc agaactggtc tgcacattg	2100
ctactgggaa tgatgttata ttccacatta gcatgatata catactctct gtaaagttac	2160
tcttggttgc ttgataggta ggtactcacc tattctcaca gatctccttt tgcggcctt	2220
ggttgggaca acataagaaa ctccaggttt catgtccatg tactcattag tactatcgct	2280
gctgggagag atgaacaag tcatgactga atcaagtggg acatgtagaa gggcactcat	2340
gggtcatgct ctacctctc atcccccttg ctacataata gactggacca atttgaggaa	2400
agtcatgtaa agtttgaata aagagtttga aaatcctggt ctgtaagaaa tgagttttta	2460

ataatcgata ttgggggtcca tgcccagaaa ctaggtgtcc tttttgtgta taatcatata 2520
 gaggactcag gttagaaatt tcccgtctct tgacacaatg aatttaatgg gagacagaga 2580
 gccaaatatg gtatcccgtta ttacctcaaa ctctctaaat gagccccagg agacaagatg 2640
 aaagaaagac aaagaagagc ttccaagacg tgttatgcag gaggcagaga tcgttaacat 2700
 atagtgcactg atggaggaag gtttaaaaaa aatcaagtt ggttcagata aacaccaata 2760
 atttgatga ttttctgaac catctggacc tcttcaatct gcaacatttg gctggagact 2820
 cttcaagatt tctagtactt cctgcttctg attagcatag aaacaccatg acaacaatct 2880
 ccttcagagt gtgctggtgg ttccaatccc atatg 2915

<210> 53

<211> 1557

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (876)..(876)

<223> baySNP2078_G876T

<400> 53

tacctcccca caaagccttg tacacaaatg cttataatgc ctatattcat tatagtaaac 60

aattggaaac catccagtct acatccatgg gtgaatcgat acattgtggg acatagatac	120
aataaacact acttagcaat gaaaagaaaa aacggatgca cgcaatgaca tggatgcttc	180
tcaaagtctt catgctaagt gaaagaagcc agatatgaac aagtacatct ggtatgattc	240
catttacaat atataagtcc tcaaaacatg atttcttagg taaacagcaa catataggga	300
tcaaaatcag atgagtgggt gtcaaggagc agagggtgagg ggtggagcaa aggggtacta	360
ggaaaatgct tgggtggttg aaatggctct tgtctttttt taaagtgtta gaaataatgt	420
tttattgtca cccagatggg atttgagttt atagtcttca tgctttatat tttttgtaa	480
attaaaaaaa ttacaagttt taaatagcca atggctgggt atgttttcag aaaacacgat	540
tagactaatt catgaatggg ggcttcaagc ttttccttat gggctccaga aaattcacc	600
accttttgc ccttcttaaa aacttggat gttggcatgc attcggcttc acactctgaa	660
gcaacatcct gacagtcac caccctact tcaaggaata ccacgctgga atactttcca	720
gagaggggat aaagaaaggc ttgatcattt tgcaaggccc acaccacgtg gccgagaagt	780
caactattac aagtttatcg cctgtggcat ccaaggcttc ctaaaaagca agtttgctct	840
cgatctcctt caccatcttg gctgctgagg tctgakgagc ggcttttttt tttttaatag	900
ggaactgacc gtattcattt gtagcctgtt accccataat tctttaggat gttcaaagct	960
ggagtgacca tatgcccgtc cctgttcctc ttgacactca gtgagaggca gccatctgag	1020
taagtggaag tgtgatattc gctccgggca ttatgtcatg agccttaaata ccagaataca	1080
ctggattgag tctttcagcc caatagtttg ccgccgttgc cagatttggg agcatccgag	1140
gagagacctc aaatcataat ggggtgggtgc agggctcccc cataactcaa aaactttccg	1200
tgtgttttcc aggcaagtgt ctttctcctc gaatacaaca atcttggtta caactgacag	1260
tagtgcaata gatcggtcag tacactgac caggaacatc ttgatgggtat agcatgttgt	1320

cattcgcaact ctaccagcca ctagtctaac ctggtcgagt agctttttcc agggactcaa 1380
 attctccatt atcaaagcac agacaagtgg tccgaccac ggtctcgaat taaaccagtt 1440
 agtcaccagc cctgcgttgt cattgagtga caggttggca ccatccctgt gtggttggtcg 1500
 ttggagagac accatcaggg tcttgaatca tttttgagcc tagagactat tagcatg 1557

<210> 54

<211> 503

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (415)..(415)

<223> baySNP2085_G415T

<400> 54

gggcagtccg tatggtggtg gttatggatc tgggtggtgga agtgggtggat atggtagcag 60
 aaggttctaa aaacagcaga agagggttac agttcttaag aggggagaga gcaagaagtt 120
 gttaggaaag ctgcaggtta ctttgagaca gtcgtcccaa atgcattaga ggaattgtaa 180
 aaatctgccca cagaaggaac gatgatcgct agtcataaaa gttactgcag cttaaacggg 240
 aaacccttct tgttcaggat tgccatagcc acagtttgca aaaagtgcag ctattgatta 300

atgcaatgta atatcaatta gatgtacatt tctgaggtct tttatctggt gtagcttttt	360
cttttcatta catcaggtat attgcactgt aaattgtggt agtgttacca gaaakaaaaa	420
attaaagaat ttttaacttt tcaaaaaaaaa gaaaagaaat aagatttctt taagttcttc	480
agtgctctctg attctaaaag agg	503

<210> 55

<211> 553

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (183)..(183)

<223> baySNP2095_C183T

<400> 55

ggtaaatacc tctgtattga gaaatattca ttcttgcaga tctatgtcgg tcttccaccc	60
attgggttac aatatcccaa acagagagct agagattgag aaaattgggt gagataaacg	120
atgagttatt tgggtgtttc tctcctctc tatattttgt gtaggtgtgc accgggatat	180
ttygggaatc cccagaaatt cggaggtagc tgccaacat gcagttgtaa cagcaatggc	240
cagctgggca gctgtcatcc cctgactgga ggtaaggccg acccacacc ctgctaactt	300
gcatttataa agctgggtata acttaacagc ctaagaaccc aagcacacat cttcaggatg	360

cataatacac aattccagcc agcaagctgt cccaggatg cataatacac aattccagcc 420
 agcaagctgt ccccttggtt tgacaaacct gggaatgctt agatagtatt ttcagctttg 480
 gtgaataacc tggttcaatg cacttttttt ttttaaaaag tgaattgttt ttgaaactta 540
 cctaattata acc 553

<210> 56

<211> 275

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (67)..(67)

<223> baySNP2119_A67G

<400> 56

gtcagccatg atgtagggct ggaagtgggt tttgttcagg ctttcgtcca gcacttctgg 60
 agccatrtag cgtttgggtc ccaccctggc attcaagggc acatcaactt catttgtgtc 120
 actgttgaat ttaacagcaa ggcccagggtc agcaatgcag caactcccat ttttcttgat 180
 gaggatgttt ttgctcttta ggtctcgatg agcaattgcg ggctttcctt ggggtgccata 240
 aatttctgtg tgcaggtggc acagaccaca ggag 275

<210> 57

<211> 393

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (176)..(176)

<223> baySNP2141_A176G

<400> 57

gaatggccat caggacctat aaaggctgag gaagaaaggt ttggtctgca ctaccctac	60
ctgtgaccac aagctccagg gggctcgctgg gggctgacca caggatggg tccctgctgg	120
agaagctgta gcatcggtag gttccgctgt gggcggcggt caccgtgatg atggggraaac	180
tagccctgta ccatctctcg ggattcttgt agggcgcagg gtccccctcc ttgtacagag	240
caaattggtc aaagccatac cgagtctgac actgtagggt tacgtcccct cctgacgaca	300
ccgccgggcc gggctgggct gagagcgagg gtttggcaaa aactcctggg agaaaaagaa	360
agtctgatgt tgaaggcagg agccagcatc tca	393

<210> 58

<211> 423

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (318) .. (318)

<223> baySNP2182_A318G

<400> 58

gaattcccat tcaggacca gacctgaaac ccaggggaatc caccctcag accccttatt 60

tttgggagaa tgggttcccc cagcttcctg cccctgcag cgtgtctcct ttctctctcc 120

ccttctgtca tgtttccata tggccctagc cctcaggtg tgttctcacc agtcagctcc 180

attctggccg ggggtgtctg ctggcgtggc tccttgtttg gggcctctcc cctgaatcct 240

tcctggggcc atggaggcgg cttaggctct tgcacttctg ggcagagtag ggtggggcaa 300

aggcgggcca agggtgarga atctatcctg aaagtagcaa gaagagtga cattaacca 360

agtttctagg aagagactgc ctggcagggt gaacagatgc tggggagggc ttcagatgct 420

gac 423

<210> 59

<211> 542

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (296) .. (296)

<223> baySNP2234_G296T

<400> 59

ccccagttct accccacctt cctgggggtct ggcccagcca ggccccccgc accgtctatg	60
gggtgtccggg ccacaggagg agcttccctg ctgtgtcggg gcatgctggg tgcaggggca	120
gggttggttcc agggcgctat ttcagaggca gcatggggac acagaaacaa ggacaggggtg	180
ggccacaagg actgtcttgc ccaactgctcc aggggggcaca atatctgccg ggaacagtgc	240
gcctcacaac acaatgctgg ggcgcccag aacagtgtga accagcccc tggaakcaag	300
acagaaaggc acccggcctc tccacaaatt ggcccagccc ctgcagcctg gaccctgaca	360
ccctaaagca agtcacagta ggggatgggg gggggtggag caaggcccc cactcccact	420
caggcctccc cattctctca gatccgaccc ttctctgagc ttcacccgta aggcttattc	480
cacttgtaac attgtcgact tccagaccag gccctgctaa gccctggccc tggcgcttgt	540
gt	542

<210> 60

<211> 859

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (227) .. (227)

<223> baySNP2281_A227C

<400> 60

aatctgtgag gctcaccagt caggcacacc aactcaagac tgaacaacaa aattagtgtc 60

gcaaagaagc agagcgtctc cctggctgag ccgtggagcc acagtgccca gtgctgggta 120

ttcagttgga aggtgccagt cacaggggct gcagtgtcaa acaggtgttc agagcactga 180

cctcaggctg cattggagag gactgatcct gtttgcatac cacaaamcca ggtctccaag 240

cctgctcagc aatgcatgag tcacctggaa ttctttgaat atccttttca atatccattc 300

tttgaacatc cgtttcttta taagttaacc ggagctgggt tatgttacct gcaactaaga 360

accttgctt atatagaagt tgggtgtcagg agtgggttaca ggcagtggat gttggaggaa 420

gctcggagaa gctggaattg gttatctgga ctgcttgggg ctgaagtcag taaaaattca 480

gcacatcata agggctcaga tctggaagcc atggcatgca ggggaagcag aatgtcagat 540

ttgccacctg gagtcaccgg gaaggaagag cccgttgaaa acaaagcttc attgagaatt 600

cattgcctta gaaaagaatg aaaggaatga ggaattagac tgaatgggct ctacagcact 660

gcactgttaa agatgcagaa gcccgctctcc taaattccta aattcttggc tcagaccag 720

- 76 -

atcaaaaact gagacttctg ggccaggtgc agtacctcat gcctgtaatc ccggtacttt 780
 gcgaggccga gcaggaggat cacttttctg cagagtccga gaccacctgg gcacatatga 840
 gaccccatct ttactagta 859

<210> 61

<211> 371

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (77) .. (77)

<223> baySNP2298_A77C

<400> 61

gccctccgag agcccagtga cccacaggc gctggtacct gctagtgttt tctggttgca 60
 tttttctatc atgggcmitt caagtgttt tagatcaagt ctacacggtg ccagaaacc 120
 taacaaagca gatatgaaa caattcaata tctaaatatt ccctaatact tggatttatg 180
 gcatcaggaa ggtaaaactt acaatctgtt gaatggaatt ttcatttcga tgttggggga 240
 tgagtatact caccacacca cctatcagtt acagtgtgca tacggcttca ggctctctc 300
 ctctaaaaga tagcaaagct gagctcaagt caggtgttca cggactggcc ctgccactca 360
 ctggctgcaa a 371

<210> 62

<211> 825

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (286)..(286)

<223> baySNP2341_C286T

<400> 62

tgttgtggtg actcatgtcc caacctagct gcctctccca ggagactttc ccctggggac	60
aagggggagg gaatggcatg gaggaggccc acatcaagcg gggccaggaa cccacggtgg	120
caggagctgg gctggtgacc taccagggc agaaggggccc gggactcatc cagaggggaa	180
ggaaggggtc ttcaggaaga ccacggagat gccacaggca gaattggctt cccatctggg	240
agatagggtg ggagaccctg gcattttgac agccagaacc tggggygctg agcagaatct	300
tcatgcctgg cctggccgct ccttcggagg gaagctggag ggtgggctgc gagaggagtg	360
gggtcagagc ccctacatcc gcaggacccc aaatcggctg ggccccaagg cccggactgc	420
gctccccggt ggccccggcg gccctccgcg aatgcgtcct gccctcccc tgcccaagcc	480
ctctgccctc acccgggtcc ggcgcgcgcc ccgaagtggc ggggaacaacc cgaacccgaa	540

- 78 -

ccttctgtcc tcgggagccc ccagataagc ggctgggaaa cccgcggggc ccgcagggga 600
 ggcccgtgt tccgcccgt aagtgcatta gcacagctca ccttccttat cgcgcctgcc 660
 atcggacggg cagtgccg ccttgctttt gggcccccgg agcgaccaca gcggagccgg 720
 aacggactgt ccttttgggg cggggaaggg aggggggtgtc cttggagggc ccggtggcat 780
 agcaacgacc aaaaagcctt cagagggcgg gagggggaat ttttt 825

<210> 63

<211> 565

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (165)..(165)

<223> baySNP2357_A165G

<400> 63

aacaactcag atctcaagtt tgttactgat ttctcttttt ttttctttta aggaatgtgt 60
 ttactgtgaa aacaaggaaa aaggtaatat ttgcatacca tatgaggaag atattccttc 120
 tctgggactc agcgaagtgt cggacaccaa agaagacgaa aatgratccc ccttgaatca 180
 caggatcgaa gagcagacgt aacccttgcc ccacctcagc ccggcagcca gcgaggtaca 240
 ccagggtggtg cttggaagag atgaaagatc ttcattggctg tttccactga aatggacaca 300

tatgctcatg ttgctttttt tgtttttagaa aaaaaaacia catagttttc tgaaggggag	360
acttaaaact gtggagagtg gggagagttc ggaaagaaat atgtttttat atataaaata	420
tatatgtgga gttttgtggg atggggaaga gatttttagtt gttatttaac ttgagaaaga	480
ctaagcgctt cttagtgtca gggaggttgc ctcagtgttc ccagaagtc tgtgactgtg	540
acgagacctc tgtctgctgc accag	565

<210> 64

<211> 549

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (50)..(50)

<223> baySNP2366_G50T

<400> 64

gcctcttctc ccggctgttc cgaaacacgg tccagagcac cagaccgttk cccgtgggtg	60
ccaggaggaa gaccaacatg tagatggcag ggatgagggc ccccgaggat ttccagtctg	120
tgtactcaca ctcagactgg ttgtctgccc catagtagtt gtcaaaatca ccaccttcct	180
ccatgctggg gaggaggag aagacgggca gagggtccca gggacaccag ctccgtggct	240

```

ctgtcaccca ctctgcaagc agcctgaatt tctggcttga gcctcagaga gtaagaaggg    300
ctgaagatgc ccagagtcct tcccagcact caggaggagc tgcctctggg ttctccagac    360
cctggaggaa gcctgtctcc tgcagaattt cctccaccct ctcttgcctt acccccgtct    420
cagttaagac acttccttgc accctcctgc gtccctgtct cctccttgac tcgtcactcc    480
ctcctccac  ctccagacca gccctctct tgtgagtaa aatctttagt gacagccac    540
ttttttttt                                     549

```

<210> 65

<211> 609

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (170)..(170)

<223> baySNP2423_A170G

<400> 65

```

cagtaaggaa gagcccaaca ctgctggaag tgagcatgcc ccatttcattg agaaccaaca    60
gcttcgccga ggacctggac ctggaagggg agactctgct gacacccatc acccacatct    120
cacagtgagt gcctacatgt gcgtgaaggg ctgggctgga ggggactggr gctcaaggag    180
tcagacttgg tgctggggaa gccttgctct ctggccagag tgctatctac tcgcctagtg    240

```

```

cccaccactt gccgtctgcc tggccccaac acggaggcac caggcaagag aggagagcaa      300
gggcacttcc cactgagcct gggaacatga tcctcttggt ttgacttatg gaaaaccaga      360
ctgatcattt tccacttggt ttcattgctt gagagtctga gattgttttt ctctcccca      420
gccccctccc ctgcccccca aaaaagagac gactttgttt tttagcattt ccccatggaa      480
ccctggccaa agccatgggg cagatgccgg gtgcagtctg ccagttgctg ctgctgtcct      540
caggggctcc ttcaggtgga ggaaatggtt gatattccac gccttccagt tggccttccc      600
ctgaggcac                                          609

```

<210> 66

<211> 636

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (140) .. (140)

<223> baySNP2708_C140T

<400> 66

```

caccatttta tgaaggagga gaatgaactt aagaaagggt acgaaatttg cccaaggcta      60
caaagctggt agtttgaaag aggctgggat ttaaacctgt gcctgtaacc aggatgtcct      120

```

- 82 -

```

gctgcctctc gtaaaagccy gccaggtcc cactctcctg agtcagactg tcatccccac 180
ccctgccccac ctgccaaga agagggctgt ctgtgagagg cgtgcccagg cactggggg 240
tcctcttacc atctgtcggg ggtgttgatg agagtggaga tctgctcaag gtattccttg 300
tcatagacca caataggctc ggattcattg atctccacgg ggtagaagat ggtgttgaga 360
aaaggcaacc agttgatggc gggtgccaag gtctgcaagg gaaaaggaca gtgtgaccct 420
gtggggctgc tcctcctcac agcccagggc tctaggacgg gcttctacag gaagcaaagg 480
aaagagcttg ggcttggcgc catctgacag cgcaccgggc agagagtcaa gcggagcctg 540
gcgggctttt gtcagagatg ctgtaggtag aattctaagg agtccaacac caaaatttaa 600
cctgaaatgg aatgaggatg caatgagaag atgcag 636

```

<210> 67

<211> 620

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (299) .. (299)

<223> baySNP2995_A299C

<400> 67

```

ctgtgctgca gaggggagca gcatcagcag gcgtgtggag tgagtgagcc ccgtcctccc 60

```

cctcctcctg tcattgactc tcattgccta acccccttgt gtcttgcccc caggttgatt 120
gtccggggct accgccagcc cctggagggc agtgacctct ggtccttaaa caaggaggac 180
acgtcggaac aagtcgtgcc tgttttggtg aagaactgga agaaggaatg cgccaagact 240
aggaagtaag tgtgagtttc cttgtcctcc aggatgcctt ggtcacctcc ttccactmc 300
tgtggcctca atccaggatg gggccctggc agtgctgcct gttactagct ttgtggttct 360
gggcaagatg cctcacttct cctcctggcc tcagtttgct tttctgcaa atggggtagg 420
atctcacatg tcattaaagc aactgggcag agaaaagaag aaagaagctg ggtgcggtgg 480
ctctcgtgtc taatcccagc actttgggag gccaaaggcag gcggatcact tggtcgggag 540
tttgagacca gcctggccaa catgggtgaaa ccctgtctct actaaaaata caaaattagc 600
taggcatggt ggcaggcgcc 620

<210> 68

<211> 934

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (777) .. (777)

<223> baySNP3360_G777T

<400> 68

ttgaattatg attcaaagat atgatatga tagaatgagc aaaactcagg aagagataaa	60
agttgaacac aatgatacta atataatagt aagagaaatg atcaggcttg ctaactatga	120
accagctact gtactacttt ctacaattat ctaccaacct cacaattatc ttgcaaatta	180
ggcattatta aatccatttt tcatatatga aactaaagtc tggaaaaatt gaataagaac	240
tcatattcca taagtagtga ctacctata acctgtatct agcttgacag atgaagggtca	300
gcctgatttt taaaaaagtc aaagagagaa gcctatgttt atgtacaaca acatgtaaaa	360
ttttcatccc tcaccagtg gacaatagag ggacgatttt cttttctcca gagaagagac	420
attgaccaga gttaagaatc taactgttta tgagttccag tgacatttac aatcaattct	480
ggtttggett ggtttctctc attccctctt aaccctgact tgtgatattg ccgtgaaggt	540
gatggagaag ctcttcata tcccagggtg agccctcaat tctggaataa ccacaggaat	600
gttggttggc ttggaatgga tgaagggaat tggaaccggg ccagtaaaga gaaggcttgg	660
atctgttcta ggcctggctg atcctgaatt agttcaattc ccaaagatct gggcttcacc	720
atgggttcat taccttgact gactttgtta cttaaacctc caactatata ggagcckagt	780
gtgactogga ctatggattg ttattcttaa ttataatgtt ttccctctca tttttctggt	840
aggtatcaga aacatttaga aaatgccaaa gagattggaa ttaaaaaagc tatttcagca	900
aacatttcca tgggtattgc ctccctgtta atat	934

<210> 69

<211> 372

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (110)..(110)

<223> baySNP3464_A110G

<400> 69

gttgctgcac ctgaagaacg agctgaaccg aggagatttt ttcatgaccc ttcggaatca 60

gcccatggcc ctcagtttgt accgacaggt gtgtgtagtg ggcagggttr tgggtgtagcc 120

ttctgagcac ttgagttggc cttgctgact gattgcctgc ctgtggcccc agttctgtaa 180

gcatcaggag ctagagacgc tgaaggacct ttacaatcag gatgacaatc accaggaatt 240

gggcagcttc cacatccgag ccagctatgc tgcagaagaa gtctgagatc catggggcgt 300

gtggggcggtg tggggcatgt gggctggggc tgttggtccg gttcctcagg aatctaggcc 360

ttctgttggg tg 372

<210> 70

<211> 652

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (298) .. (298)

<223> baySNP3689_C298G

<400> 70

```

cttatttttaa acctttatctt ttggtcaatg gatttacact aatattcatc tcgaaaaata      60
aaaagaaaga aaactttaaa aagtagtagc atgtatcact gactaaagga aatggagaag      120
aagagagaaa aagagcactg accatggagt tgtaaggaaa tcaaaaacaa attcatccat      180
ttcacaattc acaattctgt gtaggctgac cctgaccttc atactcaaag caacacatgc      240
accattagcg tttctcattt tttaaataata tccaagcaaa taatgccccat ggagatgsca      300
ccaacctgat ctgtttgtgg cttcacttgg ttctacaaca aactgtagag aggcttcttt      360
cttcttttgaa gaaactggaa ctgactttgg atgtgatttc tggcactgag cacagaagaa      420
atacaacatt agaactatctt tattaactta ccaattcaat gaaatatatt tgtttttttaa      480
atgggggggaa aaacaagtat tctaaaacaa caaaccagct gttaagagtt ttatactact      540
ttttatttta tttctaaagt aatagctact ttggaaaaca atctggcatt attcagtaaa      600
gctgaaatct catacaacct atcacagaaa caatattact ctaaacagca ac      652

```

<210> 71

<211> 442

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (65) .. (65)

<223> baysNP3975_A65C

<400> 71

gtctccttct agaaaagaac cctggtgaag agcaggaggg caggcagtct gtattgactg	60
ggctmtccct gactcccatg cgtgggaata acttgaaagt gatgaataca taattctggc	120
cctgcctggg atctgctgtg gggccttagt cctcatttcc tccatctgca caatgagggg	180
gcaagacaag ctctggattt agtgatgcag acattcatgc ccaaaccagc cagcctgggc	240
agtgacaaac agtgacacag gcagggacag ctccttccat ctcttttata agggttgggg	300
gtcacagttc ttgtacaaa gcccaaatac cattatgcag aggtttgggt cttcttagtg	360
aggggaggaa gagccagttg taagatgctt acttgcacag agtggttaga aactgagaca	420
gtactccatt ctcccctgag ct	442

<210> 72

<211> 442

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (239)..(239)

<223> baySNP3976_A239G

<400> 72

gtctccttct agaaaagaac cctggtgaag agcaggaggg caggcagtct gtattgactg	60
ggctctccct gactcccatg cgtggcaata acttgaaagt gatgaataca taattctggc	120
cctgcctggg atctgctgtg gggccttagt cctcatttcc tccatctgca caatgagga	180
gcaagacaag ctctggattt agtgatgcag acattcatgc ccaaaccagc cagcctgggc	240
agtgacaaac agtgacacag gcagggacag ctccttccat ctcttttata agggttgggg	300
gtcacagttc ttgtaccaa gcccaaatac cattatgcag aggtttgggt cttcttagtg	360
aggggaggaa gagccagttg taagatgctt acttgcacag agtggttaga aactgagaca	420
gtactccatt ctcccctgag ct	442

<210> 73

<211> 486

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (304) .. (304)

<223> baySNP4206_A304T

<400> 73

aattctgggt ctaccacttt ctgtgcagcc ttggcccagg tagttaatct ttcagtgcaa	60
gcagtgttgt cattcataaa atggagggtga tgcctaccat gaagtgttgc tatggaaatt	120
aactgatctg tgatattaaa gcatagtcac tgggtacttg gggtaccta tctaaatgcc	180
agaggagtga tttacaagg gaggaagac cctttctttt tagccaagt gagttagcaa	240
agtatgtttt gtatgtggaa agtctacttt tgaattgtct tcgtttctgc ctccactacta	300
atgwttttct ctctgcctgg tctaggatta acacagattc ctcagatcca gaagactgaa	360
atttcctttc gtccaatga tccaagagc tatgaggcat atgtactgaa catagttagg	420
ttcctggaaa agtacaaga ttcagcccag agggatgaca tgatttttga agattgtggc	480
ggtaag	486

<210> 74

<211> 801

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (583) .. (583)

<223> baySNP4838_A583G

<400> 74

tttaaccaga accaagtgtt cccccccac agaatgtaca tgaaacacta gaggactgca	60
tgtttttccc tgagagaagc gtaagacaaa cagaagtcaa aaagtagtca ctgggagcgc	120
catcctteta agcaaatacct ccttttcctt tttggaggat ttgccgaac tacgtagcca	180
gtcagcactt agaccacctg cctcctcctc cccctataaa cccaccactc cctcctcct	240
ttcccaaacc acttgggggtg tctaagccc tcaactgcccc aagcccaaaa tatcaactaa	300
gaccttgtc tgtatttcca cagtcatacc taatgaattg ggaagtgggg cccctaaaaa	360
ccaattcaca tctatgcact tgtttccact ggatttggca gacaggcttt tttagttacc	420
gtaaccagat cttaagatta attaaaaact acataaagtg cttttaggtc cttagagata	480
catgatataa ataagcggct tatgatcaag aacgataaat acataggtaa aaatagctct	540
agcaaagatg accttatggc tctgagatgg gcaggcaggg carttcttcc ccattacatt	600
cttagtcac ttattcatat ctatttttaa atggagtcca cagactaaag gtcatgttcc	660
gagactgaag ctttcaaagt accctagttc caatatagac actttcttca gtttatcagt	720
agcttttaaa ctctgagggtt aacacagctc actctttctg taatttagtg agcatactcc	780
tatacaaggg aaacttagag a	801

<210> 75

<211> 921

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (74)..(74)

<223> baySNP4912_A74G

<400> 75

cccttcattg cggcgggctg cgggccaggc ttcactgagc gtccgcagag cccgggcccg	60
agccgcgtgt ggargggctg aggctcgctt gtccccgccc cccggggcgg gccgggggcg	120
gggtcccggc ggggcggagc catgcgcccc cccctttttt ttttaaaagt cggctggtag	180
cggggaggat cgcggaggct tggggcagcc gggtagctcg gaggtcgtgg cgctgggggc	240
tagcaccagc gctctgtcgg gaggcgcagc ggtaggtgg accggtcagc ggactcaccg	300
gccagggcgc tcggtgctgg aatttgatat tcattgatcc gggttttatc cctcttcttt	360
tttcttaaac attttttttt aaaactgtat tgtttctcgt ttttaatttat ttttgcttgc	420
cattccccac ttgaatcggg ccgacggctt ggggagattg ctctacttcc ccaaactact	480
gtggattttg gaaaccagca gaaagaggaa agaggtagca agagctccag agagaagtcg	540
aggaagagag agacgggggtc agagagagcg cgcgggctg cgagcagcga aagcgacagg	600

ggcaaagtga gtgacctgct tttgggggtg accgccggag cgcggcgtga gccctcccc 660
 ttgggatccc gcagctgacc agtcgcgctg acggacagac agacagacac cgcccccagc 720
 cccagctacc acctcctccc cggccggcgg cggacagtgg acgcggcggc gagccgcggg 780
 cagggggccgg agccccgcgc cggaggcggg gtggaggggg tcggggctcg cggcgctcga 840
 ctgaaacttt tcgtccaact tctgggctgt tctcgcttcg gaggagccgt ggtccgcgcg 900
 ggggaagccg agccgagcgg a 921

<210> 76

<211> 2679

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (2613)..(2613)

<223> baySNP4925_A2613C

<400> 76
 cccagctct gcgatgatgg cagaagagca cacagatctc gaggcccaga tcgtcaagga 60
 tatccactgc aaggagattg acctggtgaa ccgagacccc aagaacatta acgaggacat 120
 agtcaaggta ggctctgcag gcctgcctcg gcgggcccgg agtggtcaggt ttgcgagacg 180

tgggcgcttg gcaggggagg gtatctgctg cagacacagt ttccctgaaa agagacttgt	240
tgctctgttg tctctgtatc acccccccaa cccacccca cccccaaaaa aaggcttcta	300
aatcacggaa ggatcttttag caaaatcaag agcaaaaaat tagcctcatc tccatgacct	360
aagtgctaata cagggcagga ggagcgagtc acaaagaaaa tccctcctta ctactgtgac	420
gctcctgcca ctactcctg gctctcacc tgggaggaac aggaacgggc ggccaagttg	480
ggctcctttc tgtgccaagg ggcattttctg cggctctctc agtgggtgca gggttaatcc	540
ccagagggca gcttcagca gggccggcag cccctcgagg tacactcact ccccagagc	600
actgcccgaat atctgtcccc aaggccgagg gccatgcca gccctcccct agctaccccc	660
tcaccccagg tctagtggcc aggacagggc agacggcacc cgggaccctc gaagagaaag	720
ctcgggggttg tctagccctc agggagtctc tcagcgtctg aagtggggcc tcttccctcg	780
cctcctggtg aactagcgg ccctgctgcc tccaggcca caccttcaat ccaacttcca	840
gccagtaccc agagggatct ttcttttttc tttttgagac agtctctctc tgtccccaag	900
gctggagtgc agtcgcacac tcacgcctca ctgcagcctc aacctcccag gctcaagtga	960
ttctccctcc tccacctcct gattagctgg gaccacaggc gaggccacc atgccagct	1020
aatttttgta ttttagtag agactgggtt tcattatgtt gaccaagctg gtatcaaaact	1080
cttgggtca agtgatcctc ctgcctcca aagtgtggg attacaggtg caagactcca	1140
caactggctc agaggtacct ttctaaagca gaattcctcc aagaagggtc cccagccacc	1200
agcatctgag tcaactggagg ggctgttaag aggcaggtg ctgaggcctc tcagatccta	1260
ctgaaagcat tggaatctca ggccagtgt gtccaatagg gatactgtta ccacaaggaa	1320
tttaaaattt tctagcagcc acattttaaa atgcgaaagc aaacaggtga aattaatgtt	1380
cctgatattt cttacttaac cctatatatc taaaatagta ttatttcaac atgtaagcaa	1440

tataaaacaa ttatcaatga gctattgtac agtcttcaag tttgaaatcc agtgtgcttc	1500
ctatacccac agtatatttc agttcagacc ccacattttc atccgaaatg cttgttctgc	1560
atttagattt cataaaatgt acatgtgaaa atcgattcgc atgcctgtac tgtttcaaac	1620
attctgcaaa aatttttcaa taatgaaatc ggggtttaca ttttaattaa agttaaacia	1680
aatctagaat tcttcagttt cactagccac atttcaagcg ctcaaagctc ctggccactg	1740
gatcagacag gcctgtattg cggcttttca gtggggcacc tcccatgctg gagaagccta	1800
gcctctccac gtggctgtcc aaaccaaca caatctggcc ccaacctgct tcttctgcct	1860
ggttggctcc cacctgccag cccaccacc agagtacatt cctgtgccat tgccagaagt	1920
gcctgtctc tcttctccag gtggtgaatg cctcactcag ccttcaaggc ccaactcaaa	1980
tgcaacctcc tccagaaagc cttccctgac tctccaggc aattagttgc tccacttct	2040
gtccccctgc ttcactcagg gcattcctcc accacagctc ttcttatact ggatattata	2100
tttctataca tcgttagtga tggagataga gtatacagta tagcacagtg tgaaagctga	2160
aatgaggaaa attaggaaac aaatttcaca aactgtaaag cactatatac atgtaaataa	2220
aattgtacct gtaaaatatt attagttatg gtttccatca gtgtcatcta gcaggaatag	2280
tcttggaatt gactttaata gacttgattt caaatccagt ccattttacc taaaaatgat	2340
aacactggac aaaccaacta ggttttctga gactcagttt cccctgtaaa gtgggaataa	2400
tatcatttcc caatttacct ccaccaggta aacgaatctc aaagcagcac tgtgcgttag	2460
aaatatagca tgaggattga atgagatgaa gggtttgaaa gtgtctatca cagtccctgg	2520
caccagcaa ggatgagaca gtgtgagtca aagaagggtc tcaaagagct tgcagtctag	2580
agggcaagag agctaagcca ggagcctgcg tcmgtcccag gtagccatct ggtacacca	2640

ggtagggctgc agggagatgg gaaagaggcc ccccccccc

2679

<210> 77

<211> 1025

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (807)..(807)

<223> baySNP4966_A807G

<400> 77

aggtctcacc taatatcatc agaattctgt ctttaactct tattctgtaa atgtgttttg. 60

tagagtgttg acttatgctt ggggtgttgca gaacatgttg gaccatgtag gagccatgtc. 120

aagacatgct ggggtgtgctg taccatgtca ggggtgtatca ttgctctata gtgttggtgc 180

agcctagtcc ggtccccctt atgcccccca cctcctttc ttcttctgcc catggcctcc. 240

ttcttgctat gctgggcttg gagaaaagac gtccaaacct ctggctggga gccaccctcc 300

atacccaaag tccctcctct attcctctcc atggaccctg atggctctca ttcatgtcag 360

atgccattac agacaaggac atagtcttct acaagaccct gaagccctgg ctgggtaagt 420

aactgtaggt ggacgggacg gggaccaact tttgtggcca ggggaagatt ctgcccttgc 480

ccacagcctt tggtgccgt actaggggat gggctcttgt taagtgttgg tgacaagtgg 540

```

agacaccacc gtcgcttggt acgcctgcct tccatttcaa catcctgaag ccctatataa    600
agatttttcag caagagtgc aacatcatgc atgtgagtgc cttgaactca gcatcccagc    660
tgcagccttg ggggtggaggg atcacatata attgggtctg gaatgttggc tctcctgggt    720
gggtttgggg ccattgctct tcctctctgt gccttgattt ccccatgagg ctaataatcc    780
tcactaaaag gtggtaggag catgtartgg actcatgtct ctgacactta gtaggtgggc    840
agaaggagtc aatttccaca tttttctcac agaagccctg taaactcaag aaaggaatga    900
tgacacgtgc atagtagtca ttgctgagta cagatcactt caaaactaat tggtttagag    960
caataagggt ttatatattgc taacaaatct gtgggactgt tggccagccc ttctgcatgt   1020
ggata                                                    1025

```

<210> 78

<211> 2246

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (2057)..(2057)

<223> baySNP5014_A2057G

<400> 78

tcactggaaa aaggaattct gattgttcaa aagcacagga tatattaagg gcctcatata	60
atgcctggca cataagagac ctcagcaaat tacgggcatt catattatgt ttatacagtg	120
aaggcatcaa gggtataagc attctctttt ttcttttggg tagactgaag ctcagagagg	180
ttgagtggct tacttaaagc tgcacagcta ttagtaggca gatcaagatt agagttcaga	240
acttctcact ccctgcccag tttctgcttt ctttaccctt tgccctcttc aagttgtggg	300
tctgccggcc aggtgggagg tgctgtctgc aaagggttc cctttctctt tggccactat	360
ctggctgggg agaggcctca cctagatgtt gttgaaggcc tggtacagcc gctttattgg	420
ggattttctg gcgatgagaa cgtgtgaatg tcctggcctt tagtcaactc cctacacctc	480
tgagagtgtc agacaagaga gcccatcaca ctgggtgggat tgcaatcttt gcctctacca	540
ctgcttagct gcctttcctt agggcaagtt acttaatggg tctgtgactc agtttccctg	600
tttgtgaaaa gtgaaggtta atagtaccca ccatataggg ctgttagaat ggagtggaa	660
aattcatgta gaataagtat gtataacagt ggctaaaaca tagtcaggct gggcgcggtg	720
gtcacgcct gtaatcccag cactttggga ggccaaggca tgtggatcac gtgaggtcag	780
gagctcaaga ccagcctggc caacatgggtg aaaccccgtc tccactgaaa atacaaaaat	840
tagctgggct tgggtggggg tgctgtaat cccagctact cgggaggctg aggcaggaga	900
atcacttgaa cccaggaggc agagggtgca gttagccaag atcacaccac tgcaactccag	960
cctgggcaac agagtgagac tccgtctcaa aaaaaaaaaa aaaaaaata gccagttgcc	1020
tagaatagaa ccaactaaca gtgggtttat ttttactgca aaaaataaaa ataaaaatag	1080
gagtagtgca agcactgggc cacatcacta caaaacaagt gtatctcagc atctcccacg	1140
agaataccac tcagggtcaaa acatgatata gtgaagtggg gatgaaaagg atccaaccat	1200
gggcagaacc tgggggtctg tgccagtgga gacagcccca gtgtctagca tgagacacgg	1260

ggaatgttcc gttggagggg gggatatgatg actctcctga aagcttccct ccctccagtc 1320
 cagatggccc ctccatccct caacgtgacc aaggatggag acagctacag cctgcgctgg 1380
 gaaacaatga aaatgcgata cgaacacata gaccacacat ttgagatcca gtacaggaaa 1440
 gacacggcca cgtggaaggt gagggccttt gcccgaggag gggagaaaca ctggggaggg 1500
 cgggagaagg gaaagcaacc agaggcattc cacctgcaag gcgtcggggc cttggcaggt 1560
 gaccagtga aggtagccac tgggacgtgg tgatcactag gctgtgtggt cagcaggtca 1620
 ctgtcctgtc tcttggtgaa gtaactgagg tttggaaaag tggcgtggct tggccaacgt 1680
 gaacagctga ccctgagtcc ccaggcaaca gaagaccctc tgggcaggga ggggttgaaa 1740
 ggccactggg aagaaggttt tcaaaagtca tgaaagtttg gggttatttc ctcagaggaa 1800
 tctcatctgg acacacatgg aggctcagac agagctgctt ctaatgagtc gggggtgcgc 1860
 ccaggccagg gctcggtccc ctgcctccac agagcccaga acagaaacca cagaaccaac 1920
 cccacacctt cagtctagaa atggggcaac tgaggctagg agggaggtgg gccagtgggtg 1980
 gagccaggag cgggcccctgg ggtcctgaac cccattctc agggccaga gtccagtcgg 2040
 cctgcactgc gttcctraaa aggccacaat atgggtgcaa gctgccccag aagggtggg 2100
 agctgagaag gctcaaaata ggggtgggaca ggtggcttca gggttctggg cctcagtgtt 2160
 gtcaatgtca ggggctgcac tgacaggtgg agtccccggg gccatccgaa gtgctgtccg 2220
 tgggtggggc ctcaggagg atccac 2246

<210> 79

<211> 486

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (366) .. (366)

<223> baySNP5296_A366G

<400> 79

tggtggtgcc acacacacct taacacctgc acgctggcaa caaaaccgtc cgctctgcag	60
cacagctggg gtcacctgac ctttctctg tccccccac ttgagctcag tggctgggca	120
gcaggggatg catggccact ggccggccag gtgcagctct cagctggggg gctcagagga	180
cgcctgtgtc ctcccctccc ccatccctct gtcacccttg gaggcagaga actttgcccg	240
tcagtcccat ggggaatgtc aacaggcagg ggcagcactg cagagatttc atcatggtct	300
cccaggccct caggctctc tgccttctgc ttgggcttca gggctgcctg gctgcagggtg	360
cgtecrggga ggttttctcc ataaacttgg tggaaggga gtgggcaa at ccaggagcca	420
gcccgggctt cccaaacccc gcccttgctc cggacacccc catccaccag gagggtttct	480
tggcgg	486

<210> 80

<211> 486

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (172)..(172)

<223> baySNP5298_C172T

<400> 80

tggttggtgcc acacacacct taacacctgc acgctggcaa caaaaccgtc cgctctgcag	60
cacagctggg gtcacctgac ctttctcctg tccccccac ttgagctcag tggctgggca	120
gcaggggatg catggccact ggccggccag gtgcagctct cagctggggg gytcagagga	180
cgcctgtgtc ctccccctccc ccatccctct gtcacccttg gaggcagaga actttgcccg	240
tcagtcccat ggggaatgtc aacaggcagg ggcagcactg cagagatttc atcatggtct	300
cccaggccct caggctcctc tgccttctgc ttgggcttca gggctgcctg gctgcagggtg	360
cgtccaggga ggttttctcc ataaacttgg tggaagggca gtgggcaa at ccaggagcca	420
gcccgggctt cccaaacccc gcccttgctc cggacacccc catccaccag gagggttttc	480
tggcgg	486

<210> 81

<211> 458

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (101)..(101)

<223> baySNP5320_A101G

<400> 81

tggtgctagg tgctcgggat atatagtaga aaaacaagcc tgcctttttt aatgtatgca	60
ggaaatctct ggagaagtaa gagagggttaa ggaaagctgg rtatgtgcct gctttacatg	120
gagtagtagt gattaagttg gccagtgcgc agaagtgcct actgggtgcc aggattggtg	180
ctgtggaata tcgagtacca ctaactttta aattcttcaa agagggctgt gctgaagttt	240
gctgctgcc ctggagccac tccaattgct ggccgcttca ctctggaac cttcactaac	300
cagatccagg cagccttccg ggagccacgg cttcttgtgg ttactgaccc agggctgacc	360
accagcctct cagggaggca tcttatgtta acctacctac cattgcgctg tgtaacacag	420
attctcctct gcgctatgtg gacattgcc tcccatgc	458

<210> 82

<211> 1975

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1604)..(1604)

<223> baySNP5361_A1604C

<400> 82

catgaagcgg actagtccca gaggacaaac agaatctttg cctcctgtc tgctagtcca	60
gtcttttccc tgctggatca ttgtgtgcct gtgccatgag gtttctgcca tctaacaaac	120
agtgccagcc aagcaaagcg ggcattgcagg cctgcaagtg gttctcatgg aagctgttcc	180
tccccacagt ttgggacact gaccaacagt ccttttagcag gaggtcgtct tagtccattt	240
ggtctgctat aacaaactac catagactgg gtggctcata aaaacaggac tttattttctc	300
acagttcttg aggctgggaa gtccaagatc aagggtgccag cagattcagt gtctggtgag	360
ggcccttgcc ttgggtttata gagggaacct tctcactgtg tgctgatatg gtgtaaggag	420
caagggaatg ctctggggtc tctttcataa gggaattaat ccactcttg agtgetccac	480
cctcatgccc taatcacctc caaatacctt cacattgggg attaggtttc agcatatgaa	540
tttgggagaa gggacagaca cagtcagtct atagcagagg tcactctttt tcagtgtcga	600
aaaatgttgt tgagtccac acaaaggaag ttctatttta ttttatttta ttttatttta	660
ttttatttta ttttatttta ttttatttta tttctggaga tagggtatct ctatgttgcc	720
caggcaggtc tcaaactcct ggcttcaagc aatccttcca cctcaacctc ccaaagtgtt	780

gggattactg gcgtgagcca ccacactggg cctatcttca atatctgtta ttttaaaaca 840
 tttttaatag tcaacagcca ctagaaaacg taatgacact taaaaagatt gttattttac 900
 ttaaccaata acatctgcat gcaagtgagc gatgaacata cacaatggga aatggattaa 960
 gaggttctca gataagggtt gctagtttag accaaatgag atcaggaggt tctagaacac 1020
 aagggaggaa agcagcatct gtccacccca agccaagtta ctgccaaccc aaggcaatgc 1080
 ttagtggata aataaaaaac tgaacaaaat gcagtacttc atgtgagagg tggtttctgt 1140
 ggacttggat tcttaccgta tttcctctaa tatctgttca ttacaagcac catgtaaacc 1200
 tgttgcccta aaaactcttg aaaagggtgc ctttggggga atgtgcttgg ggaagcaac 1260
 ccttaagcat ggctgtctgc tgcccagccc cactcccaca ccttgctcag aagttcctcc 1320
 accatcaaca gcaccactga gcttgtgtcc agaaggccct caggaggctc aggtaagagg 1380
 atgctttgta tcagtggggg cagggatggg agaggtaata agagccggga tgggggccag 1440
 gggagtgact gggttctggt gagcatacag aagctttgct gttattcagg aaggaatgca 1500
 ggttttgcag aaagcacatt gggcatttca tcacgtagaa agctactgaa actgacacta 1560
 cacgccttca gccagggagt cccgctaagg gattatgaaa ggcmggctga ttccaaaact 1620
 acaaatccca ggctcccccg ggggatggac acttgtgaga ggaagtgggt tagccagtca 1680
 aacctccagg gtttcagcca gttgagaaag gatagggagg gaagttttaa aaggaatgtg 1740
 ggcccacaag cctgggatct gtctctctct ctcagtctga tgcggcctcc tgtctaattg 1800
 tttcagtctg tccgagctgg taaatcccta agcacatagt caatttacac tcagcttaaa 1860
 agctctagag ggagacagga aaaatttcca gtgagaccac tcactcacct acaactgcta 1920
 gattaacett ctgcatttta actgagttaa ctcatatgtt ttcttagtgg gagga 1975

- 104 -

<210> 83

<211> 527

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (134) .. (134)

<223> baySNP5457_A134G

<400> 83

tgaggctgac atgttgcagc agaatgggca atagaaatca attactaaga ttaaaataca	60
gctttttacaa cagtgcagtgg aaaggactga ccttctaaat taacagcagc ctaaattggaa	120
agcctacttt ctttgtgtgc ttaattcaca tctggggacc tgatttaaac atgtcttgcg	180
ctgttgtgtgc catggttgct ttgcccatcc catcaacctc atcctgtcac ttttctctct	240
gacttctttc tctgccaca tctctccctc cctgctgctc ccgtctctctg tcttcttctg	300
gccatttgag atgttccagc agaagatgac ccttcccctt gtgcgctgga aacggggccac	360
gggcggcagt gccagaacgg cacggtgtgc aagcccggct gggatgggtcc caagcacggc	420
atcaccaact ttgacaactt tgccttcgcc atgctcacgg tgttccagtg catcaccatg	480
gagggctgga cggacgtgct gtactgggta cgtagcatga gtgggca	527

<210> 84

<211> 562

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (61)..(61)

<223> baySNP5704_C61T

<400> 84

actctgacag ccataacagg agtgccactt catggtgcga agtgaacact gtagtcttgt	60
ygttttccca aagagaactc cgtatgttct cttagggtga gtaaccact ctgaattctg	120
gttacatgtg tttttctctc cctccttaaa taaagagagg ggttaaacad gccctctaaa	180
agtaggtggg tttgaagaga ataaattcat cagataacct caagtcacat gagaatctta	240
gtccatttac attgccttgg ctagtaaaag ccatttatgt atatgtctta cctcatctcc	300
taaaaggcag agtacaaagt aagccatgta tctcaggaag gtaacttcat tttgtctatt	360
tgctgttgat tgtaccaagg gatggaagaa gtaaatatag ctcaggtagc actttatact	420
caggcagatc tcagccctct actgagtccc ttagccaagc agtttctttc aaagaagcca	480
gcaggcgaaa agcaggggact gccactgcat ttcatatcac actgttaaaa gttgtgtttt	540
gaaattttat gtttagttgc ac	562

<210> 85

<211> 2246

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1960) .. (1960)

<223> baySNP5717_A1960G

<400> 85

tacttgaaa aaggaattct gattgttcaa aagcacagga tatattaagg gcctcatata	60
atgcctggca cataagagac ctcagcaaat tacgggcatt catattatgt ttatacagtg	120
aaggcatcaa gggtataagc attctctttt ttcttttggg tagactgaag ctcagagagg	180
ttgagtggct tacttaaagc tgcacagcta ttagtaggca gatcaagatt agagttcaga	240
acttctcact cctgcccag tttctgcttt ctttaccctt tgctctttc aagttgtggg	300
tctgccggcc aggtgggagg tgctgtctgc aaagggcttc cctttctctt tggccactat	360
ctggctgggg agaggcctca cctagatggt gttgaaggcc tgttacagcc gctttatttg	420
ggattttctg gcgatgagaa cgtgtgaatg tcctggcctt tagtcaactc cctacacctc	480
tgagagtgtc agacaagaga gcccatcaca ctggtgggat tgcaatcttt gcctctacca	540
ctgcttagct gcctttcctt agggcaagtt acttaatggt tctgtgactc agtttccttg	600

tttgtgaaaa gtgaaggta atagtaccca ccatataggg ctgttagaat ggagtggaat	660
aattcatgta gaataagtat gtataacagt ggctaaaaca tagtcaggct gggcgcggtg	720
gctcacgcct gtaatcccag cactttggga ggccaaggca tgtggatcac gtgaggtcag	780
gagctcaaga ccagcctggc caacatggtg aaaccccgtc tccactgaaa atacaaaaat	840
tagctgggct tgggtggcggg tgccgtgtaat ccagctact cgggaggctg aggcaggaga	900
atcacttgaa ccaggaggc agagggtgca gttagccaag atcacaccac tgcactccag	960
cctgggcaac agagtgagac tccgtctcaa aaaaaaaaaa aaaaaaata gccagttgcc	1020
tagaatagaa ccaactaaca gtgggttttat ttttactgca aaaaataaaa ataaaaatag	1080
gagtagtgca agcactgggc cacatcacta caaaacaagt gtatctcagc atctcccacg	1140
agaataccac tcagggtcaaa acatgatata gtgaagtggg gatgaaaagg atccaaccat	1200
gggcagaacc tgggggtctgg tgccagtgga gacagcccca gtgtctagca tgagacacgg	1260
ggaatgttcc gttggagggg gggtatgatg actctcctga aagcttcctt ccctccagtc	1320
cagatggccc ctccatccct caacgtgacc aaggatggag acagctacag cctgcgctgg	1380
gaaacaatga aaatgcgata cgaacacata gaccacacat ttgagatcca gtacaggaaa	1440
gacacggcca cgtggaagggt gagggccttt gcccaggagg gggagaaaca ctggggaggg	1500
cgggagaagg gaaagcaacc agaggcattc cacctgcaag gcgtcgggcc cttggcagggt	1560
gaccagtgag aggtagccac tgggacgtgg tgatcactag gctgtgtggt cagcagggtca	1620
ctgtcctgtc tcttggtgaa gtaactgagg tttggaaaag tggcgtggct tggccaacgt	1680
gaacagctga ccctgagtc ccaggcaaca gaagaccctc tgggcaggga ggggttgaaa	1740
ggccactggg aagaaggttt tcaaaagtca tgaaagtttg gggttatttc ctcagaggaa	1800

tctcatctgg. acacacatgg aggctcagac agagctgctt ctaatgagtc gggggtgcgc	1860
ccaggccagg gctcgggtccc ctgcctccac agagcccaga acagaaacca cagaaccaac	1920
cccacacctt cagtctagaa atggggcaac. tgaggctagr agggaggtgg gccagtgggtg	1980
gagccaggag cgggccctgg ggtcctgaac cccattctc aggggtccaga gtccagtccg	2040
cctgcactgc gttcctaaaa aggccacaat atgggtgcaa gctgccccag aagggtggg	2100
agctgagaag gctcaaaata ggggtggaca ggtggcttca gggttctggg cctcagtgtt	2160
gtcaatgtca ggggctgcac tgacagggtg agtccccggg gccatccgaa gtgctgtccg	2220
tggtggggcc ctcaggagg atccac	2246

<210> 86

<211> 564

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (71) .. (71)

<223> baysNP5959_A71G

<400> 86

taaaccacaa accaagagcc aaaccatgcc tgacttaacc agaaacaaat gccaccact	60
gtcgaatgtg rctgcccagc ctcttaacac catcttctca ggtggctgac atcccttgg	120

ttcacactgg gggccttgcc ctggattatt tactttcttt tatttagctc aagttagaag 180
 caattttaca cctgaagttg aatgacttcc aaatggattt tagcatagac ccagggaga 240
 gtgtaagaaa gaggacagga aacaattctc ttgacattat tttcaaggca ggagagaaaa 300
 gaccatctca tggcctttgg gtacaaacct ttggcctatg taaatagagc cccactttc 360
 tgccctctga atctcatacc ttgcttccac tgattctgga tttttttacg gtatgatgtg 420
 taacatcgat ccaaggcccg caagtagcac tggatggaaa gcttcccatc cactattggg 480
 tactccgagg ccaaatttgg tttgtagaag tcatacacat tctccatatg gggtccctc 540
 agccctggaa aggcacacaa agtg 564

<210> 87

<211> 494

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (340) .. (340)

<223> baySNP6162-C340G

<400> 87

gaaggtccag ctgttacaaa atgaagacag acaacacaac atttactctg tggagatatc 60

ctactcatatc tatgcacgtg ctgtgatttt gaacataact cgtcccaaaa acttgtcacg	120
atcatcctga ctttttaggt tggctgatcc atcaatcttg cactcaactg ttacttcttt	180
ccccagtgtt gttaggagca aagctgacct gaacagcaac caatggctgt agatacccaa	240
cctggcaata aaaggaaaat atattaattc aaactctatg gaaacttaat acttctctct	300
accaggaatt ggcttattct gttaaattttc tttttgagas tgttgcccag gctgcagtgc	360
agtggtgcaa ttatggctca ttgaagcctc aaccaatcct cccacctcag tttcctaagt	420
agctgggact ataggcacat gccgccacag ccactaatt tttaaatttt tttgtagaga	480
cagggctctcc ctgc	494

<210> 88

<211> 1898

<212> DNA

<213> Homo Sapiens

<220>

<221> variation.

<222> . (906) .. (906)

<223> baySNP6236_C906T

<400> 88

gagccctcag aaataacacc gcatacttac aactatctga tcttcggcaa catctgccgc	60
acacacaagg caaattggtg cgaaatggat ttccctatta taactaaatg gtgctggaga	120

aacactgggc tagaccacta tgtacgcaaa gctgaaactg gatccttcct tacacctata	180
caaaaatcaa ttcaagatgg attaaagact taaacgtag acctaaaacc ataaaaaccc	240
tagaagaaaa cctaggcatt accattcagg acataggcat gggcaaggac ttcattgtata	300
aaacacccaaa agcaatggca acaaaagcca aaattgacaa atgggggtcta attaaactaa	360
agagcttctg cacggcaaaa gaaactacca tcagagtga caggcaacct acaaaatggg	420
agaaaatttt cgcaacctac tcttcggaca aagggtctaat atccagaatc taaaaaacac	480
attaataaaa gctttgaatc cacatagatc actctcaaca gaaagatgtc tccagatgga	540
agatgcagct ggagatcaac agtgaacatc aaaggacata ttcagtgtacc tccaatcttc	600
cctctgatcg ttccataggaa tgggaggggc acagccagca tccccatatg cagaaaagt	660
ataagagatc ccctgattta ctacgttcac ttccccagag atgactacag catttctgca	720
acctgtgtta actttcttcg gccatttgga caggaaaatg gaaagatact aaaaaatacc	780
gtaatgaaat actggccagt gtaatttttg aaattttctc caacctgagc atctcaaata	840
cctttatctg aaattctact cttctataat atgcctagga tagatgtacc ccatcctact	900
cagcayttta aatagaagta ggttattcca tcaaaagctc aaatgtgtcc aagatacaaa	960
ataaatagtg accatatgaa ctctctattc tatcataaca gttcctttca aggtttcaga	1020
caaacatatt atttccttgt tttttcttcc tacagtcact ttaggaaggg cctgagcata	1080
aagagtttgc tagcatgcat accacaacta ctttattttc catataagca taatcagcaa	1140
gtataactgt ttctcaattt gttaaagcct accataaaat cagttcaagt aactaacctt	1200
gactagtaca ccatatgtgg attacacat tttttccttc tttttattgt agtttctcta	1260
cgtgatttta aatgctagtg gatgccaga tttagctaga aatttcacct atttatgaaa	1320

- 112 -

```

atgaatgagt gctttttctc acatagaggt gattttatac ttatttgccc aatgatccac 1380
ccaaaatccc acgtggaaag agggatcctg gtataatctg gttaagagtg tttcttacct 1440
ctcttggtt actggcaatg gcaacactgc catctttggt gtatttgatg ggcgatcctc 1500
cttcttgtag caggggtcca taccctgttg ggggtgtaaaa tgcaggaact ccagccccgc 1560
ctgcacggat cctctctgca agtgtgcctt gcaagtgagc aaccaacacc ccataagttc 1620
actaagcaca cttctctatg tggacacaaa catttagacg tggttcctac tatctagagg 1680
cttataattc taaaaagtag ctagcattgt acattagcat acttcactaa tattgtatgc 1740
tagaagatca attttaagaa gttactgccc ctctagaacc attctaaatc cacattcaaa 1800
atgtaaccgc ttatttgtag agtcatgcat tgagcttcca tacctctcaa tgatctcttg 1860
acacatttaa atgtgtctat ttttgatatt ctaagtca 1898

```

<210> 89

<211> 1351

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (151) .. (151)

<223> baySNP6482_A151G

<400> 89

aaacctgac atatacacaac agtataaatg caagaaaagc tctatgcttt gtagttagcc	60
ctgaatgggt gtttgacaga tacagaattt tttaaaccctc attctctcat agtttaggat	120
aaacaaaagg gattcaaaca gatctgggtc rcctctgggt tgtggcggtt ccatgacaag	180
cttttacact atgcacctac tttcattegg gaaacgggtc tattgatctc ttctacatcc	240
ccaacagtga caatgttgga cttcagcatc tggctgatta ataccagcca gtcggctagt	300
tctgttatag ttttatcaag atcagcagga attgaaattt ccgaagtacg atgagactga	360
acaggaatat ctgacgcaga tgatactagc accacctttt ggacattagg atgagctgaa	420
atgaaaaatg tagcaaaaga gaaattaatc aacaggatgt ttttaattatg gtgggtgtcat	480
ggtgacacgt gtatgtgtat ttaaataaaa tttagtttaa gtaaaaaaaaa ttctaagagg	540
ttattttttc atactgaaat ggctatggta ttacctgtaa tatccatatg tctttggtag	600
ctatcaagcc aacaaaacag ttttgcaaca ttctataaca taatcagcac tgacactgag	660
aaaaattaaa agtacaaatg tgggagaact ggaagtatta ttttattttg gcaagatgat	720
tttaattata aagccaactt attcataatt ttttattttt ttcatttaac tttataatgt	780
gagcatattt tattcttagt aaacacaatt atgaatacct atgtaataac ctatacccat	840
attcactttt atttaaccct tggatattta gattgctcct gaaattttat ttttaattttt	900
taaaaaactt gcaaagaata tcttttcattg tagagtattt tgcacatttc tgatctctat	960
cttagcatag atttcccaag tagaattact gagtcagaaa atacaaaaaa aagtatgtat	1020
ttaatattca ttgccaaatt gattgggttt gatacaataa gtagttgaat tagtaattaa	1080
aactatctgt aacctacttc aggtatgata tattagatga ggcttaaata attttctaaa	1140
atgtatagcc aatctgtaaa ttcagcacia tcttaataaa aatcccaaca ggcttgaatg	1200

- 114 -

taacaaaatc attaattcaa atttctgggt ataaaattaa tattgaagag aaaaggacaa 1260
 aaaacagtca aattatTTTT tgatagagga atatgccctc ccagatatta agttatatta 1320
 ttttagcta atattattaac tcagtatatatt a 1351

<210> 90

<211> 851

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (289)..(289)

<223> baySNP6498_A289G

<400> 90

tgcagatgga ggTTTTgttt gggggctttg tggatctttc tgcgggtgtaa tagatcctat 60
 tactgtttct ggagcaacag ttatgggaca ctgaatatta tcagtggctg cctttcttct 120
 gtctTTTTTT tttttTTTTT tttttgagag acagggctca cctctgtcac ccgagctaga 180
 gtgcagtggg gcagtcttgg ctcaactacag cctcgaactc ctggtctcaa gcagtctctc 240
 tgtcttagcc tcccaaagtg ctgggattac agttgtgaga ttgtgccrg cccttctgct 300
 ttaattttca ctctgggctc ctcaacatgg tccttgtccc aagcccaggg actggcttct 360
 cttctctga gtgtagttat gtatctgggt tctaaccagt aaggttataa ctgtggctaa 420

```

ttcacataac ttctctgagt ctgaatttcc tgcctacaaa atggagaaat aggaccttcc 480
acacaggggtg catgtgagga tgaaaggagt gaatgtataa agacaccttt cccgataacc 540
catactaccc tcattatgac tcttaacatt agagagggct aaacaagggc agtgagaaga 600
ctggcaggca gcagaaatca ttttcttttt gatctcacac accagggcat tccccctaag 660
aggcagtgag atgtagcctg gccctggaac tagaaacaga ggtggctgct gtgctagtgc 720
ctgagatgca cgatgctggg gtcaaagact tgtgtcccca cttcagctg ccagatgcgt 780
gtgtgccgtg acagggctcc cgatcatgcc tcaggcgaca gcaggetgac ccacattcag 840
gggtggcttc t 851

```

<210> 91

<211> 2958

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (348) .. (348)

<223> baySNP6744_C384T

<400> 91

```

cacacctcag acatgggcct cggggagcag gcactcggtg ctccggggat acagagtccc 60

```

tcctaggcgc ttggccacac cagacagtcc ccactcaccc caggcccca acactgagta	120
ctgggtgttg gcatgagagg cacacagcca atggagaagt tgggagctgg tgaggaggga	180
ggcatccagg tggcttgggg gagacagggc catcctctct tagaaacaca gagatgcctc	240
aggatatata tccaggtgaa gaaagcaaaa tactgaactc ggtctcagat gctacttttt	300
gcataagaaa gggagaatga aatatatatt tgggtgtgtg tttgtttytt tttttgtttt	360
ttgggtttttg gtttttgttt tgagacagag tctcactcta tcgtccaggc tggagtgcag	420
tagcgtgato ttggctcact gtaacctccg cctcccgggt tcaagcagtt cttgtgcctc	480
agcttcttga gtagctgaga ctacaggtgt gcaccaccat gccagctaa tttatgtatt	540
tttagtagag atgggggttt gccatgttgg ccaggctggg cttgaactcc tgacctcaag	600
tgatctgccc acttcagtta ggattacagg tgtgagcctc cacgcccagc tcaaatatgt	660
attagtaaaa cagaagtatt agaactgtaa gaacaccatg acagtgcctt gacatctcca	720
ttgcctcatg gaatctcatt ctgagcttcc ttgggttaca gtgagaattt ttcacatggg	780
tattgctgta ggtatgtatg ttgagtaa at gacacaggtc tcaactgtgt cccaggtcg	840
aagtgatctt cccacctcag cctcccagta gctgagacca caggtgcaca cccacacacc	900
cagctagtga gagatggggg ctcactgtgt tgcccaagct ggtcttgaac ttctgggttt	960
aagtgatecc ctgagctgtg attgtgcgac tgcactccag cctgggcac agagtaaggc	1020
cctgtataaa acaaaaaata aaccgagggc tgggccaggc acggtggcta acgctgtaat	1080
cccagcactt tgagtggctg aggtgggcag atcacttgag gtcagcagtt cgagaccagc	1140
ctgtccaaca tggggaaacc ccgtctctac taataaaaaat taataaactcg actgggttga	1200
gtgactcatg cctgtaagcc cagcattttg ggaggctgag gtgggcggag cacgaagtca	1260
ggagatcgag accatcctcg ctaacacggg gaaaccccat ctctactaaa aatacaaaaa	1320

attagctggg catggaggct ggcacctgta gtcccagcta ctggggagac tgaggcagga 1380
 gaattgcttg aacctgggag gtggaggggtg cagtgaagccg aaatcgcacc actctactcc 1440
 ggcttggtcaa cagagcaaga ctccctctca aaaaaaagc actaacaaca actacaacag 1500
 aatcagctgg gcatgggtggg agatgcctgt aatcccagct acctgggagg ctgaggcagg 1560
 agactcgctt gaacccggga ggcagagatt gcagtgaagc caggtgggtgc cactgcactc 1620
 cagcctgggc ggcagagcaa gactgtctca caacaaacga accaaaaaac gaaggaccaa 1680
 tgctcaggcc atccagttcg gaatgcacta aattcagttt tatgaaattc aaagtaactt 1740
 tttccttcat cccttatctt gtatggatta catttatatg ttataatttc tgttttcaga 1800
 ttttgtacag cagcaatttc ttactctctc tgcaagtttt ctcccagtc acgagatact 1860
 ttgtgcagct gcttatctcc aggccttatt aaaaaggtag gttcactctt ttcctatctt 1920
 tccattctgc catacgtttc aggtttacgc agctttcgga ccggaaggcc gaggtctgct 1980
 gccgctttgt gcccatctca ggggcagctc ctgggtcagg ctggctgtca tggggcagct 2040
 cctgagtcag gctggctgtc atggccacct ctgctgtctg cttaggcagc ctgactgctg 2100
 agtgctgcct ttccttgtgt tctctgagt taaagtgaag ttgtatgaag acaactacaa 2160
 gtctgtaatt gtaatgaaat agatgttggc atttatagga tagatgaatt aaaagatcag 2220
 tattcataat aagtatcttt ccctggaaag aagaattctt attcctctca tctagtaaatt 2280
 gttccttaca ttgttcagac aaaggaattt tttttttttt ttgagatgga gtcttgctct 2340
 gtcgcccagg ctggagtgca gtgggtgcgat ctgggcccac tgcaacctcc acctcccggg 2400
 ttcaggcagt tctcctgcct tagcttccca agttgctggg attacaggca cgtgccacca 2460
 taccgggcta attgttttgt atgtttttta gtagagatag ggtttcacca tgttggccag 2520

- 118 -

gctgttttcg aactcctgac ctcaagtgat ccacccgcct tggcctccca aagtgctggg 2580
 attacaggcg tgagccgctg gtgcccggcc cagacaaagg aatttaaaga tgagcattgg 2640
 aaaccctgaa tgtcaaaagt aaaggtgaaa tggcactgca aaccagtgtt gtccttttat 2700
 aggattttta tgaacgtctc gtgtataaaa tagtggtttt caggctgggc gtggtggctc 2760
 atgcctgtaa tcccaacact ttgggaggcc gaggcgggca gatcatgagg tcaagagatc 2820
 gagaccagcc tggccaacat ggtgaaacct ggtctctact aaaaatacaa aaattagcca 2880
 ggcgtggtgg cgcacgcctg taatcccagc tacttgggag gctgaggcag gagaatcgct 2940
 tgaaccaggg aggcaaag 2958

<210> 92

<211> 689

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (63) .. (63)

<223> baysNP7133_C63G

<400> 92

tgtccagctt tgagacccta cagagccatg ttcacctagc acgtatcccg tctgcgggtca 60
 cgstcatttc ttaccttatt ccagggtttt cacctcagct tgccaggctg gagccaaggg 120

ccaacgcagc cgcgccttgt tcgcgatggg agcttcccag gagcccccta tggttccgga 180
acgcgctgcc ggccccatcc tgtttgctac ctcttaaagc caaaggcact ggcgggccgg 240
gccagcttct aaagtcgcgc aaggttagaa ggttccggac aggaacggcg tgaggccaat 300
ggaaggaggt acttcagttt ccctccagat gccacgcgat gggctcagag ctcttgaga 360
actcgggaaa ggaagcaggg tctctgaaga aatacttcag gagtagaaag aggaagctag 420
agggttaaat gcactacaca ggaacagaaa tgagtttttc ttagagttag tatatgtcta 480
gaggtgtagt aaactaaaac aagtcttgaa ttgcataccg ccacgtaggg aagaaatgaa 540
aacctttgaa tattagttaa aaaagggaaa ctgcaacgcc tgtattacta gatagctttc 600
atcaacagct caaaaccgac agatttaaag aagcaacacc gcattttggc tttctaaagc 660
tttaatttgg tttggatccc atgcccattg 689

<210> 93

<211> 2184

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1603)..(1603)

<223> baySNP8021_A1603G

<400> 93

atctctgagg cccacaggg agagctttct ctggaacaaa gagaggaaaa ccttgggctg	60
tccctgcagc cactactgtg gcttagggga catcactagg ggcttgagag ggccttagac	120
tctagcctgc atgggacagc aggggtcaaat tcagactgcg ggggtctgtct tggctccatg	180
ggctgggtga cctctgactc ctgggttcaa gtgattctcc tgcctcagcc tcctgagtag	240
ctgggattac aggcgccccg catcatgccc ggctaatttt tgtattttca gtagagatgg	300
ggtttcacta tggtggccag gctgggtctca aactcctgac ctcaagtgat ctgccacct	360
cgggtctcca aagtagtggg attacaggcg tgagccaccg caccggcct ggaacaggcc	420
ttcttggcag gtgagggtgc ctgtgccagg tcaggtttgc catggatggg cacctggacg	480
tggttttctc ccaagctggg cagtgggacc ttcagagggc cagttccttg gcctgagagg	540
agcatcagca ctgtccaatt ggctgttttg ctgtgaaggt tgtttagagg aagggccaca	600
aactggcagc ctgtgggctg gatggggcct taaatttgtt gtgtggacca tgaggtgttt	660
cagtgagaag tgaacaagta gggccgggct cacggctgta atcccagcac tttgggaggc	720
tgaggtgggt ggatcacctg aagggtcagga gttcgagacc attctgacca acatggagaa	780
accctgtctc tactaaaaat aaaaaattag ctgggcatgg tgggggagag cctgtgatcc	840
cagctactag ggaggctgag gcaggagaat cgcttcaacc cgggaggcag aggttgcggt	900
gagctgagat cgcaccactg cacttcagcc tgggcaacaa gagcgaaacc catctcaaga	960
aaaaacaagt agggctgggt gtgggtggctc acctctataa tcccagaact ttgggaggcc	1020
aaggcaggca gattgcttga gctcaagagt tcaagaccag cttgggcaac ctagtgagac	1080
cctgtctcta caaaaaataa gatgtcaaaa aatcaaaaaa ttagccatgt ggaggggagc	1140

gcgcctgcag ccctagctac tcgggaggct gaggcaagag attggcttga acctgggagg 1200
 eggaggttgc agtaggccca gattgtgccca ttacactcca gtctagggtga cagaccaagg 1260
 ccccatctca aaaaaagaaa aaagaaaaaac agaaaactga gcaagttggc agtgtttctt 1320
 ctgtctgtga agcagttggt tggtcggtga ttcaaggaag ggtgattgag ggccttctat 1380
 gtactaggcg ctgggaagcc ggcagggcga gatgctcatc aaagaaagca ataaagaaac 1440
 acacaccaa aagtctgata gggctgaggt gctgcagaaa gagttgaatt tggccgggcg 1500
 tggtggctta cacctgtaat cccagcacta tggaagaccg aggcagcagg atcacttgag 1560
 accaggagtt tgagaccagc ctgggcaaca caggagacc ccrctctaa aaaaatacaa 1620
 aaattagcta ggtgtggcgc cgtgctactc ccagctactc cagaggctga ggtgggatga 1680
 tcgcttgagt ccgggagggc caggctgcag tgagtcgaga ccacaccact gcactccagc 1740
 ccgggtgaca gaatgagacc ctgcctgaaa aaattaaaat aaatattaaa aaagattgat 1800
 gcctccagaa agagcgtttt ctgcaggtct ttagaggaca tggagacact cctggacttg 1860
 ggcaaaccta gaagggtgtc ccgggggttg acacagtccg ggcaaaggga gagtgatggg 1920
 caagtaggga atcagtttgg ggctgggtgt gcagatgccc ccaaaggggc agaaggtggg 1980
 ctgggagtct gctggtagat gacacctttt caagtgaggg gagaggtggg tgggtacatg 2040
 gggagtttgt ggggacccct gcaaacacag gaaaccgagg ctcaaaaagt atcacgcagt 2100
 gggcaagtgg cgggttttagg atttgaatcc tggactgact ggcctacagc cccggccctg 2160
 gcctctctgt gcatggccaa aatg 2184

<210> 94

<211> 607

- 122 -

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (118)..(118)

<223> baySNP8060_A118G

<400> 94

ctactcaact tatggtttcc atgctcagaa cctcatgaga tacattgcac gttactgtag	60
tacctgaatc cttcattgct attgaatgga tgtgccttat tttccactcc cacctggrga	120
atccaaacat atgctgatgc catgcaaact catgcaaagc gttttgagtg gaatagattt	180
tccacagttg ggatggggaa aggtacaatt aaagaaggga agctgacatt gctgtaatgt	240
aaaaaaatat tttatatgga aatttagcat ctcagacttt ggcttcagaa cataaggaac	300
aagatttacc ctttttctca acaactagac aggcagacaa aacatataaa acagaagttt	360
tcagacatcg aatgacagac aactcaagac agtaaaagaa gagtaacaaa ccagatgtgc	420
cctatgagca cctaaactta ctgcttgaag agtgtttcca gggaacagca caagcaggga	480
gaaccagac agagtctcta tgggttgagg aaatagagtt tggacttcgg agaagctcaa	540
atggctagaa tttgtgattt tagggcagag tctgcagag gacagtataa tcacagagaa	600
agagctt	607

<210> 95

<211> 1151

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (255) .. (255)

<223> bySNP8210_A255G

<400> 95

tggatcccc	atcagttgac	ccaatgcaag	aatctcagac	acacatgacg	caccagttac	60
aggggttggt	tttaaagaaa	aaaacaatcc	cagcaggagg	gattgctggg	attgtttttt	120
ctttaaagaa	gaatgttaat	attttacttt	tacagtcatt	ttcctacatc	ggaatccaag	180
ctaatttcta	atggccttcc	ataataattc	tgcttttagat	gtgtatacag	aaaatgaaag	240
aaactagggt	ccatrtgagg	gaaaacccaa	tgtcaagtgg	cagctcagcc	accactcagt	300
gcttctctgt	gcaggagcca	gtcctgatta	atatgtggga	attagtgaga	catcagggag	360
taagtgacac	tttgaactcc	tcaaggacag	agaactgtct	ttcatttttg	aaccctcggt	420
gtacacagag	gcgggtctgt	aacaggcaat	caacaaacgt	ttcttgagct	agaccaaggt	480
cagatttgaa	aagaacagaa	ggactgaaga	ccagctgtgt	ttcttaacta	aatttgctct	540
tcaagtgaag	ccagcttcct	tcattctctaa	ggctaaggat	agggaaaggg	tggatgctct	600

caggctgagg gaggcagaaa gggaaagtat tagcatgagc tttccagtta gggctgttga	660
tttatgcttt aacttcagag tgagtgtagg ggtggatgat ctaccattac tgtgaggacc	720
taccagtgtg gctggagcag ggactctctc ccaggccttt tactcctcag cacctccctg	780
catactgatt gttgttttta gtttctgtga aattatattc atgaaatgaa aatagcgcat	840
tttactttgc tgtagtgttca taagggttta tacaaaaaag caagtaaata tggcagaaaa	900
gcactcattt gcccctgctc cctcaaaaca ccacagaatg acatagaact aaaggcggca	960
ggaatctaca agaatgaaga aaacacagtg atgctacctg caaatcttg ggagccagaa	1020
agcaaatgga caattgataa tagagttaca agatgagaga aaacaaaaat gtaacctgtt	1080
agttggggga gcctagaaac atcctgtttt gtaccacaga cccctagaaa gtttcaagat	1140
gtaaaaacac t	1151

<210> 96

<211> 518

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (46) .. (46)

<223> baySNP8592_C46T

<400> 96

accagcctct tccctgagac accatggtga aggtgaaggc cagagycaac ggattggact	60
atattgggca cccggtcact agggctgctt ttaattctgg taaagtggat attgtcacca	120
tcaatgaccc cttcattgac ctcaacaaca tagtctacat gatctagtat gattccaccc	180
atggcaaatt ccatggtaca gtcaaggctg agaatggaaa gctcgtcttc aatggaaatc	240
ccatcatcat cttccaggac caagatccta ccaaaatcca atggggtgat gttggcacta	300
aatgtgttgt ggagtccgcc agtgtcttca ccgccatgga gaaggctggg gctcatttgc	360
agggggagcc aaaaaggcca tcctctctgc cgcctctagt gatgaccccg tgttttgtgat	420
gggcgtgaac tatgagaagt atgacaacag cctcaagatt gtcagcaata cctcctgcac	480
caccaactgc ttagcacccc tggccaaggt catccatg	518

<210> 97

<211> 538

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (181)..(181)

<223> baysNP8816_C181G

<400> 97

- 126 -

gaaaaggggtg tagcacctgg gaaagggcgat caactcccag tcagggagcc cacgggtgata 60
 acaccagtca gacgatcaca ccatggaagg gtccaatgag atccaatgga aagacttaga 120
 acatctaagg ttggggggagg tgcaaccttc tgctattcag cccctctgct ccaagcggaa 180
 sctttttttct caggaggtaa tctctaataa caagcagagt gccctctgga gcctcctcgc 240
 tggatatctca gtgcctggac agaggggggac acaccacagc acaaacacgt ggcacagact 300
 caatcccaac acacagccag tcaacgagcc tctggcccct tcctctgggt cctgatacag 360
 agctggcagc gagggcctct gaagagggtta caggagagccc aaggagagtgt caggtagagg 420
 cagcaccagg tcccggaggg acagatgagg gatccctagt aaacagctcg tggacgcact 480
 tgactagcag ttcgaaagca aaaagagatt cggattacaa gagacttttc ccttgcaa 538

<210> 98

<211> 524

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (196) .. (196)

<223> baySNP8846_A196G

<400> 98

tggctgcccc tcggcgcgcg actggacgcg cgggccttgc cagcgagcac cctcatcggg 60

ctgtcgctg acagcatacc tcaaaaggcc ctagctaata aacctgtaag cccagcattt 120
gagagaaggt aggggtgtgta tatataaaag gttgtgtaca actccacgag gtgaaaaata 180
ttcagtaact tgttttrcata gcatttgtgt aaagactatg atctcatccc aataaaatga 240
tatattaaac cttcagatta atgactggct acagagtaac aaaaaataaa gaatttaatg 300
tacagtaa at tctctcccat acaaaggctct agtctgatgt tttgtgtaca aactcacatc 360
tccaattaac agtattttatt gaggggtgact ttgtattgca ctaacgtcta ttgctattac 420
ctgttgtgat tgataagtaa agccactcat tgaaaaaccc aattccaaac accacagttt 480
gtgacacatg aagtaatgaa tgactcttgg tatgaaaacg tggc 524

<210> 99

<211> 1150

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (351) .. (351)

<223> baySNP8943_A351C

<400> 99

ttctgcttca ccaccttgct tgcactggct atttttaaag atttggtcat ctagtaattg 60

taaaagtatc aagttgcctt actttttatctt ctttgattag tagtaaaggg taggctgggc	120
atgggtggctc acacctgtaa tcccagcact ttgggaggcc gaggcaggtg gatcacctga	180
gatcaggaat tcaagaccag cttggccaac atgggtgagac cctgtcgcta ctaaaaatac	240
aaaaattagc tgggcatggg ggtgggcacc tgcagcccca gctactcggg aggctgagac	300
agaagaattg cttgaactcg ggaggtagag gttgcagtga gctgagatcg matcactgca	360
ctccagcctg ggcaatagag agagactcca tctcaaaaaa aaaaaaaaaa aaaaaaaaaa	420
gagctaacag tttgtcatgg acttcttact acttatatctt tctgtacata ttatatgtac	480
atctatagag tggtttcctg ttaccattgc tcattttctt taatgtcaaa ccttttgaga	540
tagtttaatt atattgttta acagcagctt tataaaagaa ataaacagat ataagatgat	600
aaataaaaaa atataactag taagtgaaaa taaaatggcc aatttgaagc atttttttct	660
caatatcaaa tagaggaaag acctcaattt tgaaattctg atttttttaa ctaaagactt	720
gttttctagg catcgctctc tgcttctgct gctcagacca agggttatgg caggggaggg	780
actggtgcca tgatgaccgc cccctgtgc tactcacaga gtgaatggga tgttctcact	840
ctcgccacg gtgccataca gagaaatctc aaaggcctga ttggtatggg tttcactctc	900
agtcccagaa aaatgaatct ttacttggtg atggaagact gttggggagg aaattcgaac	960
atgttgatca atctttatga aaatatcaca accccaaata gtcaggcaat tcagaaccac	1020
agaagtatct cactagcact caaaccggaa gtgcacacac atggaaccac tgggtgtggc	1080
tggaaagact tcatcatgca cagtgttcat acctagaaaa tgcagacctt gaattctact	1140
ccctttcaga	1150

<211> 783

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (88)..(88)

<223> baySNP9193_C88G

<400> 100

```

ctgcgggcggc ggggtgcagta gcatcagcgg gctcggagac acgctgttga gtgggggggaa. 60
acccccccagg ccgttgaggc cgaacgcsgc agcctcagac ccgggggcgt aggggaggcc 120
ggcttgaccg tagacctgcg cgttggcggc ggccgcggcg ttgaactcgt aggcggcgcc 180
ctcggggtag ttgtacacgg cgggcttgct gctgtccagg tacacctcgc ccaggggccg 240
ctccaggggg atcttgagct gcggacgggt caggggctcc agctcgttcc cttggatctg 300
atgcagtagg gccatcccag atgctttggg gtggagggtc atggtcattg tccgtggccg 360
cgggcagggg gcagaccgtg tccccgcagg gcagaaggct cagaaaccgg cgggccacct 420
ggaaaaagag cacagcccga ggttagaggc gacgcatcgc atgtcccgcc gacacgcgag 480
ctctggcccc ggccctgccc cgggagcctg cgggtccggg gaagccgggc gacccgacgg 540
gagcaagtgc agtcccagga cgaacgcctt ccgtcagctc ctgggctccc gggcctccaa 600
ctttaagtac tggctctccg agctcatatg cattacaaag gtgctggagg acggccaggg 660

```

- 130 -

actgttgcc tgcctgaca ttggcttaaa catcaactcca agcacaactc gatttggagc 720
gatcccaaag agcagctttc ctgaacctta ctttacttgt ctttcctgc tggatagagg 780
ctg 783

<210> 101

<211> 611

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (329) .. (329)

<223> baySNP9443_C329T

<220>

<221> misc_feature

<222> (391) .. (391)

<223> Unsure

<400> 101

tctagaacaa tcctcctgcc acaactttca ccctaccccc acccgacccc acccttttat 60
acacatcacc attgccagta ttgccttggt ttagccaatc aagatattac catcctcaaa 120

- 131 -

atatacgatg aacaaggaaa aaggtaattt tggagcaggt gagactctta agacagtctc 180
caccctcctt cctttccctt caagttcact tttgtcactc aaaactgcct gtcacccctgg 240
agaatacatt tagagattcc aaatgtaaaa catgcatttt tggagaaaac aaaaataaat 300
tcataatcag gattatgaag cagaattgyt tcaaaacagc aagctttcat tttcaatgca 360
atgccaaggt cattcactaa tttgtaagag ntaacctgag cagtacctga ctctgatcag 420
tccagatcga ggggagatct catttctaaa agaatttcca atctgggcag cagcaaaaagg 480
caactttcct tgggtgaact ccaaaagtcg tttgaaattc aagaaaatcc cctgtgcagt 540
ttctgggtctc aagtacctat aaatttaagt aagtcagtct gttacaaaga aagaaattat 600
gttttccaac a 611

<210> 102

<211> 589

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (187) .. (187)

<223> baySNP9516_A187G

<400> 102

ccagagactt tccagatatc tgaagaagtc ctgatgtcac tgccccggtc cttccccagg 60
tagagcaaca ctctctgccg caacccaact ggctcccctt accttctaca cacacacaca 120
cacacacaca cacacacaca cacacacaca caaatccaag acaacactac taaggcttct 180
ttgggarggg gaagtaggga taggtaagag gaaagtaagg gacctcctat ccagcctcca 240
tggaatcctg acttcttttc cttgttattt caacttcttc caccctatct tttaaacttt 300
agactccagc cacagaagct tacaactaaa agaaactcta aggccaattt aatccaagggt 360
ttcattctat gtgctggaga tgggtgtacag taggggtgagg aaaccaaatt ctgagttggc 420
actgggtgtac ccttgtacag gtgatgtaat atctctgtgc ctgagtttgc tcactataaa 480
atagagacgg taggggtcat ggtgagcact acctgactag catataagaa gctttcagca 540
agtgcagact actottaccc acttccccca agcacagttg ggggtggggg 589

<210> 103

<211> 1584

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1546) .. (1546)

<223> baySNP9698_A1546G

<400> 103

gcccagttgc ccctggtccc caagcagcag cccctctgc ctccaggggtg ggccctggagc	60
aggagggggg cctctgcccc ggggcggggc tctctggggc cgccgtcgcg ccgccccctc	120
cccgccaccgc ataccttgcc cacagccgag cagctgggag gctatttata aaggcgggtg	180
agatcagcgg ccggccaagg ctataaatc gcaggccgcg gccggggccc acaggagcag	240
ccgccccggg caccggagct gcgggctgcg tggccgggat gagcgccagc acgggcgggtg	300
gtggggacag cggcggcagc ggcggcagta gcagcaggta gggctcggct ggggcacccg	360
gagccccctg cgtctctcat gccactgcc actcaccca cccgcagctc acaggcctcc	420
tgcggggccc agtcctcggg ctccgaacta gccctggcca caccggtgcc tcagatgctg	480
cagggccttc tgggctccga cgacgaggaa caggaagacc ccaaagacta ctgcaagggt	540
gagacttggc cttggggaca tgcggcctca cggccactgc agggacccag ggcagtcctg	600
ggccacatg ggccagatgg tcaatggggc cgagggtgtc gggggcccag gggagtgaga	660
accccccca cccaatcta catctcccct gggcaggcgg ctaccacct gtgaagatcg	720
gcgacgtgtt caatgggcgg taccacgtgg tgcgcaaact gggctggggc caettctcca	780
ccgtctggct ctgctgggac atccagtgag tgctccttc gcctccgggg ccagcactg	840
gctgggatcc tgtccctggg cttgcttggg gccaccctga tccccgccgt ggtcctgcc	900
agggccacag cctacaaggg tctcgggtatt gcaggcgcaa gcgctttgtg gccctcaaag	960
tggtgaagag tgcggggcat tacacggaga cagctgtgga tgagatcaag ctctgaaat	1020
gtgtgaggca cctccctacc ccactcccag ctcccctgga gctgcctggg gcctggcaat	1080
gcgggtgcaa ggcctgccgg ggctctgtgg gcaggggcg ggctccctga ggggcagcct	1140
ccagctggct gtgccaagg gggaggatct ggaggaacag gcgagggaca ggaggggtg	1200

gcggcctttc ttccagcagg gccagctgg agcaggagaa gggtaactg aaggagctg 1260
 tgggcttcag ggcagggtgg aaccatctgt ggccccttgg cttttgctcc aggtccggga 1320
 cagcgacccc agtgaccca aaagagagac cattgtccag ctcattgatg acttcaggat 1380
 ctcaggagtc aatggagtcc gtatcctttg caggaagagc aaagcagtgt ggcagccaag 1440
 ggccggcaaa tggggggggc ctcgctgcta gagcctgtct gcagaccgc acaatgggct 1500
 tgcacccctc ccagtaacgg gagcctctgg cagcaccgc ccccraggta actgtgttta 1560
 cgtggaggca gtaacaagct agcg 1584

<210> 104

<211> 744

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (277) .. (277)

<223> baysNP9849_C277T

<400> 104

gggctagagg ctgagcacct ttggaaacaa catttaaggg aatgtgagca caatgcataa 60
 tgtctttaa aagcatgttg tgatgtacac attttggtat tacctttttt gttgttttgt 120
 agcaaccatt tgtaaaacat tccaaataat tccacagccc tgaagcagca atcgaatccc 180

tttctcactt ttggaagggt acttttcacc ttaatgcata tccccctctc catagaggag 240
aggaaaaggt ataggcctgc cttactgaga gccaaayaga gcccaggaga ctccactatg 300
ggaaacctca ttgctctgta caaagtacta gctaaaccag aaagggtgatt ccaggaggag 360
ctagccaaac aacaacaaaa acaagaaatg ttctgttcaa gttttcagct ttaagatatc 420
tttgataat gttatttcta ttttttattt ttttcattag aagtgaccaa attaagatgg 480
taagacctct gagaccaaaa ttttgtccca tctctacccc ctcccacctg cttacagaat 540
ggatcatgtc ccccttatgt tgagggtgacc acttaattgc tttcctgcct ccttgaaaga 600
aacaagatc gtgtttttgc cactgattta gccatgtgaa actcatctca ttaccctttt 660
ctggggttga agctgctgtc tctagaagtg ccatctcatt gtgctttgta tcagtcagtg 720
ctggagaaat cttgaatagc ttat 744

<210> 105

<211> 560

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (249) .. (249)

<223> baySNP9883_A249G

<220>

<221> misc_feature

<222> (506) .. (506)

<223> Unsure

<400> 105

gatctgactg tegtgtgttt tgttcctttt tttctttttac actaagtatt ccattaattc	60
tcagagaaca tttccacaac ctcaaaacca cagagagggga ggctaggggt tagaaçtcac	120
ctggcagtga agagcctgcc tagacctgag ggtgccagag cgcaggccac agcgcaaattg	180
ctccggagag tagccctcag ccagccactg tgaggggtgcc caggacagag gagacgggaa	240
aggggaggrg tgagccacgg ccacggccac catggcgçct ccctgttcac cagggtcçct	300
tcgatgggct cgggtggggtg ggggtggçttg tccctgtgct gctgagçttg caggactgtg	360
cçttttttta aaggattagg agçctgccgc ccçttgggtc tggttactaa ttçttactct	420
ccçtcçccçc tgcçtttttc aaaattcaag gtgaaatctg tgcactgtca agctggagac	480
acagttggag aaggggatct gctcgnggag ctggaatgaa ggatttataa cçtttcagtc	540
atcacccaat ttaattagcc	560

<210> 106

<211> 555

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (249) .. (249)

<223> baySNP10079_A249G

<400> 106

gtaccgaggc aggccgcagc tcccaccatt gcgtacagcc ctggcgtgac acagtctgca	60
ccgggtctgc accagttcct gaagatgac cagtcattgg gatggtaggc cagctgctcc	120
acgccaattc ccaccatcct gcccgctatc gcgcccacag ccatgctggg gatgaagagg	180
cccgacggga tcttgaggag acacagagaa aagcaacatg agggaaaaag accaagtccc	240
cgcttcacra cccccaagaa acacattccc cctcgacggg cttgcattta gcttcagtct	300
tcagaggagg tgcaactctg caaaataggt cagctgggga aagggtgggac aaataatttg	360
acctgcctag tcagtcatat ctactgcaac ttagagagga cgcaatttta tacttttgatt	420
ccctctcctt caaaagctgg ctgggtttgc ctgctgtgga ttaaagaatg ataagcccca	480
ctgcaaataa cattcaaagt gagcatctgt cagttgagac accactttct ctgccccctt	540
gccatgtcat tcaga	555

<210> 107

<211> 609

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (107)..(107)

<223> baySNP10481_A107T

<400> 107

gaactgcggg ggactgggcc gcgggcctcg ggggagggcg gccgccggcc catccagagg	60
tgccccacgt agcgggacag cgctgtcggc ccggcgcgcc tcggagwgtc acggcgccctc	120
gtccaagtgg agccccgaac ccctgaaggc gcggcaggct ctggagagcg gggctcttg	180
cgccctgggcc aggtctgggg gctcttgcca aactgcacgt ggccctgtact gctccagggc	240
cccttggggc tcgtccccga gcggggactg cggggggggtc ccccgagcag catgttttcc	300
acagcgcgtt atgtttggag cgggccctgc gccgcctgtc gccatggaaa caaacagg	360
gcggtggcgg cggccggagc ggaggccggg ctggggcttg ggtgggggag ggggaagagag	420
gctcgcaggc tgcgcttag gtgacgggaa ctcaggcgcc cctctgcttc atccgggtca	480
cgccccgtcc gctagtaccc acagtgttcc acagtctggt ccttggtccc tcgctgtac	540
ccctggtctt ctgcgcctgt ccctggtgtc cctttcctct tttttggttt cttcactctg	600
acctcactg	609

<210> 108

<211> 2388

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (367)..(367)

<223> baySNP10542_C367T

<400> 108

ctctaacttg ctgtgtgatg agtgaattcc tttcggaagg ctccagtttt ctctgtccc	60
cctttctggg ctgctgctgt cgagatgttc agggcagact caagtcgcca agatggctcct	120
ttgataaatc tcatgggtgtg gagtggagcc aggtcatggg gagacactgg gggagcaggg	180
cagcctctct ccccttccag actctgcaact taggctggct ccctgtgtc cctgtctcca	240
gtctctcctg gcttcagctg tgtgactttg agtaagtcac ttaacctctc tgagcctcag	300
catcctcagg tgtaaaatac actgggtcct gcttcctctc tgggcttctt tctcttcct	360
ccccttytct gggctcccct gacccccage ttcacctca cctgtgtgtc caccacttg	420
gcaccctggc tgggtgtgtc cacatggccg tagaagtga caggtagcgt gaactcgggc	480
cgggccttct cccaggggtt gccgtagcga agccagtcac cggcctcctc catctgcacc	540
caaggcaggt cagggagaaa ggccagcagt atcagtacag gcactcacag tgcacgggtg	600

ggcaggggtgg gggctgtggg cgggtgtacc ctacaccaag tataagtcag gagctctgag	660
gtggggccct ggtctgctgg gctatcgagt gggacacgga ccacctgttt caggggcacc	720
agctggcttt gggtcggggg gtggggagca gcaaggatgc tttccacaga gcttgcgggg	780
ctgtttcggga ctttccaga gatgataaac aagtgggggt cttccccatc ctgactagac	840
cccacaagtt agagccaagg ctgctcacct gccagcccc ggagatcttc tggttaaaaa	900
tcccaaactc atagcgaatc ccgtagccat aggcggccag gcccagtgtt gccatggagt	960
caagaaagca ggctgggggt gtgcagggag gtggctgtca gggaccacgc aaggaggacc	1020
ccatcgcccc actccaccct cagggcctg tcttcttacc tgccagccgg cccaggcccc	1080
cgttgcccag ccccgcatcc tctcaattt cctccagctc ctccatgtcc aggcccagct	1140
ggaggagtga gggtgacagt ggtcagggtc aagtgtcagc agtggaatcc cccagtcccc	1200
acggcttgcc ccaccccaca cacacctggt aggtggcctc gtcacaggca ttctctaagg	1260
ccagggtcac catggtgttc tgtagcgtec gtcccatata gaactctaaa gacaggtagt	1320
agatcctctg cccagagaga cggatgggca gggaatgggg tcagggccac acaccaacac	1380
tcagccaggc ccagccacgc ctggacctct ggcccgcctg ccctgctcag cagtcccatc	1440
cctgtcccca atttgtttct ccctgtctca ggctttgggg cccagcggtt aaggttctgg	1500
tcccagcatt cctctgactt tggacaaatc actctctttg gcctcagtct cctcatctgg	1560
gaaatagcgc tggccatacc cacttcaggg actgaggtac tcgggagaat gggcaccct	1620
tccccctgca cacaccccc cgcacagccc agcaggatgc caggacatgt ggaagcgcct	1680
ccaagagctc cccaggaggg caaggccaag gccagagaa aaaagtcatt tgctcaagg	1740
cacacagtgg ctagagactg ggctagagac tgtcacctcc catccttgca ctgtccagtt	1800
ccccttggcc ctcaagcctc aatcccaagg agaccagag gcaccagaaa ctaggatgct	1860

gccagtgcct ggtctcccag tttcctgggt cccctcgtgg gccgtctgcc cgtcccctccc 1920
 ccactcccca ccgaggcgtg tcagggttgc gacatttacc agtgacccca ccggacactt 1980
 gatctctgcc gcccagctg cccagcccc gcctgctgca caggcacacc gcgcatacat 2040
 gcagcaactg atgtgtcctt ccacctgggc ccagccaggc cacaggcgcc gtctctgcca 2100
 ccagcaccga ctccaacctt ctccgagtgg gcactgacct tttgcagcca gccacactgc 2160
 tctgagctcc ctgaccccca ctctgcccc aggtttctcc ctccagattgt cccagcacc 2220
 cttgtgcctg gcacccctgg attctccacc cccaagaacc tagagtgacg aggggcagcc 2280
 acttaagtca agatcgccag ctccctggca gcgccttcag cccatacccc cccccaggc 2340
 tccccagcag caccttgggg tccttctcat agtagtgctg ctgcgtgc 2388

<210> 109

<211> 597

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (510) .. (510)

<223> baySNP10600_A510G

<400> 109


```

gggaagggaa aggacctgcc agtgggcagg gtccttaagg aggccatctg ttttggcagg      60
atacgtacta tcagccccgt gccctggaga aacatgctga cagcatcctg gcactgggtat     120
gtctaccctg gcatctggga ctctgcatct ttcagacca cctgtcctct tgaacttagc      180
cctccctaac ttgggagcaa cagtgccctg gggttggggg atgccctggg ctctgcagca     240
gacctctcca acacagacac acaggcacac tctaaatgtg cataacttggc actccccctt    300
ggtatgtagc actgctttct ctgggggcaa cctgagccgt aaggaaaaca tgtttactct     360
tgggaccatc tgcagggtgt aagtctgca gttccccagt gacctgtcct ccctggcaac      420
taacctcttt ggctgcaggg acagctgttc tttctggcac agttcctgtg gtgacgtttg     480
cgcatctctt ggggaccagg ccaggggctr tcctgagcag ggccaattga aaaggcttga     540
ttaacttgag tagacagaga gactgccttt aaatgtgaga gaattatgtc tggagat        597

```

<210> 110

<211> 569

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (402) .. (402)

<223> baySNP10621_C402T

- 143 -

<400> 110

acatgtatgt ccgtgttgca aaaataatac atgcctcaaa aacctgccta ggggagccct	60
agtgcctggg tgctgtggcc tgaggtagca ggtgggaagt tagggatgtc acagaaatgt	120
ctgtgtctga atccaggatt ggggtgggtg ttggagaggg ctttcagctc ccctcctccc	180
aggggggcct ctttttttaa cggctgccgt gcccttcctg gcccagccct aaacctaaat	240
tcaaattctcc tccatgcctt tgcgcaaagg acctccctct tgcactctaa gccttagttt	300
cctcctctaa aaaaaggggg tctctaaaca ggagctacct cataggggtg ttgaggatta	360
agtgaaccaa tacatataca gtgcttagca ctttaataagt aytccccct gcgacaccta	420
gctgaactat ggtttggtgt ctgatcttga gaggttgatg taacctttta aaggcctcag	480
ttcgctcacc tgtgaaatgg gtctaagaat agcactgatc tcacagggtt gtgatgcaga	540
ttaaaggaga tggcatgtgt aatgtatac	569

<210> 111

<211> 631

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (431) .. (431)

<223> baysNP10745_A431G

<400> 111

```

aggcatctac ctgggtcttc atggtgttct gtgtagacac aaagagctcc atctcccctg      60
cctcgccctt tggaacagca atggtgcagt gagtctccag gtagaagtgc tcttggccac      120
cgatgtatat ctcccctggg gaagcagtga gatccctcac agtgagccca atgctgcaga      180
aggggccagc ttgcctaagg agagagtata ctctgccaa ggtctggggc aggaagcaat      240
ggctacctga ggggtaacct caaggtttcc cacttggggg ggaaaaggat cccaaagtct      300
tagctatctg ggagctgagt gctccagcct catccccacc ccacaacaa agaaagaacg      360
acactgaaat gcatccagtc caaagttctc ttctcactgc agcttatgga aatcaaggat      420
ttcaaaaacc rtcattgtaa aattttggaa aaagtaaagc agggattaat agatgtgatt      480
gaaacactga aaaccagcgc atgttcccg acctaagcta ccaggcctgg tggagagtcg      540
gcttcatacc aggcttggtg gagagtggc ttcatagtga ctttgcaaag cacaacagcc      600
aatgtaaaaa acagttccaa aagaggtagt c                                     631

```

<210> 112

<211> 2956

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (2831) .. (2831)

<223> baySNP10747_C2831T

<400> 112

taatacatgc acatccaggg acggggagct cactcctcta cacaggcagc ccattctcag	60
ttacctcaat tgtgataatg gctggtagtt cttcataggt gattttcacc ccttgggcag	120
ctctctgtgt gtgttccggg gtgtcagcaa ccacagcacc aatgatatgc ccaacacaag	180
taacctagta gcagagacag actgttaaag aacgcaacca ggctcatggt gaaacaaatt	240
atTTTTggat tgttcaaaaa gccaaaagaa gtccctgccc tcacaatcaa agcacacttt	300
aggaatgcc tagggcctct taatttcctt atcctactga ttgaggatca ctaggatcaa	360
gatggcaaac acatttcac tcaagggcca attctgagta tttagtactg gcagactatt	420
gagaagctga accagataga atgtggcaat tgattccttg tttgccatga gcagaaaggg	480
ggatatggca ccaggaagtg catttgtcaa ttcggattca ctccaacacc attggtcttc	540
ctatggagac tcagaaggca aggccacatt tggctagtta ctattgacag atcatgacta	600
accttaggcc ctgaccccca gttttatttt cttttcacct caccactctc ttttatgttc	660
tatttcccag atttatacca aaagcttctc aaaggctgta aaggctgtaa gcatcaatat	720
aaggcctgta agacacgtac ttacaagaca tgatacttta agtatcatgt cttatacttc	780
aactaatacc caaaagcagt agctctcaaa tactggttct tagacttgat gaccataaaa	840
aatatTTTTa aaaatttata tgataatgat tgttgtttta ttttgtttta taattcagtt	900
tcataaaaagc ttaatggatc tccttcagag ataattgtca tccaacatcc ccgaaaaagt	960
aaacaacaaa aaatttttgt acaacacatc actttagaag atgaagtttc tgacaatagg	1020

aaccaacaat tagtatgcat gtctctgata attatctctt atggcccaaa taagctattg 1080
actcagttgg ttagtgcaat ggtgggttaa tctggctggt ggttattgca atgggtggta 1140
aatctggctg actttcacta gccataatgc tagcactgct ctgagaagct cttaaagtat 1200
gtaaagcaat ttgttcttct atgaaatgct ctctcatgg agtctttggt ctcatatttt 1260
tagttttttg ttatctcctt cactttttaa tcaataataa gatgaattca ctcttcagaa 1320
gtacccactc atgtetaatt tgcaacattg gatgtctatt ggaattacaa aatgactgtc 1380
gagaactatc ctatgagtaa aatataagga cttttgtagc agctgtctta aacatttgaa 1440
aaattttggt tgttggtgaa gaattccaca tagttgaaat caatagataa actttcatgt 1500
aagtgaatta ccaattcacg tagtggtggt attgtgattt ctagttagtg tactaaatgt 1560
attcttattt tattttaatt aaagagctta ctgttgctcc ttaagaaccg aattgtagt 1620
tcaaatgcaa tcaccagtgt tgttttactg ccactttggc atagagacat cctgccatgt 1680
acaaacagca gccatcaatt aaataaacia gtaacatatt ctatcttttt ggattgtcct 1740
gaatatgggc caactggatg atggccataa tccatgcaaa tgtataacct ttccagatca 1800
ggagtttggg gcaatgtaca caaattaaaa cttcaatact tattcaattt acttcatata 1860
aaaaaatcca agacttacct tatccttcgc aaagactgtc tcatcattac aaattccagt 1920
tatgttactc ccaggaacat catcagcgga aatgaaacia acaaaccctg gaaccttctt 1980
agcttctgat gtatctatgg acctgcaaga atgagtgggt tgagggggcca ggtcagcaag 2040
ctggagcagg ggacccatca cctgggttgg caaccctgtt cttattttga ttggcttggc 2100
tccatcctaa ttctctgatt ctctgcttct tttctattag attctaattc aattatatcc 2160
tattctgcaa atgttgatta aatcctcacc atgttcaggc cactatgctg aatgttgctg 2220
gggatataaa gtgaataagc cagccaggca cagtggctca tgctataat cccagcacct 2280

tggcaggtca aggtgggagg atcacttgag cccaggagtt taagaccagc ctgggcaaca	2340
tagcaagatc ctgtctccat ttaaaaataa ataaagtga gaaggcaggc caggcctctt	2400
tggatgttac gtgatgctct gtctggtctc caagtacaag caagccatat cagaacgaac	2460
agcacttact ctggagcgct ctggctcatg cacacatcac acctaactcc ctcccaaat	2520
cagcacatgg agcccggctg tgccactgat ccaatggccc tgaacagctt cataaagctg	2580
gatttgctct cccacattca ttgtgctatc ccagcatgac agggcatcct accataatta	2640
ggcaacacga accgcaaagg gagaatgccc gactatatga tcaaggataa cagtctcaac	2700
tatgtactca tcacactggc acatgcccc atggggaaat agggcaacac atttcaggga	2760
aaggtatgta aactgccctg aagttctaac catcttccaa atgcttaatc ctcacaagaa	2820
accctgaaag yacttatcct aattcccatt ttatgtttgg ggaaactcag actcaaggaa	2880
gttaggtagt ttttccaaag tcactaagcc agaaagcagt gtgactggga ttattggaac	2940
tgaggttaag ttagga	2956

<210> 113

<211> 557

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (64) .. (64)

<223> baySNP10771_C64G

<400> 113

ggaggtagg gtccccaggg aagagcagaa cctgggcca cagagttact gaaggcaagg	60
aagsgtggcc tgtgtcacc tggcggccct gcctgggtct gctcctcgct gtgcacactg	120
catcacgccc cgctggctgc ctccctctgc ctcttcccgt acagacgcac actcacagag	180
atcatgcaca cgacacgggg cggggacgga gggcccatgg cagagaaggg agcatggggg	240
ccgggagggg ggggtgctctg agccagaggc ggggggttggg agggcagccc agccagggtg	300
cagcagccag ggcctccttg gagtggcca cctggagtgg agtggcagtt tgggtggctt	360
ctaggcgaag atgccccaa cagtggaggc gatgacgatg cccaggatca cacagcagat	420
gatgatcatg attctcttct gcatgggaag cgggcaagag aggcctcata cagtgttggc	480
ggcacgtggg gtgggactat tgcaaaggct gatgactgga cagtcggagg ggatccaagc	540
aagggaaggt gactgcc	557

<210> 114

<211> 544

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (339)..(339)

<223> baySNP10870_A339G

<400> 114

```

ggcagttctc gatattcacg atcacggcctt tgaagtcccg gtcaacctgc ccctctctgt 60
ccccggcatt cattgacacg ggctttccct ggctgggat cccatcccaa cacacacgac 120
agaaaacagt gcaaaataat aacacaaatg ccaaattgtac acagtgtaca actctgaact 180
gagaaagtgc aaggagacca cgggaatgga agtgggtagg ggtcgggagg atgggcacca 240
ggctggtgtc ctgacagcca cacctgggtg caggccacgt gtcctcacgg ccaaggtaac 300
cgggtgtctc aggcacttaa taaatattaa gggtgaccrg tgactcagge tctgcctctg 360
ggaagtggca tcatttggtg aatgagtttg gtctcgggtc caccacggat tcagccagat 420
catttccgac gccatgaatc cctttcctgg cttaaggaag gtacaaaccc acctcgaaaag 480
acactgggtg ggtcatgatt cgggggtgac agggcaaagg ctaacctggc tgtctagcaa 540
ggct 544

```

<210> 115

<211> 1357

<212> DNA

<213> Homo Sapiens

- 150 -

<220>

<221> variation

<222> (1290)..(1290)

<223> baySNP10877_A1290C

<400> 115

```

ggtaagaatc aatacatata acacagggga ttttaggata gagaaactat tccatgtgat      60
attcgaatat ttgccaaggt cacagagtta gctgggcca gacttaaact caagtctctg      120
actcccaagt tcatgctctt tccattaatc taagttgctt cttttgatat ggaatataac      180
aaagactaca ttgactatga aaatataaac ttaggggagg aaaaggcaac tgggaaagaa      240
aaaatatatc cttagtctgt caatcagaga aaactgttag cttgagcagc ttcaacttgg      300
ttaatcagta tccctctctt ctaccattaa gaaagaatac gtacttgcaa aagaattaag      360
gaatctatcc tctcttccaa agatgtccga cggctttacg ataatggctt ccggaatgc      420
atctctcact actttctctc caacagccta aacaataacc aaacaaacct gttttgagtt      480
tagagacaag tgaataaagc atccattctt tccactatta agacatgact tgtatttcaa      540
aggcgatatt ttctccaga taaaggtaat catgtaattc ataaaactca gttacacaga      600
acttttaaaa aatataatcc acaaaaatgt cctgcacctt acagattggg ttgggtctct      660
tccaattttt ttattttaag ggaagcttac attgaagaag gagaaaaatc aaagtagaat      720
ttcttcagcc tccatttttc cttctattta cagattctct ggtttggtgc aaccatctag      780
cagcctgtta gaaaaaggac agtatgggtg cagcaggctg caataatgga agtgtcacca      840
gtacctacat atccaaagga gggtggggat agagtcacta atcctcctaa tctcaattgc      900

```

- 151 -

tgtaccatcc ttacttggtta tcatctacta gcctcctagg caagtcttct tgttcgatga 960
 agatatcagc acctaattca gtcttccttt ctacttccac caccactgga ggtgacatga 1020
 tgtccaagtg ggcttggact tctcaggttc ttgagctgct caactccaac gacctcctct 1080
 tccttccacc tctaccactc ttaacttggg tacaccacct actgtatcaa catctggaat 1140
 tgctcttctt ctgaggtatt aaatgaagac atcctgctct tggatgtcca tttcctacaa 1200
 tttccagcct gcttggttctt tgttcatctg ctctgggat acctgttctt caaccttctc 1260
 aagaactcta gtgcaactgat tctgcttccm ctgtatcaac tcttccgact gttcctgtcc 1320
 ttccctctga attccagatt aggttccata gaccatc 1357

<210> 116

<211> 623

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (140) .. (140)

<223> baySNP10948_G140T

<400> 116

gagtccagat cccagcccc ctctccagat tacattcatc caggcacagg aaaggacagg 60

gtcaggaaag gaggactctg ggcggcagcc tccacattcc ccttccacgc ttggccccc 120

gaatggagga ggggtgtctgk attactgggc gaggtgtcct cccttcttgg ggactgtggg	180
gggtgggtcaa aagacctcta tgccccacct ccttctctcc tctgccctgc tgtgcctggg	240
gcaggggggag aacagcccac ctctgtgactg ggggctggcc cagcccgccc tatccctggg	300
ggaggggggag ggacaggggg agccctataa ttggacaagt ctgggatact tgagtcctac	360
tcagccccag cggaggtgaa ggacgtcctt cccaggagc cggtgagaag cgcagtcggg	420
ggcacgggga tgagctcagg ggcctctaga aagagctggg acctgggaa ccctggcct	480
ccaggtagtc tcaggagagc tactcggggt cgggcttggg gagaggagga gcgggggtga	540
ggcaagcagc aggggactgg acctgggaag ggctgggcag cagagacgac ccgacccgct	600
agaaggtggg gtggggagag cag	623

<210> 117

<211> 555

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (286) .. (286)

<223> baySNP11001_C286T

<400> 117

- 153 -

```

gggccaaagcc tgcaaacttc ttgatattcc ctcgatatca caaagaccct cagaaaacat      60
cctcggcgac  cacacaggca cgaggatgac gctgcacaga gaaggagcca ctgggcaccg      120
ggcggccccc  ttcccaaaga cccacagtgt gggggcacac accacgatca tcatgtagcg      180
ccggccgccc  tgggtgcagct cctgcaccat ggccgggaag tcccggaagc catccttgtt      240
gaacgtgaag  tccctccggg agtccatgta gtccaggtcg ttccaytgga cgtcctgcag      300
ccacaacacg  ggaccgtctg ctggggcctg aggagacgcg tcccggccag ccccttgctt      360
cccctgccac  ccccccaact caccaggggg aagtgggccc tggtcatgtt ctccaccacc      420
tggcgggtga  tagcgggtgga ggagtagccc cagcggcaca ggtggaagcc caggccccag      480
tatggcggca  tgaacgggta tcctgcaggc caacgccgac ttcatgaggg agggaggagg      540
gagccttggg  gcggg                                           555

```

<210> 118

<211> 1051

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (215)..(215)

<223> baySNP11073_C215G

<400> 118

gctgcgtecg ggcccccggc tgtcggcgcc ctgcgggctc agatcatccg ggcgttgag 60
 agggaggcag agagcgggtc ccggagaagg aggaggaaga gccgaggact catcgctttc 120
 ggcctcagc tgtctagagt cccccaccc cccctcccc aaccaccgt tccggagcaa 180
 cagccgcctg aggacccgaa gctgcgggcc ggacsagcgc cgagaccact gctctctagc 240
 tcccgcgcgc gctcccgtec ctagcgccgc caccgcccgc gccgcccgcct ctagcgcggc 300
 cccgcgcagg cgcgctcacg accgcgtcgc cctccccca cccctccgct cgcgccccc 360
 cgctggctcc gccgcgcga cagctgcggc gcggcgcgca gctacagaga cccggatgtc 420
 gttgggcagg aactgcggtg agggctggcg ggcgggggag gggccgccac agatgacgtc 480
 actgccttac ccagcttctt tctctgccgc tgetgctgcc gccgcctttg ccttacggcc 540
 tggagcacca ggccgaagcc gaagggagcg tccggatccc ggatagcagc caggaccccg 600
 gccttcacgt tccggcgcca gggactggac agaattgtgc gctattaggt gccagtaga 660
 tcgacagccc ctccgtgccg gcccttgccc aagtagggac tcggaagcta cccctacggc 720
 gtccgcgccc ggagccctgg ctcttctacc tgctgcaga taaaacccc actccctgcg 780
 aagatggtgt acacgcagcc ccgagcacag acccgaagct gtccaccctt cttgggcgcc 840
 gtcgcggtct ggccgctgcc cttcgaaccc atggtgggtc ccaggcagct gccagacccc 900
 cctaccccag agtcccactc ctccagagcc ttcctctccc agtgacccca ggaagcccaa 960
 gcaggtgcca cggccacaca cctcgcgacc caaagggcag agacacaagc acgctaccac 1020
 cgcccaccaa tgtgcgagtg caactgattc a 1051

<210> 119

- 155 -

<211> 478

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (116)..(116)

<223> baySNP11153_C116T

<400> 119

ccactaccct acagggccctg cgagtgggaa gaaaagtaga aactgcttag ctaatgattg	60
acctcagccc ttcttctact gctttgggct tagatggaga ggtcaaagct ctcaayggcc	120
tctaccctat cttgggcgct atgcccagta attctaggca ggcagtcatt cttagaggag	180
cagccccccag cccccacgaa cacagcccag cagctattgg gaagttggaa tgcccagatt	240
tagttcctcc ttccaaagct gggccagagc tgagtcttga attgagctgc aacaacttta	300
ccattcttgt tcccttattc tgccccgagt tgggtcagcg ggtcgtctc cctgaagtcc	360
tgttatcttt cagcagctta tgtaaggca gccagcattc tcacgtagg aatggaaagc	420
ctgggaaaat accctcctca gctctcagta agtagtgctg gcttcatttc taagtaga	478

<210> 120

<211> 1197

- 156 -

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (194)..(194)

<223> baysNP11210_C194T

<400> 120

ttaaccagaa ggcagtacgg agaggaaaaa gtgtaaaggc tctctcagta gcagaagaga	60
atgaaaaagg gagaaagttt ggaacagagg agtgagggaa agtaaggctt aagacgaggc	120
aggagaaagg agcaggagtc ttggccaaaa taaagatttg ggttttgttc cctaagccag	180
gaaatgacat gatyagattt gcttttaagg atccttccaa actgctaaag acatgtagat	240
caagtattca ttggctgggc gcggtagccc acgcctgtaa tcccaccact ttgggaggct	300
gaggcgggaa gatcccttga ggccaatagt tctagaccag cctgggcaac acagtgagat	360
cccatctctc tccatttatt tatttttaaaa agagactcag gccgagcgcg gtggctcacg	420
ccagtaatcc cagcactttg ggaggctcac gaggtgagga gttcgagacc agcctgacca	480
acatggtgaa actgcagtct ctactaaaaa taccaaaatt agccagtcgt ggtggcgcg	540
gcctgtaatc tcagctacgc aggaggccga ggcaggaaaa tcggttgaac ccgggaggcg	600
gaggttgacg tgagccaaga tcgcgccact gcaactccagc ctgggcgaca gccaagact	660
ccgtctcaaa taaacatata aaaagaaagt caaggttatt cattgcctcc cttggagact	720

gtactccccc ccaccatgtc aatcaacaaa tatctgaaca cctattttttt tttttttttt . 780
 tttttttttt gagacggagt ctcgctctgt cgcccaggcc ggactgcgga ctgcagtggc . 840
 gcaatctegg ctactgcaa gctccgcttc ccgggttcac gccattctcc tgcctcagcc 900
 tcccagtag ctgggactac aggcgcccgc caccgcgccc ggctaatttt ttgtattttt . 960
 agtagagacg gggtttcacc ttgttagcca ggatgggtctc gatctcctga cctcatgac 1020
 caccgcctc ggcctcccaa agtgctggga ttacaggcgt gagccaccgc gcccggcctc 1080
 tgaacaccta ttacatacgg ggatacagct aagaactttt cacagagacc cccgccccta . 1140
 aaaaaacttt acctaaaagg gttgggagca tgtcctactc tagtttcatt ccccggt 1197

<210> 121

<211> 500

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (225) .. (225)

<223> baySNP11248_C225T

<400> 121

acgcccctgg cctcccaccc tccaacccca aaaagctctg gaagccgggg gagggacgga 60
 gcgaagcccc ggctccctga gttgaacagc acttggcgac agccggtgcg cgccctgcc 120

- 158 -

```

cttcttgcgtt gctatagtta gaaaaaata tatatatatg catctaccg gcgccaata 180
actagccaga cccggctgaa ggaaagctaa ctcccctgac gcgaygcaa gcgaaagaat 240
cagcagtcga gtgagccggt cgctttggta agattttccc tcccttacc ttcaactcct 300
cccgcctgcca ggagagctgc caggtaggac ggcgggcaaa gcgcttcttc aagttcctgc 360
gctggagtca ccacccgaga ggcacgcgcg tctggcgctt gtgtctgagc agaagccgca 420
ggaaccagcg ggagcagcag gaggagctgc gggactcgtt tgccgaggct cgtgttctgc 480
tcaaaagttt gtagacgcgc 500

```

<210> 122

<211> 2955

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (1110)..(1110)

<223> baySNP11372_A1110G

<400> 122

```

tcccacctg ccctctaaag tgctggatta caaacatgag ccacgacacc cggcctgaat 60

```

```

aaatgctgat ctttatatag aggaaagttc ttcacattct gctcctgatt atcttaccct 120

```

gggagggtgag ggaaaatagc aaatgttaat catattaatc atcttttaggc actgttttaa 180
 gaagacagaa gagcatttat caacctcccc tcctgagatc aaactacagc catagtcaag 240
 gcacttacag gtataatggc acttaatggt aatgtgggca aacattgggtg gattttgcac 300
 cactaattgc tctaagatgt tataaatagt aactcacaga actcttccaa gaacctagga 360
 agtgtgtacc attggtattt ccattttcag gtaagaaaac tgaaacagat gttcagtgac 420
 ttgcccagc tcagaatcta ctacgtggta aagactgggt tcccaccag acagacggac 480
 tcaagaactc acgcactgcc tctgcaccct ctgctgccaa tgaaaattta aatgagggca 540
 acaggagatc agagatgcca agagatgttg gaaaacagaa ctggctgaag aaatgacaac 600
 tgaataaaga ggggtgaagg gagctgtgaa ccacagcaat gccaagaggg catccagcca 660
 ggcagagtgg tctactaggc agagcctcag agaggggagg agttcaccag gcccacgtgc 720
 catatgggat tcatgccagc cttgagtcta caccagtga aaaaatcaga gagttcatga 780
 ctgaagcaat atgccccaga aataatatct ttgtattctg acacttcagt gggttcccat 840
 tcaatcacc tacaggaag actgccagta gacctgcccc ccaccccggt caatatgaat 900
 agatctagga tcagaaattg gagaaagggt aaagtgggga aacagaccaa gatgaccaa 960
 tacaaaagga gtccagaaca aacaagtaat tttttaaatc tcaaaccat gtcctcaggg 1020
 agattaaaaa atattttatt cataaactta aaacaagata tatagaaaag aagaaaaatc 1080
 aatgaaacaa acaaaaaaag agattttctr gaaactaaaa ggtgatgatc aaataaacia 1140
 gtctagagag accatgtgaa agaaagtcac ggaaatcctc cagaaaataa accaaaaaga 1200
 tgacagagga aaaggagcta tatggggaat agaaaagtta ccaggcacag ggtcacaggg 1260
 tgttctaaga aagctacttg agaatgagcc accgggagga agaaaggggtg ggtgggtggg 1320
 tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tatgtgttgt gcatccatgg agggcaggtg 1380

gggataacca agaaagaaaa agacatggga tccagaaaac aggaaaatca acccagagag 1440
 aagggaatct gaggatcaca gtgggacatg cagtaggcct acaaaacgac cagtccagga 1500
 tggaataaaa agggaatggt tctgtgggaa aaagggactc aatagaatac ctcaaaggat 1560
 tcacagtttg agagaaaactg aggaaatgaa gaaggcaagc agtacaaggg aggaaaaaaa 1620
 acaaaggcaa ttagaaacat caggaaaaag taaagctgtg ccacaaaaca tgtgcaaaca 1680
 tgggtgtacaa ctcagctcca cagtaaatac tattttaaac atcacaaaat gtaaactc 1740
 ttgattgatt ttttaactttg agaacagaac agagcatata aatatgagaa ctaaatac 1800
 ttgttaccga ttagtacaaa cttaaagcac aaaggtagca gttgggatgt gaagcactga 1860
 acgaaggaga aggaggatta atattgtcat cttttaaaga ggggagtcaa gaaatactag 1920
 gtaaaactga gagtataaga aagaaagttg taagtaaatt gtttacagct acaaagttgc 1980
 taatggagga cataaaactg gtgatacaat attaggaaaa ggtggagagg agagatagag 2040
 ggagtgtaca aacaagatga aaatgactaa taatgacact ataagtaata atgataatac 2100
 cgattcaggc ccatcccagt tagggggcgc tccaaaatca ccattgttct tttctcacct 2160
 tgtgtctctg cgcaactccc ggcacacca cttccagcag ctggtctttg tttgcagact 2220
 ttattttaac agctcagtgg ttcccgggca tcctccagct cttatacaaa agccccctcc 2280
 tcaaaagcca ctgcctccc tctttccact tcccactct gtttcagggt cgaggcatcc 2340
 agatatctgt cttctggggc ccctacgcag caagactaaa agggggaccc agtcctgggc 2400
 agcagttcac caggggagta tgcagagggg catctggaca cttcttgctg taagggacgg 2460
 ggtgacggga gggggtcttc ccttccccctt cttctgctt tgttcaactct gtgacaccct 2520
 aggccagggg agctgtctca acgccatctc atgagccatg agaaccagga ggaccaggag 2580

ggagaagagg agcaggaggg cagacagagc tggggcctcg gacctgcca atacttgtga 2640
 ggagctgcat ccaggatccc atcctcctgg gtcattgttg gcctggctcc cacctttgtc 2700
 tggagcctct gctggggggtt gaggctggat actgcccctc aggcttgact aggacacagt 2760
 gtgtactcca tgggtgagcc tgcaggctgg tcaattccgg tgtccaactg agcgacctgg 2820
 aagaggagcc ctccctccca cctcagctct gagccaagct ctccagatgc agaggacagg 2880
 gactctcagc aaagcatctc cctccaagtg gttgtggggc atcctccttg ggcagggaaa 2940
 gaggagtcga aatga 2955

<210> 123

<211> 1004

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (486) .. (486)

<223> baySNP11449_C486G

<400> 123

taaataaata aaataattct tggaatgttt tttcttctat atcccactat ccttggtcag 60
 atttttttct tatttgtgtt actgtctatt aaatgtattt totcttaagc tgagacacag 120
 atctcttaag actgatgggt tagaatatag cagaccatat ttttatgctg ctttagactc 180

```

ttgtccaggt gaaaaaattt ttaataaatg ttgtgaactt ctgataacaa tctctatttt 240
gtttagatac atctcttttt ataattaaaa agtagtcaga tactaagcaa aaacagaaga 300
acaacaacaa aacccacag ctactaaaag atgaagagac attgaattga gaattaagca 360
aaacccttgc aggcagcagg acaggccaga gctgaagaag ctgggagtgg tgaggtgccc 420
ctaggggaca ctgacagagc cttgaaccca ctggtgcagg aggcagggat gagtgaagcc 480
tgtctstgtc ttcaagatta tgggtcccaca gtcctctctt tacctcatac gcattgcctg 540
atdddgaaga gtttaaggttt ccttgaagca caggtgcctc aacctctata ccacgaaaga 600
cacctctaca gattctaaga atcaccttac acatgggtgc catatgtttt acctggggcc 660
actgttcttt aatatcatcc cttccctcag gtttccatct ggattccaca aaagccaccc 720
ttcctgaagt tgggtccctct caccggattt atccgaagac ctctctctc attttccgac 780
cattccttta ggtctgcctc taaacaagag gccaaagctt aaattcaagt gtgaaacaaa 840
ctcctggcaa aatggcagta tcttagaagg tgtgagatat tcttgccctc caggaatagt 900
tgcatttaaa aagacagatg aggccaagga gggcagatca cctgaggtca gcagttcgag 960
accagcctgg tcaacacggt gaaaccccct ctctactaaa aata 1004

```

<210> 124

<211> 1004

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (489) .. (489)

<223> baySNP11450_A489T

<400> 124

taaataaata aaataattct tggaatgttt tttcttctat atcccactat ccttggtcag	60
atTTTTTtct tatttTgtgtt actgtctatt aaatgtatTT tctcttaagc tgagacacag	120
atctcttaag actgatgggt tagaatatag cagaccatat ttttatgctg ctttagactc	180
ttgtccaggt gaaaaaattt ttaataaatg ttgtgaactt ctgataacaa tctctatTTT	240
gtttagatac atctctTTTT ataattaaaa agtagtcaga tactaagcaa aaacagaaga	300
acaacaacaa aacccacag ctactaaaag atgaagagac attgaattga gaattaagca	360
aaacccttgc aggcagcagg acaggccaga gctgaagaag ctgggagtggtg tgagggtgcc	420
ctaggggaca ctgacagagc cttgaaccca ctggtgcagg aggcagggat gagtgaagcc	480
tgtctctgwc ttcaagatta tggTcccaca gtCctctctt tacctcatac gcattgCctg	540
atTTTgaaga gttaaggTTT cttTgaagca caggTgcctc aacctctata ccacgaaaga	600
cacctctaca gattctaaga atcaccttac acatgggtgc catatgtTTT acctggggcc	660
actgttctTT aatatcatcc ctTccctcag gtttccatct ggattccaca aaagccaccc	720
ttctgaagt tggTccctct caccggattt atccgaagac ctCctctctc attttccgac	780
cattcctTTa ggtctgcctc taaacaagag gccaaagctg aaattcaagt gtgaaacaaa	840
ctCctggcaa aatggcagta tcttagaagg tgtgagatat tcttgccttc caggaatagt	900

- 164 -

tgcattttaa aagacagatg aggccaagga gggcagatca cctgagggtca gcagttcgag 960

accagcctgg tcaacacggt gaaacccccct ctctactaaa aata 1004

<210> 125

<211> 540

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (511)..(511)

<223> baySNP11470_C511T

<400> 125

ccattcttgt gcgggtccat ttatatatgt tctgaacag ctaatatttc atttagtttc 60

caattaaact tgctcaaata cttttttgaa gtgcattgct taaaatttac attcaaggca 120

agaaaacgag tttgtcagta aatgtagtaa ttaaggaagt cccaagtctg tattttttaag 180

atactagagg taattgtaac taatcacttt aacttaaaga aatagaattg gaaatacccc 240

cctccccccg ccacccccta ccaaaccat accttagtca ctttgaatt ataaccgtct 300

ttacgtcta tcaatataaa tgtattgcat ttggcattca aattactttc aaagggataa 360

atttgaatt tttttttttc attgtagctt ctgatcttta aatgtactga acaggaggat 420

ttggggagct tgtcttgtct gataggtggt aagtatctat gacgacaaat ttgagctgaa 480

gcaatgtgca atatggacta gtaatatctt yacaagacta ttttggaat tctcacgttg 540

<210> 126

<211> 641

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (556) .. (556)

<223> baySNP11472_A556T

<400> 126

aaacacaaaa agtaagactt ttcaagacaa cctcattcac actgtttact tgaattattt 60

actcttggtt tattattaat ttttatgctg ttcaattgac tacaattcaa aaccagtggt 120

attcatacca tgtgctaaga tatgctcctt cctatatgtg ttctctctaaa gaaccatctg 180

gatcttggtg gggatatttt cctttgtggt atcaaagcca ggagctcgtg gttttccttt 240

attttttaag ggaacactat catgtagcat ctgggaccag aaagaaatct tgatgttata 300

tattttacag atattttctt tttggatttt ttttcctcta agagaaaagc ttttggtaat 360

gtgtcatgta aaaatacatt aactagtaac ttgtcaagaa gtgctagatt ccattcttgt 420

gogggtccat ttatatatgt tctgaacag ctaatatttc atttagtttc caattaaact 480

- 166 -

tgctcaaata catttttgaa gtgcattgct taaaatttac attcaaggca agaaaacgag 540

tttgtcagta aatgtwgtaa ttaaggaagt cccaagtctg tatttttaag atactagagg 600

taattgtaac taatcacttt aacttaaaga aatagaattg g 641

<210> 127

<211> 1547

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (485)..(485)

<223> baySNP11487_A485T

<220>

<221> misc_feature

<222> (848)..(947)

<223> N_region

<400> 127

gccaggcact gtgcaaagca ctttgtatga actagctcat ttaattctca ttcaatcagc 60

atttaatgta taatttttca attttgcaga taaggaaatt gagatacaga tagattttta 120

aaaatttacc caaagccata tagctaataa atggtagtca agatttagaa tcaagtaatt	180
gggtgcttaa caatatgctg tatagcctct tattctgaag agtggttacc accaagaata	240
tccagattgc atctcctaaa atgacagtat ttacttcata gggctggtgt aagaattaca	300
tgagatgtgg caaaaatctt agcagagttc ctgacgtaca gcatgtgctc cacaggtgtc	360
agctggtagt attactatctt ttactgtctg ttcaagagag cagctagact gagactagac	420
tcttagtatt gatttcaagt tatctttgaa gggattcaga ttggcaagca caagagtcag	480
accwatcct gagccctcaa ctgtttgcag gaaggaataa tctcttgtgt cagatgcagc	540
ttgctggggc ttcaccttgt gaattagga cagggggaga agtgttgga ggcagcctac	600
catctcaagt gatgcaaatt ataatctatc aaaggaatga atgaacgttg gtctggcaac	660
aaatatcacc atcccatctt atttactaaa ctactaaac cacttttagca agttaaaagt	720
agcactgaag gcagatttac atattctgag ctctgaagtg aggcctttct tttatgggct	780
atattgatgg tagctttaaa actacaaata tcagaaaaac taaatttaca gtggattaag	840
gaaagtgnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	900
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnncta acccgcttta	960
gcaagtttag agtagccctg aaggcagata cactattgtg agctctgaag gagggctttt	1020
cttttatggg ctatatgatg ggtagcttta aaactacaaa ttcagaaaa aactaaattc	1080
ccagtggatt aaggaaagtg gggtttattt tttctccat aaccataagt ctggagacag	1140
ggctggcatc tatgaggatc tcttagccac tttctcaagg ttgcaaggga gacaggtgct	1200
gggaatgact gttagaaggt cagctatgtg agcagataag tatttgactt caaaagaaac	1260
ataacactta gtggaactat gttctttgca gagccctacc taatccattc atctaaaagt	1320

- 168 -

gttgcaacat aggtaggaga atacgttgtc tgggaaacca caaattacag tactatgtgc 1380
 atcccctcat aatttcacct taacaatttc gttacagagg aagggtgcatc cagttcctca 1440
 tgctcggaaa cctactgtgg actttatcct gagtcagaac cagaagtga ggcagtggct 1500
 agtttcttga gaagaaatat caaccagatt aaagcataca tcagcat 1547

<210> 128

<211> 1547

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (533)..(533)

<223> baySNP11488_C533G

<220>

<221> misc_feature

<222> (848)..(947)

<223> Unsure

<400> 128

gccaggcact gtgcaaagca ctttgtatga actagctcat ttaattctca ttcaatcagc 60

atttaatgta taatTTTTca atTTTgcaga taaggaaatt gagatacaga tagattTTtta	120
aaaatttacc caaagccata tagctaataa atggtagtca agatttagaa tcaagtaatt	180
gggtgcttaa caatatgctg tatagcctct tattctgaag agtggttacc accaagaata	240
tccagattgc atctcctaaa atgacagtat ttacttcata gggctgggtg aagaattaca	300
tgagatgtgg caaaaatctt agcagagttc ctgacgtaca gcatgtgctc cacaggtgtc	360
agctggtagt attactatTT ttactgtctg ttcaagagag cagctagact gagactagac	420
tcttagtatt gatttcaagt tatctttgaa gggattcaga ttggcaagca caagagtcag	480
acccaatcct gagccctcaa ctgtttgcag gaaggaataa tctcttgtgt casatgcagc	540
ttgctggggc ttcaccttgt gaattagggg cagggggaga agtgttggaa ggcagcctac	600
catctcaagt gatgcaaatt ataatctatc aaaggaatga atgaacgttg gtctggcaac	660
aaatatcacc atcccatttt atttactaaa cttactaaac cacttttagca agttaaaagt	720
agcactgaag gcagatttac atattctgag ctctgaagtg aggcttttct tttatgggct	780
atattgatgg tagcttttaa actacaaata tcagaaaaac taaatttaca gtggattaag	840
gaaagtgnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn	900
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnncta acccgcttta	960
gcaagtttag agtagccctg aaggcagata cactattgtg agctctgaag gagggctttt	1020
cttttatggg ctatatgatg ggtagcttta aaactacaaa tatcagaaaa aactaaattc	1080
ccagtggatt aaggaaagtg gggtttattt tttctcccat aaccataagt ctggagacag	1140
ggctggcatc tatgaggatc tcttagccac tttctcaagg ttgcaaggga gacaggtgct	1200
gggaatgact gttagaaggt cagctatgtg agcagataag tatttgactt caaaagaaac	1260

- 170 -

ataacactta gtggaactat gttcttttgca gagccctacc taatccattc atctaaaagt 1320
 gttgcaacat aggtaggaga atacgttgtc tgggaaacca caaattacag tactatgtgc 1380
 atccccctcat aatttcacct taacaatttc gttacagagg aaggtgcatc cagttcctca 1440
 tgctcggaaa cctactgtgg actttatcct gagtcagaac cagaagtga ggcagtggct 1500
 agtttcttga gaagaaatat caaccagatt aaagcataca tcagcat 1547

<210> . 129

<211> 799

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (171)..(171)

<223> baySNP11493_A171G

<400> 129

agcacccect gggactccat tctctcagct tgctgccaaa agccttttgt gttttgtttt 60
 gtatcattat gaagtcatgc gtttaatcac attcgagtgt ttcagtgcct cgcagatgtc 120
 cttgatgtct atattgttcc ctatttttgc agtgggaact cctaaatcaa rttggcttct 180
 aatcaaagct tttaaaccct attggtaaag aatggaaggt ggagaagctc cctgaagtaa 240
 gcaaagactt tcctcttagt cgagccaagt taagaatgtt cttatgttgc ccagtgtgtt 300

tctgatctga tgcaagcaag aaacactggg cttctagaac caggcaactt gggaactaga	360
ctccaagct ggactatggc tctactttca ggccacatgg ctaaagaagg tttcagaaag	420
aagtggggac agagcagaac tttcaccttc atatatttgt atgaccta tgaatgcata	480
aaatgttaag ttgatgggtga tgaaatgtaa atactgtttt taacaactat gatttggaaa	540
ataaatcaat gctataacta tgttgataaa agatttaaaa acaactggct gtttttttac	600
actgtggtgt ggaagattgt gttggttcac aacttttcac ttcttccct gtgtgattac	660
acacacctgc cccttgtggt gtgacttgca gtgcgccta caggccacac acccatgcc	720
ctccaccact ggctctgctg ctggaatgtg agcagaaggg acatctgcct tattcaagca	780
aagcctttgc ttagcccca	799

<210> 130

<211> 535

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (455) .. (455)

<223> baySNP11502_C455T

<400> 130

- 172 -

ccttggcagc agcaccccca tggcgtctcc tgacctcctt ccagaggacg tgagggagca 60
 cctogaaggc ttgatgctct cgctcttcga gcagagtctg agctgccagg cccagggggg 120
 ctgcagtaga cccgccatgg tcctcacaga cccacacacg ccctacgagg aggagcagcg 180
 gcagtcaagt cagtctgacc agggctacat ctccaggagc tccccgcagc cccccgaggg 240
 actcacggaa atggaggaag aggaggaaga ggagcaggac ccagggaagc cggccctgcc 300
 actctctccc gaggacctgg agagcctgag gagcctccag cggcagctgc ttttccgcca 360
 gctgcagaag aactcgggct gggacacgat ggggtcagag tcagaggggc ccagtgcagt 420
 agggcggtc cccagggacc gcccagatcc cagcyttgag agaggagtgt gtgtgcacgt 480
 attcatctgt gtgtacatgt ctgcatgtgt atatgttcgt gtgtgaaatg taggc 535

<210> 131

<211> 630

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (258) .. (258)

<223> baySNP11534_G258T

<400> 131

tgggacctaa ccagggactg ggagagaccg ataggagtgg aggcaggaag gctgtcagtc 60

- 173 -

gggccatcgt ctttcocctat aggctcttga gtgtgtggga tgggaggaag gcaagtgctc 120
tgtggtatcc ctgggggaac ctccctgaag agtgccctgg tcacagcacc ottgaagaca 180
gccattggcc atgggtcagt gttgagtttg gttggccctg tgacacgctg gagctctctt 240
tccagtgcgg tatccttkgc cctggtgggt ggaggggggc tcaggcttgt gtgtggatga 300
tgctggagcg aggaaggagag ttttgctctg gagaagtgag aaggcctggc tgtctccccg 360
gttgctggat gaagccactt gttgctgggg gaaaccagtc agggctgctt gggcctctgg 420
gcctctgagc ctctgagccc accaggcctc tgcgccccct ggagagagaa ggagggagga 480
gggaggttca gcaactggac tgcactgact cacaggagag ctgggggcag ggtggctgag 540
cctggggaaa ggccgatttc ggaggcgatt aaaaatattt gtacaactga ttccagggaa 600
gtgaagcaaa aggccctttt gtccagaaaa 630

<210> 132

<211> 1854

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (274) .. (274)

<223> baySNP11537_A274G

<400> 132

ccactgcact gggctgtgcc tcctctgccc cgtgtcccct gccagtcctc tcctcacctg	60
tgtagctgct ggaaggaagt gcatgctgtg gtccccatt gagctctggg gctccttctg	120
cctctgccac ttctctcttc tcctcctctt ccgggacctc aggggcttcc tcctgtggct	180
gctccatggc tgatctcccc tcggcgccac acctgcaggc ccagtcatag ctctggcatc	240
gtctgggtct gaacgcagat ggacctctac aggrtggttc ccatcagcct gggcagagga	300
gaagacagga agaggtcagg ggaggcagtg acaaggaaga ggatgggtgcg agtggggcac	360
gcttgggggc tgetgtcatg gaggggggtc ttctgtcctt gctccttccc tagttcctgc	420
agtgtatac catggtctct gtccttgta tcacaagtca cctgccctat cacccttccc	480
acctggctct tgtagtgggt ttgtgggggt cggagcaggc tccataaact agagaggtga	540
cacatcactg tgccaccctt ccctgcctcc tctgtgcct tctgttctga gtctccagga	600
agcacattgg aatgacttga ggggcttttc ccaactctcc agcccacctg gagatccaga	660
tatgcatcac gcctcccatc ccgaccctg tccctatcag cactcaggcc caagaatcac	720
ggctctgctg tgctactgtt cctgaagggg tgagtcccat cctttcagtg gttgggtgtg	780
gaaaaaagac ataaagccct gctgttcttg gctcatgttg acagcagatc tgcaaccatg	840
gcctcaatag cagagacatc agaaaaagga agatgtgctc catcctggag tctttccaag	900
gtgacaactt actgggtggt gatgccacgt ccacatcacc caggaggaga cagttccaac	960
ccttagcaag taaaacatta tccacaaatg ccacagtcag agatgataag atcatgaggt	1020
actgtggaga gtctcccagc ggggaaatgt ctgcaccaga ccttgtggaa ggatcaggag	1080
aagaaaagat ctgctttaag atgttaagca tctgtgggac cccaactctc agatatttta	1140

- 175 -

ccgacagctc aaactcaatc tatccaaaca gaacccatca ttttcccaa acccattcgt 1200
cctctagtaa tctttacttt agcaaccac ctgcctgtct acccactcat cagaaccaga 1260
acctggagtg atcagagact ccttctgctc tctctccctg ctctagacct gccaaactcg 1320
ctgtacactg tagtcactgg ggagttttta aaaagacaga tgcctgggtcc catccccaga 1380
gattctcctt tgattgggtt ggggagcagc ttggacattg ggtttcttat tttttaattg 1440
tcctgggtgat tgtaatgtac agccaagttt gtacaaaaca tgttaaggct acacattcat 1500
ttccaccagg ccttcccttg cttggactta acaataacct cggggcctac ttgagggtgg 1560
aggctgggag gaggagagga gcagaaaaaa taactatcgg gtactagtct tagtacctgg 1620
gtgatgaaat aatctgtata ataaacgcct gtgacacaag ttcaccacaca taacaaacct 1680
gcatctgtac cctgaacctt aaataaaaaca ccaccacaaa actcttagct gttttctgat 1740
gggttttttt gttgttggtg ttattgtttt ttgagacagt ctactctgt cgcctaggct 1800
ggagtgcagt ggcgcaatca tggctcactg cagcctttat ctcccggtgt caag 1854

<210> 133

<211> 588

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (185)..(185)

<223> baySNP11560_A185G

<400> 133

tgtgggcctc agtttcccta tctgtagtaa gaaggctaaa ctataaggcc aaaagcacga	60
ggctctgata ttgcaggtag aagagtttca atgaggatga tgacagtggg gatgggtggg	120
ctgccaagcc cccctcctcc aactccttta cccctagggc cttctttctt gaggccagaa	180
cccgractag ggagggggaca ggggaacagg gacaatocca tggctaagta agacaaccca	240
gaaggtgact tggctgtggc tgggtgggat ctcagggctt gggaacgacc cctcaggatg	300
cagtgagaag tatttgccac ttggtcctgt gcacttcaga ggtgccaggc actgtgctca	360
ctaagccctt tcagaccttc ataccctttt atcatgtaaa ctttttcaga ctcacaaagc	420
agatgtataa ttagctccac ttacacttg ataagctaag gctcagagaa gttcagtcac	480
ttgtccagcg ccacacagcc tggaggttgt ggagccaata ctcaaggcgg agccgcttcc	540
ttcctgaaat tatactccag tgggaaggag agaggaacaa cgaggcag	588

<210> 134

<211> 620

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (353)..(353)

<223> baySNP11578_C353T

<400> 134

cacctatgtc tgtgtttctg tggcatgtta tctaaagagt aaaggtacca tgcctttgcc	60
tttctggggc ttgaaatctg ttgtactcag acaactccct catctcaaac ctccctgttg	120
cgtgagggca tccgacttgc ctcacagagc caactaatta tcatcggtgg caatccctggg	180
caattatgtc tggctagata tgccataaag ctacaaatta attaccactt acagctggga	240
agatctctct cggcgtgctt ggtaataaca ttggaagaaa cacgtgcgtg ggtccatgca	300
ggctcggcct ctgaagcaag ggcgggggct ggcaagttgt tccatcccac ctyggtctcc	360
acctgggggt gtgggcaggc cagggcttgt ttgagattcc tccagagttc ggctccgtgg	420
ctgcctcctc cacggaggag gcacgagagg cagcgtttcc cagattgtgg aggacactgt	480
ccctgcgggt gcttgggatg gcttcagaag gtccaaggag gtgagagtga gcttctgggt	540
ccatgctctt ttctccttg ccatcacctg caggagaagg tctcttggtg ttgagaggac	600
ttgaagagcc ttccacactc	620

<210> 135

<211> 501

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (328) .. (328)

<223> baySNP11594_C328T

<400> 135

tgagtgagag ggtggtgtga ggaggcacag gcaggtcctt actaatcaca cagcatcaga	60
gctgccaaact cgagtgtcga cagcctttcc tgggcacacc ttctgaact cactctgaag	120
ggagggagggc tattaggaaa gaaatataag ctgaaaatgc ccccgaaagg tccactcaca	180
gaaaaccaag agctggccac caccctgccg gcagtgggtga cgggaatcat gccagtgact	240
caggcagcag ccacagctcc aaagtcctgg agccggcccc gcccaacaca ccggatgccg	300
caaagcacca cctacctgag catactgytc cttgagtggg ccagagagcc ggaggacagc	360
acagacatca gctccaagtc tgcaggacag ggagatcaga atccagttag cctagaatct	420
ccaggagctt ccatgtccca gaaagggagt caagaggcct gtgttgaagt cccatttcta	480
ctactggtat tatgtaactt t	501

<210> 136

<211> 1395

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (912)..(912)

<223> baySNP11624_C912T

<400> 136

atgctggtgt gctgcacca ttaactcgtc atttagcatt aggtgccatt atccaaataa	60
caagtaccag aaacactgat tctttatgct ccaccagatt gaaagcctgg agatggagga	120
ggtaggggag ggtgagaagg ggccacggga ggcctcagaa gggatgagtc ccaagagaag	180
gagcagcacg ggtgacaagg gtcagatggt gggacccccg agagccacag cgcagtggcg	240
gcagagccca gggtgagtgg gatgaggcaa tgagaacaca ctctgttttt ggacctatgt	300
ggcgtgggtg tcagtggaca cggggcaatg cacaccaggc tgtggtgatg agagccagga	360
agaggaggac gtgaagatgt ggggtccccg cttagcaggc agtaacagag gaggaaaagc	420
tacaatactg cctggtatat atacttgaca acacagcatc tgagcctctg gtgaccttg	480
ggaagacctg atggagctcc ctgtcaggac caaatcctgg agggagggga gggagctgac	540
tgagctccca ctatgcgtca cgctcccact caagcctcgc cagcccccat taaggcotta	600
taggcccccc ttgcagatga caaaagtgc aggcctgagg atcccaacag ggcattctcag	660
aacatgctag aggacgaagc agaaaacggc agagcttcgg acacagcagg actcgagccg	720
ggccaggccc tgacagctgt gtgcactggg ccgtgttact cagcagagcc tcagctccca	780
ctcccacata tgagctggta gtgggttttt ttcaccagaa ccggtaaaac tgttctcagt	840
ttcgggaggt gtaagtaagt ggttgcctct tagactcaga tgcagttctg gactctggct	900

- 180 -

```

agagttctga ayttagggacc aggggtctcta gttcccacgc tgacatctct ccctagcctg      960
gaattgtctc ttctgactgt ggcctctcaa ggacaccagt gaagaggaag gggagctgta      1020
gcctggctgt tctaaaacct acccacgtcc cttgggctgc tcctatttag attgaactgc      1080
tgtgctgcag cccatccctg cattttgccg gaagcctgcc attttcatat ggccctcctg      1140
ctccatctac agctgaggtc tgtcatctac cctgagccaa ggttgctccc tggttctcagc      1200
ttgcccagcc aggagcaacc ttgacccta ggctctctcc cctgaccacac tggacctagg      1260
cccactgtct agattttctc aggtagctgc caccacaccc accacaattc ctgcaatgaa      1320
ccctattctc ctcttccttt ctttaagcct ggcaactaaag atagcacagg ctgggctggg      1380
catggctcat gcctg                                     1395

```

<210> 137

<211> 572

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (277)..(277)

<223> baySNP11627_C277T

<400> 137

```

tcacacatca cttaatcgac ccagtgagat gagtgaaggc agggctattt catttatcac      60

```

tacaccccct actctgaggg aagctctgac tggctcttgc tegcctgtga atgctctagg	120
tgaggggacg aaggctggtg gtaaggagaa gggcagccac tgagtgggtg gccagcaggc	180
cccatgagag gcaatgaaac tctgactggc ccaggagaaa tgggacgtgc aattgcagcg	240
gggaggcagg aatagggatc tgcagggcag agagacytct caaccttccc agggagagag	300
gagacatgga aaaatoccac agttaagctg tgattggtcg gtctgtccag gagaaccag	360
ggatctcaag ttcaagtctc acctaaaagc gttcacgttc ttgacccta tacttcccct	420
tataggaaaa cactgagctg ttactgcaa tgttatttat aataacaaaa aatcagaaat	480
ggcccaatgc ccaataatag aggaatgggtt aaatatatta gggcacaccc agacaactga	540
gtattaccta gtcattaaac tcatgttttc at	572

<210> 138

<211> 558

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (419) .. (419)

<223> baySNP11644_A419G

<400> 138

- 182 -

tgtactgcct tgcaacactg tgccattttc tgcataaacc tgtgtcactt taggttcttc	60
gtttagaatg ttctggattc gaagcacctg tggaagaaat aacattgggt taatattttt	120
gttaagtcac ttaaaacaac cttatgcata ataggggtcat cctccataag aagccatata	180
atccttataca atgagataaa tcctattttg ttccaaaatt acacttaaca cacctgtttc	240
ttcattttggg aacaggtggg tactgatctc aagtgatctt tagcagaggt ggagagtatc	300
tagacctaca gggatgaggc aggaaatgca aatgagcagc gcatcctgga tgtgggacat	360
tagggagcag tggggatttc agtaaattgtg gagggaggaa gctgttactc agtatgatrg	420
ttaataactga gagtcaactt gattggattg aaggatgcaa agtattgatc ctgggtgtct	480
gtgagcgtgt tgccaaagga gattaacatt tgagtcagtg ggctgcaaaa ggcagaccca	540
cccttaatatc ggggtgggc	558

<210> 139

<211> 597

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (146)..(146)

<223> baySNP11650_A146G

<400> 139

```

agcagtcccc cgggaggatt ccgatggaag tgggtgtgggg tgggggtggg gggcttccac      60
tgtctgtttg ggtcttcgta tatccgtccc ctgggagcct cctccacccc ctggtacctg      120
cctcacgctg gccatgctct ggggggcttt tagacatttg gccagggggg ggcagaacta      180
gatcaaccgc taccaggtct taaccacgcc cacctaggga catcgtggga atgtgcctgc      240
tccagtggac agagaacaac gtccaactct gtcttgggga tgttctgagc tgggtctcaga      300
gaaaatagac gcagctactg agcgcacatc ctgagggcag cagacaggac tccccagcag      360
ggagctgggc cctctcccca ttctctcctg cgggtctgagc ccttaggggt ctgtcctggc      420
cttgtgggtg ggtaaggtaa gacaccttac ccacagagt acagcatcat ccttcctttc      480
tcccctctcc tgctacggag tgactgagac atgaattggc gatctttaac atgtgctaata      540
gagtgttagc tgaaccacct tccaagagga gagtgaaagg caaggaggta agtgaga      597

```

<210> 140

<211> 501

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (402)..(402)

<223> baySNP11654_A402G

<400> 140
 ggggattgga aatgctgctc aagagagggga aaataggata tcacgattgg ctcaacaatt 60
 ccctgtgtta agagcgggtcc ttttctatct ggtagggtgt ggggcaaata catagctagc 120
 tcaggtgatg aaatctttca tctcttttagt ttgtgtactt ttaaccaagg actgcgtatc 180
 tcttgccctt cttgtgggtt tcacctgcaa ctttaataatt ataccattgt acaccttacc 240
 ctcttttccc atattcaaga aagattatct ccaactctta ctgtttttaa actcatgtgc 300
 ttacttcaaa tatttctgca ctaaagctgt aatattacaa gtttggtttc ctattagagg 360
 tttccatttc catccattta tcttttactt gaaaggacac crtatttttc acctaattcc 420
 tcaattttat tgggtggggaa ggcataagag aagttcactg catacaatct aaggtctaag 480
 atcccccaaa atttccagca g 501

<210> 141

<211> 501

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (331) .. (331)

<223> baySNP11655_A331C

<400> 141

ggggattgga aatgctgctc aagagagggga aaataggata tcacgattgg ctcaacaatt	60
ccctgtgtta agagcgggtcc ttttctatct ggtagggtgt ggggcaaata catagctagc	120
tcagggtgatg aaatctttca tctcttttagt ttgtgtactt ttaaccaagg actgcgtatc	180
tcttgccctt cttgtgggtt tcacctgcaa ctttaataatt ataccattgt acaccttata	240
ctcttttccc atattcaaga aagattatct ccaactctta ctgtttttaa actcatgtgc	300
ttacttcaaa tatttctgca ctaaagctgt matattacaa gtttggtttc ctattagagg	360
tttccatttc catccattta tcttttactt gaaaggacac cgtatttttc acctaatccc	420
tcaattttat tgggtggggaa ggcataagag aagttcactg catacaatct aaggtctaag	480
atcccccaaa atttccagca g	501

<210> 142

<211> 1224

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (897) .. (897)

<223> baySNP11656_C897T

<400> 142

tgatctcgaa ctctgacct caggtgatcc accgcctca gccccgcaaa gcgctgcgat	60
tacaggcatg agccaccgtg cccggccgaa atgggaccat ttttattatc ccgtcatgac	120
tctctctgag ataagacctt ctcttggcct tgtaagtttt attttaacag tgacaaaaca	180
caggaatata aaaggaccag tcttggtggc aacatgtggt ttcaaggagt ctgacttttc	240
ccggcctggg tctctggaac tgctgcagac tctaagagcc cactccccag aacgaccctc	300
catgccctgc gtctgatga ctttgactcc tgacctcaa ggttgccag tcttggtcgg	360
cttggtcttt catgagaact tcaattcttt atttttagtt gtattttttc taccatgtg	420
atggaaaata attcccgtcc aatgatgggg atggaagggt tgaggagggt ggtaggagga	480
agaactttcc aaagaaaaac aaacggaatt gattttccaa ggtctgtgcc tacatgggtg	540
tttttcctc taaaaacata gcaggctgag ttgattgact ttaattatat tgacttacag	600
ttcttgattg ttgttactct ttcctggca tctttgggag aaattatagc ttgcttttac	660
tctgaaataa agatgtttcc ctttttgcac ggtctggtct aaatgcttaa tcatatggga	720
agaaaaagag aagccagtgg attggcctta tggaaatgaa cgtagagga taaacagtta	780
ggggcttgat gaaatgttca aaggcttttc ttgctgattt tcatgattgt ctttattcac	840
gctgttgtea tctgcccagc ccaagtacag ctgcgtctgt gatgctgggt ggatgtyttc	900
acccaacagc cctgcctgca cgctggacag agacgagtgc agcttcacgc ccgggccttg	960
ctccacactt gtgcagtgtt tcaacactca aggcctcttc tactgtgggg cctgtccaac	1020
aggtacattc tcagggccac aagccaggct ctgcatgcca ggttggcgag gtgccagaac	1080
caattttctt tcactattga tgagtaagaa gacaattctt aggaggtgtt caaatccagt	1140

tttgtgtcct ggttctgctc gacgatctca ctgctatcac aattccaagt caaaaggggg 1200

aggcttgtcc aaaactgtgc taga 1224

<210> 143

<211> 608

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (277)..(277)

<223> baySNP11825_A277G

<400> 143

tgtgtgttct catgtattga gatcattact acggctatca ggaagggttt ttgtagtttc 60

atattttgct tgagaaatac taagataaag cctaaaatgt ttatgtcata tatgtcataa 120

atataacacc aattgtggaa tgcaccacaa tgcagcatt gtcctctgac ttgacatgaa 180

cttaaacttg taatgtgacc ttggaaataa tggagggtcaa tatataaata ttctacaaa 240

tcattaagga aaatgctaac aaccagcaa aaatggrcaa aagatataaa taaaagttc 300

acaagaaaga aaatgcaa atggtctta atgtcttaaac aatctcaata tcaactcagag 360

tacaaatata aattaaaact actataagat acaattttca cttatcaggc tggcaaaggc 420

aattttcgtc cctgtctatt caaagtaaca ccattttctt tattagttcc agtgggcaag 480

taagagcaag gagtccacat agcggtggcc aaccaaagtg atgaaaggaa ggcacatttt	540
taaaaattca tagatccaaa tccacgaaaa aaattctcag tgtattaggc catagaattt	600
attaaaaa	608

<210> 144

<211> 574

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (246)..(246)

<223> baySNP11914_A246T

<400> 144

agaaaaacta aaatagactt ttgaatcaag acacttgagc ttaaaaaatg tcattttctaa	60
ctaaaaaaag tgacctccat tgcattgaagg tttctgattt attgtattca taaaatagtg	120
tagtaagtat atgaatataa cttatttttaa atgtgatgct gaggagtggg gatggggaag	180
cattttttat tggaagtgag ataagatagg tgattaaatg ttccaaagat aattaaaatt	240
tttttwcctc tgatgtctgt tttctttcat ttacttgtgt cagcatagtt tcccgatgct	300
acacattatc tttcttcatt tttaaagagt tttttctggc atttttacaa ggcgttacta	360

- 189 -

gttggtgcct tgtaacctc tcattctcac cgtgattctg acattgagat gttcaaccag 420
 ttgaggaatc tttcccagag cttataaatt agtgtgttgc caagaataat gtatgcgtac 480
 attaaaatca tttatcctcc ctttattaag gttactgttt aaaaagggtca aggccctgct 540
 gggaggggaat gtccgcatga tgctgtctgg aggg 574

<210> 145

<211> 569

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (449)..(449)

<223> baySNP12008_C449T

<400> 145

ttgttcctc caaccaaaga agttttacca caggtgcccg accaagccct cagcggccat 60
 gccagtactt ccagcctctg ctttttagta tgctgctttg ccctgagatt cagaggggggt 120
 actgaagact tggacatgga ggaaatacct agttgttggg aaagtatcta ttggtggttag 180
 aattattact taaggaacta atttgggaag cagaagctct gccaggaag cagcatagat 240
 ataagcacat tacatcatcc tgcgggtacgg tgtctttcat accggtgatc attgtgggtcg 300
 gggcgaaaag aatcatctta actgagaatt ataaagaacc gaagaccaag acgcaggact 360

ttttaaagca gagcatcctc cacacagttc tctccccagg agaagtctgc tgtaaaacat 420
 cagtcataaa caagaaattc tgtttatayc atagagcttt attttccata aaaaaatttc 480
 cagatattcc attttcattt taaattcaga gccttgtttt tatggaagac attttcactg 540
 caattttgga tataatgtct gtatgacaa 569

<210> 146

<211> 1619

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (411)..(411)

<223> baySNP12097_A411G

<400> 146

tgcattgggag ccttgaaaga tatgatactc aaagaatggc ctgatgattg aagcttaaata 60
 agcattctga gctataaaaa tgtagtatct tctgatgggg agtgggtgac acaagacatg 120
 agagagtggag ggaagaaaaa gcatgataaa caaaagtcac cttattataa tgtctgtcag 180
 gcatcagtgc tccaaagaac aagtattatc aaccttagtc tccctttctg tgagctaata 240
 ttattttttt cttttttttt tcttttagac taagttttgc tcttggtgtt caggctagag 300

tgcaatggcg caatcttggc tcaactgcaac ctctgectcc agggttcagg cgattctcct	360
gcctcagcct ccogagtagc tgggattgca ggcacctgcc accacaccca rctaattttt	420
gtatatttag tagagacagg gtttcatcat gttgaccagg ctggtcttga acttctgacc	480
tcacgtgac caccacctc ggctttccaa agtgctggaa ttacaggat gagccaccat	540
gcctggccct gctaagattc tttttcatga gattataggg agggggctca agaccattgc	600
tttttttag gaggatcttc ctttaggtat gagaacttca gagaaagccc cttcctatat	660
tttgggagaa atagcagggt tgggagacag gagaacataa gagttagctt ggttctgaag	720
actttctgag acctttcaat ttcttttggg tcaaagtcct caacatgctt aagtgcata	780
ttttgggggt tcatttttgg agccccaact ttccctgtc ataaacttcc ctagaaaatg	840
tacatactaa agctgagttg atgcttgtgg agaggacaat tgaattggta gctgagtcgc	900
aaggaatcac attaaaccag tataaaccag tctcacattc ctagcaatgt caatccagtt	960
aaacagctgt gcctcatttc aggaggtgat gttgcaggtc tgctgtcatg aaagataggt	1020
ctgtatatgg tgcagtaaa caggtaacta ataagaggtc attctaccaa agcaaaagga	1080
gaccaaagt taatcattta gcagactagt ttctgagttc acagggcagc cagacaaaaa	1140
gatttctaca tgttggtttt gaaacagctc cagttggagt agaggtaggc aatgggtgac	1200
tgacagattt ttttctctc ctatagctcc ttagggccag atctgaaaga ctttaagttg	1260
ttgcaatttc tctggagtct gctctatcac aaagaattct gcaaaaatca catttcctgc	1320
ctttgtggac caaaccaatg tatttcttaa atgtatttga tatctcatgc ctccctaaaa	1380
gaataaaacc aagctgcacc ctgaccacct tgggtacatg ttcttaagac ctctgaagg	1440
ctgtgtcatg ggccatggtc actcatattt ggcccagaat aaatctcttc aagtattgta	1500
cagagtttgg ctctttttgt tggcagcatg tattaactca ttctctatta caattcccct	1560

gtcttgatga atgggctctg ttgaggcagg gggcaagggtg aatctcttgg gtgggttaca 1619

<210> 147

<211> 482

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (412)..(412)

<223> baySNP12366_A412G

<400> 147

ctccccaacc cggccaggac cccttggcct cactggaacg cacagacggc acccagcagg 60

taggcatggt ctcaggggtg gccagcaagg gctctctcag ggtacagctg ggagaagcgg 120

ccgagggccc agatggggaa gatgttcctg tagctcgtgt aggagatggc acaggacttg 180

ttgaagaccc cagcaatggt ttcctaaaag aacacagaga aataaacaca aaggcttcac 240

cagtcagctg agggctagtc cctgaactgg agccctggct gttggcttgg ctggcttgtg 300

ggtgagtcag cctggaaagg gctaattaag caagagcata ggaaagcaag tagtccatcc 360

cgcatcagtc atggcaccat cagcccagct cagactcccc gcctgcagc araccctaag 420

ccaggggtcac cagccctca caaccacatc agcttcacc aactcagcct catcccaggg 480

ga

482

<210> 148

<211> 624

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (25) .. (25)

<223> baySNP12619_A25G

<400> 148

tcttggttgt gtcacagtgc tctgrgggca gaagagactc ctggggactg aatacagatg	60
gcttctgaat ttgtttacat tttctatcag aactgacatt tacttctggt cacacgatgt	120
ttttcttcta tcacctttac cctcttttgt gttctctttt ctgtctttta tcctttatca	180
gtcaaagtcc agccagaaaa acagaaacca tgctaaatat ttcaaacaca gggggactac	240
tagatagaac atgttacaaa agcactggga gggctgagag agccacaacg aggagagggg	300
aggaagatga gctaccacag agattggaaa ttccaggaag ctgtgatttt ccctaggact	360
gaaggaacca aacaaggggg ttctagagcc cagtagcaca gtggtggctg accctgctgg	420
aggctgcagc tgctattcaa agaaatcact gctgcactgt agatagcaac aagaggccat	480
tggaagctgc agctacctgc tgctgctgct gctgctgctg ctgctgctgc tgctgctgct	540

- 194 -

gctgctgctg ctgctgctgg gtctagagcc atctctgggc cctgtaggta ttggccactt 600

ctggccatca cccacagcag ccac 624

<210> 149

<211> 648

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (585) .. (585)

<223> baySNP13025_A585C

<400> 149

gtggaaaaat taaaaaagga atggaatggt atttgtatta ctgatgttgt ctacaatcat 60

actggtatga gcttcattga ctgccttcat taattttgat gagaatttat gcacacacac 120

atatacacac aaataagaga aaggaagaaa gaaagagaaa ggaaaggggc taacataaat 180

tttaaaaaca caaatgatga ttaggtgtcc ttctgtttaa aaaattaata tttttccttt 240

caaagaaaac attcttaatt gaggattaag tcaatatata agtatcttgc atctgttgct 300

tataaataca ggagagtgat catagaagga acataatgat cacatatttc aacttacagt 360

acagtagtcc ccccttattc gcagttttgc tttctgaggt ttcagttacc tgcagtcaat 420

- 195 -

cacatttcaa aaatattgaa tattccagaa atcagcaatt cataagtttt aattttcatg	480
ctgttttaag taacatgaca aactctcatg ccacccctgct ctatcccacc tggaatgtga	540
ctcatccttt tgtccagtgc atccatgctg taaatactac ctgtmcacca gttacttaat	600
agcctgctca gttatcagat aaaaaaacac aaaatatcaa aatatata	648

<210> 150

<211> 625

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (504) .. (504)

<223> baySNP13191_A504G

<400> 150

aagctgggaa ttacgtctca aagtaggaac tattggcaaa aggatgggat gaagatttca	60
atggaggaag gctatgttta ctgtaggaaa atgttgtagt cttataataa aagtcttaat	120
agacttttat taaggcctta agtgctagat tcaagatggc tgccccctctt gttctgtggg	180
tccagtgttc tatttggttg actaagggtg accttgtagc cccttacagc ccagccaaga	240
gagcttcact gtgaaggggc agacatcttc attactatctt tctcttccaa aaactcatat	300
aactctttgt gagtactgcc tcttctcctc attccacagt gaatttctcc ccacctggtg	360

- 196 -

acacaaacag ccttttccca ggtacttggg acctggagcg agtggacgag cagcatcgcc 420
gaaagtatgc ccggcgctccc gtctaaaggt ggtgagttag agtttgcaga gttgggtggca 480
taaaacccta atgtcttctt ctgrgtaaca acacagagag agaaggtggg gacaggtgca 540
gggagaagaa agtttaattg aagaggattg gggtagacagg agaaatggga gaattatctg 600
tggaattttt aaaaggaaaa gcaag 625

<210> 151

<211> 581

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (47)..(47)

<223> baySNP13937_A47C

<400> 151

cctccttgta atacatcatg cacttaatga cagctcccat tggaagmcgc tgaattaact 60
ggtttctctc tgctggaagc tctgggtctga agtgaatctt ggcagtcaag gtcggagggg 120
tcgcattaat tacgtatttg cactaaaaca cacacaagca aaatattacc tcaaattgtga 180
gctgcagtct ttgtggcagg cgtgaaaaat catctttatc acttctaaac aacattgagc 240

agtaaaaaca tacaaaatga gaaaatgagg caactgtgag gcaacaaaac agatcaaggt 300
aggtcaacca aggctggtaa tttggaagac tgaggcggaa acatgtcagc attaattatg 360
ctactgcttg aattatatct ggtagaaac tgcaaaagac acaaggccta tttactatat 420
gctccttttg actaaactga gttacctcat aatgttcatg gttcagcgtc tctatgatga 480
tgttgtcact tgactgggtca acgtgagtga caggatgggt cagcttcact tggctccga 540
ggaggtccat tatcgttcg ctcaattgac cagatccacc t 581

<210> 152

<211> 751

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (371) .. (371)

<223> baySNP900002_G371T

<400> 152

tctcaggagc tgaggcagga gaattgctcg aacctgggag tcagaggctg tagtgagcaa 60
agattgcacc actgcactcc agcctgggtg acagagtgat aaaaaccaga ttcttagatc 120
cctctttgaa tattcgctt aagtttctct aggccgaagc ctggaatccg tagcagtttg 180
accagcaacc cttgggaatt tttatagaaa taggaaccac tgccttagaa cattgggcag 240

ggataagaga aaagtgtgga gatttttagac catcttcctt ttttaacatc tgacttttgt	300
acaaccacaca cccatgttca ttaccaccg acactgctaa gctgctttca cacagcagtt	360
cacgcagacc kgcagaacat accgcattct gtgattcatc aggggtgacac aactgctctg	420
taagcaggtc ttgtgcagtt aagtgaaaat gatgtatttt atccttgata ttttaaaatg	480
actgaaaaat gggagacaac caaaaggagt atctccgat gataagaccc ctaagtcctt	540
aacccactg gacaaacagg ggtatcagta ggtaggtgaa cagtgatgaa gtgatccctt	600
caatcatact tattggcaaa cttaagctga ttaaaattgg gaagggaataa aaataagccc	660
tggaggaaaa gtccacatg tattttttgag atatatttaa aggggagggg gactgatatt	720
agggggattt taactttttg aaagggactt g	751

<210> 153

<211> 511

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (322) .. (322)

<223> baySNP900025_G322T

<400> 153

ggacttgctt gtaaatatgt taatatttga tcttaataag ctctgtcata ctaacactgt 60
 ttattaaact ttgtggtaga attactaccc ataactaaag aatgaaatgc atatatttgc 120
 aaattgttaa aaatttataa atcgatagaa aagttgaatg aatagtgaac acccttgtgt 180
 ctttcactaa ctcaagggt cacttgctaa cgtttgcctc atttgcttcc tctgtttata 240
 aagacatata tacttttttt attcccctga gccatttgaa agtaagctgc aaacatcttg 300
 acatttaact tctaaacatt tkagcacgtg tctcctaaga gcaagggtgt ctctctgaag 360
 agttacatta tcatacttaa gagatatagt attaatacaa tattatctaa catgtgatcc 420
 ctatttaaatt ttcatttatt ttcttcccca gaacagttct ttatagatgt ttttaatttt 480
 gatccagaaa ccaagggaaa aaatatatct a 511

<210> 154

<211> 598

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (261) .. (261)

<223> baySNP900032_C261T

<400> 154

tccctgtgca ccctgggtgga gtgcctttac ttcgtcagca tgtacggaag cgtcttcacc 60

atctgcttca tcagcatgga ccggttcttg gccatccgtt acccgctact ggtgagccac	120
ctccgggtccc ccaggaagat ctttgggatc tgctgcacca tctgggtcct ggtgtggacc	180
ggaagcatcc ctatctacag tttccatggg aaagtggaaa aatacatgtg cttccacaac	240
atgtctgatg atacctggag ygccaaggte ttcttcccgc tggaggtgtt tggcttctc	300
cttcccatgg gcatcatggg cttctgctgc tccaggagca tccacatcct gctgggcccgc	360
cgagaccaca cccaggactg ggtgcagcag aaagcctgca tctacagcat cgcagccagc	420
ctggctgtct tegtgggtctc cttcctccca gtccacctgg ggttcttctt gcagttcctg	480
gtgagaaaca gctttatcgt agagtgcaga gccaaagcaga gcatcagctt cttcttgcaa	540
ttgtccatgt gtttctccaa cgtcaactgc tgctggatg ttttctgcta ctactttg	598

<210> 155

<211> 1086

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (116) .. (116)

<223> baySNP900045_C116T

<220>

<221> misc_feature

<222> (986)..(1085)

<223> N_region

<220>

<221> misc_feature

<222> (986)..(1085)

<223> Unsure

<400> 155

tggccatctc ctgatccaag tccaggggtga cgtagcacag cttctccttg atgccatgca 60

cgatttccca ctgggcgggtg gtgggtgaagc tgtagcggcg ctccacgagg atcttyatga 120

ggtaatcagt caggtcctgg tcagccaggt ccagaaacag ggtggcctgg aggagggcct 180

acccctcgta gatgggcaca gtgtgggtga ccctgtcgct ggagtccatc acgatgtggc 240

cagaagcgta cagggacagc atggcctgga tggccatgta catggctggg gtgttgaagg 300

tctcaaacat gatatgggtc atcttctcgt gattggcctt ggagttcagg ggggcctcag 360

tcggcactac gggtgctcct tggagccaca cgcggctcgt tgtagaagtt gtggtgccag 420

atcttctcca tgtcatccca gttgggtgatg atgctgtgct ctatggggta cttcagggtc 480

aggatacctc tcttgctctg ggccatca ccctcgtagg agtccttttg acccatgccc 540

accatcacac agatgtggaa gggcagcgga gctctgtgct cgcgggggtgg acgcggtcct 600

- 202 -

```

agcagtctgt tctacattct taaccttttt tttttatgga cctcttgget ttctggtaga 660
gtctgggacc ccctttttcaa agtaatgctt ctatgtgcat aaaacaaata catgggatta 720
caaggcaaac caactatatt gaaatacagt tgcctccttg gatcctatgg aggtccaagt 780
actcaagtga aaaattttcca taagagctgg gtgcgttggc tcacacctgt aatcctagca 840
ttttgggagg ccaaggcagg cgtactgcct gagttcagga gtctgagaac agctcaggca 900
acacagtga accctgtctc tactaaaata caaaaaatta gcttggcatg gcagcatgcg 960
cctgtagtct cagctacttg ggaggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1020
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 1080
nnnnnc 1086

```

<210> 156

<211> 1864

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (877) .. (877)

<223> baysNP900065_A877C

<400> 156

```

tagatgacgg gttgataggt gcagcaaacc accatggcac atgtatacct atgtaacaaa 60

```

cctacgcatt ctacacacat atcccaaaac ttataagtaa aacagaaaaa aaaagaatta	120
gttttataaa aatcaataaa ttataactcag tgggtttttt tttttttttt tgagacggag	180
tctcgctctg tcgcccaggc tggagtgcag tggcgggata tcggetcact gcaagctccg	240
cctcccgggt tcacgccatt ctctgcctc agcctcccaa gtagctggga ctacaggcgc	300
cgcgcactac gcccggttaa ttttttgtat ttttagtaga gacggggttt caccgtttta	360
gccgggatgg tctcgatctc ctgacctcgt gatccgccg cctcggcctc ccaaagtgc	420
gggattacag gcgtgagcca ccgcgcccg cctcagtggt gttttaataa aatatttttag	480
ggccttttta gcttatttat ttaaaatttc aagatcatat agtcttgaag tgaacccaaa	540
aaatcagaaa gagttacca ctttacctat ggtatgtgag gcaagctttg aatgagtaaa	600
taaggagtga atctgtgtaa tcgtcagctt ccatttttgt ataattctgc ttcttattcc	660
caatctgggt ttacgtttta tctttgcaat tatattcatt ctttatttat ttttatttat	720
tttttttgag atggcatctc acctctgtca cttaagctgg agtgcagtggt tgcaatctca	780
gttcactgca acctccacct cccgggttca agcgattctc ctgcctcagc ctcttgagta	840
gctaggatca caggtgctg ccaccatgcc cagctamttt ttgtattttt agtagagatg	900
gggtttcgcc atggtggcca ggctggctc aaactccgga cctcaggtga tccaccgct	960
tcagcctccc aaagtgcctg gactacaggt gtgagccacc gtgccaggcc aactttctta	1020
aatctcgaac aaagcattta cttactagtt agtggaaca agattcacat tgcacatag	1080
gtattccaga tactttcagt gatgtggaaa tcagaaaccc ataaaattaa gtatgccaga	1140
aagcagtttt gtacacatct aagtaaattc tctcttaaac aagagaaagg aataaataga	1200
taccaataaa catgcatctt tatctcaata atattttaat gattatttca atgatattta	1260

```

aaaaatcatc atgacttgat acaattgttg gtacacaaaa tgacgccact atggttctca 1320
tggaaagtgt gacctcatga acgactgaac aatctgacag attcattcaa atatgtctaa 1380
cagaccctgg gtgagtctgg aagctttggc agtgaaacca gaaggactca gcctgtgagg 1440
gaaggttggt ttgtctccaa ctggaactgg gaaatacctt ctaataagat gacactgttc 1500
ttgggaattc cagaatcatg aaaaggcagt ggaaatcact ggggtgtagga atcagcagct 1560
gtgggcttct ggaaataacg tcctggcact tacacgacct tgttccaatt cagagttaag 1620
gctgctctac actgtgtgca ttctgtgccg taaagaaagt agcaaaataa aatcatgac 1680
tggtttccat tttaggctc actctttgca gtgtccttct tcattcccaa atcttccatg 1740
ttgggaaaat taaggtaaca agaaaatctc ctctgttctt tttccactaa atccaaaatc 1800
atgacacaga actctgttga aatacatcat aaaggtagaa ttttaaaaca aaaggctgaa 1860
taaa 1864

```

<210> 157

<211> 535

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (375)..(375)

<223> baySNP900082_A375G

<400> 157

gcaaacatgt tccaccagat catcagtcag aggatctgaa cttgatcccc cttttttgta	60
tttactggag ctggaggtag tagagcagca ctgtatctct tgtgtctggc attgttcaat	120
ccagatgtta gttgggacag aaagaataac ccagagccct ggaacaaact ggggcccaat	180
gatctataca agttctactc agtgaatgtg gattacagcc aactgaagaa agaaggcca	240
gattttctaaa tgaaatgttt cactataaag ctgctttaga atgaaggctt tccagaagca	300
atccacacaa ttttccactt aaccaggaaa tattttctct ctaaatacat gaaatcatgt	360
tgatgtaatc tactrgggag attacactga ttaataaata actgaaactt gaaaaaaaaa	420
gttattatcc aacttgatag aaaactggag tctggaaatc tgaaatatca ccttctctct	480
ttcatgcggc tcttcttctt gcttggtcaat ggaattcact ttccgtggta ccatg	535

<210> 158

<211> 708

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (136) .. (136)

<223> baySNP900096_A136G

<400> 158

agtggccctg tgctcgtcac aggctggtgt cctctgctct cctccctca ctctggggc	60
aagcaacagt ggtgttccat gtgtgagctg gacctaccac tagtggtggc ttgtttaaat	120
tctctgacag agacaractg tcccgggggg cggggaaggc agtggtggagc tcacccctg	180
agggagcagc attgtctctg tgggctttgg ctgggaatgt ttctgaagac gccctaatec	240
cttgccctgc ctagecctcaa agtctctatc actcagagga gtactgggag ggctcagtg	300
gagccatcag aaccttccag ggtatcttcc cttgcttggt ctctttgcgc agtccacttg	360
gtttgctaaa ctctgctct tccatcaaga cccaactcaa ggccaggcac ggtggctcac	420
gcctgtaatc ccagcactct gggaggcaga ggtgggcca tcacttgagg tcaggagttc	480
gagaccagcc tgggcaacat ggtgaaacac catctctact aaaaacacaa aaattagcca	540
ggtgtggtgg caggcacctg cagtcccagc tactccggag ctgaggcagg agaattgctc	600
gaacctggga ggcaggggtt gcagtgagec gacatggcgc cactgcactc cagtctgggc	660
gacagagtga gaccctatct caaaaaaaaaa aaaaaaaaaa aaaagacc	708

<210> 159

<211> 790

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (426) .. (426)

<223> baySNP900107_C426T

<400> 159

```

cccacatgtg gctcccgaga tgggagctgc tccttgcata ccctgtgccc tccggagggt      60
gcacctggag tgcttctca cacatggctt tctccctcc cggccctcc cctcccttg      120
gtctgtttct ctcccatgg tctaagcatt tattttatgc cattctttat gtaacaacca      180
ccccagaagg cggatgtgaa cacttggatt tgggattttc aaattcctta tctttcactg      240
agtcattttc cattttattc aagagcacat ggagaaacca agggatatct taatggaagg      300
agacctttcc tgggtagaac aggaagactg aagatgaagg attcctctgg gatataaatg      360
gctcccttga gactaattac aaggcctttg ggtggggcac cagcccacac tctgaacctg      420
ggggayaggt caagctgagg ccctgagacg ttaccctagt ggtcagtggg ggcacgtggg      480
tgaaggctga tgggtaactc tacctgaaaa agcccttgca tccttcacat gtcatgacat      540
tgaagtgata gccagtggcc ttgtcccccac atacacggca gatttgggga cctccgactt      600
cctcatctgc gttgacactg ggctttccag gaacagactc tgtgtcctca cagtgtacaa      660
agtcagcatg gttccagctt tctttgggtc tcacctcag gtttgcttct gggcctcttg      720
gactagaaat gagaaaacca cagagaatga aaagactgga cagggatgtg tagaggcctc      780
agaggaaaca                                     790

```

<210> 160

<211> 558

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (263)..(263)

<223> baySNP900121_G263T

<220>

<221> variation

<222> (263)..(263)

<223>

<400> 160

atctttacct atttttcctg cctacagaat cttcctaaaa ggactgtgtc actgtggtct 60

tacataaaca gccagctgga agactteact aatcctctct atgggagcta ttccaatcat 120

gtcctttatc cagtagccag catgcgccac ctagagctct ggggtgggata ttacataagg 180

tggaatccac ggatgaaacc acaggtatgt gccttacaat atacaatggg agttttcatt 240

catgcagtgc aactttgtct ccktaaaagc agctggaaag attatctgtg catatttaaa 300

actttactcc ttacccattg atagttaaca attgtatagt agaaaaatac tacactgggg 360

cagggtaatc agtataacctg gttcttagga ctgcttgtat gacattggac aaatcactgc 420
tctctttttct tgcattctcc ctctctgtgc tggataacct ctaggggggc ttgttttaat 480
aagctgaaga aagtagcttt aggaaagtta aaagctgaac aaaattctgg tctactgtga 540
atatgtttat ggaatatt 558

<210> 161

<211> 101

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (51) .. (51)

<223> baySNP900115_A51G

<400> 161

tccatctctg agcccggtgc acagatccag aagatgaaag aaggaagtga rcatcctttt 60

gctctgtcct cccacccccg atagtgcacac atcttcaggc a 101

<210> 162

<211> 1345

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (816)..(816)

<223> baySNP900078_A816G

<400> 162

ctgcagtgac cactgccccca tcattgctgg ctgaggtggt tgggggtccat ctggctatct	60
gggcagctgt tctctttctct cctttctctc ctgtttccag acatgcagta tttccagaga	120
gaaggggcca ctctttggca aagaacctgt ctaacttgct atctatggca ggacctttga	180
agggttcaca ggaagcagca caaattgata ctattccacc aagccatcag ctccatctca	240
tccatgccct gtctctcctt taggggtccc cttgcccaaca gaatcacaga ggaccagcct	300
gaaagtgcag agacagcagc tgaggcacag ccaagagctc tggctgtatt aatgacctaa	360
gaagtcacca gaaagtcaga aggatgcata gcagaggccc agcaatctca gctaagtcaa	420
ctccaccagc ctttctagtt gcccaactgtg tgtacagcac cctggtaggg accagagcca	480
tgacagggaa taagactaga ctatgccctt gaggagctca cctctgttca gggaaacagg	540
cgtggaaaca caatggtggt aaagaggaaa gaggacaata ggattgcatg aaggggatgg	600
aaagtgccca ggggaggaaa tggttacatc tgtgtgagga gtttggtgag gaaagactct	660
aagagaaggc tctgtctgtc tgggtttgga aggatgtgta ggagtcttct agggggcaca	720
ggcacactcc aggcataagg aaagatctgt aggtgtggct tgttgggatg aatttcaagt	780

- 211 -

atTTtTggaat gaggacagcc atagagacaa gggcargaga gaggcgattt aatagatttt	840
atgccaatgg ctccacttga gttttctgata agaaccaga acccttggac tccccagtaa	900
cattgattga gttgtttatg atacctcata gaatatgaac tcaaaggagg tcagtgagtg	960
gtgtgtgtgt gattctttgc caacttccaa ggtggagaag cctcttccaa ctgcaggcag	1020
agcacaggTg gccctgctac tggtgcagc tccagccctg cctccttctc tagcatataa	1080
acaatccaac agcctcactg aatcactgct gtgcagggca ggaaagctcc atgcacatag	1140
cccagcaaag agcaacacag agctgaaagg aagactcaga ggagagagat aagtaaggaa	1200
agtagtgatg gctctcatcc cagacttggc catggaaacc tggcttctcc tggctgtcag	1260
cctggtgctc ctctatctgt gagtaactgt tcaggctcct cttctctgtt tcttggactt	1320
ggggtcgtaa tcaggcctct ctttt	1345

<210> 163

<211> 204

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (103) .. (103)

<223> baySNP10000002_A103G

- 212 -

<400> 163

aattcatttt ccaactaata gaagataaca ttaaacagct gaaagagatg aaatttactt 60
atcttattaa ttatatccaa gatgagatca acacaatctt cartgattat atcccatatg 120
tttttaaatt gttgaaagaa aacctatgcc ttaatcttca taagttcaat gaatttattc 180
aaaacgagct tcaggaagct tctc 204

<210> 164

<211> 210

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (107)..(107)

<223> baySNP10000006_G107A

<400> 164

cgagtcttcc actcgctggc caaggtagct ttccaggatg gccgcctcat gctcagcctg 60
atgggagacg agttcaaggt gagtgggtgg ggctgggctg ctaggggratc cagatggcat 120
gtggtatgtg tgtgtgtgca cacgcatggg gaggagggag gaaactcgga aacttgggtg 180
tgggcaaaag aactaagctg gagcaatagc 210

- 213 -

<210> 165

<211> 399

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (153)..(153)

<223> baySNP10000014_A153C

<400> 165

ttcagttaaa gtctatggca ctctgtagga ctgctgatgt ctctgttgca cactgttgat	60
tctaaaatca aaggcactca gtataagcac agtaatagtc ctctcatca tgctttgtat	120
tttccgtagc tgctgtacc aatacatcct gcmgtggcca cggatgaatgt gtagagacca	180
tcaataatta cacttgcaag tgtgaccctg gcttcagtgg actcaagtgt gagcaaagta	240
agtctgggtc ttgcctcttt cttcacttga gatggttagca ccctctcacg tcctagctgg	300
cattagagtc aggtctgcat gccttcctt ccctggtgca gatggtgtca tatggtgatc	360
gtgagctgag actatgaagt cagaccctgc tgggtttga	399

<210> 166

<211> 587

- 214 -

<212> DNA

<213> Homo Sapiens

<220>

<221> variation

<222> (291)..(291)

<223> baySNP10000025_C291T

<400> 166

tcttccttct tttggtctct cctgtcagaa tcagcggctc ctgcctcacc ccttctctgg	60
cgagagactt gtccctcacc acagggcctg gggcttttta cagaatggag gaagggatcc	120
tctctgtctg gttatcttgt catcgccacg ggggtgccct gcagaccaca gctctgtgca	180
gacctccggc ctggcaggac ctgccaatat actgtccttg tctgatgtcc cctccctgcc	240
cctcttctag gtgccccctt gtttctctcc catcctcact tcctcaacgc ygacctgggt	300
ctggcagaag cggtgactgg cctgcaccct aaccaggagg cacactcctt gttcctggac	360
atccaccggg tgagccccctg ccatacctctg tgggggggtgg gtgattcctg gttggagcac	420
acctggctgc ctctctctc cccaggcaga gagctgctgt gggctggggg ggtgggaagc	480
ctggcttcta gaatctcgag ccaccaaagt tccttacttc accccgactc catagttcaa	540
ggtagttcaa gggttttatg atccctgtac tggtttctat aaatggg	587

<210> 167

- 215 -

<211> 3877

<212> DNA

<213> Homo sapiens

<220>

<221> variation

<222> (2503) .. (2503)

<223> baySNP900173_G2503T

<400> 167

gaattcaagg tctgcatttt ctaggtatga acactgtgca tgatgaagtc tttccaagcc	60
acaccagtgg ttccatgtgt gtgcacttcc ggtttgagtg ctagtgagat acttctgtgg	120
ttctgaattg cctgactatt tgggggttggt atattttcat aaagattgat caacatgttc	180
gaatttcctc cccaacagtc ttccattacc aagtaaagat tcatttttct gggactgaga	240
gtgaaaccca taccaatcag gcctttgaga tttctctgta tggcaccgtg gccgagagtg	300
agaacatccc attcactctg tgagtagcac agggggggcgg tcatcatggc accagtcctt	360
ctcctgccat aacccttggt ctgagcagca gaagcagaga gcgatgccta gaaaacaagt	420
ctttagttaa aaaaatcaga atttcaaat tgaggtcttt cctctatttg atattgagaa	480
aaaaatgctt caaattggcc attttatttt cacttactag ttatattttt ttatttatca	540
tcttatatct gtttatttct tttataaagc tgctgttaaa caatataatt aaactatctc	600
aaaaggtttg acattaaaga aaatgagcaa tggtaacagg aaaccactct atagatgtac	660

- 216 -

atataatatg tacagaaaat ataagtagta agaagtccat gacaaagtgt tagctctttt	720
tttttttttt tttttttttt tttttgagat ggagtctctc tctattgccc aggctggagt	780
gcagtgattc gatctcagct cactgcaacc tctacctccc gagttcaaac aattcttctg	840
tctcagcctc ccgagtagct ggggctgcag gtgcccacca ccatgcccag ctaatttttg	900
tatttttagt agcgacaggg tctcaccatg ttggccaagc tggctcttgaa ttctgatct	960
caggtgatcc acccgctcgc gcctcccaaa gtgctgggat tacaggtgtg agccaccatg	1020
cccagcctac cctttactac taatcaaaga aataaaagta aggcaacttg atacttttac	1080
aattactaga tgaacaaatc tttaaaaata gccagtgcag acaaggtggg gaagcagaac	1140
atgcgaacct accatgcac cttcacggct agaaccctcc aggtgcggaa ggtagtattt	1200
taataacttt ccatagctac aaaatattat tacatagaag ggagtgattt ttttctaata	1260
tttatcctaa agaaatagtc aacaaacatt tttaaaaaca tcaattacag tcgtacctat	1320
actagcataa attagaaacc cagtatccaa cattgaggca gtgggtaaat gaatcgtggg	1380
ttatcaagtc attaaaaatca atctagcctt taaaaactat aattgtagga aaccagga	1440
aacatagtaa aaaatggaat ataaaatctg aagagaataa agaatagaga atcgtatgtg	1500
tgctatgatt gtagctaaat aatgttcaag tatcaacaca aattgaaaag gaatacatga	1560
aatgaaaat tatatttctg aatgattgac ttcaggattt tcttttagaa ttgtattaaa	1620
tagttcatgt cattaggata aatgctggaa tgtggatata atttaaaata tactaaatgc	1680
catcgacctt cattttgagt tctttgttgg acatttttgt gcatttttaa aatatccct	1740
aaataataaa gctatttata tttggagagg agaaaaaaaa gtgggggggca gggagagctg	1800
atctctataa ctaaccaa atttattgcttt tttgttttagg cctgaagttt ccacaaataa	1860
gacctactcc ttcttaattt acacagaggt agatattgga gaactactca tgttgaagct	1920

caaatggaag agtgattcat acttttagctg gtcagactgg tggagcagtc ccggcttcgc	1980
cattcagaag atcagagtaa aagcaggaga gactcagaaa aagtaattaa atgtattttt	2040
cttccttcac tttagacccc cacctgatgt caggacctag gggctgtatt tcaggggcct	2100
tcacaattca gggagagctt taggaaacct tgtatttatt actgtatgat gtagattttc	2160
tttaggagtc ttcttttatt ttcttatttt tggggggcgg ggggggaagt gacagtattt	2220
ttgtatttca tgtaaggaaa acataagccc tgaatcgctc acagttattc agtgagagct	2280
gggattagaa gtcaggaatc tcagcttctc atttggcact gtttcttgta agtacaaaat	2340
agttagggaa caaacctccg agatgctacc tggataatca aagattcaaa ccaacctctt	2400
ccagaagggt gagattccaa gataatctca acctgtctcc gcagccccac ccatgtgtac	2460
ccataaaatg aattacacag agatcgctat aggatttaaa gcktttatac taaatgtgct	2520
gggattttgc aaactatagt gtgctgttat tgttaattta aaaaaactct aagttaggat	2580
tgacaaatta tttctcttta gtcatttgct tgtatcacca aagaagcaaa caaacaaca	2640
aaaaaaaaa gaaaaagatc ttggggatgg aaatgttata aagaatcttt ttacactag	2700
caatgtctag ctgaaggcag atgccctaatt tccttaatgc agatgctaag agatggcaga	2760
gttgatcttt tatcatctct tggtgaaagc ccagtaacat aagactgctc taggctgtct	2820
gcatgctgt ctatctaaat taactagctt ggttgctgaa caccaggta ggctctcaaa	2880
ttaccctctg attctgatgt ggctgagtg tgacagttaa ttattgggaa tatcaaaaca	2940
attaccagc atgatcatgt attatttaaa cagtctgac agaactgtac ctttgtgaac	3000
agtgcctttg attgttctac atggcatatt cacatccatt ttcttcaca gggatgatt	3060
ctgttctagg gagaaagtgt ctcatctgca gaaaggaaag gcacctgcgg tatttgtgaa	3120

atgccatgac aagtctctga ataagaagtc aggctggtga gcattctggg ctaaagctga 3180
 ctgggcatcc tgagcttgca ccctaaggga ggcagcttca tgcattcctc ttcaccccat 3240
 caccagcagc ttgccctgac tcatgtgatc aaagcattca atcagtcttt cttagtcctt 3300
 ctgcatatgt atcaaagggg tctgttgctt tatgcaatac ttctcttttt tttctttctc 3360
 ctcttgtttc tcccagcccg gaccttcaac ccaggcacac attttagggtt ttattttact 3420
 ccttgaacta cccctgaatc ttcacttctc cttttttctc tactgcgtct ctgctgactt 3480
 tgcagatgcc atctgcagag catgtaacac aagtttagta gttgccgttc tggctgtggg 3540
 tgcagctctt cccaggatgt attcagggaa gtaaaaagat ctactgcat cacctgcagc 3600
 cacatagtcc ttgattctcc aagtgccagc atactccggg acacacagcc aacagggctg 3660
 cccaagcac ccattctcaa aaccctcaaa gctgcccaagc aaacagaatg agagttatag 3720
 gaaactgttc tctcttctat ctccaaacaa ctctgtgcct ctttcctacc tgaccttag 3780
 ggctaatcca tgtggcagct gttagctgca tctttccaga gcgtcagtac tgagaggaca 3840
 ctaagcatgt gaccttcact actcctgttc tgaattc 3877

<210> 168

<211> 620

<212> DNA

<213> Homo sapiens

<220>

<221> variation

<222> (309) .. (309)

<223> baySNP900013_C309G

<400> 168

ctgtgctgca gaggggagca gcatcagcag gcgtgtggag tgagtgagcc ccgtcctccc	60
cctcctcctg tcattgactc tcattgccta acccccttgt gtcttggccc caggttgatt	120
gtccggggct accgccagcc cctggagggc agtgacctct ggtccttaaa caaggaggac	180
acgtcggaac aagtcgtgcc tgttttggtg aagaactgga agaaggaatg cgccaagact	240
aggaagtaag tgtgagtttc cttgtcctcc aggatgccct ggtcacctcc ttccactmc	300
tgtggcctsa atccaggatg gggccctggc agtgctgcct gttactagct ttgtggttct	360
gggcaagatg cctcacttct cctcctggcc tcagtttgct tttctgcaa atggggtagg	420
atctcacatg tcattaaagc aactgggcag agaaaagaag aaagaagctg ggtgcggtgg	480
ctctcgtgtc taatcccagc actttgggag gccaaggcag gcggatcact tggtcgggag	540
tttgagacca gcctggccaa catggtgaaa ccctgtctct actaaaaata caaaattagc	600
taggcatggg ggcaggcgcc	620

PCT Application

EP0309126

